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SUMJIARY 
In this thesis, the development, refinement and standardisation 
of a wide range of coagulation and fibrinolytic assay techniques are 
described. Particular attention was directed towards the assay of 
Factor VIII, cryofibrinogen and fibrin /fibrinogen degradation products 
(F.D.P.). A new type of coagulation end point recorder was investigated 
and the use of the Atlas computer in the analysis of results is outlined. 
In addition, a study was made of various standard plasma preparations for 
the control of coagulation factor assays. 
Using these laboratory techniques, the effect of severe and 
moderate exercise, adrenalin infusions and beta- adrenergic receptor blockage 
on selected parameters of the coagulation and fibrinolytic systems, in 
normal volunteers, were studied. No correlations were observed between 
parameter changes in either system, and contrary to some reports, Factor XII 
was not increased post exercise. Some subjects exhibited a low fibrinolytic 
response to the exercise procedures, confirming previous work from this 
laboratory, but the coagulation response in these individuals did not appear 
to differ in any constant manner from the normal pattern. The adrenalin 
induced changes in Factor VIII were completely blocked by Propranolol, but 
this drug only partially lowered the response to adrenalin of plasminogen 
activator. The new beta -adrenergic blocker drug, ICI 50172, was fouhd to 
have only minimal effects on the two systems. These results are fully 
discussed in the light of presently available concepts of the haemostatic 
mechanism. 
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In the studies on pregnant subjects, parameters of coagulation 
and fibrinolysis throughout the gestational period were measured. One new 
finding was that of a significant increase of serum F.D.P. in late pregnancy. 
It was also found, in another study, that the reactivity of the fibrinolytic 
system to an exercise stress in the third trimester was greatly impaired in 
some subjects. Further coagulation and fibrinolytic studies in pregnant 
and non -pregnant patients undergoing intra- abdominal surgical operations, 
demonstrated that significant changes occurred in euglobulin lysis activity, 
fibrinogen and F.D.P. levels. The application of specific coagulation and 
fibrinolytic tests to clinical haemostatic emergencies of pregnancy is 
described in the final section. All these studies have provided a basis for 
a fuller discussion in each section, of concepts such as the Shwartzman reaction, 
disseminated intravascular coagulation, and haemorrhage and thromboembolism. 
It is concluded that although some of the physio- pathologidal 
interrelationships of coagulation and fibrinolysis are now becoming clarified, 
many problems still remain, and these may only be resolved when improved 
methodology becomes available. The extension of work reported in this 
thesis may aid in the elucidation of important aspects of haemorrhage and 
thrombosis. 
T'.idTRODUCTIOTr 
A fundamental alteration has now taken place in the approach of 
research workers to blood coagulation and fibrinolysis. In the past much 
exacting work had been directed to the simple identification of pathological 
disturbances of haemostasis, and from this approach there has arisen a 
clinically orientated concept of the two systems as well as many therapeutic 
advances. Recent investigations, however, have been increasingly ditected 
towards the pathophysiology of these systems with three main goals in view, 
namely, the purification and characterisation of specific components, the 
establishment of the exact mechanism of interactions by which these factors 
integrate to form and dissolve fibrin clots, and the study of the theory 
of a dynamic balance between these two functionally antagonistic systems. 
The problems of investigation have been formidable, but as new 
laboratory techniques have evolved,a much more complete understanding of the 
complexity of the systems governing blood fluidity has arisen. This 
physiological research has been stimulated by the realisation that one key 
to the problems of atherosclerosis and thrombosis may lie in the elucidation 
of these mechanisms of haemostasis. Yet despite progress, our accumulated 
knowledge remains limited and many questions remain unanswered. The work 
in this thesis therefore is presented as a study of problems relating to 
physiológical and pathological coagulation and fibrinolysis utilizing 
both well established and recently developed laboratory techniques. 
SECTION 1 
FUNDADDITTAL CONCEPTS OF COAGULATION AND FIBRINOLYSIS. 
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CHAP= I. 
HISTORICAL DEVELOPMENT OF THE CONC 2TS OF COAGULATION 
AND FIBRINOLYSIS. 
A. Coagulation. 
Dr. William Hewson (1771) was perhaps the first research worker 
to clarify some of the basic facts of blood coagulation. In a series of 
experiments, a few of which are the prototype of techniques used to -day, 
he demonstrated that the coagulative portion of blood resided in the 
plasma and not in the red cells, that clotting of blood was not due to 
changes in temperature or the absence of motion and that stagnation of 
blood within vessels was important in intra- vascular clotting. Further 
progress was not made until 1845 when Andrew Buchanan reported that 
washed fibrin would promote the coagulation of hydrocoele fluids and in 
1879 Gamgee was able to report that the active coagulant was a protein 
belonging to the globulins. Schmidt (1872) confirmed these observations 
and called the active coagulant thrombin which, he hypothesised, was derived 
from an 'nactive precursor, prothrombin. Virchow (1856), had by this 
time postulated the existence of fibrinogen and this was subsequently 
isolated by Denis in 1859. 
The stage was thus set for the classical observations of 
Morawitz (1905) upon which the modern theory of coagulation is still 









As with many theories, it was not generally accepted, and it was 
not till 30 years later, following the experiments by Quick (1935) and 
Warner, Brinkhous and Smith (1936), that its validity was established and 
tests derived for measuring its components. However, experience soon 
demonstrated that anomalies incompatible with the theory occurred and the 
presence of other coagulation factors was suspected. 
The first to be discovered was Factor V by Owren (1947) and this 
was followed by Factor VII by Owen and Bollman (1948); Mann and Hurn (1950) 
and Alexander et al. (1951). Factor X was identified much later (Telfer 
et al., 1956; Hougie et al., 1957). These factors were necessary in 
clotting mixtures activated by tissue thromboplastins. 
It had been realized much earlier that the Morawitz theory did 
not explain the clinical state of haemophilia and it was therefore concluded 
that there was an alternative pathway for the activation of prothrombin. 
It became evident that haemophilia was due to a lack of a specific clotting 
factor and the defect was localised to the globulin fraction of plasma by 
Patek and Taylor (1937) and subsequently labelled "antihaemophilic factor" 
or Factor VIII. Pavolovsky (1947) later made the observation that blood 
from Lwo haemophilic patients were mutually corrective and based on this 
finding, separate investigations by Aggeler et al. (1952) and Biggs et al.(1952) 
clearly demonstrated the existence of a hitherto undescribed coagulation factor, 
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named at that time 'plasma thromboplastin component' (P.T.C.) or "Christmas 
Factor ", and now known as Factor IX. Both these factors were apparently 
important in prothrombin activation in the absence of tissue extract. In 
1953 another new clotting factor, plasma thromboplastin antecedent (Factor XI), 
absent in certain patients, was described (Rosenthal, 1953), and this was 
followed by the discovery of Factor XII, in 1954, by Ratnoff. These latter 
two factors, both active in the early stages of coagulation, and named the 
'contact factors' were shown to be essential for the development of prothrombin 
activator. A further factor, Factor XIII, essential for the polymerisation 
of fibrin to form insoluble fibrin was detected in 1958 (Lorand et al.) 
However, the identification of these separate components did not 
explain their mechanism of reaction to form prothrombin activator. 
Initially, the clotting sequence was arbitrarily subdivided into an "extrinsic" 
and an "intrinsic" pathway, the former initiated by tissue extracts, and the 
latter by surface contact. From considerable deductive experimental work, it 
became apparent that process of clotting appeared to consist of a series of 
stages in a chain reaction in which coagulation factors were acting as 
proenzymes for other factors. Such a scheme was outlined by Macfarlane in 
1964, and is now referred to as the "cascade theory" of blood coagulation 
(Fig. I:1). 
This concept unifies much of the available information on 
coagulation and has been accepted by most workers. A more biochemical 
explanation of coagulation has been evolved by Seegers et al. (1962) based 
upon the autocatalytic conversion of prothrombin to its various enzyme 
derivatives. This theory, although of considerable theoretical interest 
CURRENT SCHEME FOR THE CLOTTING MECHANISM 
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Fig. 1:1. Current Scheme for the Clotting Mechanism 
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does not lend itself so readily to the study of abnormal haemostasis and 
has not generally been accepted by clinicians. However, present concepts 
of coagulation do not yet fully explain all the phenomena observed and 
further advances in knowledge can be expected. 
B. Fibrinolysis. 
The earliest known observation relating to fibrinolysis was 
made by Morgagni in 1761 who remarked on the post mortem fluidity of 
blood in cases of sudden death. John Hunter in 1786 also observed this 
phenomena but it was not till 1838 that Denis described the actual lysis 
of whole blood. Further progress was slow but in 1893 Dastre proposed 
the word fibrinolysis. Nolf (1908), with considerable foresight, 
postulated that fibrin deposition and removal were in a state of balanced 
equilibrium within the circulation, but little further interest was taken 
until the discovery of streptococcal lysis of fibrin (Tillet and Garner, 
1933). Subsequent work by Milstone (1941), and Christensen and Macleod 
(1945) characterised the components of the fibrinolytic system, providing 
a basis for further research into lytic mechanisms. 
Interest in the fibrinolytic system is a comparatively recent 
development, as compared with the coagulation system. It was soon 
realised that fibrinolysis was a basic physiological process, which was 
operative not only in the vascular system but also in tissues, and other 
body fluids. It was postulated that fibrinolysis was active in preserving 
the patency of various types of excretory ducts (Astrup and Sterndorff, 
1955), in the physiology of endometrial activity (Albrechtsen, 1956), and 
_7 
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Fig. 1:2. Simplified Scheme of the Fibrinolytic System. 
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in wound healing (Astrup, 1955). A major function ascribed to the 
fibrinolysic system was the clearance of fibrin from the vascular bed 
( Astrup, 1956). 
A modern concept of the fibrinolytic system is summarized 
in rig. 1:2. This physiological system is constantly active in normal 
circumstances and is held in check by potent inhibitor systems. The 
formation of plasmin is normally quickly neutralized by antiplasmins, but 
if excess plasmin is produced, it may transiently appear in the blood stream 
with marked proteolytic effects on other blood proteins. 
In Section 1:3 a fuller consideration will be made of the 
proposed inter -relationships existing between coagulation and fibrinolysis. 
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CFL4PT- II 
COMPONENTS OF THE COAGUL.9.TION AND FIBRI1.10LYTIC SYSTFi^ 
A. Coaulation. 
(a) Factor I (Fibrinogen). 
Fibrinogen, a plasma protein of molecular weight 340,000 -360,000 
(Caspary and Kekwick, 1957; Blombáck and Laurent, 1958), is probably 
produced in the liver (Tocantins, 1938), by the liver parenchymal cells 
where it has been identified by fluorescent antibody studies (Barnhart 
and Anderson, 1962). Electron microscopy studies indicate that the 
molecule consists of three globules in a. row connected by thin filaments 
(Hall and Slayter, 1959) and the dimensions of these components had been 
established (Blomb,ck, 1967). The analysis of human fibrinogen shows the 
presence of all the common aminoacids and the difference between it and 
bovine fibrinogen is small (Henschen and Blombáck, 1964). The molecule 
also resembles the structural proteins of skin (epidermin) and muscle 
(myosin) (Bailey et al., 1943). It has the built -in property of "self 
assembly" after thrombin activation, to form orderly molecular aggregates 
recognizable as fibrin. 
Fibrinogen is a sensitive substrate for the proteolytic enzymes 
of blood, notably thrombin and plasmin, and both these ractions are 
discussed in a later section (Section 1:3). It is not known if a 
continuous low rate of clotting and lysis contributes to the metabolism 
of fibrinogen turnover, but in pathological states of plasmin release, 
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marked changes in fibrinogen levels can occur from both disseminated 
coagulation and fibrinolysis (Schneider, 1964). Normally, the concentration 
of fibrinogen in the blood is maintained between narrow limits. Its half 
life is between 2.1 and 3.8 days (Macfarlane et al., 1964), and 75% of total 
body fibrinogen is contained in the intravascular compartment (Adelson, 1965). 
Fibrinogen turnover estimated in grammes per day is approximately 1,5 - 5.Og 
but this may be apparently increased in certain situations of relative 
hypercoagulahility (Galewski et al., 1965). 
Numerous methods are available for measuring the concentration 
of fibrinogen. These include estimating the amount of fibrin evolved 
after the addition of thrombin (Ratnoff and Menzies, 1951); salt 
precipitation methods (Goodwin, 1961); heat precipitation methods 
(Stirland, 1956); electrophoretic determinations (Berkes et al., 1956), 
and an immunochemical method using sensitised tanned red cells (Fox, 1964). 
Assays measuring the thrombin clottable protein have proved the most 
reliable in clinical situations. 
(b) Factor II ( Prothrombin . 
Prothrombin is a plasma protein, produced in the liver parenchymal 
cells, migrating electrophoretically in the 4g2 fraction and having a 
molecular weight of 70,000 (Aronson and Preiss, 1962). It has been studied 
extensively by Seegers (1967) whñse biochemical approach to coagulation 
has attracted considerable interest. It is a relatively stable protein, is 
closely associated with the activity of Factors VII, IX and X, and is present 
in Cohn alcohol Fraction III, from which it can be concentrated. 
Activation of prothrombin leads to the generation of thrombin and 
much of the current research work in coagulation is orientated towards 
elucidation of the factors which convert prothrombin to thrombin. 
Prothrombin deficiency as a congenital defect is very rare but acquired 
partial deficiencies (anti - coagulant therapy and liver disease) are 
relatively common. 
Thrombin, the active enzyme from its stable precursor 
prothrombin, can be purified from Cohn alcohol Fraction III (LIiller et al., 
1965), and when concentrated has high stability on freeze drying. 
Chromatography on Sephadex G -100 has been used to estimate the molecular 
weight of thrombin to lie between 26,000 and 35,000 (Miller et al., 1965; 
Lanchantin et al., 1963). Chemical analysis yields much lower values with 
minimum values of 8,000 - 9,000 g (Laki and Gladner, 1964). The amino 
acid composition of thrombin has been determined, twenty acids having 
been identified (Miller et al., 1959). 
It is a highly specific proteolytic enzyme but will hydrolyse 
not only a fibrinogen substrate but also p- toluene sulphonyl -L- arginine 
methylester (TAME) (Troll et al., 1954), lysine ethylester and methylester 
and the lysylalanine bond in the oxidized B chain of insulin (Scheraga, 1958). 
It is adsorbed readily onto glass (Seegers et al., 1952) from 
which it can be removed with difficulty. Its activity is very sensitive 
to salt concentration, colloidal substances and calcium eoncentration 
(Seegers and Smith, 1942), and it tends to be unstable in low concentrations. 
In vivo, its activity is held in check by various powerful anti - 
thrombins only one of which is generally accepted as being of physiological 
- 12 - 
importance (Anti - thrombin III). 
(c) Factor III (Tissue Extract). 
Considerable investigation still has not clarified the nature 
of tissue extracts or thromboplastin. The consensus of opinion is that 
the active agent in thromboplastin preparations, whether derived from. brain, 
lung or placenta, is a lipoprotein, in which the lipoid partis closely 
related to cephalin (Chargaff et al., 1944) and has a high molecular weight. 
It converts prothrombin to thrombin in the presence of Factors V, VII and X, 
calcium chloride and phospholipid. 
(d) Factor IV (Calcium). 
Calcium is generally required in the coagulation process but 
its exact mode of action has not been clarified. 
(e) Factor V (Proaccelerin). 
Factor V is a trace plasma protein that is essential..for the 
rapid conversion of prothrombin to thrombin in the presence of a brain 
extract and calci gun. It is very labile and attempts at purification have 
been difficult (Lewis and Ware, 1953; Surgenor et al., 1961; Aoki, 1963). 
A preparation made by Esnouf (1963) was homogeneous on ultracentrifugation 
and its molecular weight was estimated to be 290,000 which was in agreement 
with Lewis (1964) who, using a Sephadex gel technique found a molecular 
weight for Factor V of over 200,000. The exact site of its bio- synthesis 
is not known with certainty but work by Barnhart and Ferar (1963) using 
fluorescent marker techniques suggest that the liver may be at least one 
site. 
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It is unstable in stored plasma and is very susceptible to the 
action of plasmin (Johnson et al., 1957; Ouchi et al., 1961). Deficiency 
of this factor results in a moderate bleeding tendency, and relatively few 
cases have been described (Biggs and McFarlane, 1962). 
(f) Factor VII (Proconvertin). 
Factor VII, a / globulin, which is closely related to coagulation 
Factors II, IX and X is produced in the liver. It is an accelerator in the 
formation of prothrombin activator by tissue extract (de Vries et al., 1949), 
and is present normally in serum. Little is known of its biochemistry due 
to its difficulty of separation from the other clotting factors (II, IX and 
X) and lack of homogenicity on purification, but its molecular weight has 
been estimated as lying between 50,000 and 100,000 (Lewis, 1964). 
Deficiency causes a rare haemorrhagic state, which has also been 
recognised in a colony of Beagle dogs (Gainer, 1967). 
(g) Factor VIII ( Antihaemophilic Factor). 
Antihaemophilic factor is probably a trace protein of normal blood 
the lack of which results in a clinical bleeding diathesis called haemophilia. 
.Patek and Taylor (1937) were the first to show that addition of a small 
amount of globulin to haemophilia blood corrected the defect and much 
subsequent work has been directed towards identification and purification of 
the active factor. Factor VIII migrates on electrophoresis with either the 
c2 (Barkhan et al., 1963) orle globulins (Van Creveld et al., 1956; 
Shinowara, 1964). The amibo acid composition is not known but some 
authorities have suggested that Factor VIII may be a lipoprotein (Blomback 
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et al., 1962a; Simonetti et al., 1964). Its molecular weight has been 
assessed as over 200,000 (Michael and Tunnah, 1966). 
Factor VIII is usually found in close association with fibrinogen 
from which it can be separated by curtain electrophoresis and other techniques. 
(Pavlovsky et al., 1961; Blomback et al., 1962; Rizza et al., 1965). It 
is unstable on storage and very sensitive to the action of plasmin (VTagner 
et al., 1959). In vitro experiments have demonstrated that there may be a 
link between the lysis productsof fibrinogen and Factor VIII activity 
(Triantaphyllopoulos and Triantáphyllopoulos, 1967). 
In vivo, the half life of Factor VIII is between 8 and 15 hours 
(Biggs and Denson, 1963; Pool et al., 1967), and the level above which 
normal haemostasis can be maintained is near 30¡á of normal plasma activity. 
Its site of production is not known; but recent work implicates the spleen 
and particularly the reticulo endothelial cells of the body (Webster et 
al., 1967). 
(h) Factor IX (Christmas Factor). 
Factor IX migrates on electrophoresis with the,g globulins, and is 
probably also synthesized in the liver. It is closely related in structure 
to Factors II, VII and X, and has a molecular weight of between 100,000 and 
200,000 (Lewis, 1964). It is required for the formation of blood 
prothrombin activator and its activity in vitro increases during clotting 
(Ratnoff and Davie, 1962; Cattan and Denson, 1964). Its deficiency 
results in a severe bleeding diathesis, closely similar to Factor VIII 
deficiency. 
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(i) Factor X (Stuart Prower Factor). 
The activity of Factor X can be found on electrophoresis in the 
of globulin fraction, has a molecular weight between 50,000 and 100,000 
(Lewis, 1964), and is present in plasma and serum in trace amounts. Its 
chemical structure is similar to others of the prothrombin complex, and it 
is also produced in the liver. It can be separated only with difficulty 
from Factors II, VII and IX, but pure preparations which are antigenic in 
rabbits have been obtained (Denson, 1967). The factor is named after the 
first two patients discovered in whom a deficiency was detected. 
(j) Factor XI (Plasma thrombo lastin antecedent). 
This factor has not been satisfactorily purified but migrates on 
electrophoresis between the, and Ó globulins, and one estimation of the 
molecular weight (Lewis, 1964) is between 100,000 and 200,000. It is 
present in plasma and serum and its absence causes a mild haemorrhagic 
disorder. It is converted to the activated form by activated Hageman 
factor, which in turn can activate Factor IX (Ratnoff and Davie, 1962). 
(k) Factor XII (rIa, eman Factor) . 
Human Iiagernan factor, a protein present in plasma in trace 
amounts, migrates upon electrophoresis between the, and globulins 
(Haanen et al., 1961), and has a molecular weight between 100,000 and 
200,000 (Lewis, 1964). A little is known of its chemical nature as 
Speer et al. (1965) has shown that end group analysis of the molecule 
reveals the presence of arginine and methionine. Complete amino acid 
analysis also demonstrated a high content of serine and glutamic acids, 
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and it is possible that Hageman Factor can be classed as glycoprotein 
as it also contains hexoses, hexosamines and sialic acid (Schoenmakers 
et al., 1965). 
Knowledge of the existence of Hageman Factor arose from the 
discovery of a patient, P,Tr. Jack Hageman, who was found to have a greatly 
prolonged clotting time but without any evidence of a haernorrhagic diathesis. 
Ratnoff (1954) was able to show clearly that the abnormality was due to the 
deficiency of a single clotting factor which was therefore named Hageman 
Factor, and its deficiency, TTageman trait. Many other patients exhibiting 
the coagulation anomaly have now been described and statistical analysis 
has shown that Hageman trait is inherited as an autosomal recessive 
characteristic (Margolis., 1956; McCain, 1959; Veltkamp, 1967). 
The presenting haematological picture of Hageman trait is 
characteristic. All tests involving the intrinsic pathway are abnormal 
and small amounts of normal plasma or serum will correct the deficit 
(Jim and Goldfein, 1957). The deficit is one confined to the initial 
stage of activation of the intrinsic pathway of coagulation. Contact 
activation of Hageman factor in vitro can be achieved by glass, kaolin, 
diatomaceous . earth, charcoal, ellagic acid and many other substances 
( Ratnoff, 1966). In vivo, the stimulus for activation of Hageman Factor 
is not known although Niewiarowski's observations (1964) that 
preparations of bovine collagen fibrils activate Hageman Factor suggests 
one method of action. The Hageman Factor is apparently adsorbed onto 
the activating surface, converting Factor XI into an activated form 
perhaps by an enzymic process (Ratnoff et al., 1961). 
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Considerable interest, however, has been aroused in other 
postulated biological functions of Hageman Factor. These include an 
effect on capillary permeability (Spector, 1957), the kinin forming system 
(Armstrong et al., 1954) and on fibrinolysis (Niewiarowski and Prou -Wartelle, 
1959; Iatridis and Ferguson, 1961, 1962b; Aznar et al., 1964). However, 
the significance of activation of Hageman Factor within the body is still 
unknown, as subjects with this trait do not appear to be particularly 
handicapped by the inability of their blood to react to contact activation, 
kinin formation or fibrinolysis. 
(1) Factor XIII (Fibrin Stabilizing Factor). 
Fibrin stabilizing factor (F.S.F., Factor XIII) is a plasma 
protein, migrating electrophoretically with theol2 globulins and having 
a molecular weight of about 350,000 (Loewy et al., 1961). Patients with 
a deficiency of this protein exhibit a severe bleeding diathesis and their 
fibrin clots lack the typical cross striation normally seen on electron 
microscopy (Duckert et al., 1960). F.S.F. may also be connected with the 
normal growth of fibroblasts (Beck et al., 1961). It can be found in a 
wide variety of tissues including brain, kidney, lung, liver and muscle 
(Tyler and Lack, 1964), and is also present in red blood cells and on the 
surface of platelets (Buluk and Ib'falofiejew, 1955; Luscher, 1957; 
Kiesselback and Wagner, 1966). 
Fibrin clots, stabilized by F.S.F. are insoluble in 5 M urea 
solution ( Laici and Lorand, 1948) and in monochloroacetic acid and methods 
of assay have been devised based on these properties (Duckert et al., 
1960; Sig, 1966; Das, 1968). Tyler and Lack (1965) have shown that 
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fibrinolysis may be affected by F.S.F. as clots formed in the absence of 
F.S.F. are more susceptible to lysis, perhaps by altering the ability of 
fibrin to adsorb plasminogen activator. 
(m) Platelets. 
An active substance known as Platelet Factor 3 has been extracted 
from platelets by Alkjaersig et al. (1955) and others. Such phospholipid 
preparations are known as partial thromboplastins and can also be extracted 
with chloroform from organs such as the brain (Bell and Alton, 1954). 
Phospholipid is essential for normal coagulation via the 'intrinsic' 
system. 
(n) Cryofibrinoen (Heparin Precipitable Fibrinój;en, H.P.F.) 
Cryofibrinogen is a clottable protein with physical and chemical 
properties similar to fibrinogen, but exhibiting the property of reversible 
precipitation on cooling (Lipinski, 1965). Its precipitation is enhanced 
by the presence of small quantities of heparin; it is then known as the 
Heparin Precipitable Fraction (H.P.F.) of plasma. Small quantities of 
cryofibrinogen can also be demonstrated in citrated or exalated plasma 
(McKay, 1964) . 
The first reports of a cold precipitable form of fibrinogen in 
the plasma of patients was made in 1946 by I. Morrison. He detected a 
substance .named_ "Contractinogen" that precipitated when some plasmas, 
particularly from those patients who had high erythrocyte sedimentation 
rates, were cooled. In 1948 a similar protein was found in normal plasma 
(P. Morrison et al.). The first extensive study of cryofibrinogen as 
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measured by the H.P.F. technique was made by Thomas (1954). Heparinised 
chilled plasma from rabbits submitted to an injection of endotoxin was 
found to contain a redissolvable precipitate and electrophoretic studies 
demonstrated its similarity to fibrinogen. Smith (1956, 1957), working 
in conjunction with Thomas, investigated H.P.P. in both normal subjects and 
patients with a variety of diseases. He was able to demonstrate H.P.F. in 
the plasma of normal individuals and in patients with inflammatory and 
necrotizing disorders. A gradual increase of H.P.F. throughout pregnancy, 
as well as low levels in newborn infants, was also noted. Reports soon 
followed of cryofibrinogenaemia in varied pathological states. It was 
demonstrated in diabetes, duodenal ulcer, and myocardial damage (Ritzmann 
et al., 1963); leukaemia and meningitis (Jager, 1962); lung cancer (Korst 
et al., 1955); cancer of the stomach, ovary and prostate ( Kalbfleisch et 
al., 1960; Kessel, 1960).; and in multiple myeloma (Henstill and Feinstein, 
1957). A form of primary idiopathic cryofibrinogenaemia was also reported 
with clinical symptoms of purpura, vascular occlusions and finger tip 
necrosis (Harville, 1966; Reiter, 1962; Harmel -Tourneur and Kalis, 1964; 
Robinson et al., 1966). McKay and Carey (1966), suggested that cryo- 
fibrinogen (H.P.F.) could be found in the blood of patients with diseases 
characterised by the deposition of fibrin either extra- or intravascularly, 
and regarded cryofibrinogenaemia as a hall -mark of disorders accompanied by 
intravascular coagulation. 
Despite considerable investigation, the exact nature of this 
cryofibrinogen remains uncertain. One source of confusion is the variety 
of cold precipitable proteins described as cryofibrinogen. Heparin will 
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precipitate a form of cryofibrinogen from plasma, but Smith and von Korff 
(1957) found that other heparin -like polysaccharides, e. .,sulphates of 
alginic and polymannuric acids and chondroitin sulphate, produced similar 
precipitates. Another substance very similar to H.P.P. is the Fibrinogen B. 
described by Lyons (1945). This is a coagulable protein precipitated from 
plasma under the influence of certain derivatives of naptho- quinone. This 
protein was not demonstrated in normal subjects but occurred in large 
amounts in similar types of disorders which are usually accompanied by 
increased cryofibrinogen (Dunn et al., 1949). Cryofibrinogen can also be 
demonstrated using other anticoagulants, e.g. E.D.W.A., citrate and oxalate, 
and using plasma or pure fibrinogen similar complexes can be formed by the 
use of alcohol (Godai and Abildgaard, 1966) and chondromucoprotein 
(Anderson, 1963). It is probable that all these substances represent 
combinations of fibrinogen, fibrinogen derivatives and other proteins, 
differing only in the proportions of the various components. 
Electrophoretic studies of cryofibrinogen (H.P.F.) have shown that 
its electrophoretic mobility is identical to that of fibrinogen (Smith and 
von Korff, 1957) and that traces of other proteins are usually present, 
such as prothrombin and proaccelerin ( Kalbfleisch and Bird, 1960). On 
ultra centrifugation of purified cryofibrinogen two peaks of constant 
sedimentation were observed and Korst and Kratochvil (1955) suggested 
that the protein was a form of partially polymerised fibrinogen, either in 
combination with fibrinogen or other plasma proteins, and was produced by the 
action of thrombin in vivo. 
Shainoff and Page (1960, 1962) prepared a form of cryofibrinogen 
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named cryoprofibrin from rabbit plasma by use of a Cohn alcohol fractionation 
process. According to their experience, subthreshold amounts of thrombin, 
constantly being formed intravascularly, split fibrinopeptide A from 
fibrinogen. This altered fibrinogen then polymerises with unaltered 
fibrinogen to form a complex soluble at high concentrations of fibrinogen 
at 37 °C, but insoluble at 4 °C, this being the definitive cryoprofibrin. 
Their studies have been most extensive and they further showed that if the 
complex polymer formed exceeded more than 10 -15% of the total fibrinogen 
concentration, as in some abnormal conditions, the solubilising capacity 
of fibrinogen was exceeded and fibrin conjugates of high molecular weight 
were precipitated (Shainoff and Page, 1964). This work was confirmed by 
Lipinski et al. (1964), and extended to show that cryofibrinogen was not 
simply a fibrinogen- fibrin complex requiring the presence of calcium for its 
precipitation but that fibrinogen degradation products were also present. 
These degraded fragments of the fibrinogen molecule, produced by the action 
of plasmin, were capable of co- polymerising with fibrin monomers. 
Particular interest has been re- aroused in cryofibrinogen, as 
related to the concept of disseminated intravascular clotting. Thomas's 
first work on cryofibrinogen was in endotoxin treated rabbits and the 
appearance of H.P.F. paralleled the-incidence of the generalized Shwartzman 
reaction. As a Shwartzman -like reaction is thought to occur in man (McKay, 
1962), it has been hypothesised (McKay, 1965), that "the appearance of large 
amounts of (heparin) cold precipitable fibrinogen ( cryofibrinogen) is a common 
feature of disseminated intravascular clotting ". However, few reports have 
become available in which cryofibrinogen has been assayed in humans 
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demonstrating features of the generalised Shwartzman reaction, and thus this 
concept, in man, has yet to be fully established. In vitro work, however, 
clearly shows that if suboptimal amounts of thrombin are added to plasma, 
i.e. insufficient to cause coagulation, cryofibrinogen formation is enhanced 
(Heinrich et al., 1963; van der Weerdt and Vreeken, 1965), but the in vivo 
significance of these observations are not yet clear. 
Thus the exact significance of cryofibrinogen awaits fuller 
investigation. In this thesis, it has been assumed that the measurement of 
H.P.F. reflects to some extent, changes in cryofibrinogen. However, the 
qualification must be made that measurement of H.P.F. may not necessarily 
reflect alterations in the cryoprofibrin of Shainoff (1962) which, from 
his results presented, is more likely to be the relevent measurement to 
assess in vivo thrombin activity (Shainoff, 1967). Cryoprofibrin assays are 
unfortlately much more difficult and require ultracentrifugation techniques. 
B. Fibrinolytic System. 
(a) Plasminogen. 
Plasminogen, the enzyme precursor of plasmin,is aid globulin 
with a molecular weight of either 83,000 (Davies, 1960) or 143,000 (Robbins 
and Summaria, 1963), and is present in the euglobulin fraction of plasma 
(Plilstone, 1941). It can be partly purified by treatment of Cohn 
Fraction III (Kline, 1953) and further purification has been achieved by 
chromatography (Hagan, 1960; Walldn and Bergström, 1960; Robbins and 
Summaria, 1964). There is some evidence that human plasminogen may be 
heterogeneous in nature, perhaps depending on its method of purification 
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(Rybak and Petakova, 1963; Alkjaersig, 1964), and this could explain the 
variability in the molecular weights found. 
Plasminogen is probably produced in the liver (Sherry, 1965) 
although Barnhart and Riddle (1963), from immunofluorescent studies, 
suggest that bone marrow cells and eosinophils may be the main source of 
supply. The control mechanism of its production is unknown, although steroid 
metabolism may be relevant (Pilgeram et al., 1964). 
Plasminogen has a strong affinity for fibrinogen and most 
purified fibrinogen preparations are contaminated to a greater or lesser 
degree. However, the fibrinogen can be separated by gel filtration (Berg 
and Korsan- Bengtsen, 1963). Plasminogen may be adsorbed to fibrin in vivo 
thus promoting optimal conditions for fibrin lysis (Sherry, et al., 1959b). 
Plasminogen is widely distributed in tissues, and is present in 
circulating blood at a level of 0.1 - 0.2 mgm. per ml. of plasma. 
(b) Plasmin. 
Plasmin, the fibrinolytic protein derived from its inactive 
precursor plasminogen, is a potent enzyme which will digest fibrin, 
fibrinogen, several of the coagulation factors (II, V and VIII), some 
components of complement,ACTH, growth hormone and glucagoh, as well as 
proteins from other sources such as casein (Sherry et al., 1959p). Its 
action is normally curbed by the presence of various antiplasmins 
(Christensen and Macleod, 1945; Norman, 1966). 
It has a molecular weight of about 107,000 (Shulman et al., 1958), 
but its structure awaits clarification. Plasmin probably splits the 
arginine and lysine bonds in proteins (Troll and Sherry, 1955). It digests 
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fibrin and fibrinogen at equal rates (Ratnoff, 1953), and its action in the 
proteolysis of fibrinogen will be considered further in a later section. 
(c) Plasminogen Activators. 
These are substances which will convert plasminogen to 
plasmin. 
(i) Physiological Activators. 
Plasminogen activators are widely distributed in body organs 
and fluids, and are named as to their site of origin. 
Tissue Activators. 
Most human tissues contain variable amounts of plasminogen 
activators, apparently located in the cytoplasm of cells (Astrup, 1951), 
and with the highest activity being found in the lysosmal fraction (Lack 
and Ali, 1964). The placenta and liver are notable for the lack of these 
enzymes, while the uterus, adrenals, prostate, lung, and lymph nodes contain 
very high levels (Albrechtsen, 1957). Activators have also been detected 
in milk, tears, saliva and urine. It had been considered that the tissue 
activators were stable and firmly bound to structural proteins requiring 
potassium thiocyanate for extraction (Astrup, 1947; Permin, 1950), but 
Albrechtsen (1958) was able to extract measurable amounts of activator from 
tissues by using physiological saline, suggesting that at least a part of the 
available activator was less firmly bound. 
Fibrinolytic activity in most normal human tissues, as assessed 
by a histological autograph preparation technique (Todd, 1958), is directly 
related to their vascularity, and particularly their content of veins and 
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venules (Todd, 1964). It is not yet clear if the fibrinolytic activity 
observed by this technique represents the total tissue content of 
plasminogen activator, and the relationship between the activity observed 
by Todd, tissue activator as assessed by thiocyanute extraction methods and 
blood activator, has not yet been clarified. 
Tissue activator from pig hearts has recently been isolated 
and purified (Bachman et al., 1964) but the preparation was still heterogeneous 
as assessed by electrophoresis and ultracentrifugation. Astrup and Kok 
(1965), were also able to prepare an activator from the ovaries of pregnant 
hogs, and this had a molecular weight of 58,000 and showed only two bands 
on starch gel electrophoresis. These preparations both showed certain 
physical and biological similarities to urokinase. Further biochemical 
investigation and purification will be of considerable interest. 
Tissue activators may make a significant contribution to 
circulating blood activator (Maki et al., 196) and be important in 
regulating the development of reparative connective tissue (Astrup, 1966). 
Blood Activators. 
Spontaneous fibrinolytic activity is a property of normal blood 
and the temperature labile factor responsible for this is a plasminogen 
activator. Activity is increased after a variety of physiological or 
pharmacological stimuli such as exercise or adrenalin (Biggs et al., 1947; 
Fearnley, 1952). Flute (1960) was able to separate electrolhoretically 
a fraction of normal plasma which had similar properties to blood activator, 
but little else is known about its physico- chemical properties. 
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Todd (1959), Warren (1963) and Kwaan et al. (1956a), all suggested 
that one site of production of plasma plasminogen activator was probably the 
endothelium of capillaries, venules and veins, and that both vaso active 
changes and anoxia are related to its release (Holemans et al., 1965). 
It is not yet clear whether blood activator is a form of tissue activator 
similar to that extracted by Albrechtsen (1958) from saline washes of 
tissues as differences in stability to physical conditions and chemicals 
appear to exist between these forms of plasminogen activators. 
There is some evidence that there may be a form of physiological 
control of the release of circulating plasminogen activator by neurogenic or 
hormonal mechanisms (Kwaan and McFadzean, 1956a, 1957; Schneck and Von 
Kaulla, 1961; Benetato et al., 1964). It is possible that a specific 
hypothalamic area is involved in this process. Other controlling mechanisms 
for circulating blood activator are poorly understood. Physiological stress 
such as exercise, pharmacological stimuli (adrenalin, nicotinic acid), 
will increase the levels of blood activator, while pregnancy decreases 
activity. There is now some evidence that specific organs may contribute 
to blood activator levels, particularly the kidney (Buluk and Furman, 1962; 
Holemans et al., 1967) and uterus (MacKay et al., 1967). However, the 
evidence regarding the release from the kidney is still controversial as 
Kucinski et al. (1968) were not able to demonstrate any difference in 
fibrinolytic activity between renal vein and inferior vena cavae blood. 
Activator is rapidly removed from the circulation apparently by the liver 
(Fletcher et al., 1964), or kidney (Celander and Guest, 1960; Holemans 
et al., 1966). The 50íó in vivo clearance rate of plasminogen activator is 
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only 13 f 5 minutes (Fletcher et al., 1964; Bachmann, 1966). 
The mechanism by which plasminogen activator produces thrombolysis 
has been a subject of extensive study, as it is known that fibrin dissolution 
can occur without the appearance of free plasmin activity in the circulating 
blood. At least three theories have been advanced. 
The first to be devised was that of Sherry et al. (1959). 
Plasminogen, which is normally in close association with fibrinogen, is 
trapped in the interstices of blood clots during their formation. Plasmino- 
gen activator penetrates into the clot and is actively adsorbed onto the 
fibrin (Sherry, 1154). Within the clot, the entrapped plasminogen is 
converted to plasmin with consequent local, but not systemic lysis. The 
function of circulating anti -plasmin in this situation is to neutralize 
any free plasmin that should arise. 
Another theory has been advanced by Ambrus et al. (1960). He 
proposed that small increases in the circulating levels of plasminogen 
activator produce plasmin which can subsequently be bound by antiplasmin. 
Upon contact with a clot, the plasmin -antiplasmin complex releases plasmin 
and this is transferred to fibrin, a substrate for which it has great 
affinity. In this scheme, circulating plasmin -antiplasmin serves as a 
reservoir of available plasmin for any substrate that has a greater 
affinity for plasmin than antiplasmin. 
Wolf (1968) recently proposed a theory for the physiological 
action of fibrinolysis, similar to that earlier suggested by Olesen (1965). 
It was postulated that plasminogen activator and anti- activator exist 
as an easily dissociable complex, and this complex dissociates during 
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the diffusion of plasma proteins through the clot. Antiplasmins and anti - 
activators penetrate the clot less rapidly due to their large and /or 
assymmetric molecules. Thus by diffusion and dissociation, plasmin is 
formed internally in the clot, with subsequent clot lysis. 
It is not proposed to discuss the pros and cons of these three 
theories as further investigation is required before definitive conclusions 
can be reached. Each, however, presupposes a key role for plasminogen 
activator in the physiological control of fibrin lysis. 
Urokinase. 
This physiological activator is present in normal urine, and can 
be purified (Ploug and Kjeldgaard, 1957; Fletcher et al., 1965) although 
contamination with thromboplastins has been a problem. It is now being 
utilized in thrombolytic studies on a small scale. Its physiological 
function could be to maintain patency of the urinary tract. It cannot 
be detected in peripheral venous or renal venous blood and is immunologically 
distinct from plasma activator, milk activator or tissue activators derived 
from the adrenals (Kucinski et al., 1968). 
(ii) Non -Physiological Activators. 
Streptokinase was identified by 1933 by Tillet and Garner, and 
has subsequently been purified for use in thrombolytic therapy. Initial 
material available was pyrogenic, but subsequent purification has reduced 
the incidence of such reactions. It is probable that streptokinase acts 
directly on plasminogen and /or plasmin converting it to an activator, at least 
in human plasma (Alkjaersig, 1964). Other non specific substances which 
-29- 
may cause plasminogen activation, at least in vitro, include peptones 
(Astrup and Olesen, 1957); urea (Von Kaulla and Smith, 1961); heparin 
( Halse, 1960); and protamine (Von Kaulla, 1952). 
Other activators have been identified such as those derived 
from liquid cultures of As er illas oryzae (Stefanini et al., 1959), and 
from cell free filtrates of staphylococci (Lewis and Ferguson, 1951). 
(d) Inhibitors of Fibrinol sis. 
These are substances of endogenous or exogenous origin that 
will inhibit the action of plasmin or plasminogen activators. The in vivo 
parameters of the inhibitor system are less clearly defined mainly due to 
technical problems in the purification of reagents. 
(i) Physiolorical inhibitors. 
Antiactivators. 
The separate existence of this type of inhibitor has not been 
proved as methods used for its measurement have not always distinguished 
it from antiplasmins. Some evidence exists for its presence (Lewis and 
Ferguson, 1951a; Kwaan et al., 1959; Flute, 1960; McNicol et al., 1963), 
but on the other hand Mann et al. (1966) could not demonstrate any discrete 
antiactivator activity in electrophoretically separated antiplasmin free 
human serum fractions. Further clarification is necessary. 
Antiplasmins. 
There are probably at least two antiplasmins in serum (Norman 
and Hill, 1958), one of which, an OC globulin, reacts rapidly as a 
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competitive inhibitor of plasmih, while the other in the 01 fraction reacts 
slowly to form an inactive complex. Another antiplasmin may exist in the 
gamma fraction (Moriau et al., 1964). Platelets also possess antiplasmin 
activity (Johnson and Schneider, 1953), and these may be of importance in 
in vivo resistance to clot lysis. Normal plasma contains a great excess 
of plasmin inhibitors, presumably to prevent excessive fibrinolysis. 
Calcium. 
The mechanism of inhibition by calcium is not fully understood. 
It is possible that calcium participates in the formation of an antiactivator 
and potentiates the action of antiplasmins (Bruce, 1964). It is of interest 
that calcium appears to have different effects in the coagulation and 
fibrinolytic systems. 
(ii) Non- Pjsiological Inhibitors. 
Tr sin Inhibitors. 
Both soybean trypsin inhibitor and pancreatic trypsin inhibitor 
have antiplasmin action and are used in research. 
Chemical Inhibitors. 
(a) E- aminoc proic acid E.A.C.A.). 
This is a potent, synthetic, competitive inhibitor of plasminogen 
activator (Ablondi et al., 1959), first investigated by Okamoto (1954). At 
very high concentrations it is a non -competitive inhibitor of plasma. Its 
efficacy in selected disorders of fibrinolysis has been well proved (McNicol 
and Douglas, 1964). 
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(b) Trasylol. 
This is a specific proteolytic inhibitor, extracted from bovine 
lungs, primarily inactivating plasmin but also preventing the activation of 
plasminogen. It also has an anti -thromboplastic activity (Amris, 1965; 
Nordstrom et al., 1967). Experience with its use in clinical conditions 
is growing (Dubber et al., 1965). 
(c) Aminomethyl Cyclohexane Carboxylic Acid (A.TI.C.H.A.). 
This is a competitive inhibitor of plasminogen activator at low 
doses and a non - competitive inhibitor or plasmin at high doses. It has 
about twice the potency of E.A.C.A. but experience with its use is 
limited (Dubber et al., 1965). 
(d) p- aminomethylbenzoic acid (P.A.M.B.A.). 
Investigated by Okamoto and Okamoto (1962), and Lohmann et al. 
(1964). It is similar in action to A.M.C.H.A. 
(e) Fibrin%Fibrinoyen Degradation Products. F.D.P.) 
The importance of these split products of fibrinogen or fibrin 
in syndromes of pathological haemostasis has only recently been recognized. 
A full description of the spectrum and origin of these products is included 
in Section 1:3. 
F.D.P. are derived by the proteolytic digestion of fibrin or 
fibrinogen by plasmin. Full digestion results in the formation of three 
classes of plasmin- resistant fragments. These include a fragment of 
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molecular weight 88,000 (the D fragment), another of molecular weight 
30,000 (the E fragment), and a heterogeneous collection of low molecular 
weight fragments (Nussenzweig and Seligmann, 1960). Once formed in vivo 
the products have a half life of 9.5 hours (Fletcher et al., 1962), but their 
mode of excretion or further degradation is not known. The D fragment has 
antithrombic activity (Niewiarowski and Kowalski, 1958; Alkjaersig et al., 
1962) as well as other effects on thromboplastin generation and platelet 
adhesiveness. 
F.D.P. can be demonstrated by an immunological technique in 
most normal sera (Das et al., 1967). 
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CHAPTER III. 
THE PHYSIC -PATHOLOGICAL CONCEPTS OF COAGULATION AND FIBRINOLYSIS 
Introduction. 
Both coagulation and fibrinolysis are intimately concerned with 
fibrinogen and fibrin. Recent research work has considerably clarified 
our knowledge of the proteolysis of these proteins by thrombin or plasmin; 
and as an understanding of these reactions is important in the interpretation 
of both physiological and pathological haemostatic changes, these subjects 
will be outlined in further detail before considering the postulated 
relationships between fibrin formation and lysis. 
1. The Proteolysis of Fibrinogen by Thrombin. 
The final step in the blood coagulation sequence is a complex 
but orderly reaction and has been studied extensively (Laki and Monmiaerts, 
1945; Lorand, 1951; Bettelheim and Bailey, 1952; Blombäck et al., 1962; 
Laki and Gladner, 1964). This process is known to occur in four main 
phases. 
Firstly, thrombin, a highly specific proteolytic enzyme, acts on 
the fibrinogen molecule splitting it at arginyl- glycine linkages (Scheraga, 
1961) into one major and several minor fragments. The minor fragments have 
been shown to be acidic polypeptides, and are named Peptides A and B 
(Bettelheim and Bailey, 1952). The molecular weights of these lie between 
1,000 and 2,500 (Gladner et al., 1959). This initial phase can also be 
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subdivided, as thrombin releases Peptide A much more rapidly than Peptide B, 
and this alone is sufficient to bring about coagulation (Lorand, 1965), as 
Fibrinopeptide B only appears after appreciable amounts of fibrin have been 
formed. Secondly, fibrin monomer units rapidly polymerise and form a large 
hydrogen- bonded aggregate that becomes insoluble and is the definitive fibrin 
polymer. Thirdly, activation of fibrin stabilizing factor (F.S.F.) by 
thrombin takes place ( Lorand and Konishi, 1962) in the presence of calcium 
ions. Lastly, bonding of the fibrin polymer takes place under the influence 
of the activated fibrin stabilizing factor. 
These phases may be summarised as follows :- 
thrombin 
1. Fibrinogen monomer and fibrinopeptides A + B. 
++ 
2. n(fibrin monomers)------)fibrin polymer. 
3. 
thrombin 
F.S.F. activated P.S.]?. 
Ca 
(, .5..). 





The first phase of this system has attracted great interest. For 
some time there was uncertainty as to the number of peptides released by the 
action of thrombin in its limited proteolysis of fibrinogen but further 
study, in a wide variety of different animal species (Blombäck, 1966) have 
demonstrated that two types of peptides, A and B, with few exceptions, are 
released. On chromatography two other peptides have been identified, 
peptides AP and Y, but these are regarded as being analogues. of the A. peptide, 
perhaps produced by the degradation of fibrinogen or fibrinopeptide either 
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in vivo or in vitro (Blombäck et al., 1966). Another analogue of the A änd B 
fibrinopeptides is the E peptide fraction found in bovine clot supernatants and 
these derivatives have subsequently been shown to be produced probably during 
isolation (Pirkle et al., 1966). The amino acids sequences of these peptides 
have been elucidated ( Blombäck et al., 1959; Folk et al., 1959; Sjoguist 
et al., 1960) and more than twenty different animal species have been worked 
out in the laboratory (Blombäck, 1967). For human peptide A and peptide B, 
these are :- 
Peptide A. 






Pyr -Gly- Val - Asp - Asp -Asp- Glu - Glu- Gly- Phe- Phe -Ser- Ala- Arg -OH 
The role of these peptides in physiological situations is an 
exciting new field for investigation, for not only may they act as homeostatic 
inhibitors in the clotting mechanism (Silver and Murray_,: 1966), but their 
release may be important in the control of the haemodynamics of the 
microcirculation. It has been shown that they potentiate the action of 
such substances as bradykinin and histamine (Osbahr et al., 1964, 1967) and 
have physiological effects when infused in minute doses on the blood flow 
of both the heart and lungs (Bayley et al., 1967). 
Phase 2. 
Thrombin attacks the fibrinogen molecule at a specific site, 
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considered to be the N- terminal end of the molecule (Blombäck, 1967). The 
resultant fibrin monomer can remain soluble in the blood stream but can also 
polymerise with unaltered fibrinogen in conjunction with F.S.F. to form a 
complex, soluble at high concentrations of fibrinogen at 37 °C but forming 
a cryoprecipitate at 4 °C (Sasaki et al., 1966) named cryoprofibrin by 
Shainoff and Page (1962). However, in this second stage of coagulation, 
the removal of the negatively charged peptide particles from the fibrinogen 
molecule usually appears to allow fibrin monomers to aggregate and in the 
presence of calcium, iEo._fórlp fibrin polymer (Lorand, 1965). Loss of the 
peptides may also open up hydrogen binding sites on the fibrinogen molecule 
allowing inter molecular binding (Scheraga, 1961). The fibrin units align 
themselves longitudinally, but in a staggered arrangement, giving rise to a 
periodicity characteristic for fibrin when viewed by electron microscopy 
(Hall and Slayter, 1959; Bang, 1964). This formed fibrin polymer is not, 
however, strong enough to fulfil its physiological functions, and stabilisation 
of the molecule can only be achieved when crosslinks are formed. 
Phases 3....4a1 A. 
In plasma this occurs in two stages; the initial action is of 
thrombin activating fibrin stabilising factor (Blombáck and Doolittle, 1963), 
followed by the activated F.S.F., apparently through a transpeptidating 
mechanism (Lorand, 1965), firmly linking longitudinally arranged fibrin polymers 
together, thus completing the normal fibrinogen to fibrin transformation. 
This bonded fibrin is also now less susceptible to lysis (Tyler and Lack, 
1965). 
This carefully elucidated sequence of events has clarified an 
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important aspect of coagulation, and aids in the explanation not only of certain 
clinical occurring coagulation anomalies but also many of the differences 
occurring in physical measurements between fibrinogen and fibrin as assessed 
by immunoelectrophoresis, electron -microscopy and protein finger printing 
(Blombäck, 1967). 
2. The Proteolysis of Fibrinogen by Plasmin. 
The enzyme plasmin degrades fibrinogen (molecular weight 340,000) 
sequentially into at least three classes of fragments. These comprise 
(a) a large molecular weight derivative (265,000) which although clottable 
by thrombin has an altered molecular configuration and clots slowly and 
abnormally (Fletcher et al., 1966); (b) intermediate fibrinogen derivatives 
ranging in molecular weight between 200,000 and 100,000, these products 
demonstrating varying degrees of thrombin clottability, and (c) the final 
plasmin- resistant derivatives consisting of a fragment of 88,000 molecular 
weight (the D fragment named after its fibrinogen antigenic determinant), a 
fragment of 30,000 molecular weight (the E fragment), and a variety of low 
molecular weight non -antigenic fragments. These final groups of plasmin 
resistant molecules have been extensively studied (Nussenzweig and Seligmann, 
1960; Alkjaersig et al., 1962), chromatographically (Nussenzweig et al., 
1961), electrophoretically (Fletcher et al., 1966) and quantitatively 
(Ferreira and Murat, 1963), and are usually referred to as fibrinogen /fibrin 
degradation products (F.D.P.). 
Defective fibrin polymerisation is a term used to describe the 
coagulation anomaly characterised by the appearance in the circulation of 
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these plasmin derived fragments (Fletcher et al., 1966) from either fibrin 
or fibrinogen. Two types of defective fibrin polymerisation are 
recognised: 
(i) Proteolysis of fibrinogen initially produces fibrinogen 
derivatives which are still thrombin clottable although slowly and 
defectively. This slow clotting phenomena may be explained on the basis 
of a molecular alteration that shields thrombin susceptible sites from 
proteolysis, or by a concept that the altered molecule, although susceptible 
to normal thrombin action, polymerises poorly (Fletcher et al., 1966). 
(ii) With the appearance of the non -clottable smaller molecular 
size (D and E) fibrinogen fragments and their bonding with fibrin monomer 
to forni a complex, sufficient bonding sites are not available to link 
completely with other fibrin monomers. Polymerisation therefore is slow 
and defective with the formation of a morphologically inadequate clot (Bang 
et al., 1962) which also has a marked deficiency of mechanical strength 
(Hirsch et al., 1965). 
It has now become apparent that the detection of abnormal fibrin 
polymerisation states is of considerable clinical importance. Using 
immunoelectrophoretic and immunodiffusion techniques, Fisher et al. (1967) 
were able to identify,in patients with very mild proteolysis, the appearance 
of large early fibrinogen derivatives before the development of other 
biochemical abnormalities. Thus biochemical recognition of defective 
fibrin polymerisation in its very earliest stages is now possible on a 
research basis. Much more work has been focussed on the plasmin resistant 
fragments (D and E) and their measurement has been of considerable clinical 
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use in the diagnosis of defective fibrin polymerisation (Ferreira and Murat, 
1963; Nilehn and Nilsson, 1964; Merskey et al., 1966), associated with 
disseminated intravascular coagulation (McKay, 1965). 
The liberation of split products of fibrinogen may also affect 
other haemostatic factors, besides fibrin polymerisation. They may have 
an antithrombic effect (Niewiarowski and Kowalski, 1958; Triantaphyllopoulos 
and Triantaphyllopoulos, 1966), an anti -thromboplastic effect ( Niewiarowski 
et al., 1959; Nilehn, 1967), and also affect the..adhesiveness of platelets 
(Kowalski et al., 1963). 
In this thesis considerable attention has been directed to the 
changes occurring in both physiological and pathological situations, of the 
plasmin resistant moieties, i.e. the D and E fragments of fibrin, usually 
referred to as fibrin /fibrinogen degradation products (F.D.P.). 
The proteolysis of fibrinogen by plasmin or thrombin may be 
summarised in Fig. 1:3. 
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THE PROTEOLYS I S OF FIBRINOGEN BY THROMBIN AND PLASMIN 
Fig. 1:3. 
- 41 - 
3. The Coagulation- Fibrino1bic Equilibrium. 
It is axiomatic that continuous coagulation and fibrinolysis 
must proceed in vivo at a balanced speed, if normal tissue maintenance and 
structural integrity is to be preserved. Whether normal vascular patency 
also depends on a similar process is, however, debatable. It is evident 
that some such mechanism must be present to maintain blood fluidity but clear 
definition is still evasive despite much research. 
Astcup (1956) summarised and extended the views already put 
forward by Nolf (1908) and Copley (1954), that the two systems were in a 
continuous dynamic balance of fibrin deposition and removal. In its 
fullest concept it was envisaged that fibrin deposition was a continuous 
in vitro process, in which the endothelial lining of blood vessels were coated 
with a thin layer of fibrin continually being removed by the action of the 
fibrinolytic system, thus ensuring the patency of the blood vascular system. 
Disturbances of this fine balance would result in excessive bleeding on one 
hand,and ä thrombotic tendency on the other. There was considerable evidence 
to support such a view and the hypothesis has subsequently stimulated much 
research. The concept was strengthened by knowledge of the known very short 
half lives of the coagulation factors (Bowie et al. - review - 1967), the 
demonstration of a layer of fibrin on the walls of some blood vessels 
(Copley, 1954; Woolf, 1961), and the finding of active fibrinolysis in 
normal blood. Contrary to the hypothesis was the finding of a normal 
turnover of clotting factors in patients treated with anticoagulants (Lewis 
et al., 1961), the lack of intravascular thrombi formation in subjects on 
fibrinolytic inhibitors (Gajewski and Alexander, 1963; Lewis, 1963), the 
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absence of continuous spontaneous bleeding and the normal turnover of 
clotting factors in patients with hereditary clotting defects (Adelson et al., 
1961; Rausen et al., 1961; Hart, 1965), and the fact that fibrin cannot be 
demonstrated or normal endothelium (Woolf and Crawford, 1960). 
The two sides of this convenient hypothesis have been summarised 
adequately in 1961 and 1965 by P.J. Hjort. Further evidence both for and 
against the hypothesis is still becoming available (Das et al., 1967; 
Regoesczi, 1967; Regoesczi and Walton, 1967) and it is likely that the 
theory will become considerable modified. Many authorities now agree that 
the mechanism is essentially designed for local action and that a continuous 
dynamic balance, as originally envisaged is less likely (Astrup, 1967). The 
role of the reticule endothelial system in the removal of intermediate 
derivatives of coagulation is probably also of considerable importance 
(Spaet, 1966). 
It is still possible however, that in vivo thrombin activity may 
occur continuously. Adelson (1965) and Laki (1968) suggest that partial thrombin 
polymerisation of fibrinogen with release of polypeptides may occur normally 
in the circulation. Direct proof of this is lacking but demonstration of 
these peptides in normal subjects would be of considerable interest. 
Shainoff and Page (1964) have also proposed that monomers of fibrinogen can 
also occur in the blood stream, and these may be linked with fibrinogen 
molecules in soluble conjugates which, under certain conditions, may precipitate 
as fibrin. 
Very little is known as to the overall controlling mechanisms of 
the coagulation and fibrinolytic systems. Although it is evident that hormonal 
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changes, as in pregnancy or in exogenous oestrogen or progesterone treatment, 
probably influence the absolute levels of both clotting and fibrinolytic 
factors, the physiological role of these and other hormones is unknown 
(Thompson and Poller, 1965; Brakman et al., 1967). There is some 
evidence that neural pathways may, in some way, modify the systems 
(Kudrjashov, 1959; Markosian and Yakounine, 1961; Gunn and Hampton, 1967; 
Correll, 1968), but little accurate information is available. 
4. Disseminated Intravascular Coagulation. (D.I.C.) 
The concept of disseminated intravascular coagulation as an 
intermediary process in many separate disease processes, has been 
developed in recent years by the experimental work and clinical observations 
of both McKay (1965) and Hardaway (1966). It may be regarded as a logical 
extension of the postulated theory of a physiological balance between 
coagulation and fibrinolysis, with a marked shift in equilibrium resulting in 
the pathological formation of fibrin and a subsequent activation of fibrinolysis. 
Its full description, however, includes more than the simple formation of a 
thrombus and McKay and Muller- Berghaus (1967) have defined it adequately as 
"a biological process involving many chemical substances and physiological 
responses. It begins with the entry of a pro -coagulant material or activity 
into the circulating blood; progresses to the stage of platelet aggregation 
and fibrin formation which may or may not result in thrombosis of capillaries, 
arterioles and venules of various organs; it is associated with activation of 
the fibrinolytic system, with dissolution of fibrinogen and fibrin and the 
_q4_ 
release of fibrin split products into the plasma; and is not complete until 
the haemostatic mechanism and vasomotor apparatus have returned to normal, and 
the last significant amount of fibrin split product has been cleared from 
the blood." 
The degree of D.I.C. occurring may vary greatly. Although it 
is possible that minor degrees of D.I.C. may occur in response to physiological 
stresses, the syndrome has been most commonly recognised in pathological 
states associated with haemolysis, release of tissue thromboplastins, 
bacterial endotoxins, proteolytic enzymes, anoxia and anoxemia and endothelial 
damage. In some patients, intravascular coagulation may be dominant, while 
in others, fibrinolysis overshadows the initiating coagulation process. The 
laboratory findings usually include diminution of clotting factor levels, and 
evidence of activation of fibrinolysis. The demonstration of fibrin split 
products is strong confirmatory evidence. The degree of change found in 
these parameters may vary widely, and this may depend to some extent on the 
severity of the disease process and the clinical stage at which blood is 
tested. 
It is possible that the pathological sequelae of D.I.C. occur; 
only when the total capacity of the body's reticulo endothelial and 
fibrinolytic systems are unable to cupe rapidly with the clearance of 
coagulation intermediates and fibrin. Such would appear to be the case 
in obstetric emergencies,, e.g.. amniotic fluid embolism and abruptio placentae, 
and perhaps also in incompatible blood transfusion reactions. In other 
situations, the initiating mechanism is not always so clearly defined, but 
may be related to anoxia, intravascular haemolysis and the local release of 
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tissue t'nromboplastins. 
Well documented reports of D.I.C. have become available in such 
varied conditions as carcinomatosis, acute leukaemias, overwhelming infections, 
thrombotic thrombocytopenic purpura, severe.. shock, following extra corporeal 
circulation, snake venom poisoning and many others (Sherry, 1966). It is 
likely that identification of D.I.C. will increase as methods of recognition, 
such as F.D.P. assays, become generally available. 
Although the concept clarifies many aspects of abnormal haemostasis, 
it is still necessary to avoid over interpretation of its incidence or 
importance as some of the experimental work on which the theory is based 
may not be necessarily applicable to disease in man. Nevertheless, it is 
providing a significant focus for further research into the causes of 
haemorrhage and thrombosis and will almost certainly provide new advances 
in present therapeutic regimes. 
5. Shwartzman Reactions. 
The classical generalised Shwartzman Reaction is produced in 
young rabbits by the intravenous injection of Gram-negative endotoxin spaced 
24 hours apart. After the first injection a few fibrin thrombi may be found 
in liver, lungs and spleen. After the second injection fibrin thrombi can be 
detected in glomerular capillaries and splenic sinusoids, resulting in 
bilateral renal necrosis and splenic haemorrhage and necrosis (Thomas and 
Good, 1952). 
Thrombin (Lee, 1962) or antigen -antibody reactions (Lee, 1963) 
can substitute for the second "provoking" injection. The first ( "preparing ") 
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injection can be replaced by pregnancy (Apitz, 1935), ep.sílon -amino caproic 
acid (Lee, 1962), steroids (Thomas and Good, 1952), and "Thorotrast" (Good and 
Thomas, 1952). The reaction is regarded as being caused by acute intra- 
vascular coagulation, and heparin protects against the reaction (Good and 
Thomas, 1952). 
This classical reaction can occur in man as evidenced by 
therapeutic misadventures whereby repeated doses of typhoid vaccines were 
administered for other purposes. At least three patients died with severe 
liver and renal damage; the latter disorder reported as acute tubular 
necrosis (Lewis, 1941; Urbach et al., 1944; Love and Driscoll, 1945). 
However, it is now clear that the complete Shwartzman reaction is rare in 
human diseases, but modified forms do appear in certain clinical conditions 
associated with disseminated intravascular coagulation. The most common 
examples are those associated with complications of pregnancy, such as 
premature placental separation and septic abortions. 
This concept, as applied to human diseases, has created considerable 
scope for research, to which must be added areas of the work included in 
this thesis. 
6. Fibrinolysis and Occlusive Vascular Disease. 
If fibrinolysis is the physiological antithesis of coagulation, 
its study should be relevant to the problems of occlusive vascular disease. 
Rokitanski (1842) suggested that deposits of fibrin on the arterial wall 
caused atherosclerosis,and Astrup (1956) linked this theory with the 
dynamic equilibrium hypothesis of haemostasis and also to that of Duguid 
(1949, 1955), who had revived the idea of fibrin being an aetiological factor 
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in arterial degenerative disorders. The factors affecting the resolution of 
fibrin could therefore be of some significance and considerable effort has 
been undertaken to assess the relevance of depressed fibrinolytic activity to 
occlusive vascular disease. Many of these studies have proved unrewarding 
and controversial (Hume, 1958; Nestel, 1959; Lackner and Merskey et al., 
1960; Ogston, 1962; Naimi et al., 1963; McKay and Hume, 1964) although 
evidence has accumulated to suggest that men with arteriosclerosis of the 
lower limbs have a greater evidence of defective fibrinolysis than controls 
(Fearnley at al., 1964). 
The results in coronary heart disease have been discordant 
although the most recent work by Chakrabarti et al. (1968) does suggest 
that significantly depressed fibrinolytic activity is found in patients 
with coronary artery disease up to the age of 60. If the results of this 
study can be substantiated, prophylactic treatment of selected patients with 
drugs (or onions - Menon et al., 1968) that enhance fibrinolysis might become 
a clinical reality. However, much more systematic study is required 
using more specific techniques, before definitive conclusions can be drawn 
on the postulated relationship between decreased fibrinolytic activity and 
occlusive vascular disease. 
SECTION 2. 
ADIS OF PROJECT AND INTRODUCTORY REVIEW. 
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SECTION 2. 
AIMS OF PROJECT AND INTRODUCTORY REVIEW 
AIMS OF PROJECT. 
This thesis has three main objectives in view. 
1. The development, refinement and standardisation of a wide 
range of coagulation and fibrinolytic assays, to a level suitable for 
research into physiological and pathological states. 
This work is described in Section 3. 
2. The further investigation and extension of previous research 
work on the "fibrinolytic reactivity" to various stimuli, in both normal 
and pregnant subjects. 
This work is described in Sections 4 and 5. 
3. The collection of the normal values for pregnancy of the 
various fibrinolytic parameters as performed in this laboratory, as a guide 
to the further interpretation of pathological variations occurring in the 
haemostatic mechanism. 
This work is described in Section 5. 
At this juncture, it is appropriate to review briefly the concept 
of "fibrinolytic reactivity" as originally developed in this laboratory. 
This concept will be referred to and elaborated in the discussions associated 
with each subsequent chapter. 
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INTRODUCTORY REVIEW. 
The concept of the reactivity of the fibrinolytic system being 
of relevance in physio- pathological situations is not new. Fearnley et al. 
(1951) first attempted to investigate this hypothesis using injections of 
adrenalin, but met with little success, probably as a result of the inadequacies 
of methodology at that time. It was not until 1966 that work in this 
laboratory defined the concept of fibrinolytic reactivity more clearly 
(Cash, 1966). Using exercise and adrenalin infusions, and measuring changes 
in euglobulin lytic activity with carefully controlled techniques, it was 
shown that fibrinolytic response in an individual was a reproducible phenomena, 
and that responses in an apparently healthy population followed a normal 
distribution, with both high, moderate and low responders. It was also 
demonstrated that the response of each subject was similar when different 
stress methods were used, i.e. a low responder would remain in this category 
when stimulated with either moderate or severe exercise, or adrenalin (Cash 
and Allan, 1967; . Cash and Woodfield, 1967) . 
From this work, it was postulated that the poor fibrinolytic 
responder might be more susceptible to conditions in which either focal or 
disseminated intravascular coagulation could occur. The ability to rapidly 
generate plasminogen activator to stress procedures could thus conceivably 
be an aetiological factor in the pathogenesis of such disorders as atheros- 
clerosis, irrerereible shock and thrombosis, conditions in which a defective 
fibrinolytic system has been suggested as playing some part. 
The evidence for a fibrinolytic response being of significance 
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in patho -physiological events was, however, meagre. If it could be shown 
that other physiological stimuli could affect the fibrinolytic response, or 
that patients with vascular pathology also exhibited impairment of response, 
this would be at least some proof of the hypothesis. Both these facets were 
subsequently studied and it was discovered that the fibrinolytic response could 
be modified by mental stress (Cash and Allan, 1967) and was lowered in 
diabetics (Cash and McGill, 1968). 
It was from these studies that the present work was developed. 
Assuming the coagulation and fibrinolytic systems are dynamically balanced, 
it was suggested that the poor fibrinolytic responder might not necessarily 
be at risk if the coagulation system was compensating by forming less fibrin. 
The reactivity of the coagulation system to exercise stresses and prolonged 
adrenalin infusions were therefore investigated and the results have been 
documented in this thesis in Sections 4 :1.,2. Also, in view of the modification 
of the fibrinolytic response to mental stress, and the accumulated evidence 
that the neural system could be involved in the control of coagulation and 
fibrinolysis, the effect of 4-receptor adrenergic blockade on these systems, 
were also studied. 
It was also possible that the fibrinolytic response could be relevant 
in clinical conditions associated with episodes of disseminated intravascular 
coagulation. In pregnancy, the incidence of this complication is relatively 
high, and an investigation was therefore undertaken of the fibrinolytic 
reactivity of pregnant women to exercise stress, this being documented in 
Section-5:2. Concurrently, the normal values of fibrinolytic parameters 
at the varying stages of gestation were assessed (Section 5:1). 
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In a further study (Section 5 :3), the reaction of the fibrinolytic 
system to an operative surgical stress, both in the pregnant and non -pregnant 
state, was intensively investigated. Such a study extended even further 
than the concepts of the fibrinolytic response, and it was considered that 
the results could be of relevance to both clinical bleeding and thrombotic 
disorders. 
Finally, patients in whom the syndrome of disseminated intravascular 
coagulation had occurred were carefully investigated using all available 
coagulation and,fibrinolytic assay techniques (Section 5:4). This study 
assessed, in a more general sense, the reactions of both the coagulation and 
fibrinolytic systems to a pathological stress. 
In these studies, use has extensively been made of a recent 
developed technique for the measurement of fibrinogen /fibrin degradation 
products (Merskey et al., 1966). This assay undoubtedly introduces a new 
approach to both the physiology and pathology of the haemostatic mechanism 
but also raises fundamental problems in our previously held conceptions of 
the coagulation and fibrinolytic systems. 
A fuller discussion of the various separate but interrelated 









Oertling R.20. L. Oertling Ltd., Orpington, Kent. 
2. Centrifuges. 
(a) B.T.L. Bench centrifuge, C 6/0075. 
Baird and Tatlock Ltd., Chadwell Heath, Essex. 
(b) M.S.E. Mistral 4L, refrigerated centrifuge. 
Measuring and Scientific Equipment Ltd., London, 
England. 
(c) M.S.E. Minor bench centrifuge. 
Measuring and Scientific Equipment Ltd., London, 
England. 
3. pH Meter. 
Beckman Zeromatic, Beckman Instruments Ltd., Glenrothes, 
Scotland; with glass electrode supplied by Activion.Glass Ltd., 
Kinglassie, Fife, Scotland. 
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(c) Pyrex Glass Centrifuge Tubes - 10, 50 and 100 ml. 
(d) Glass Pipettes 0.1 - 25.0 ml. Trademark "E -Mil ", 
H.J. Eliot Ltd., Glamorgan. 
(e) Plastic tubes, made of clear polystyrene and produced by 
Teklab Laboratories, Hockley, Essex. 
9. S rimes and Needles. 
(a) Disposable plastic syringes (2 -50 ml.). Plastipak, 
produced by Becton, Dickinson & Co., Drogheda, Ireland. 
(b) Glass syringes (50 ml.). Sterilised in a hot air oven in 
special packs. 
(c) Needles: 20G x 1i sterile disposable; Becton, Dickinson & Co. 
21G x 12 sterile disposable; Gillette Scimitar, 
Middlesex, England. 
10. Microtiter set. 
Produced by Cooke Engineering Company, 735 North Saint Asaph. Street, 
Alexandria, Virginia 22314, U.S.A. 
The Microtiter Kit consisted of :- 
(a) Lucite transparent plates, each containing 96 conical bottom wells. 
(b) Calibrated pipette droppers (delivery volume 0.025 ml.) made of 
semi -transparent polypropylene with stainless steel droppers. 
(c) Microdiluters, made of stainless steel and calibrated to deliver 
0.025 ml. 
(d) A multi- microdiluter gun, this instrument enabling rapid performance 
of dilution processes. 
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4. 12ectrophotometer. 
Unicam S.P.600. Unicam Instruments Ltd., Cambridge, England. 
5. Coaoulometer. 
Four channel automatic clot timers built by Depex, de Bilt, 
Holland, were used. Full details are included in Section 3:4. 
The electrode cleaner for the machine was built in the department. 
6. Clot 1Sis Recorder. 
A twelve channel clot lysis recorder designed within the 
laboratory was used (Cash and Leask, 1967). The apparatus records 
in graphical form, the alterations occurring in optical density as 
lysis occurs in plasma clots. 
7. Constant Infusion Pump. 
Harvard two channel constant infusion pump with variable 
infusion speeds. 
8. Glass and Plastic Ware. 
(a) Clotting tubes (5" x 2"; 3" x 24'; 52.5mm x 11.5mm). 
Tubes selected for use were produced by Samco, 
S. Murray & Co., Old Woking, Surrey. These were 
of plain glass and were not washed prior to use. 
They were siliconised as required, by the method 
outlined in the Appendix. 
(b) Test tubes (5" x i"; 5" x á") 
Plain glass. 
Washing procedure as per Appendix. 
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11. Glass Cuillary Tubes. 
Produced by British Drug Houses, Poole, England. Length 10 ems., 
internal diameter 0.1 cm. 
12. Petri Dishes. 
Supplied by Staynes Laboratories Ltd. Each dish had an internal 
diameter of 8.8 ems. and was disposable. 
B. Reagents. 
1. Fibrinogen. 
(a) Human and Bovine fibrinogens. 
A preparation supplied by Labi Pharmaceuticals, Ealing, 
London, was used. The fibrinogen had a clottability of 94 and was 
prepared by the method of Blomback and Blomback (1956). 
(i) For use in fibrin plate assay method. 
7.5 gm. of fibrinogen was added to 500 ml. of tris buffer 
pH 7.8. The fibrinogen was dissolved at 37 °C with gentle stirring, 
and then stored in small aliquots in plastic tubes at -40 °C. 
For use, this 1.5 gm./0 fibrinogen solution was diluted 1 in 10 
in buffer. 
(ii) Standard reference preparations for F.D.P. assay. 
Fibrinogen was diluted to concentrations of 5, 2.5 and 
1.25 mgmfml. in buffer and stored in small aliquots at -40 °C. 
(b) Bovine fibrinogen. 
As supplied by Diagnostic Reagents Ltd., Thame, Oxon, for 
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use in coagulation techniques. Batch Numbers F.N. 31 - 33 were used. 
2. Thrombin. 
(a) Bovine Thrombin. 
Supplied by Parke Davis & Co., Detroit, Michigan, U.S.A., 
containing 5,000 N.I.H. units per vial. It was diluted to varying 
concentrations for different tests. 
(i) Euglobulin lysis time assay. 
A solution of 5 U /ml. in veronal acetate buffer (pH 7.4) 
was made, and small aliquots were stored in plastic tubes 
at -40 °C. 
(ii) Fibrin plate assay. 
A solution of 50 U /ml. in tris buffer (pH 7.8) was made 
and small aliquots were stored in plastic tubes at -40 °C. 
(iii) Fibrinogen assay (Ellis and Stransky method) 
A solution of 10 U /ml. was made in 0.9/2 saline, and to this 
was added an equal volume of 1.12 M solution of calcium chloride. 
Aliquots were stored in plastic tubes at -40 °C. 
(b) Human Thrombin. 
Supplied by the Blood Products Laboratory, Lister Institute, 
Elstree, Herts (Batch Number 545D). This was used for coagulation 
techniques and was diluted to a concentration of 50 U /ml. in tris 
buffer (pH 7.4) and stored in small aliquots at -40 °C. For use, it 
was diluted in buffer to give a clotting time on normal pooled plasma 
of between 12 and 15 seconds. 
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3. Thromboplastin. 
A phenolised suspension of rabbit brain thromboplastin as supplied 
by Diagnostic Reagents Ltd. was used. Batch Numbers. K.B. 60 - 62. 
4. Arvin Snake Venom. 
Supplied by Twyford Laboratories Ltd. in ampoules containing 
0.9 ml. of specific activity 82 units /ml. Batch No. T.80. 
5. Phospholinid. 
Prepared according to Bell and Alton (1954), and supplied by 
Diagnostic Reagents Ltd. Batch Numbers R.B. 19 and 20. 
6. Kaolin Platelet -Substitute Reament. 
Supplied by Diagnostic Reagents Ltd. Batch Numbers 0.14 - 0.22 
were used and fuller description of reagent is included 
Section 3:2. 
7. Purified Factor V. 
Supplied by Diagnostic Reagents Ltd. Batch Numbers F.B. 23 - 25. 
8. Russell's Vi er Venom Ce halin Mixture. 
Supplied by Diagnostic Reagents Ltd. Batch Numbers R.C. 19 - 21. 
9. Heparin B.P. 
Evans Medical Ltd., Speke, Liverpool. Ampoules of 5,000 I.U. /mi. 
were diluted in saline to a concentration of 20 U /ml. and stored at 4 °C. 
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10. Urokinase. 
The standard preparation used was produced by Leo Pharmaceuticals, 
Denmark. Vials containing 2,400 Plough Units were diluted to 3 units /ml. 
in tris buffer pH 7.8, and aliquots were stored at -40 °C in plastic tubes. 
11. Aluminium Hzdroxide moist gel. 
British Drug Houses, Poole, Dorset. For use 5 gins. of gel were 
suspended in 20 ml. of distilled water and stored at 4 °C. 
12. alite ...Lia. 
Johns Manville & Co. Ltd., New York, U.S.A. 1.0 gm. was 
suspended in 10 ml. of 0.94 saline prior to use. 
13. Molar Calcium Chloride. 
British Drug Houses. This solution was diluted as required to 
0.025 M and 0.05 M concentrations. 
14. Collation Factor Deficient Substrate Plasmas. 
(a) Factor VIII, IX and XII deficient plasmas. 
These were collected from patients Down to have severe 
coagulation factor deficiencies. Blood was spun at 3,200 r.p.m. at 
4 °C for 30 minutes, the plasma separated and stored in aliquots of 
1.7 ml. in plastic tubes at -40 °C. Plasma for Factor XII assays was 
obtained from Professor E. Loeliger, Leiden, Holland. 
(b) Factor V deficient lasma. 
This was artificially prepared as described in 
Section 3:2. 
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(c) Factor X assa substrate plasma. 
Supplied by Diagnostic Reagents Ltd. Batch Numbers 
C. 65 - 71. 
15. Fibrinogen Antisera. 
Rabbit anti -human fibrinogen antisera was obtained from 
Hoeschst Pharmaceuticals Ltd., Brentford, Middlesex. Batch Numbers 
A.C. 806 and 1202 M were used. The antisera was diluted 1:500 in 
0.15 M citrate buffer (pH 6.4) containing sodium azide (1 mgm /ml.) and 
adsorbed horse serum 1 :250 and stored in small aliquots at -40 °C. 
16. Trasylol. 
Obtained from Farbein Fabriken Bayer A.G., Germany, in vials 
containing 25,000 F.I. Units in 5 ml. 
17. Sheep Red Cells in Alsevers Solution. 
Supplied by Burroughs Wellcome & Co., London. Stored at 4 °C. 
18. Buffers. 
As in Appendix. 
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CHAPTER II. 
COAGULATION TECHNIQUES. 
For the investigation of blood coagulation most techniques were 
carried out at 37 °C in a water bath or heating block. Dilutions of plasma 
as well as certain reagents were kept on melting ice in a water bath at 4 °C. 
1. Whole Blood Clotting Time. (W.B.C.T.) 
The method was similar to that of Lee and ;Trite (1913) but as 
described by Macfarlane and Biggs (1962). 
The technique was as follows :- 
(a) Glass Clotting Time. 
Three new, unwashed, non -rinsed 3" x 2" test tubes were placed 
in a water bath at 37 °C. Venous blood was obtained by careful venepuncture 
and minimal venous occlusion, using a plastic syringe with a needle of gauge 
size 20. A stopwatch was started as the blood entered the syringe; 1.0 ml. 
of blood was then transferred to each clotting tube. The tubes were left 
undisturbed for 4 minutes, then tilted gently at 30 second intervals until 
unequivocal solidification had occurred. The clotting times of the three 
tubes were recorded and the average of these tests was taken as the clotting 
time. The mean value of 15 estimations on normal subjects in the 20 - 30 
year age range was 3.9 ± 1.6 minutes. 
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(b) Silicone Clotting Time. 
The technique was identical to the above with the exception that 
siliconized tubes (I.C.I. M550 silicone in trichlorethylene), were used and 
these were left undisturbed after the addition of blood for 12 minutes. The 




2. Plasma Recalcification Time. (R.C.T.) 
The method was as described by McDonald and Fullerton (1958.). 
(a) Platelet Rich Plasma. 
Venous blood collected by the usual method was spun at 1,000 r.p.m. 
(150g) at room temperature for exactly 5 minutes. The plasma was then removed 
using a siliconized pipette and tested immediately. 
0.2 ml. of plasma was warmed to 37 °C for exactly 2 minutes, either 
in triplicate 3" x 3' clotting tubes (for visual clotting times) or 52.5 mm x 
11.5 mm tubes (for coagulometer clotting times). 0.2 ml. of 0.025 M calcium 
chloride was then added and the clotting time recorded. The mean value for 
this test was 112 -h 14 seconds as measured in 20 normal subjects. 
percentage error as calculated from 30 tests was 2.10. 
The mean 
(b) Platelet Poor Plasma. 
Venous blood, collected in the usual manner was spun at 3,450 r.p.m. 
(2,230g) for 20 minutes. The plasma was separated with a siliconized pipette 
and tested immediately. The procedure was otherwise as for (a). 
The mean value for this test was 171 - 46 seconds as measured in 
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50 normal subjects. The mean percentage error, as calculated from 50 tests 
was 2.4 %. 
3. Kaolin -Cephalin Clotting Time. (K.C.C.T.) 
The test is sensitive to changes in the levels of clotting 
Factors I, II, V, VIII, IX, X, XI and XII, i.e. the intrinsic system of 
coagulation. The method adopted was similar to that described by Matchett 
and Ingram. (1965). Surface activation of the plasma is supplied by kaolin, 
and a partial thromboplastin reagent is also added to increase the rate of 
reaction and reduce any effect of varying plasma platelet concentrations. 
(a) Kaolin -platelet substitute reagent. 
The partial thromboplastin reagent used was a commercial preparation 
also incorporating kaolin. (Kaolin -platelet substitute reagent - Diagnostic 
Reagents Ltd.). 
This lyophilised product contains kaolin (2 mgm /ml.) and a platelet 
substitute (rabbit brain phospholipid prepared according to Bell and Alton, 
1954), and is supplied in 10 ml. vials. In view of reports of instability 
of certain platelet substitutes available (Veltkamp, 1965), and the importance 
of the reagent to many of the assay techniques, the following experiments were 
performed. 
(i) Stability after Reconstitution 
The kaolin -cephalin clotting time was performed, at intervals 
of 1 hour (throughout a day) on freshly thawed aliquots of fresh frozen plasma, 
0 0 
using kaolin -platelet substitute reagent stored at either 4C or 37 C. The 
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results of experiments on three separate plasmas are summarised in Table 3:1. 
There is no significant alteration in the stability of the reagent over the 
time period studied (7 hours) between the reagent stored at 4 °C or 37 °C. 
TABLE 3 :1 
THE STABILITY OF KAOLINrPLATKLET SUBSTITUTE REAGENT 
ON STORAGE AT 37 °C AND 4 °C. 
Hours 0 1 2 3 4 5 6 7 
Plasmas K.C.C.T. in Seconds 
1 40.9 40.9 39.0 38.8 39.9 39.4 39.0 37.2 
37 °C 2 39.0 39.0 38.8 39.0 38.2 39.2 39.4 38.4 
3 36.o 36.6 37.1 36.4 36.4 35.4 37.4 36.9 
Mean 38.6 38.8 38.3 38.1 38.2 38.0 38.6 37.5 
I 
1 40.2 39.5 39.4 39.6 38.9 39.5 38.9 39.4 
4 °C 2 39.4 39.5 39.6 38.8 38.5 39.6 38.4 33.8 
3 36.5 36.5 36.5 37.0 36.6 36.7 36.4 37.8 
Mean 38.7 38.5 38.5 38.5 38.0 38.6 37.9 38.7 
t r 
(ii) Intra -Batch Variation. 
This next experiment was designed to establish if different 
batches of Kaolin- platelet substitute reagent were of similar activity. 
Four freshly withdrawn plasmas were tested with different batches of Kaolin - 
platelet substitute reagent, using the kaolin -cephalin clotting time test. 
The results are tabulated in Table 3:2. 
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TABLE 3:2 
Ti]E INTRA -BATCH VARIATION 
OF KAOLIN -PLATELET SUBSTITUTE REAGENT 
j Batch No. KC17 1 KC18 
! 
KC19 
K.C.C.T. in Seconds 
Plasma A 40.6 44.5 40.3 
B 35.3 40.6 34.7 
C 41.2 46.4 42.4 
D 32.4 35.8 32.2 
Mean 37.4 41.8 37.4 
There was a significant variation between some batches. 
Accordingly, the same batch of material was used for a series of experiments. 
(iii) Plasma Activation Rate. 
The action of kaolin in the kaolin- platelet substitute 
reagent is to provide uniform activation of the contact factors (Factors XI 
and XII) in the initial stages of coagulation. The rate at which this 
activation occurs was therefore investigated. 
Three plasmas were incubated with kaolin- platelet substitute 
reagent in a Factor VIII assay system for varying times up to 30 minutes. The 
results are summarised in Table 3:3. Maximal activation occurs within 10 minutes 
incubation and there was little change thereafter, up to 30 minutes. In the 
work described in this thesis, a 10 minute incubation period was used, although 
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in some assay experiments, the incubation period was increased to 15 or 
20 minutes, and occasionally to 30 minutes. 
These findings are similar to Hardisty et al (1962), 
Veltkamp (1968) and Hunter and Houghton (1968). The advantage of using 
conditions giving minimal clotting times is that small variations in kaolin 
concentration and incubation time have little influence on the final clotting 
times, thus facilitating more uniform results. 
TABLE 3:3 
EFFECT OF INCREASING INCUBATION TIME OF PLASMA 
WITH THE KAOLIN -PLATELET SUBSTITUTE REAGENT IN TIE 
FACTOR VIII ASSAY SYSTEM. 
Minutes of Incubation 
1 2 ¢ 6 8 10 12 16 20 24 28 30 
Clotting Time in Seconds 
Plasma A 92 87 77 73 - 70 72 72 71 70 - 74 
B 77 74 67 63 61 59 6o 61 59 61 60 59 
C 76 71 62 57 58 56 55 55 56 54 - 56 
Mean 82 77 69 64 (60) 62 62 63 62 62 (60) 63 
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Incubation Mixture: 0.1 ml. Factor VIII deficient plasma. 
0.1 ml. normal plasma at a dilution of 1:10 in buffer. 
0.2 ml. kaolin -platelet substitute reagent. 
0.1 ml. 0.025 M calcium chloride. 
Similar results were obtained using the kaolin -cephalin clotting 
time test. 
(b) Technique of K.C.C.T. 
0.1 ml. of test plasma sample kept on ice was added to three non- 
siliconised pre -warmed 55 x 11.5 mm. tubes, and incubated at 37 °C for 1 minute. 
0.2 ml. of kaolin- cephalin reagent was then added, the solution 
mixed thoroughly for 5 seconds and incubation continued for exactly 10 minutes, 
without further disturbance. 
After this time, 0.1 ml. 0.025 M calcium chloride was added and 
the clotting time recorded in the Coagulometer. The mean of the three 
values observed was taken as the clotting time. In 96 determinations of 
the test in 90 normal individuals (age range 20 -60 years), the mean value was 
38.2 seconds 13.1. The mean standard error for a single clotting time was 
11.06 seconds. This corresponds to coefficient of variation of 3.02g, for 
experimental error. 
4. One Stage Prothrombin m Tie. (P.T.) 
This test is a measure of the extrinsic system of coagulation 
as it is sensitive to changes on Factors II, V, VII and X. Plasma is 
clotted in the presence of an optimal concentration of brain extract and 
calcium chloride (Quick, 1935). 
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The method was as follows. To triplicate 3" x -' clotting tubes 
was added 0.1 ml. of brain thromboplastin (phenolised rabbit brain thrombo- 
plastin - Diagnostic Reagents Ltd.) and warmed to 37 °C. 0.1 ml. of citrated 
test plasma was then added, followed by 0.1 ml. of 0.025 M calcium chloride, 
and the clotting time recorded. The control plasma used for the test was a 
fresh frozen plasma pool that had not been stored for longer than 21 days 
(Hougie, 1963). Fresh normal plasmas were also frequently included as an 
additional check. The clotting times of these plasmas were invariably 
between 12 and 15 seconds. 
5. Calcium -Thrombin Time. (T.T.) 
Human thrombin, as supplied by the Blood Products Laboratory, 
Lister Institute, Elstree, Herts., was used as suggested by Hardisty and 
Ingram (1965). The lyophilised thrombin was reconstituted as directed 
and stored in 0.1 or 0.5 ml. aliquots in sell tubes at -40 °C. For use, 
an aliquot was thawed and diluted 1:30 in 0.025M calcium chloride. The 
clotting time of normal pooled plasma using this dilution was between 12 
and 15 seconds and was always checked on normal plasma with each separate 
test. 
The test was performed by adding 0.1 ml. of 0.05 Al tris buffer 
and 0.1 ml. of test or control plasma to a clotting tube and warming the 
solution to 37 °0. 0.1 ml. of calcium -thrombin solution was then added and 
the clotting time recorded in triplicate tubes. The results were then 
compared with the control plasma. 
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6. Arvin Time. (A.T.) 
This test makes use of a purified coagulant fraction ('Arvin') 
derived from the venom of the Malayan pit viper (Agkistrodon rh:odostoma). 
This fraction has a thrombin -like activity, clotting fibrinogen directly, 
but unlike thrombin is not affected by the presence of heparin or heparin - 
like activity (Regoeczi, 1966; Eenouf and Tunnah, 1967). 
Arvin was supplied (Twyford Laboratories Ltd.) in ampoules 
containing 0.9 ml. specific activity 82 units /ml. These units were 
arbitrary, but were of similar order to National Institute of Health (N.I.H.) 
thrombin units. The Arvin was buffered in 0.1 M sodium phosphate /saline 
(pH 7.0) and was stable when stored at 4 °C. 
For use in the Arvin time, the contents of 1 ampoule was diluted 
in 7.0 ml. of 0.05 Id tris buffer. 1.0 ml. aliquots were then stored at 
-40°C in small tubes. When_required an aliquot was thawed and 1.0 ml. of 
0.025 M calcium chloride added and the solution kept at 4 °C. 
The test was performed in an identical manner to the calcium- 
-thrombin time. To 0.1 ml. of 0.05 M tris buffer was added 0.1 ml. of test 
plasma and the solution warmed to 37 °C. 0.1 ml. of calcium -Arvin was then 
added and the clotting time recorded in triplicate tubes. The results were 
then compared with a pooled normal plasma similarly treated. 
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7. Factor I (Fibrinogen) Assay. 
Three methods were used. 
(a) Fibrinogen Assa as described b Ratnoff and Menzies (1951) 
as modified by Alkjaersig (1960). 
This was used as the standard reference assay with which other 
fibrinogen assay results could be compared. The technique was investigated 
and modified in this laboratory by Mackay (1967). 
In this assay the test specimen is diluted in buffer containing 
E.A.C.A. (to prevent further proteolysis) and clotted with thrombin. The 
tyrosine released from the fibrin by hydrolysis with sodium hydroxide is 
estimated with Folin Ciocalteu's reagent, and the fibrinogen concentration 
calculated from a standard tyrosine curve. 
The technique was as follows. Into each of four 5" x non- 
siliconized test tubes was added 6.0 ml. of E.A.C.A.- saline, and 0.2 ml. of 
2.5% calcium chloride solution. Into three of the four tubes was added 
0.1 ml. of thrombin (100 units /ml. in O. saline). To each tube was then 
added 0.2 ml. of test solution; the tubes mixed, covered with parafilm and 
left at 4 °C for at least 12 hours to ensure complete coagulation. 
On the following day a constant amount of well- washed glass 
Ballotini beads (diameter 0.15mm) was added to each tube, which was then 
centrifuged at 3,400 r.p.m. at 4 °C for 5 minutes. The supernatant was 
then removed leaving a small amount of solution containing the glass beads 
and entrapped fibrin. Three washes were then performed using 0.9% saline, 
care being taken to ensure that beads were not lost on removal of the 
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supernatant. After the last wash, 0.4 ml. of 10o sodium hydroxide was 
added to the four tubes and mixed. Hydrolysis was completed by boiling 
the tubes in a water bath for 20 minutes with intermittent shaking. The 
tubes were cooled, and 0.6 ml. of tric'hloroacetic acid added. 2 ml. of 
0.5 N sodium hydroxide was further added followed by 0.6 ml. of Folin and 
Ciocalteu's reagent (diluted one volume to two volumes of distilled water) 
and mixed well. Without delay, the tubes were centrifuged for 2 minutes 
at 4,000 r.p.m. at room temperature. Using the non -clotted tube of the 
quadruplicate as the blank, the tyrosine released was assessed by measuring 
the colour density developed in a Unicam S.P.600 at 650uousing the red filter. 
The tyrosine released was then calculated from a standard tyrosine curve 
previously prepared and this reading converted to fibrinogen concentration 
by multiplying by 11.7. The mean difference between triplicate observations 
over a wide range of fibrinogen values, expressed as a percentage of the mean 
of these observations was 6.27. 
(b) Fibrin- °en Assa as described bLEllis and StransI (61 ). 
This assay was used as a routine assay, the method being rapid, 
reproducible and easy to perform. 
In the assay, the increase in optical opacity resulting from the 
formation of fibrin, in thrombin clotted recalcified citrated plasma is 
measured, and compared with non -clotted plasma. The result can then be 
calculated by comparison with a fibrinogen standard curve previously prepared. 
The technique was as follows. To 5.5 ml. of barbitone saline 
buffer (pH 7.2) in a glass test tube, 0.5 ml. of test plasma was added, the 
tube covered by parafilm and mixed by inversion. 3.0 mi. of this solution 
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was added to a Unicam cell ('test cell') and the remainder to another cell, 
hereafter referred to as the "blank" cell. Using a micro -titre pipette 
dropper (delivery volume 0.025 ml.), 2 drops of a calcium - thrombin solution 
was then added to the test cell, and mixed by inversion over parafilm for 
15 seconds. The cell was then left undisturbed for 20 minutes at room 
temperature and the density evolved measured in a Unicam S.P.600, against 
the blank, at 470 mµ with the blue filter. The percentage plasma fibrinogen 
was then calculated from the standard curve. The standard error of this 
method, as calculated from a plasma assayed 48 times by two technicians over 
a period of 8 weeks, was ±6.5% 
(c) Fibrinogen Assay using the Tho rpe Nephelometer. 
The method is based on the use of the Thorpe Micro -Nephelometer 
(I.C.I. Pharmaceutical Division) illustrated in Fig.3:1, and investigated 
in this laboratory by Mackay (1967). Using the instrument, a beam of light 
is passed through a diluted plasma sample and the resultant light scattering 
by the particles measured by photometers incorporated in the machine. In 
the assay, the light scattering index (L.S.I.) of the test plasma is recorded, 
the plasma is then heated to 56° for 10 minutes, cooled, and the L.S.I. 
again measured. By reference to standard tables the difference in L.S.I. 
can be assessed and the percentage of heat precipitable fibrinogen present 
calculated. 
Fibrinogen assays, using the Thorpe Nephelometer, the Ratnoff- 
Menzies assay and the Ellis -Stransky assay, on the same normal plasmas showed 
a good correlation and the results will be published elsewhere (Mackay, 1967). 
Fig. 3:1. The Thorpe Micro- Nephelometer. 
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The mean standard error of this method of fibrinogen assay was 
3.6¡ as assessed by 15 separate assays on one standard plasma. 
8. Factor II prothrombin) Assay. 
In this assay plasma prothrombin is progressively converted to 
thrombin in the presence of a diluted brain thromboplastin solution and 
calcium chloride. This clotting mixture is then sampled, at spaced intervals, 
into a fibrinogen solution and the clotting times are recorded. The total 
number of generated thrombin units can then be compared with a control 
normal plasma, similarly tested, and the percentage of prothrombin by 
comparison estimated. 
The method was as follows. Brain thromboplastin (Diagnostic 
Reagents Ltd.) was diluted in 0.9% saline to give a one -stage prothrombin 
time of 25 -30 seconds on a normal pooled plasma. The usual dilution was 
between 1:10 and 1:30. 
Tubes containing 0.4 ml. of bovine fibrinogen (Diagnostic Reagents 
Ltd.) were placed in the water bath at 37°C. In another tube, a mixture was 
made of 0.4 ml. of test or normal plasma and 0.4 ml. of diluted brain. 
Recalcification was then perförmed with 0.4 ml. of 0.025 id calcium chloride 
and a timer started. The resulting fibrin clot was removed with an orange 
stick and at minute intervals 0.1 ml. of the incubation mixture was transferred 
to a tube containing fibrinogen. The clotting times were then recorded. 
Testing was continued until the clotting time exceeded 200 seconds. 
To obtain quantitative results, the clotting time of the fibrinogen 
samples were converted to thrombin units from a thrombin /fibrinogen curve 
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prepared as follows :- 
Tubes containing 0.4 ml. of bovine fibrinogen were placed in a 
water bath at 37 °C. Dilutions of thrombin (Parke Davis & Co.) from 20 to 
0.5 units /ml. were made and kept on ice. Clotting times of the fibrinogen 
were recorded by the addition of 0.1 ml. of thrombin dilution. The clotting 
times were then graphed against the units of thrombin and a thrombinffibrinogen 
curve obtained. From this graph, the number of generated units of thrombin 
in an unknown test sample could be read off directly. 
The percentage of prothrombin was then calculated, i.e. 
Thrombin units test lasma 
Thrombin units control plasma 
X 100' 
The percentage prothrombin could also be calculated as recommended 
by Hardisty and Ingram (1965), i.e. 
of Reciprocals Clotti Time lasma) 
Result = Sum of Reciprocals of Clotting Time control plasma) 
X 1O0". 
9. Factor V (Proaccelerin) Assay. 
The method was as described by Biggs and Macfarlane (1962). 
Artificially prepared substrate plasma was used; this being devoid of 
Factor V, but supplying Factors I, II, VII and X in excess. On the addition 
of thromboplastin, calcium and a plasma dilution, the rate of conversion of 
prothrombin to thrombin: reflected in the clotting time of the fibrinogen 
in the substrate plasma, is proportional to the amount of Factor V present. 
Method: 
(a) Pre oration of substrate _lasma. 
400 ml. of blood was collected in 50 ml. of 0.1 M sodium 
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oxalate. The plasma was separated by centrifugation and incubated at 37 °C 
until the one stage prothrombin time was longer than 90 seconds. The plasma 
was then stored in small aliquots at -40 °C. This plasma substrate was 
exceptionally stable when prepared and stored in this way. 
(b) Performance of Test. 
Dilutions of pooled control frozen plasma were made in veronal 
buffer (pH 7.4), from 1/1000 - 1/10, and kept on ice. 0.1 ml. aliquots of 
substrate plasma were pipetted into a rack of coagulometer test tubes. 
Triplicate tubes were then warmed to 37 °C and 0.1 ml. of dilution, 0.1 ml. 
of brain thromboplastin (Diagnostic Reagents Ltd.) and 0.1 ml. of 0.025 M 
of calcium chloride added and the clotting time recorded in the Coagulometer. 
This was repeated for each dilution and a standard curve prepared, this being 
plotted on double logarithmic paper. Usually three dilutions of the test 
plasma were tested. The best parallel line was drawn against the standard 
curve and the percentage of Factor V read off the ordinate axis. 
To test the reproducibility of this method ten analyses were 
performed on a single plasma sample. The mean standard error was found to 
be ±6.5% 
10. Factor VII (Proconvertila):., Assay. 
The method was based on the correction of the clotting time, using 
Factor VII deficient Beagle dog plasma, of dilutions of test plasma as 
compared with control plasma. The procedure is basically the same as the 
Factor V or Factor X assay, and is as described by Garner et al. (1967). 
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Dilutions of pooled and test plasma, ranging between 110 to 1/1000, 
were made in glyoxaline buffer (pH 7.3). 0.1 ml. of substrate Factor VII 
deficient plasma was added to triplicate clotting tubes and pre -warmed to 
37 °C. To this was next added 0.1 ml. of test or control plasma dilution 
and 0.2 ml. of thromboplastin/calcium chloride mixture (0.025 M_.) and the 
clotting time recorded. The concentration of Factor VII in the test plasma 
could be ascertained by comparison with the standard curve prepared from the 
control plasma dilutions. 
The human brain thromboplastin used in the assay was supplied 
by Dr. R. Garner (I.C.I.) as was the substrate plasma. Only limited 
experience was gained with the assay and no comparison could be made with 
results using a human substrate Factor VII deficient plasma. However, 
the assay gave consistent results and low values of Factor VII were obtained 
on plasma from patients undergoing anticoagulant therapy. 
11. Factor VIII (Antihaemophilic Factor) Assay. 
In the course of early experimental work, two methods for the 
assay of Factor VIII were investigated. 
A. Two- sta.ae Factor VIII Assay. 
The first method is based on the thromboplastin generation test 
(Biggs, Eveling and Richards, 1955) and is the standard procedure used in the 
Clinical Coagulation Laboratory of the Edinburgh Royal Infirmary. This method, 
with its numerous modifications (Pitney, 1956; Biggs, 1957; Pool and 
Robinson, 1959), has given satisfactory results in the hands of these workers, 
and experience in the Coagulation Laboratory of this hospital has confirmed 
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these observations (Cumming et al., 1965). 
Nevertheless, this assay is difficult to perform, requires 
considerable attention to both reagents and technique and exhibits marked 
day to day variation in results if performed by different technicians. It 
also requires the services of skilled technical staff if consistent results 
are to be obtained. Because of these features, the reagents were 
standardised as far as was possible and this improved the reproducibility 
of the assay. 
(a) Modifications of Reagents. 
(i) Use of a standard Bovine Preparation of Factor V. 
A lyophilised Bovine Factor V reagent (Diagnostic Reagents Ltd.) 
was reconstituted with distilled water and then divided into aliquots of 0.1 ml. 
and stored at ° -40 C. Aliquots thus frozen, showed no significant loss of 
Factor V activity when stored for periods up to 2 months. For use, 2.9 ml. 
of 0.9% saline was added, and the solution kept on ice for up to 2 hours. 
This preparation of Factor V did contain detectable VIII activity on repeated 
assays of different batches, as assessed by a one -stage assay. 
(ii) Use of a Standard Phospholipid Reagent. 
The phospholipid finally chosen was brain phospholipid prepared 
according to Bell and Alton (1954). This was distributed in aliquots of 
0.6 ml. and stored at -40 °C. There appeared to be no loss of potency on 
storage for at least 6 months. For use, it was reconstituted with 2.4 ml. 
of 0.9 saline and also kept at 4 °C. 
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(iii) Use of a Standard Dried Human Serum. 
Two methods were used: - 
(a) 200 ml. of human blood (without anticoagulant and in a non- 
siliconised M.R.C. bottle) was collected from a blood donor, incubated 
for 3 hours at 37 °C, followed by 18 hours at 4 °C. The serum was 
separated, spun for 1 hour at 2,000 r.p.m., and the top two- thirds 
of the serum collected. This was divided into 1.0 ml. aliquots 
into new test tubes and freeze dried. The tubes were then sealed 
and stored at -40 °C. For use the material was reconstituted in 10 ml. 
of glyoxaline buffer, and left to "activate" for 24 -48 hours at 4 °C 
in the glass test tube. This serum was of consistent potency, and 
was the usual source of the serum factors in the two -stage Factor VIII 
assay. 
(b) A serum was prepared as described by Kekwick and Walton 
(1964). This also gave satisfactory results, and was more convenient 
to use as it could be stored frozen in the activated form and thawed 
just prior to use. 
(iv) Use of Axed A.C.D. Plasma as Substrate. 
Out -dated plasma (over 21 days old) that had been collected in 
acid- citrate -dextrose anticoagulant was found to be an excellent substrate 
for use in the assay. Aliquots of 10.0 ml. were stored at -40 °C and thawed 
as required. Low levels of Factor VIII were present in this substrate. 
(b) Technique of Assay. 
The technique of assay was that described by Biggs et al. (1955). 
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The method is based on the thromboplastin generation test and 
consists of testing three dilutions of both adsorbed control and test 
plasma. Minimum clotting times obtained in this system are proportional 
to the amount of Factor VIII present, as all other factors are present in 
excess. Sub -sampling of the incubation mixture is performed twice when 
a stable plateau of thromboplastin formation has been reached. 
The mean 95% confidence limits _of 35 randomly selected routine 
Factor VIII assays, of values lying between 20% and 300% of normal plasma, 
was 75% to 133% of the observed result. The widest 95% confidence limits 
for an assay was 55% to 183%, the narrowest, 90% to 111 %. 
B. One -stade Factor VIII Assay. 
The second type of Factor VIII assay available is the method based 
on the correction of clotting time that occurs when a dilution of a test 
sample is added to a plasma congenitally deficient in Factor VIII. These 
assays are referred to as "one- stage" assays, as sub -sampling of an incubation 
mixture is not required. 
This method of assay has been improved considerably by the 
standardisation of contact activation in the incubating mixtures, and by 
the use of a phospholipid which eliminates variations in platelet numbers 
between tubes. The method selected was similar to that used by Hardisty 
and Macpherson (1962) as modified by Veltkamp (1966) but with the following 
changes in techniques. 
a) Kaolin- cephalin reagent was used as a combined source of contact 
activator and phospholipid. 
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(b) All dilutions were made in tris buffer pH 7.4. 
(c) Four dilutions of both test and control plasma were tested in duplicate 
and in balanced order to reduce the effect of any - "drift" in the 
reagents used (Ingram, 1966). 
(d) All dilutions were kept on ice until used, and substrate deficient 
plasmas were from haemophilics of proved very low levels of 
Factor VIII. 
(e) Small aliquots of substrate plasma were stored for up to 3 weeks, 
before being discarded. In some experiments, out -dated Factor 
VIII deficient plasma was reinforced with Bovine Factor V (Diagnostic 
Reagents Ltd.) and the results of these assays were in good 
agreement with assays using fresh substrate plasma. 
Assay Techniques. 
A series of disposable 55 x 11.5 mm. tubes kept on ice were 
filled successively with 0.1 ml. freshly thawed substrate Factor VIII 
deficient plasma and 0.1 ml. of dilution of test or control plasma. After 
an incubation period of 1 minute at 37°C, 0.2 ml. of kaolin -cephalin reagent 
was added, and incubation continued for a further 10 minutes. 0.1 ml. of 
0.025 M calcium chloride was then added, and the clotting time measured in 
an automatic Coagulometer, in duplicate, or in some experiments in triplicate. 
Dilutions of test plasma were so arranged that clotting times of both test 
and control plasmas were similar, to avoid extrapolation of the final 
standard reference curve. The coagulation times obtained with the various 
concentrations of both the reference and test plasmas were plotted on semi - 
logarithmic paper, the lines of best fit drawn, and the percdntage values 
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of the test sample read off directly. In many experiments, however, 
confidence limits and percentage values were calculated statistically by 
computer. 
The mean 95 confidence limits for 76 randomly selected Factor 
VIII assays of values lying between 0 to 600A of normal standard plasma was 
81 -125A of the observed result. The widest confidence limits were 61% to 
165, the narrowest 9V, to 106Á. These confidence limits are similar to 
that of Simone et al. (1967), and Veltkamp (196e), both of whom used automatic 
end point recorders. These confidence limits include the experimental errors 
of both the standard curves and test plasmas, the slopes of the dose response 
curves with regard to the degree of parallelism and the related potency of the 
test versus control plasmas. The experimental error, as assessed by 12 
separate determinations on a single plasma (mean value 103A) was 6.3%. 
This compares favourably with Veltkamp (1966) who found his experimental error 
to be 5.70. 
This one -stage assay was, in our hands, technically easier and 
more reproducible than the tiro -stage assay (see confidence limits) and was 
thus used extensively. Occasional anomalies occurred, but on repetition of 
the assay, this was nearly always due to either technical fault or unsatisfactory 
reagents. It was found that with consistent practice, the 95°A confidence 
limits of the assay improved, i.e. in the most recent work, the mean of the 
confidence limits was è3% to 117f of the observed results. 
The two -stage and one -stage assays were performed on 25 separate 
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Fig. 3:2. Correlation between "One- stage" and "Two- stage" 
Factor VIII Assay Systems, on 25 Separate Plasmas. 
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with the two -stage assay tending to give slightly higher values of Factor VIII 
than the one -stage method (Fig. 3:2) (r = 0.9348, p < 0.001). 
12. Factor IX (Christmas Fa ay ctor) Ass. 
The technique used was based on the one -stage assay method 
described by Hardisty and Macpherson (1962). Substrate plasma deficient 
in Factor IX was used, and to this was added dilutions of test or normal 
plasma, the solution activated by the use of a kaolin -platelet substitute 
reagent, and the clotting time recorded. 
The method was identical in procedure to the one -stage Factor VIII 
assay apart from the preparation of the substrate plasma. 
For substrate plasma, only plasma from patients with severe 
Factor IX deficiency was used. This was stored in small aliquots at -40 °C. 
For use, it was mixed with an equal volume of adsorbed citrated fresh normal 
plasma, the latter supplying supplementary Factor V and Factor VIII, which 
may have deteriorated on storage of the substrate plasma. 
The mean 95% confidence limits for this assay for 25 randomly 
selected assays with values lying between 0 -136% normal plasma was 79 -122%. 
The reproducibility of the technique was checked by assaying the same plasma 
sample eight times. The mean value was 100 f9.1 %. 
13. Factor X (Stuart Prower) Assay. 
The method was as described by Denson (1961). Commercially 
available Factor X deficient substrate plasma, prepared from filtered ox 
plasma, is also deficient in Factor VII, but contains Factors I, II and V. 
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Russel's Viper Venom (R.V.V.) can convert fibrinogen to fibrin in the presence 
of these factors and phospholipid, in the absence of Factor VII. The clotting 
times so obtained are, under specified conditions, proportional to the amount 
of Factor X present. 
The technique was as follows. Accurate dilutions from 1:10 to 
1 :1,000 of pooled normal plasma were made in veronal/saline buffer (pH 7.4). 
To triplicate coagulometer clotting tubes was added 0.1 ml. of Factor X 
deficient substrate plasma, and 0.1 ml. of plasma dilution. The tubes were 
then warmed to 37oC and 0.1 ml. of Russel's Viper Venom/Cephalin Mixture 
added. At exactly 30 seconds after this addition, 0.1 ml. of 0.025 M 
calcium chloride was used, and the clotting time recorded in the Coagulometer. 
The test plasma dilutions were usually tested at two dilutions (1:10 or 1:20). 
The percentage Factor X present could then be calculated by comparison with 
the standard curve when charted on double logarithmic graph paper. 
The reproducibility of this assay method was tested by assaying 
the Factor X level ten times on a single normal plasma. The mean value 
was 100 ±5.3jó. 
14. Factor XII (Hageman Factor) Assay. 
The method was identical to that of the Factor VIII and Factor IX 
assays, except that siliconized tubes were used both for preparing dilutions 
and also for the clotting procedures. Factor XII deficient substrate plasma 
was kindly provided by Dr. Loeliger, Leiden, Holland. Dilutions in veronal/ 
saline were usually started at not less than 1 :40 as advised by Veltkamp 
(1967), and dilutions of the test plasma were so chosen as to avoid extra- 
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:polation of the standard control curve. 
The mean 95% confidence limits for this assay, calculated from 
20 assays was 77sí to 131`jó of the observed results. Six assays performed on 
a normal pooled plasma gave a mean value and standard deviation of 100 f12/. 
15. Factor XIII IILmin Stabilizing Factor) Assay. 
The method was that as described by Das (1968). Fibrin clots, 
obtained froma test plasma and standard substrate fibrinogen in the presence 
of mono -iodoacetic acid, were treated with the solvent mono -chloroacetic acid. 
The residual fibrin clots were hydrolysed and the tyrosine release measured 
in a spectrophotometer. The percentage of Factor XIII present could then be 
calculated by comparison with the normal standard from a previously prepared 
tyrosine calibrated curve. 
The technique is similar to that of the fibrinogen assay as 
described by Ratnoff and Menzies (1961), apart from the initial stages of 
preparation of the test specimen. 
16. Assa;of Contact Activity _(Factors XI and XII). 
In this assay,test plasma is exposed to celite, the adsorbed 
contact product subsequently eluted, dilutions made in saline, and these 
added to fresh normal non -glass contacted plasma and the clotting times 
recorded. The percentage activity can then be calculated from comparison 
with a normal plasma, similarly treated. 
The modified method used was similar to that described by 
Nossel (1964). To two volumes of normal platelet poor non -contact plasma, 
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collected in plastic tubes, was added one volume of celite 512 (100 mgm/ml. 
in 0.85% saline). This was incubated at 37 °C for 10 minutes with constant 
agitation and the celite deposited by centrifugation at 2,500 r.p.m. for 
5 minutes. The supernatant plasma was carefully decanted and the celite 
resuspended in normal saline of volume approximately equal to that of the 
original plasma. The celite was again deposited by centrifugation and the 
supernatant decanted off and discarded. The procedure was repeated three 
times. The washed celite was then suspended in a volume of 1 saline 
equal to the volume of the original plasma. The mixture was kept at 37 °C 
for 10 minutes with constant mixing and the celite removed by centrifugation. 
The supernatant was dialysed (Visking casing) at 4 °C with continuous stirring 
(magnetic stirrer) against exactly ten times the eluate volume of distilled 
water. The dialysed eluate was stored in aliquots at -40 °C until assayed. 
In the assay, dilutions of the eluate were made in saline in 
silicone treated tubes. Mixtures (in silicone treated tubes) were then made 
as follows :- 
0.1 ml. fresh normal non -contact plasma 
0.1 ml. Bell and Alton Platelet substitute. 
Incubated for exactly 1 minute. 
0.1 ml. eluate dilution 
0.1 ml. 0.05 M calcium chloride was then added, and the clotting 
time recorded. 
The resultant clotting times were plotted on double logarithmic 
graph paper and the percentage contact factor activity calculated from the 
control contact product eluate curve. 
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17. Heparin Precipitable FractionjH.P.F.) Assay. 
A modified assay system was devised, based on the method 
described by Smith (1957). Heparinised plasma was incubated at 4 °C overnight 
to allow precipitation of the H.P.F.; the precipitate was then centrifuged 
and washed with a buffer to remove extraneous protein, and then hydrolysed 
with a strong alkali. The tyrosine released from the H.P.F. was then 
estimated with Folin- Ciocalteu's Reagent in a spectrophotometer. 
A. Technique of Assam. 
5.0 ml. of blood was collected in polystyrene tubes containing 
0.1 ml. heparin (1,000 u /ml. saline) and mixed well. This was then 
centrifuged at 4,000 r.p.m. (R.C.F. 2,652) for exactly 15 minutes at room 
temperature. The plasma was separated and aliquots of 0.5 ml. were added 
to three non -siliconized acid cleaned 5" x 8" test tubes. The tubes were 
covered with parafilm and placed at 4 °C overnight (18 - 24 hours). 
On the following day the plasma was centrifuged at 3,200 r.p.m. 
(R.C.F.) for 15 minutes at 4 °C, and the supernatant plasma decanted off. 
The precipitate was then washed three times using approximately 5.0 ml. per 
tube of 0.05 M phosphate buffer (pH 7.4) at 4 °C, for each wash. After the 
third wash the tubes were drained thoroughly. Hydrolysis was carried out 
by adding 0.4 ml. 100 sodium hydroxide and boiling in a water bath for 
20 minutes. The tubes were then cooled under tap water and 0.6 ml. of 5 
tricholoroacetic acid, followed by 2 ml. of 0.5 N sodium hydroxide, added. 
0.6 ml. of Folin- Ciocalteu's Reagent (diluted 1:2 in distilled water) was 
added and the solution centrifuged for exactly 1 minute at 2,500 r.p.m. 
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(n.C.F. 1,036) at room temperature, to remove any precipitate which 
occasionally appeared. The colour intensity developed was read in 
a Unicam S.P.600 at 650 mµ, using the red filter against a reagent blank. 
The H.P.F. concentration was calculated from a standard tyrosine curve 
previously prepared. 
B. Investigations of Assai Techniques. 
(a) Concentration of Heparin. 
The effect of heparin concentration on the yield of H.P.F. was 
investigated. Blood collection tubes containing between 2 and 80 units of 
heparin per ml. of whole blood were prepared And the H.P.F. yield measured 
on the same plasma. 
The results of four separate experiments are illustrated in 
Fig. 3:3 and Table 3 :4. As heparin concentration increased, the yield. of 
H.P.F. also rose. The slope of increase also varies between plasmas 
(Fig. 3 :3), two of the four plasmas assayed demonstrating a marked change 
with increasing heparin concentration while changes in the other two 
plasmas were less pronounced. A concentration of 20 units of heparin per 
ml. of whole blood was selected for routine use. 
(b) Incubation Time of He arinised Plasma. 
In two separate experiments, plasma was stored at 4 °C for periods 
varying between 16 and 48 hours. There was no change in the amount of 
H.P.F. obtained with increasing storage time, the yield at 16 hours being 
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Fig. 3:3. Effect of varying concentrations of heparin on the yield of H.P.F. 
TABLE 3:4. 
THE EFFECT OF VARYING CONCENTRATIONS OF HEPARIN 
ON THE YIELD OF H.P.F. 











4 - - 39.2 40.5 
8 - - 42.5 44.1 
12 - 39.4 47.3 44.8 
16 - 40.4 47.6 47.1 
20 39.6 39.3 51.4 54.6 
24 - 41.0 49.8 51.5 
28 - 41.2 60.8 74.2 
32 45.4 44.2 54.6 56.8 
36 - 44.4 - - 
40 44.3 44.9 54.6 - 
6o 45.6 46.7 - - 
80 - 47.4 - - 
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was left overnight and the storage time by this method varied between 
18 and 24 hours. 
(c) Stora,Fje of Heparinised Plasma at -40 °C. 
Heparinised blood was centrifuged, the plasma separated, one 
sample assayed for H.P.F., and the remainder frozen at -40 °C. This latter 
plasma was thawed completely at 37 °C, and then assayed fat H.P.F. 
In Table 3:5 is shown the results of ten experiments :- 
TABLE 3:5 
RESULTS OF TEN PLASMAS ASSAYED FOR H.P.F. BEFORE AND AFTER 
STORAGE AT -40°C 
Plasma 
Fresh Plasma Frozen Plasma 
H.P.F. - igm /100 ml. 
1 109.8 167.7 
2 57.1 66.9 
3 55.4 56.5 
4 37.7 44.7 
5 193.0 122.9 
6 52.6 56.3 
7 49.5 50.9 
8 58.5 59.7 
9 90.1 83.9 
10 50.2 45.1 
Mean 75.4 75.5 
(t = 0.0072, p = N.S.) 
- 91 - 
There was no statistically significant difference between the 
paired results (t = 0.007). Heparinised plasma can thus be frozen and 
assayed at a convenient date; the longest period plasma was stored at -40 °C 
was three weeks. 
(d) Technique for Precipitate Washing. 
H.P.F. was washed either two or three times with buffer. Two 
washes were found to be sufficient, although three washes were used 
routinely. 
(e) Type of Tube used in the Assay. 
H.P.F. was assayed in both siliconized and non -siliconized tubes. 
There was no significant difference in H.P.F. values between the type of 
tube used. 
(f) Cryofibrinogen in Oxalated and Citrated Plasma. 
4.5 ml. of blood was collected in either 0.5 ml. of 3.8 w/v 
sodium citrate or 0.5 ml. of 1.34% w/v potassium oxalate. The plasma was 
separated and assayed as for H.P.F. 
In four separate experiments, the mean value of the cryofibrinogen 
obtained in the citrated plasma was 3.9 ±0.8 mgm.ó, and in the oxalated 
plasma 5.5 ±2.7 mgm4. 
(g) Errors of the Method. 
(i) Errors between operators. 
Six samples were assayed separately by two technicians 
(Table 3:6). There was no significant difference between the paired results. 
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Usually, however, to ensure reproducibility of results within a series 
of experiments, the same technician performed the assays. 
TABIN 3:6. 
RESULTS OP SIX SEPARATE PLASMAS ASSAYED FOR H.P.F. 
INDEPERD 1 TLY BY TWO TECHNICIANS 
Plasma 
Technician 1 Technician 2 
H.P.F. - mgm /100 ml. 
1 43.2 35.6 
2 47.4 42.5 
3 50.3 44.4 
4 31.3 35.7 
5 31.4 34.5 
6 30.6 37.9 
Mean 39.0 38.4 
(ii) Assessment of Percen äß;e Error of the Method. 
Each sample was assayed in triplicate. The mean of the 
two closest observations was taken as ±èpresenting'the level of -H.P. . 
The mean difference between the triplicate results, over a wide range of 
H.P.F. values (12.9 - 156 mgm /100 ml.), expressed as a percentage of the 
mean of these results. was 5.6eó. This error is the mean value of the 
routine laboratory assay, and includes errors of both day to day alterations 
in assay technique and individual technician variation. 
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C. Normal Values of H.P.P. 
In 59 observations on 50 normal subjects, age range 20 -58 years, 
the mean level of heparin precipitable fraction was 44.5 ±10.9 mgm. /100 ml. 
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CHAPTER III 
FIBRINOLYTTIC ASSAY TECHNIQUES 
1. Plasminogen Assay. 
The method was as described by Remmert and Cohen (1949), as 
modified by Alkjaersig (1959). Antiplasmins are removed by incubating the 
plasma with acid, the acid is then neutralized with alkali, and streptokinase 
added to convert the plasminogen to plasmin. The plasmin evolved is assayed 
with casein, the amount of tyrosine released being proportional to the 
concentration of plasmin, and consequently plasminogen, present. 
A. method. 
To 0.5 ml. of plasma, in duplicate or triplicate and using 
disposable plastic tubes, was added 0.5 ml. N/6 Hydrochloric acid, and the 
mixture left at room temperature for 15 minutes. 0.5 ml. of 11/6 sodium 
hydroxide was then added followed by 1 ml. of 0.1 M phosphate buffer, 0.5 ml. 
of Streptokinase (2,000 u /ml. in 0.1 M phosphate buffer), and 2.0 ml. of 
casein solution. These reagents were well mixed and 2 ml. withdrawn and 
added to 2m1. of 10% trichloroacetic acid. The remaining 3.0 ml. were 
incubated at 37°C for 60 minutes, and at the end of this tine 3.0 ml. of 
10% trichloroacetic acid was added. The precipitates were removed by 
centrifugation for 2 minutes at 3,400 r.p.m. and the supernatant filtered 
through Whatman's No. 1 Filter Paper. For the hydrolysis stage 1.0 ml. 
aliquots was removed from each tube and added to a tube containing 5 ml.. 
of 0.5 N sodium hydroxide and 1.5 ml. of 5% trichloroacetic acid. An 
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addition of 1.5 ml. of Folin and Ciocalteu's reagent (diluted 1 part of 
Folin's to 2 parts of distilled water) was then made and after 15 minutes 
at room temperature the optical density measured, reading the zero sample 
against the 60 minute sample in the Unicam S.P.600 at 650 mem and using the 
red filter. The tyrosine released in mgm. was calculated for a standard 
curve and one casein unit was equivalent to 180 ,g of tyrosine released 
in one hour. 
The mean -percentage error of this method in 50 assays covering 
a wide range of normal values was 2.9%. The normal mean value, as 
assessed on 36 random donors was 3.67 ±0.6 c.u. /ml. with a range lying 
between 2.74 and 5.54 c.u. /ml. 
B. Preparation of Plasminogen standard curve. 
A solution of tyrosine (British Houses Ltd.) containing 
72 mgm. per 100 ml. of 0.I.N. hydrochloric acid was made up. Doubling 
dilutions of this solution were made in 0.1 N hydrochloric acid to give 
solutions equivalent to 2.0, 1.0 and 0.5 casein units per ml. activity. 
The initial solution was taken as being equivalent to 4 casein units per ml. 
To 0.5 ml. of each dilution was added 0.5 N/6 hydrochloric acid, 
0.5 1I/6 hydrochloric acid 0.5 N/6 sodium hydroxide, 1.5 ml. of 0.1 M phosphate ,,  
buffer (pH 7.6), 2.0 ml. of 5fó casein and 5 ml. of 10% trichloroacetic acid. 
1.5 ml. of Polin and Ciocalteu's Reagent was then added (diluted 1 part to 
2 parts distilled water) and after 15 minutes at room temperature the optical 
densities were read against a similarly prepared blank tube. The graph 
correlating optical density against activity in casein units was then 
plotted. 
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2. Euglobulin L sis Time Assay. 
This assay is regarded as being a measure of circulating 
plasminogen activator, in the virtual absence of fibrinolytic inhibitors. 
Euglobulin, prepared from plasma by acidification and dilution, contains 
plasminogen activator, plasminogen and fibrinogen as well as other plasma 
proteins. Fibrinolytic inhibitors are discarded in the supernatant. The 
euglobulin precipitate is redissolved in buffer, clotted with thrombin; 
and the time taken for lysis to occur observed and recorded. The method 
is as described by Cash (1967). 
Technique of Assay. 
Venous blood, collected by the usual technique and kept on melting 
ice for not longer than 10 minutes, was centrifuged at 3,400 r.p.m. for 
20 minutes at 4 °C. The upper third of the plasma was removed and 1.0 ml. 
added to a siliconized centrifuge tube containing 19.0 m1. of a dilute 
solution of acetic acid. The pH was adjusted to 6.0 with 0.25% acetic acid 
and euglobulin precipitation continued for 10 minutes at 4 °C. The tube was 
then spun at 3,400 r.p.m. for 20 minutes at 4 °C, the supernatant decanted, 
the inner side of the tube wiped dry with a tissue and the precipitate 
resuspended in 1.0 ml. of barbiturate buffer (pH 7.4). 0.24 ml. of this 
solution was transferred to three_3" x an siliconized tubes in triplicate 
and 0.24 ml. of thrombin solution 5 u /ml. added immediately. Lysis was 
recorded in an automatic clot lysis recorder (Cash and Leask, 1967). The 
mean percentage error for this method was 2.4% ±0.5. 
Euglobulin lysis times were, in some studies, converted to units 
1 using the formula ,300 of Januszko and Dubinska (1964), where T was the 
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euglobulin lysis time in minutes. 
In physiological experiments, where the presence of plasmin was 
unlikely, the units were referred to as "plasminogen activator units ". In 
other situations, where the presence of plasmin could not be excluded, the 
term "euglobulin lysis activity units" was used. 
3. Fibrin Plate Assay Technique. 
Fibrin plates were prepared by a modification of the method of 
Astrup and Mullertz (1952). Both human and bovine fibrin plates were used, 
but the human fibrin preparations proved to be more sensitive (in terms of 
area lysed). These unheated plates were regarded as a semi -quantitative 
measure of plasminogen activator although plasmin, if present in the test 
assay sample, would also cause fibrin lysis. This assay technique was of 
good confirmatory evidence for the euglobulin lysis time assay, although not 
as sensitive. 
Technique of Assay. 
10 ml. of 0.15 gm.¡ó of human fibrinogen (Y.abi) in tris buffer 
was pipetted into a disposable plastic petri dish and clotted, using a 
circular motion, with 0.2 ml. of a thrombin solution 50 u /ml. also in tris 
buffer, on a level table. After 20 minutes, when clotting was complete, 
0.03 ml. samples of the test material, plasma or euglobulin, were dropped 
in triplicate on to the fibrin films. Plates not in use were stored at +4°C. 
The plates were then incubated from between 20 -24 hours at 37°C, and at the 
end of this time, the perpendicular diameters of the lysed areas measured. 
The sensitivity of the plates were checked daily by using a standard solution 
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of urokinase (3.0 u /ml. in tris buffer) on a separate fibrin plate. The 
mean percentage error of this method was 12.4% ±0.61. 
4. Fibrinogen /Fibrin Degradation Products (F.D.P.) Assay (I). 
A. Introduction. 
The lysis of fibrinogen or fibrin by plasmin either in vivo or 
in vitro results in the formation of degradation products, some of which are 
incoagulable with thrombin, resistant to further plasmin digestion, but share 
a common antigenicity with fibrinogen. Methods to identify these breakdown 
products have attracted considerable interest as they present incontrovertible 
evidence of active fibrinolysis by proteolytic enzymes. 
It is possible to detect F.D.Ps. by simple tests such as the thrombin 
time but this method is of poor specificity and sensitivity. Immunological 
methods of identification such as immunodiffusion and inmiunoelectrophoresis 
have also been used, but again these tests are at best only semi -quantitative. 
(Ferreira et al., 1963; Nilehn and Nilsson, 1964). It was not until the 
utilization of a tanned red cell haemagglutination immunoassay technique such 
as used in the bioassay of chorionic gonadotrophin (Wide, 1962), growth hormone 
(Grumbach and Kaplan, 1962), and fibrinogen (Fox et al., 1964), that accurate 
assessment of F.D.P. concentrations became available. 
The method developed in this laboratory is similar to that 
described by Merskey et al. (1966) and investigated fully by Das (1968). 
Sensitised tanned sheep red cells are conjugated with fibrinogen and these 
can be agglutinated by fibrinogen antisera. This haemagglutination reaction 
is inhibited by the presence of lytic products of fibrinogen or fibrin or by 
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fibrinogen itself. This assay is both specific and sensitive and can 
accurately quantitate small amounts of antigenic material. It has the 
disadvantage of not being specific for fibrin degradation products, but 
reacts also to fibrinogen and other clottable fibrinogen derivatives. 
Thus considerable care is needed in the preparation of samples for assay 
to ensure removal of all traces of other antigenically active material. 
This defect cannot be overcome by using a specific F.D.P. antisera as this 
is antigenically cross reacting with._fibrinogen_. 
B. Tec'hni,ue of Tanned Red Cell Haemagglutination Inhibition 
Immunoassay (T.R.C.H.I.I.). 
(a) Preparation of fibrinogen coated, sensitised sheep red cells. 
25 ml. of fresh sheep red cells (Burroughs Wellcome & Co.) 
stored in Alseverts Solution, were washed four times with an equal volume 
of 0.9 saline. The packed cell volume (P.C.V.) was then measured by 
centrifuging the cells at 1,000 g for exactly five minutes in a graduated 
Pyrex centrifuge tube. An 8% suspension of the cells was made in 0.9% 
saline and an equal volume of 3°% formal saline added. The cells were next 
incubated at 37 °C for 20 -22 hours, with gentle agitation using a magnetic 
stirrer. 
After this time, the formalised cells were washed four times 
with fresh distilled water, followed by three washes with 0.15 M phosphate 
buffer (pH 6.4). The P.C.V. was again measured as outlined above. A 2% 
cell suspension was made in 0.15 M phosphate buffer (pH 6.4) and equal 
volume of working solution of tannic acid (1:40.000) added. The mixture 
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was heated in a water bath to 56 °C and incubated for 1 hour with gentle mixing 
at 10 minute intervals. The tanned cells were then washed three times with 
0.15 M phosphate buffer (pH 6.4) and the P.C.V. measured. Using 0.1 M 
citrate buffer (pH 6.4) a 4% cell suspension was made and an equal volume of 
a 2/40. gm /ml. solution of fibrinogen added. The mixture was then further 
incubated at 37 °C for 60 minutes with gentle stirring at 15 minute intervals. 
A further three washes of the cells with 0.15 M citrate 
buffer (pH 6.4) was then made and the P.C.V. estimated. From these cells 
a 2.5ó cell suspension was made in diluting fluid and these aliquots were 
stored in plastic disposable tubes at 4 °C. After 3 -4 days' storage 
the diluting fluid was replaced. 
For daily use, the 2.5r0 suspension of cells was transferred 
to small plastic tubes, each aliquot of 2.5 ml. providing sufficient 
suspension for use on one microtiter plate. Before use, these cells were 
washed three times; twice with citrate buffer (pH 6.4) and once with diluting 
fluid to ensure that any fibrinogen eluted off the cells on storage was not 
present in the assay system. 
(b). Collection of Test Samples. 
(i) Serum. 
5 ml. of whole blood were collected in clean glass tubes 
containing 0.1 ml. Trasylol (5,000 K.I. units /ml.), and mixed well. These 
tubes were incubated at 37oC for up to 12 hours, but as a routine 4 hours. 
The serum was separated by centrifugation and stored at -40 00 in small 
aliquots. 
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(ii) Plasma. 
4.5 ml. of whole blood was collected into plastic 
tubes 
containing 0.5 ml. of 3.8% sodium citrate and 0.1 ml. Trasylol (5,000 
K.I. 
units /mi.), the plasma separated by centrifugation, and stored 
in aliquots 
at -40 °C. 
(c) Preparation of Test Samples. 
This stage was crucial in the assay, as incomplete 
removal 
of the fibrinogen in the test sample would invalidate 
the results of the 
assay. The serum samples were thawed, one- eleventh 
volume of thrombin 
(100 u /ml. in saline) added and then incubated 
at 37 °C for 1 hour. When 
plasma samples were assayed, one -eleventh volume 
of thrombin was added and 
then incubated at 37 °C for 2 -4 hours. 
Resultant clots were removed and a 
further eleventh volume of thrombin 
incubated another hour. 
Sera were then separated by centrifugation, 
prior to the adsorption stage. 
(d) Adsorption of Test Samples. 
This step was necessary to remove 
any naturally occurring 
agglutinating anti -sheep cell substance 
present in the test sera. 
Sheep red cells (Burroughs Wellcome 
& Co.) in Alsevers 
solution and stored at 4 °C were washed 
four times with 0.90 saline. Cells 
showing excessive haemolysis after 
the first wash were discarded. After the 
fourth wash, the cells were packed 
by prolonged centrifugation and as much as 
possible of the supernatant saline 
removed. 
To each 2 volumes of test 
sample, 1 volume of packed sheep 
cells were added. The suspension 
was well mixed and incubated overnight 
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at +4oC. The following day the suspension was centrifuged, the adsorbed 
serum separated and either stored in small aliquots at -40°C or assayed 
immediately. 
(e) Assay of Test Samples. 
(i) Dilution of the test samples. 
Microtiter plates (Micro titer *, Cooke Engineering Co.) 
carefully washed as outlined in the appendix, were labelled, and using a 
microtiter dropper (delivery volume 0.025 ml.) into the first plate cup 
was added either 0.05 ml. of test sera, or 0.025 ml. of sera and 0.025 ml.. of 
diluting fluid. Precalculated volumes of diluting fluid were then added to 
the remaining cups, depending upon the dilution steps required. Usually 
doubling, with or without intermediate dilution steps were made. Using 
the microtiter multiple diluting gun (delivery volume of each head 0.025 ml.) 
and starting at the first cup, the dilutions were prepared. Positive and 
negative controls were included with each plate. 
Fibrinogen standards (1.25 mgm /ml., 2.5 mgm /ml., 5.0 mgm /ml.) 
were included with each assay and these were always diluted in an identical 
method as above. The fibrinogen content of these standards was checked 
frequently using the method of Ratnoff and Menzie (1951) , as modified by 
Alkjaersig (1960). Small aliquots of the non -diluted standards were stored 
at -40°C, C thawed, and diluted as required. 
(ii) Addition of Fibrinogen antisera. 
To each cup of the microtiter plate, and using the microtiter 
dropper, 0.025 ml. of the selected anti -'unman, rabbit fibrinogen antisera 
(Hoechst Pharmaceuticals Ltd.) was added. The plates were mixed; and the 
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test sample /antisera mixture incubated at 4 °C for either 4 or 24 hours. 
(iii) Addition of sensitised fibrinogen coated sheep red cells. 
After incubation as outlined, one drop (0.025 ml.) of a previously 
thrice -washed 2.5 sensitised, fibrinogen coated sheep red cell suspension was 
added to each microtiter cup. The plates were then mixed and stored at +4 00, 
without disturbance, overnight. 
(iv) Reading of F.D.P. Assay Results. 
The plates were removed from the refrigerator and left at room 
temperature for 30 minutes before reading. As far as was possible, an 
identical lighting source was used daily. The end point of both the 
fibrinogen standards and the test sera was taken as the last sharp button of 
non- agglutinated cells appearing in each row of the microtiter plate. Results 
were scored as -, +, +, or ±. Each plate was read twice in reverse order. 
(v) Calculation and Control of Results. 
The mean sensitivity of the system for that day was then 
calculated from the fibrinogen standards by comparing the last cup showing 
inhibition in the unknown series, with the last cup showing inhibition in the 
standard. From this, and the known dilution, the F.D.P. values of the serum 
samples could be obtained. A control serum was included with each separate 
assay as a further check against gross errors in technique. Sera samples 
from normal subjects were frequently included in the test samples as an 
additional check on the method. 
C. Standardisation of the T.R.C.H.I.I. Assay 
Initial experience with this assay suggested that the sensitivity of 
the system was varying considerably from day to day and that reproducibility of 
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results on some test samples, was not always satisfactory, when the test 
was utilized as a routine procedure. The following facets of test were 
investigated and are complementary to similar studies carried out by Das 
(1968). 
(a) ation 2f test samples. 
(i) In initial work, reliance was placed on the spontaneous 
clotting of whole blood for 4 hours at 37 °C but, in some sera from patients 
with pathological conditions, e.g. haemophilia, the conditions for clotting 
required extension as fibrinogen conversion was not complete in this time. 
Accordingly all sera samples were reclotted with thrombin as a routine 
procedure. Similar considerations apply to trasylol citrate samples and 
these were usually clotted twice with thrombin. 
This procedure was adhered to rigidly and improved the 
reproducibility of the assay on pathological samples. It was also found 
that specimens containing concentrations of heparin above 1.0 u /ml. of 
whole blood, required an extended period of coagulation and were thus usually 
clotted for 4 hours at 37 °C, and then overnight at 20°C 3.ith additional 
thrombin added. 
(ii) Dilution of the test sera by varying volumes of 
added sheep red cells in the adsorption stage could affect the absolute 
result, especially in the physiological range. The volume of sheep red 
cells added was thus standardised at 1 volume of cells to 2 volumes of 
sera, as measured by pipette. When adsorption was incomplete, the sample 
was adsorbed twice. 
(iii) All initial studies were performed on fresh adsorbed 
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serum. A study was made to ascertain if adsorbed sera could be frozen and 
re- thawed when required for assay. Ten separate sera were prepared by three 
different methods as tested in Table 3:7. It can be seen that freezing and 
subsequent thawing did not cause a change in the P.D.P. level. 
Therefore as a routine procedure, batches of frozen test 
sera were thawed, reclotted, adsorbed, and refrozen until required for assay. 
This method facilitated handling of large numbers of specimens. 
(b) Preparation of Sensitised Cells. 
(i) Washing of sensitised cells urior to use in assáy. 
In some vials of stored cells small amounts of antigenically 
active material, probably eluted fibrinogen, was detected in the supernatant. 
Cells were therefore routinely washed three times before use. 
(ii) Pre aration of human sensitised cells. 
Use of human cells would obviate the adsorption stage and 
could possibly be more sensitive than sheep cells (Weir, 1967). 
Cells from a Group 0 Rhesus Negative donor were obtained, 
sensitised and coated by the usual method (one run only was performed). 
These cells were tested in the assay system and were found 
to be of similar sensitivity to the routinely prepared sensitised sheep cells. 
However, end point formation was not as satisfactory and it was considered 
that without further experimental work these cells should not be used 
routinely. 
(c) Incubation Period of Test Specimen with Antisera. 
Considerable changes in sensitivity of the routine assay were 





























































































































































































































































































































































- 106 - 
time the test specimen was being left in contact with the antisera before 
addition of the sensitised cells, i.e. the contact time of antigen / antisera 
was varying between 1 -4 hours. Experiments were conducted to ascertain the 
effect of varying periods of incubation upon the sensitivity of the assay. 
Fig. 3:4 illustrates the results of one such experiment. 
With increasing incubation time, the end points of inhibition of both sera 
and diluted fibrinogen standard, moved to a higher dilution point, with the 
effect of increasing the calculated sensitivity of the system. Most of 
this change occurred within the first 6 hours of incubation, but a further 
change also occurred up to 24 hours. 
The sensitivity of one batch of routinely prepared cells, 
with an incubation period of 30 minutes, was 2.2 ,igms /ml. However, with 
a 24 hour antigen / antisera reaction period, the sensitivity was decreased 
to between 0.3, gms /ml. and 0.5 ,0gms /ml. Thus a method of greatly increasing 
the precision and discrimination of the assay was available which could be 
of considerable value in physiological studies. This method of increasing 
the sensitivity of a haemagglutination system is not new and has been 
described in the assay of insulin (Hales and Randle, 1963). 
As a routine procedure, antigen and antisera were incubated 
together for exactly 24 hours before addition of the cells. Where great 
sensitivity was not required, the incubation period was reduced to 4 hours. 
This change in the procedure greatly improved the routine 
reproducibility of the assay. Using this method, it was possible to 
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(d) Standards and Sensitivit of the T.R.C.H.I.T. 
Initially, only one fibrinogen standard was used in the 
assay. As there are .numerous' technical errors in the preparation of 
dilutions of this standard, it was considered that the inclusion of three 
separate fibrinogen standards would reduce this source of error. The 
dilutions of these standards were so arranged that dilution steps near the 
expected inhibition end point were close together. The mean sensitivity 
was obtained from the three results. The sensitivity of a batch of cells, 
as used in this method, demonstrated only a small variation. In 27 separate 
assays over period of four months the mean sensitivities with standard 
deviations using dilutions of antisera of 1:5,000 and 1:10,000 respectively 
was 0.57 ±0,16 and 0.45 0.14,Agms /ml. respectively. There was thus no 
great variation, over this time period, of the sensitivity of the cells, 
providing the incubation time of antigen /antisera was kept constant. 
Variations in sensitivity between days was also small. 
As an additional check of the assay system a frozen standard 
adsorbed serum, collected from a normal donor, was included with each run. 
The end point of this serum, between assays, was remarkably consistent, with 
a slightly lower standard deviation than that of the fibrinogen standards. 
This could be attributed to the extra technical handling stages required in 
preparation of the standard fibrinogens. The mean value and standard 
deviation of this serum in 59 separate estimations over a period of 6 months 
was 6.4 ±1.3,gms /ml. 
Using this system of controls, technical errors could easily 




CO r- Cr) 




Y _. . . . a 
B ( , . ft 41) * 
. . ft 0 0 4" e) 
O ,t 070, 0 , Ò * 
E C: . * 0 01* Et *0) 
F ,; ò ò J IN 
G í o 0 0) 0) ) 0) Et 
H í,'è .1 
Fig. 3:4a. Photograph of a Micro titer plate used in a 
routine T.R.C.H.I.I. Assay. 
The numbers at the top of the plate refer to the dilution of 
the test specimen. Letters to the side refer to test samples. 
The inhibition end points can clearly be seen. Samples A -G 
represent sequential specimens from a patient with a massive episode of 
defibrination. 
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sensitivity were repeated. The assay as outlined, gave consistent results 
when these procedures were strictly adhered to. 
5. Fibrin° e Fibrin degradation Products Assay 
A rapid, accurate and reliable test for fibrin /fibrinogen 
degradation products would be of considerable use in clinical work. Although 
the T.R.C.H.I.I. assay, as routinely performed, has proved a useful research 
tool it has the disadvantage of requiring 24 hours before results can be 
obtained. An investigation was therefore made of supplementary methods 
which might prove suitable for the rapid measurement of F.D.Ps. 
A. Rapid T.R.C.H.I.I. Assay Method. 
The method, as routinely performed, required at least 24 hours before 
results were available. However, if high sensitivity of the test system is 
not required an estimate of the F.D.P. level could be made within 2 -3 hours 
of receiving the serum specimen. The modified method was as follows :- 
(a) Serum specimen reclotted with thrombin as per routine method. 
Adsorption stage omitted. 
(b) Dilution steps performed as usual and fibrinogen standard set up 
in microtiter plate. 
(c) Incubation period of test specimen and antisera omitted and sensitised 
red cells added immediately. 
(d) Incubation at 4 °C was for 2 -3 hours. Non -agglutinated cells at the 
end of this time had usually settled, forming end points that could 
be read, and a preliminary estimate of the F.D.P. level obtained. 
The plates were then returned to the refrigerator and final reading 
made after 24 hours. The sensitivity of this system was as low 
as 5pgms /ml., depending on the cell batch, but this was not of 
critical importance when dealing with pathological samples. 
Alternatively, the dilutions could be made up in plastic tubes 
and all reagents then mixed in similar tubes. The end point could 
then be read after 1 hour at 4 °C. 
It was thus possible to obtain rapid results using the modified 
routine T.R.C.H.I.I. assay. 
B. Micro Haemalutination - Inhibition Assay. 
Israel et al. (1968) described a micromodification of the 
T'..R.C.H.I.I. assay. This method apparently had the advantage of being a 
rapid test and of utilising a well recognised technique for detection of 
haemagglutination reactions in serological work (Chown, 1944; Chown and 
Lewis, 1946). This assay was therefore adapted for routine clinical use 
in the laboratory. 
It was clear at the onset that the reagents were similar to those 
of the routine. T.R.C.H.I.I. assay, apart from the concentration of sensitised 
cells and antisera. Therefore, for these tests the reagents were prepared 
as for the routine laboratory T.R.C.H.I.I. assay with the following 
modifications. 
(a) Fibrinogen coated tanned red cells. 
These were stored at 4 
0 
0,as already described, in a 2.5ó solution. 
For use, the cells were reconstituted in one -third of the original volume of 
diluting fluid, making a 7.0 cell suspension. 
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(b) Antisera. (Hoechst Pharmaceuticals Ltd.) 
This was used fresh at a dilution of 1:500 in diluting fluid, and 
kept at 4 °C during the assay procedures. 
The only other specialised equipment required was :- 
Glass capillary tubes. Length 10 cm., internal diameter 0.1 cm. These 
tubes were marked with a felt writer at 5.5 and 6.0 cros. from one end. 
Viewialjilis. A box was constructed, surmounted by a sheet of white 
translucent glass mounted at an angle of 52° from the horizontal, and 
illuminated from behind by a white light source. 
Plasticine. This was used for embedding the capillary tubes against the 
glass viewing box. 
Glass microscope slides. These were used for mixing reagents. 
The performance of the test was as follows :- 
(i) Antisera was diluted and kept at 4 °C. Sensitised fibrinogen coated 
cells were reconstituted to a 7.5% suspension. A frozen fibrinogen 
standard solution was thawed and serial dilutions made. 
Test specimens were treated with thrombin, as previously described for 
the T.R.C.H.I.I. assay. 
(iii) Serial dilutions of the non- adsorbed test sera were made in diluting 
fluid in plastic tubes. 
(iv) Each sample was drawn up in the capillary tube to the 5.5 cm. mark, 
and this being followed by 0.5 cm. of diluted antisera, drawn up 
to the 6.0 cm. mark. The contents were then blown on to a glass 
slide, mixed for 5 -10 seconds with the end of the capillary tube 
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and the mixture drawn by capillary action up into the tube again. 
Sensitised cells were then drawn up the capillary tube for a distance 
of approximately 0.5 cm. and the tube quickly inverted and the distal 
end embedded in plasticine against the illuminated glass. 
Haemagglutination was apparent within 20 minutes and tended to appear 
quite rapidly. End points of haemagglutination could easily be read 
without the aid of a magnifying glass and remained stable for several 
hours after the completion of the test. 
(v) The sensitivity of the system could be calculated from the fibrinogen 
standard, in a similar manner to the T.R.C.H.I.I. assay. The mean 
sensitivity in 28 separate assays was 7.0,..ggiml. and there was only 
minor variations in sensitivity between days. 
This method proved reliable and comparable results were obtained on 
the same sera in the T.R.C.H.I.I. assay (Fig. 3 :5). A result was available 
within 30 minutes of receiving the thrombin clotted serum, and an estimation 
of whether the serum was "low" or "high" in F.D.Ps. could be made even sooner. 
The system appeared as stable as that of the T.R.C.H.I.I., and non -specific 
agglutination was not a problem in the specimens examined, even though préliminai 
adsorption of the sera was not performed. However, care was still required in 
interpretation of the results as a very occasional non- adsorbed sera assayed 
by the T.R.C.H.I.I. were found to have a strong non -specific haemagglutinin 
present that required dilutions of up to 1:32 before the effect disappeared. 
Such sera could be assessed by this method as having very low levels of F.D.Ps. 
unless dilution steps were continued to at least 1:128. 
Technical manipulations of the assay were not difficult, and the 
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Fig. 3:5. Correlation between routine T.R.C.H.I.I. and 
microhaemagglutination assay systems for F.D.P. 
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quick assay method could be suitable for a routine coagulation- fibrinolytic 
laboratory. Sensitised cells suitable for the assay are now available 
commercially (Burroughs Wellcome & Co.) 
C. Latex Tests. 
A latex agglutination test has been used in laboratory work for the 
detection of rheumatoid factor (Singer et al., 1960). Latex particles coated 
with antisera, agglutinate in the presence of their respective antigen, and 
this method theoretically provides a rapid method of assessing the presence 
of specific antigenic material. 
Commercial reagents, such as "Fi Latex" (Hyland Laboratories Ltd.), 
are available in kits for the detection of afibrinogenaemia. These fibrinogen 
antisera coated latex particles have also been utilized for the detection of 
serum F.D.Ps. (Merskey et al., 1966). A preliminary investigation was 
therefore undertaken of the value of latex coated particles in the 
detection of F.D.P. in serum. 
Two types of latex coated particles were studied :- 
1. "Fi Test" (Hyland Laboratories) Latex. 
2. Latex particles (Burroughs Wellcome & Co.) coated with fibrinogen 
antisera (Hoechst Pharmaceuticals Ltd.) 
Method: 
Frozen serum samples were mixed with the latex particles on a 
glass microscope slide and mixed by rocking. The presence or absence of 
agglutination was observed over a period of 15 minutes. 
The results in two representative patients are summarised in 
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Table 3:8. 
It is evident that both false positive and negative results are 
occurring. In patient 1, in the first two samples, F.D.P. values are elevated, 
but the Latex Test was only a weak positive after a prolonged time. 
Positive tests were also obtained when F.D.Ps., as assessed by the T.R.C.H.I.I., 
were below 60 gm /ml. In patient 2, positive tests are slow to appear and 
in the initial samples, when F.D.P. values were high, are negative. 
From these preliminary results, it was apparent that the Latex 
Test, at this stage of development was not suitable as a consistently 
reliable method for the detection of F.D.P. in fibrinolytic states.. These 
findings are similar to Merskey et al. (1966), who also found false 
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CHAPTER IV. 
END POINT RECORDING DEVICES IN COAGULATION WORK. 
Numerous instruments have been designed to measure automatically 
the latter phases of coagulation (Koffman, 1910; Dale and Laidlaw, 1911; 
Cannon and Mendenhall, 1914; Kugelmass, 1923; Mies, 1931; Nygaard, 1941; 
Hartert, 1948; Barker, 1948; Elliot, 1952; Schnitger and Gross, 1954; 
Bishop et al., 1957). Very few have had popular appeal, and most 
laboratories to -day still rely on visual observations of fibrin end points 
by a skilled technician. Many of the end point recorders built for 
coagulation studies have been of complicated design and susceptible to 
mechanical failure, but recent instruments now becoming available appear to 
fulfil many of the necessary requirements for routine coagulation work. 
Convincing arguments for the use of automatic coagulation end 
point recorders include the ability to standardise the measurement of the 
final phase of clotting, and a reduction of technical error and observer 
bias. Skilled as a technician may be, errors in assessing the end point of 
coagulation will always occur and will vary both within and between days. 
Observer bias and fatigue have always been problems in paired observations, 
and a minimisation of these factors. by an objective end point recorder 
should considerably aid in improving: the consistency and accuracy of 
coagulation results. 
However, such a machine to record coagulation end points must be 
easy to operate (for even relatively unskilled personnel), achieve reproducible 
clotting times, have the capacity to deal with at least four clotting mixtures 
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at a time, have a low incidence of mechanical failure, and be versatile enough 
to deal with a wide variety of fibrin clot end points. 
Several coagulation end point recording machines were investigated 
for possible use in these studies. 
1. "Prothrombin Meter ". Grans Electroselenium Ltd.) 
This instrument, which is based on a photoelectric principle, 
measures the change in optical density occurring as fibrin forms in a 
recalcified coagulation mixture. At a preset critical opacity, the 
circuitry operates to stop a previously activated pulse counter. 
The two -channel machine studied was of basically good design and 
laboratory evaluation revealed that reproducible clotting times were easily 
recorded. Its use was limited, however, by poor temperature control, the 
small number of operating channels, the degree of adjustment of the controls 
needed before each clotting cycle, the restriction of the volume of clotting 
mixture required, and the poor ergometrics of the machine. In spite of the 
drawbacks this instrument has been utilized successfully for routine 
coagulation work by Eastham (1966). 
2. "Fibrometer" Coagulation Timer. (B.D. Laboratories Inc.) 
This machine operates on a different principle. Two electrodes, 
one stationary, the other moving, are introduced into a clotting mixture. 
Formation of fibrin is detected by the moving electrode, this then completes 
an electrical circuit and the machine is automatically stopped. The clotting 
time can be read from the counter mechanism to the nearest 0.1 second. 
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The basic design of this machine was very good. Because of 
transistorised circuits, it.was compact and could be linked up to identical 
Fibrometer units. Reproducibility was satisfactory once experience was 
obtained with manipulation of the electrodes. It was, however, only a single - 
channel instrument so that only one clotting mixture could be tested at a time. 
Electrode cleaning was not always easy and thrombin contamination of the 
electrodes could easily occur if exceptional care in cleaning was not taken. 
The digital read -out counter, although calibrated in tenths of a second, was 
accurate only to 0.5 second, this being the time taken for the electrode arm 
to complete a full sweep in the clotting mixture. The machine is, at 
present, very expensive and to build up a minimum set of four units would 
be prohibitive in cost. 
3. " Depex" Coagulometer. (Depex Ltd., de Bilt, The Netherlands). 
This machine resembles in principle, the "Fibrometer ". It is 
designed upon the plans outlined by Schnitger (1954.), but has several 
advantages in comparison with the Fibrometer. These include multiple 
measuring channels, a superior electrode cleaning system, a minimum of 
adjustment procedures, and a much lower unit cost. 
The instrument includes a heating block, into which clotting tubes 
containing incubation mixtures can be placed. Two electrodes are then 
introduced into the clotting mixture; upon the formation of a fibrin thread 
across the electrodes, an electrical circuit is completed; this in turn 
stops the counting mechanism previously set in motion. This machine was 
the most satisfactory of those tested and was selected for routine use. 
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Fig. 3:6. The Depex Coagulometer. 
The stand for cleaning the electrode is situated 
behind the machine. 
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A. Description of the Coagulometer. 
Fig. 3:6 illustrates the general design of the machine. The 
aluminium block is maintained at 37°C by a thermostat, and acts as the 
heating block for incubating mixtures. This heating block can be left on 
throughout a day's work. The machine has four channels, each with a 
separate counting mechanism activated by a press button type tumbler switch. 
Completion of a clotting cycle by the formation of a fibrin, is signalled by 
a small red light on the front of the machine and, at the same time, the 
counter automatically stops. The clotting time can then be read in 
seconds. 
Fig. 3:7 shows in diagrammatic form the details of the electrode 
system. Two electrodes, one fixed and grounded, the other moving and 
isolated, are fixed to a metal holder. This is then inserted into the 
main machine housing and the counter mechanism started. When the electrode 
holder is placed into the machine, a revolving cam forces the moving electrode, 
consisting of stainless steel hook, in and out of the liquid once a second. 
When the movable electrode reaches its highest position, it is automatically 
connected with the grid of an anode tube provided with a negative tension of 
24 volts via a resistance of 5 megohms. When clotting occurs, the hook pulls 
up a fibrin thread forming a low resistance connection between the moving and 
stationary electrodes, thus grounding the grid of the tube and causing an 
anode current which in turn activates a relay to stop the counter (Fig.3 :8). 
The electrode housing can then be removed from the machine, the 
electrode wiped with lint or a small brush, and heated in a non - luminous 
gas flame. After cooling, the electrodes are then ready for re -use. 
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Fig. 3:8. Circuit diagram of Coagulometer. 
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B. Practical use of the Coaulometer. 
The following factors were found to be important in the use of 
the Coagulometer. 
(a) 15 minutes was required for the heating block to reach a steady 
working temperature. 
(b) It was necessary for the electrodes to be clean and straight, and 
care was required in their handling. 
(c) The height of the tube holder had to be adjusted carefully to the 
volume of the incubation mixutre (0.2 - 0.6 ml.) 
(d) The clotting tubes required insertion to their full depth into the 
tube holders; failing this the counter mechanism would automatically 
stop when the electrodes were added. 
(e) The electrode holder had to be placed completely into its grooved 
platform. If this was not done the counter would stop. 
(f) Only one size of tube could be used (52.5 x 11.5 mM.). hïajor 
variants in tube size were unsuitable for the machine. 
Disturbances in the use of the Coagulometer were relatively few, 
but the following were noted :- 
(a) The heating of the aluminium block was variable. Temperatures 
throughout a day varied between 36 °C and 38 °C in one machine and 
35 °C and 38 °C in the other. A built -in visual thermometer was not 
supplied and checks were frequently made of the temperature. On 
one occasion when the thermostat failed, the temperature rose to 
56 °C without warning and several experiments were invalidated. 
This aspect of the machine could be improved. 
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(b) After considerable use, the camshaft of the movable electrodes showed 
signs of wear, and jamming of the revolving shaft occurred. This 
was rectified by replacing the electrode, but this required considerable 
adjustment of the electrode housing before reproducible results could 
again be obtained. 
(c) The pulse counters could not always be returned to true zero. This 
fault was inherent in the design of the machine and can introduce 
random error of up to one second in a determination. The position 
of the camshaft determines whether the counter can be returned to 
zero. 
(d) Irregularities of the clotting time could usually be traced to faulty 
techniques or variations in test tube shape. The machine was 
otherwise trouble free, although reasonable care was required in 
performing tests, otherwise poor results were obtained. 
C. ReproducibilitELeriments. 
Prior to use of the machine in these studies, an investigation of 
its reproducibility was made. The kaolin - cephalin clotting time measurement 
was used as a test method. 
Fresh plasmas were obtained and maintained at +4°C. At two 
minute intervals eight tubes containing 0.1 ml. plasma and 0.2 ml. kaolin - 
cephalin reagent were introduced into the heating blocks of two machines and 
allowed to incubate for 10 minutes. At the end of this time the tubes were 
recalcified with 0.1 ml. of 0.025 M calcium chloride and the clotting time 
recorded. Thus six clotting times at each of eight measuring points were 
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obtained, a total of 48 observations on each plasma sample. A typical set 
of results is recorded in Table 3:9. 
TABLE 3:9 
THE YAOLIN- CEPHALIN CLOTTING TflItE PERFOIEED ON TIE SALE PL.SMA 
USING TWO COAGULOMETERS IN SERIES. MEAN VALUE 39.1 ± 0,9 SECONDS 
Machine 1 Machine 2 
1 2 3 4 1 2 3 4 
Seconds Seconds 
40 40 41 41 - 40 40 39 
39 39 40 39 39 38 38 39 
39 39 41 40 40 40 39 39 
36 38 40 39 39 39 39 39 
39 38 39 40 40 39 39 38 
38 39 39 40 38 39 39 38 
Mean 
38.5 38.8 40.0 39.8 39.2 39.2 39.0 38.7 
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In three separate such experiments on different plasmas, the 
mean clotting times with standard deviations were :- 
Plasma A. 40.2 1.3 seconds 
Plasma B. 39.1 ± 0.9 seconds 
Plasma C. 50.0 f 1.2 seconds 
Mean standard deviation = f 1.1 seconds 
There was no significant difference between the clotting times 
obtained with separate machines (Plasma A: t = 1.079, 0.2<p<0.3; Plasma B: 
t = 1.076, 0.2 <p<0.3 N.S.; Plasma C: t = 0.711, 0.5<p<O.4 N.S.). There was, 
however, a significant difference between channels, but this varied between 
experiments, and no single channel was consistently recording significantly 
higher (or lower) results. 
In Experiment A there was a significant difference between channels 
1 and 3 in Machine 1 (0.05<p<0.025) and channels 1 and 4 (0.1<p<0.05) in 
Machine 2, but in Experiment B there was a significant difference between 
channels' 2 and 3 (0.02<p<0.01) in Machine 1, and in Experiment C between 
Channels 1 and 4 (0.1<p<0.05) in Machine 2. These results indicated a random 
error and could be explained by random variations in technique, e.g. not 
recalcifying at exactly the same time in each tube, and delay in pressing 
the activating counter. 
Other experiments were performed to assess if the time at which 
the electrode was inserted into the clotting mixture affected the clotting 
time. Plasmas, previously activated with kaolin- cephalin reagent were 
recalcified and the electrodes introduced at varying intervals, i.e. 
immediately after recalcification, 15, 30 and 45 seconds later, and prior to 
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the known coagulation time of that plasma. The results consistently 
demonstrated that the time of electrode introduction made no difference to 
the resultant clotting time. However, in most assay systems described, the 
electrodes were introduced with 20 seconds of recalcification. 
The effect of carbon collections on the electrodes was also 
investigated. .After each clotting test, the electrodes were wiped with 
lint or a brush and flamed in a gas flame. Carbon commonly formed on the 
electrodes if these were not properly cleaned. Several experiments showed 
that if the electrodes were not well flamed irregularities of the clotting 
time were more common, presumably due to carry -over of contaminating thrombin 
or thromboplastic material. 
There was a good correlation between assays performed on the 
same plasmas by both visual and machine techniques (r = 0.888,p<0.001) in 
a small series of twelve separate plasmas. With experience the machine 
technique was found to be less tiring and multiple samples could be handled 
easily. Clotting times generally improved when the technician had become 
thoroughly acquainted with the machine and was not disturbed while running 
multiple sets of assays. 
D. Comment. 
On the basis of these tests and practical routine experience the 
machine was accepted as a reliable instrument with the provision that 
determinations of clotting time in a single plasma sample required measuring 
at more than one recording point. Therefore, determinations of clotting 
time were always carried out in duplicate and often in triplicate. 
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The coagulometer was not used for determinations of clotting time 
below 20 -30 seconds, e.g. as in the thrombin, prothrombin times, and two -stage 
assays based upon the thromboplastin generation test. The "resolving" 
power of the moving probe is ±1 second, and thus the percentage error at 
such short clotting times would be higher. Satisfactory results could be 
obtained visually. However, if short clotting times were done in triplicate 
this criticism was only partly valid. It was also found that very long 
clotting times, with slow formation of fibrin (as with dilute solutions of 
thrombin and of fibrinogen) were difficult to record with the coagulometer 
and this type of infrequently occurring gel end point, i.e. greater than 
300 seconds, was usually performed visually. 
Experience with the machine also demonstrated that different 
operators would obtain closely similar coagulation times on the same plasma 
sample. Once routines were established technician fatigue was greatly 
reduced, and many more assays could be handled with greater accuracy. 
In summary, the Depex Coagulometer fulfilled many of the criteria 
for a practical laboratory end point recorder. Its accuracy, multiple 
channel design, reggedness, and simplicity were well substantiated. The 
main disadvantage was the inconvenience of the electrode cleaning method, 
but this could be minimised by the construction of a suitable electrode stand. 
Most of the work described in this thesis was based upon the practical use of 
this instrument. Such a machine could easily be integrated into a routine 
coagulation laboratory service and the use of several machines could greatly 
increase the output of accurate and consistent coagulation work. 
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CHAPTER V. 
COAGULATION AND THE COITUTER. 
The bioassay of coagulation factors is a well recognised facet 
of the work in many routine haematology laboratories. Such assay work is 
often both time consuming, technically demanding, and is susceptible to 
varied errors. For these reasons, all aids to eliminate avoidable error 
are worthwhile, particularly if reproducibility of technique can be improved. 
One possible source of error in coagulation assays lies in the 
calculating of the final results. Most assay systems require the plotting 
of parallel dose- response curves by eye on suitable logarithmic paper and 
estimating the horizontal shift necessary to superimpose one line on the 
other. This measurement is then proportional to the potency of the unknown 
sample, and for most purposes, this type of graphical calculation is both 
quick, simple and satisfactory. However, with some results, drawing the 
line of "best fit" may be difficult, and graphical calculation may obscure 
the fact that the test and control results are lying on dissimilar portions 
of the dose -response curve. Also, graphing of results is not easy when 
clotting times overlap. Another appreciable source of error is the variation 
between observers when plotting identical sets of results. 
For these reasons computed results, based upon the information 
obtained in assays, would be mathematically sound and would reduce a source 
of technical error. Such calculations are now available but are complex 
and unsuitable for routine use, except in special circumstances (Finney, 1952; 
Savage, 1959; Hardisty and Macpherson, 1962; Baumgarten et al., 1963; 
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Ingram, 1965). 
A study was therefore made to assess if a suitable programme, 
which would routinely compute coagulation assay results, could be written 
for the Edinburgh University K.D.F. -9 Computer. 
With the co- operation of Mr. W. Lutz, Edinburgh University 
Department of Statistics, a programme was written in Atlas Autocode based 
upon the mathematical information supplied by Ingram (1965) and Hardisty 
and Macpherson (1962). The mathematics on which the programme were evolved 
are included in the appendix, statistical methods (page 134). The programme 
included not only a computation of the potency of the test as compared with 
the control sample, but also a calculation of the 95% confidence limits of 
the assay. 
1. Principles of the Computer Prograrnme. 
The basic principles were as follows, and each stage may be 
identified in Fig. 3:9.(page 134). 
Step 1. 
Regression equations were calculated for both the test and control 
plasma clotting times (the dose response lines). 
An analysis of variants ( "F test ") was then performed to test for 
linearity of the calculated lines. If either line was not linear, the value 
for F was automatically printed as well as the critical F value at the 5% 
significance level. Suitable F test tables were included in the initial 
programming. 
Although the test for linearity was not strictly necessary at this 
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stage of calculation (Hills, 1968), it was found useful as an additional check 
for gross errors in clotting time results, or mistakes in teletyping. 
Step 2. 
The dose response curves were further mathematically tested, in 
two steps, for any departure from parallelism. 
(a) Test for homogeneity of variance. 
This test was included as a check that it was reasonable to pool 
the variances of the two calculated lines, before proceeding with the next 
stage, i.e. application of a significance test (t test) for parallelism. 
Only very large variances, i.e. 5 - 1 affect the application of this 
form of t test, and again the test is not strictly necessary. However, it was 
included as an additional check for gross discrepancies in variance. A 
suitable F test table was included in the programming, and again the value 
for the pooled variances (F) was printed out, and if this was significant 
the critical F value at the 5/ significance level also printed. 
(b) Application of the t test. 
This computation is designed to assess if the regression lines 
are significantly non- parallel. Biological assays as used in coagulation 
work do not always yield strictly parallel lines, and allowance must be 
made for this in assessing departures from parallelism. It is considered 
that if non -parallelism was apparent at the 5% level of significance, the 
initial clotting results should be reassessed for technical error. 
The programming was so arranged that if the regression lines 
were significantly non -parallel (5% level), the t test result would be 
printed out along with the critical t test at the 5% level of significance, 
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and the words "NON- PARALLEL ". 
Whether the lines were parallel or not the computer would 
automatically proceed to the next stage. 
Step 3. Calculation of Common Slopes and Potency Ratio. 
If the dose response curves were not significantly non -parallel 
the potency ratio (NO could be calculated from a formula which includes a 
Value for the common slope of the two lines. The potency ratio is obtained 
from the anti -log of M, which can then be expressed as a percentage. 
Both the log potency ratio and the potency ratio (percent) were 
printed out. 
Step 4. Calculation of Standard Error and Confidence Limits of Potency Ratio. 
The formulae for this calculation is included in the appendix. 
The standard error of both the log potency ratio and the potency ratio are 
calculated and printed out. The 95% confidence limits were obtained from 
t test table entries previously entered in the computer. From the standard 
error of the potency ratio, the standard error expressed as a percentage of 
the potency ratio could be obtained. 
2. Programme Safeguards. 
There were several safeguards included in the programme to detect 
discrepancies in either experimental technique or typed results. In brief 
these included :- 
(a) In the final print -out pattern (Fig. 3:9) the original clotting times of 
both test and control plasma are included, and this allowed quick 
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Fig.. 3:9. Computer "print -out" sheet. 
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(b) If the first F value was significant, the words "NON - LINEAR REGRESSION" 
were printed out. This would be a warning to reassess the initial 
clotting results. 
(c) If the second F test (homogeneity of variance) was significant this 
would be printed out. Values of F at this stage above 5.0 were 
usually significant and commonly denoted technical error. 
(d) The final safeguard was after the t test for parallelism. If 
parallelism was not present, this would be printed out with the 
words "NON -PARALLEL ". 
These were found to be satisfactory safeguards to protect against 
errors on the laboratory side. Many hundreds of assays, of varying 
combinations of results,were tested, and although care was required in the 
interpretation of the final "read out" sheet, anomalies were relatively few. 
With more experience of the method it might be possible to abbreviate the 
"read out" sheet further, perhaps by eliminating safeguards (b) and (c), 
although it was felt that these were useful as additional checks on 
procedure. 
3. Comments and Results. 
The programme was used extensively in calculating the results 
outlined in this thesis. It was found to be applicable to one -stage 
coagulation Factors VIII, LX, and XII assays as well as to two -stage 
Factor VIII assays. It could theoretically also be used for other assays 
(Factors V, VII, and X) although this was not routinely done as only 
relatively small numbers of these types of assays were performed. 
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In Fig. 3:10 are charted.the results of both graphical and 
computer calculations of test sample potencies. There is good agreement 
between the two sets of results. 
It was noted that graphed calculations of the test sample potency, 
as determined by two separate observers, gave a mean absolute variation of 
9.5%, i.e. on the same set of clotting results, different observers would 
obtain final potency values within 9.5% of each other, over a wide range of 
values. When each observer's results were compared with the results obtained 
from the computer, the mean absolute variation was 7.e.. One conclusion to 
be gathered from this information is that if different workers are graphing 
and calculating results within a laboratory, there is an inherent absolute 
error, probably As high as 10f, in estimating the final potency of the test 
sample. Although this may not be of great significance in most pathological 
conditions, in coagulation factor replacement work and in physiological studies, 
the error may be appreciable. The other conclusion to be gathered is that, 
on the average, the mathematically computed results and the graphically 
computed results will vary in absolute values by up to 7%. It can be 
appreciated that consistent results could best be obtained if one observer 
performed all the final calculations of test potencies; such a procedure is 
technically not always practical. and thus mathematical computation of final 
results in preferable. 
It was also found that the ready availability of the 95% confidence 
limits of the assay was particularly useful. Firstly, it could be seen at a 
glance if the confidence limits for any particular assay were within the known 
acceptable range for that assay, thus allowing the rapid detection of experiments 
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o/o FACTOR VIII (COMPUTER) 
Fig. 3:10. Correlation of Factor VIII assay results as calculated 
by computer and graph. 
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or technical errors. Secondly, the confidence limits would improve with 
Continued practice of the assay. These confidence limits could thus be used 
as a guide to the technical progress of laboratory staff. Thirdly, the 
effect of variations in technique could partially be assessed by the changes 
occurring in the confidence limits, as the formula on which the limits are 
based include not only the experimental errors of both the standard curve and 
test plasma results, as obtained in the routine use of the method, but the 
slope of the dose -response curve and the potency difference between the test 
and control plasmas. 
There were thus numerous advantages in the use of the computer 
for calculating coagulation results. On the other hand, the process was 
time consuming. Not only had the results to be compiled carefully, but 
considerable time was required to teletype the results on to tape before 
programming the computer. Between 20 -30 assays could be prepared in an 
afternoon's work, and there were numerous points at which script errors 
could occur. The final results were also not available rapidly. It is 
possible that a similar mathematical programme could be prepared for a desk - 
type computer, such as the Olivetti 101. Arrangements are in progress for this, 
and if this is practical, computation of coagulation results could become a 
rapid routine procedure in many coagulation laboratories. However, it is 
clear that the computation of coagulation results is a step towards automation 
of clotting techniques. If a semi -automatic clot timing machine could be 
constructed it should be possible to feed the clotting times directly into a 
teletyper linked to a computer, thus allowing the immediate return of results. 
Such an arrangement is at present being studied elsewhere (Denson, 1968). 
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There are only a few references'in the literature to the use of 
computers in coagulation work. Veltkamp (1968) mentions use of a digital 
computer in the calculations of lines of best fit in coagulation work, and 
Grant and Biggs (1966) have used an Elliot 803 computer to compute analysis 
of six point parallel line assays. Ingram (1967) has also prepared a 
suitable programme. 
It would appear that this method of computation of clotting results 
could be of considerable use in sequential research investigstions or in 
departments which require consistent reproducibility of assay results, as 
in a Blood Products Unit. 
If a rapid method of computation could be evolved, improved 
standardisation of assay techniques is a practical proposition. 
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CHAPTER VI. 
STANDARD REFERENCE PLASMAS 
In view of the known lability of coagulation Factors V and VIII 
on storage (Bidwell, 1955; Wolf, 1959; Macfarlane and Biggs, 1962; Britten 
and Grove -Rasmussen, 1966), the choice of a stable reference standard for use 
in assay studies on these factors presents problems. There are evidently 
great differences in the standards adopted between laboratories, and these 
variations, along with the inherent error in bioassay of coagulation factors, 
often make interpretation of reported results difficult. In the work 
described in this thesis it was thought necessary to investigate the relative 
value of different types of standards, as in the research investigation of 
physiological and pathological states of haemostasis it is of some importance 
to have a reliable reference standard, particularly for serial studies. 
Much work has been directed to evolving a suitable standard 
preparation for Factor VIII (Grant and Biggs, 1966), but conclusive 
evidence for the superiority of any one preparation is still lacking. 
Preparations at present in use, or under investigation, include :- 
(a) A fresh frozen plasma, stored in small aliquots at -20 °C or below 
and collected from 1 -30 normal donors (Bergna, 1960; Preston and 
Barr, 1964; Abildgaard et al., 1967; Garner, 1967). 
(b) Lyophilised preparations made from human or animal plasma of concentrates 
(Baumgarten et al., 1963; Kekwick and Walton, 1964; Grant and Biggs, 
1966; Simone et al., 1967). 
(c) The use of a selected donor whose levels of coagulation factors have 
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been assayed repeatedly (Pitney, 1956; Pool and Robinson, 1959; 
Edson et al., 1967; Veltkamp, 1968). 
In this study, these three types of standard have been assessed. 
1. Pooled Frozen Reference Plasma. 
This was prepared as follows :- 
10 ml. of blood were collected into prechilled plastic tubes from 
12 -18 normal blood donors at the conclusion of a donation of 400 ml. of blood. 
Care was taken to avoid excessive venous occlusion and the venepuncture was 
carefully performed. Preliminary experiments were made, comparing a single 
sample of blood separately collected from a post -blood donation sample, for 
the levels of Factor V, Factor VIII, the kaolin - cephalin clotting time and 
the prothrombin time. There was no significant difference between the pre 
and post donation results and it was therefore concluded that samples taken 
post donation were satisfactory for use in a control plasma pool. No 
selection by age was made. Samples were collected between 9.00 a.m. and 
10.00 a.m. at a routine blood donor clinic. The blood samples were 
centrifuged at 3,400 r.p.m. (2,230 g) for 30 minutes at 4 °C and later pooled 
in a siliconised container, also kept at 4 °C. 
Small aliquots of plasma from each donor sample were obtained and 
the kaolin -cephalin clotting time performed on each sample. Plasmas with 
clotting times lying outside one standard deviation from the Down mean 
clotting time of this test system were not included in the main plasma pool. 
This procedure was in an attempt to screen out donors with either very high 
or low levels of plasma intrinsic clotting factors, as the inclusion of extreme 
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values of one or more clotting factors could produce a mean pool value of 
well over or under 1O4ó. 
After pooling of the selected plasmas, small aliquots (0.5 -1.0 ml.) 
were dispensed into pre -cooled plastic tubes and immediately frozen in an 
open tube rack at -40 °C. For use, the standard was thawed at 37 °C with 
constant mixing to ensure complete solubility of any cryopecipitate formed 
during thawing, and then used immediately. 
Pools prepared in this way were of surprising uniformity; there 
were only small variations between Factor V and Factor VIII levels of separate 
pools when routinely assayed against each other. 
For assay of Factors V and VIII, the pooled plasmas were not used 
for longer than three weeks after preparation. For other assays, storage 
was continued for up to two months, although in most cases the pooled standard 
was depleted in a much shorter period. _ However, it was not possible to be 
certain that all pools were exactly io 4 of normal, as a stable standard for 
separate comparison between pools was not available over the complete time 
period. 
Additional experiments were performed on the stability of Factor V 
and Factor VIII in these prepared standards. 
(a) Factor V. 
The standard curve for this assay was prepared at twice weekly 
intervals for six weeks. A standard pool of phenolised rabbit brain 
thromboplastin was used throughout the experiment and the same stored 
Factor V deficient plasma. The clotting times obtained are summarised in 
- 143 - 
Table 3:10. It can be seen that the curve is very constant for three weeks 
with only minor variations in clotting time. After this time, however, there 
is small but appreciable lengthening of the clotting time at most dilutions and 
this was attributed to deterioration in Factor V activity. Accordingly, pools 
of plasma were not used for longer than three weeks after preparation. 
(b) Factor VIII. 
A similar experiment was attempted with the Factor VIII assay 
throughout the period of study. The results were not conclusive as technical 
continuity was not possible. It was noted that variations occurred in the 
clotting times of the same dilutions of the standard plasma between days, but 
the slope of the graphed standard line did not alter appreciably. The 
explanation of this phenomena was possibly due to small alterations in 
technique and reagents. The clotting times of separate aliquots of the 
reference plasma gave virtually identical clotting times throughout a day's 
work, although there was, as mentioned, intra -day variations. 
A procedure was arbitrarily adopted whereby control standard 
plasma for Factor VIII assays was not used for longer than three weeks 
after being collected. A new pool was then prepared. 
Levels of Factor VIII may be well maintained at -40°C when the 
above collection procedure is followed (Biggs, 1964). In six separate 
Factor VIII assays on out -dated standard plasma standards, stored for up 
to three months, the Factor VIII levels lay between 85A and 100%, mean 
93ió of normal plasma. 
This form of prepared standard was used throughout all studies, 
TABLI., 3:10 
THE STANDARD CONTROL CURVE OF FACTOR V ASSAY PERFORMED 
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and was found to be a reliable preparation. The intra -batch reproducibility 
of the standard plasmas may have been related to the rigorous screening of 
samples before being included in the main pool, and to the low temperature 
storage. In support of this Edson et al. (1967) have demonstrated that-high 
intrinsic coagulation factor levels are very commonly associated with short 
kaolin - cephalin clotting times. 
2. Lypolohilised Reference Plasma. 
20 ml. of blood-was collected by separate venepuncture by the 
usual technique from 20 normal donors (equal ratio males : females; mean 
age 36 years), centrifuged at 3,400 r.p.m. (2,230 g) for 30 minutes and pooled 
in a siliconised container. Using an accurately graded siliconised burette 
exactly 1.0 ml. of plasma was added to small siliconised glass tubes and 
these were immediately frozen at -70 °C in an alcohol /solid carbon dioxide 
mixture. The plasma was then lyophilised by a careful technique, filled with 
nitrogen, sealed and stored at ° -Q.0 C. For reconstitution, 1.0 ml. of distilled 
water was added and the solution used as soon as possible. 
The results using this standard preparation are summarised in 
Fig. 3:11 , At regular intervals the dried standard was compared with a 
pooled normal freshly prepared frozen standard by a two -stage Factor VIII 
assay technique. For four months, the dried standard gave results comparable 
to the different pooled plasmas, i.e. close to 100 normal. This was 
surprising as some loss of Factor VIII was thought to be inevitable on 
lyophilization. Although the drying process had been carefully controlled, 
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MONTHS OF STORAGE OF DRIED STANDARD 
PLASMA 
Fig. 3:11. Results of repeated assays on a freeze -dried standard 
plasma over a period of nine months. 
The numbers beneath the graphed line refer to the number of assays 
performed at each test. 
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no screening for high Factor VIII levels of the samples had been performed 
before pooling was performed. The potency of this standard however, was 
assessed by another laboratory at 102% (mean of 18 assays) (Denson, 1966). 
After four months the range of values obtained on assay of the 
standard was lower, and some tubes yielded consistently lower results. At 
six months the mean value of Factor VIII was 84%. At nine months the mean 
value was 7. The deterioration in the lyophilised standard was also 
confirmed by the routine Blood Coagulation Service in separate assays in 
relation to Factor VIII concentrates. The standard was also again assessed 
by the Oxford Laboratory, and the Factor VIII level was now found to be 
83% (Denson, 1967). 
Possible factors contributing to the alteration in Factor VIII 
levels include :- 
(a) Sealing of some tubes had been unsatisfactory. Moisture is 
deleterious to Factor VIII stability in concentrates (Kekwick and 
Walton, 1964) and it is feasible that this factor alone could explain 
the change. In future preparation sealed ampoules would be more 
satisfactory, but these were not available at the time of the 
initial experiment. 
(b) Initial lyophilising may have been inadequate. The criteria of adequate 
drying has not been well defined for Factor VIII concentrates but the 
process in this department usually yield a moisture content of less 
than 0.1-0.5% of dry weight, which is comparable to other centres 
(Menarche, 1967). 
(c) The temperature of storage of the standard, which was usually below 
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-25 °C, had been inadvertently increased to between -5 °C and -10 °C 
for at least two weeks on one Occasion. Low temperatures may be 
important in the preservation of Factor VIII in dried samples 
(KekGvick and Walton, 1964; Thelin, 1968). 
(d) Variations in the levels of Factor VIII in the eight different donor 
frozen plasma standard pools may have occurred.. This was minimised 
by the use of pools prepared as in Section 1. That these pools 
were not markedly different was evidenced by the small variations 
between pools when assayed against each other. However, this 
factor cannot be disregarded, and could explain the results 
obtained in the later months. 
(e) The basic assay system may have altered. There was no real evidence 
for this, as reagents and techniques had been standardised as far 
as was practical throughout the period. Nevertheless, the assay 
system is far from precise and this factor cannot be excluded. 
It is less likely in view of the results obtained from the Oxford 
Laboratory. 
The final conclusion was that a lyophilised plasma reference 
standard could be prepared but considerable care would be required in its 
production and storage. These conclusions are similar to Thelin (1968) 
describing a commercially prepared Factor VIII standard (Hyland Laboratories). 
3. Selected Donors for Standard Reference Plasmas. 
This method of control can be applied to Factor VIII assays 
(Veltkamp, 1968). Freshly withdrawn plasma from selected donors are first 
assayed against a range of normal donors, and the mean values obtained. A 
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correction factor is then applied to convert the test sample value to a 
percentage of 10Q%. Alternatively, plasma from the same donor is withdrawn 
at fortnightly intervals and frozen in small aliquots. This method, although 
suitable if the donor is known to be exactly a 100 Factor VIII level, is not 
practical in a routine laboratory. 
Control of Factor VIII assays by this method was not fully 
investigated. In a limited study, the two individuals studied appeared to 
show variations in Factor VIII levels when assayed against a frozen pooled 
plasma both within and between days. The frequent bleeding of the same donors 
was also regarded as being inconvenient. Some workers have reported that the 
Factor VIII levels of individual subjects are relatively constant (Grant and 
Biggs, 1966), but other recent workers utilising a standard lyophilised 
reference plasma (Simone et al., 1967) have not been able to confirm this. 
In view of the known fluctuations of Factor VIII with adrenaline or exercise 
stress, it would seem unwise to regard any individual as having a constant 
level of Factor VIII. Accordingly, this type of control method was not used; 
further investigation with stable standards would be helpful in assessing the 
degree of variation normally occurring in individuals. 
Most of the above work refers to Factor V and Factor VIII assay 
systems as the problem of suitable controls is a greater problem with these 
less stable factors. Although the remaining coagulation factors are 
stable, it would be a major step forward if a suitable standard lyophilised 
preparation could be made available for use in the assay of these factors, 
thus reducing intra laboratory variation and allowing more critical comparisons 
of coagulation assay results. 
SEC'.CION 4. 
THE EFFECT Or EXERCISE AND ADRENALIN 
ON BLOOD COAGULATION AND FIBRINOLYSIS. 
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CI-+APr.l'r;rt 1. 
THE EFFECT OF EXERCISE ON BLOOD COAGULATION AND FIBRINOLYSIS 
Introduction. 
The effect of muscular exercise on blood coagulation has been 
studied widely in both man and laboratory animals (Hartman, 1927; Mills 
and Recheles, 1928; Vouri, 1950; Schneider and Zangari, 1951; Warnock 
et al., 1957; Rizza, 1961; Keeney, 1962; Egeberg, 1963; Goudeman.d et al., 
1964; Von Kaulla and Von Kaulla, 1964; Finkel and Cumming, 1965). Other 
workers have investigated the changes in the fibrinolytic system (Biggs et al., 
1947; Sherry et al -., 1959; Truelove, 1951; Fearnley and Lackner, 1955; 
Billimoria et al., 1959; Sawyer et al., 1960; Ratnoff and Donaldson, 1960; 
Ogston and Fullerton, 1961; Angelino, 1964; Jang et al., 1964; Ogston and 
McAndrew, 1964; Cash and Allan, 1967; Menon, 1967), but there have been 
relatively few studies combining measurements of both these aspects of 
haemostasis (Guest and Calender, 1960; Bcad et al., 1961; Iatridis and 
Ferguson, 1963; Ikkala et al., 1963; Burt et al., 1964). 
From these observations it has become apparent that exercise has 
an effect on both the coagulation and fibrinolytic systems, and that the 
degree of change within certain limits, is proportional to the intensity of 
the stimulus (Ogston, 1961; Rizza, 1961; Angelino, 1964; Cash and 
Woodfield, 1967; Menon et al., 1967). It is also clear that changes in 
fibrinolytic tests are more marked than those in the coagulation tests. 
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(Iatridis and Ferguson, 1963; Burt et al., 1964). Physical exercise causes 
an acceleration of various in vitro measurements of blood coagulation with 
the production of a form of hypercoaguability, while tests of fibrinolysis 
demonstrate an increased potential ability of the blood to lyse fibrin. 
Some, but not all of the changes in the various coagulation tests can be 
attributed to the apparent rise of Factor VIII 4:or known to occur after 
strenuous exercise (Rizza, 1961; Egeberg, 1963), while the alterations in 
the fibrinolytic system are regarded as reflecting increased levels of 
circulating plasminogen activator (Sherry, 1959; Iatridis and Ferguson, 
1963). 
If, as has been suggested (Astrup, 1956), the coagulation and 
fibrinolytic systems are in a state of balanced equilibrium, then it might 
be postulated that the two systems are linked by certain components which 
are common to each. There is evidence to suggest that Factor XII (Hageman 
Factor) is in some way, related to the endogenous activation of both the 
coagulation and fibrinolytic systems ( Niewiarowski and Prou- Tartelle, 1959; 
Iatridis, 1961; Iatridis and Ferguson, 1961, 1962, 1964; Holeman and 
Roberts, 1964; Aznar and Lopez- Borresca, 1965; Aznar and Macarulla, 1965; 
Iaeniewski, 1965; Holeman, McConnell and Johnston, 1966). Experiments 
in vitro have indicated that surface activation of plasma by a variety of 
physical agents such as glass or kaolin will accelerate fibrinolysis in 
euglobulin solutions (Niewiarowski and Prou- Nartelle, 1959; Iatridis and 
Ferguson, 1965; Kleniewski, 1965; Ratnoff, 1966), and this phenomena does 
not take place if the plasma is deficient in Hageman Factor. Holeman and 
Roberts (1964) have also shown that Hageman Factor deficient subjects 
submitted to venous occlusion of the forearm, exhibit a lower fibrinolytic 
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response than do normal subjects. It has also been noted that Hageman Factor 
deficient patients have a low resting activity of blood fibrinolytic activity 
(Niewiarowski and Prou -Wartelle, 1959; Iatridis and Ferguson, 1962; 
Holeman and Roberts, 1964). Also, some purified forms of Hageman Factor 
have plasminogen activator -like activity (Aznar et al., 1964; Haanen et al, 
1964). Surface contact, by way of numerous physical agents can activate the 
intrinsic pathway of coagulation and this reaction is dependent on the presence 
of Hageman Factor (Ratnoff, 1961). Thus it appeared on experimental grounds 
that Hageman Factor might possibly be a common component of both systems. 
Further evidence was provided by Iatridis and Ferguson (1963), 
who in a study of coagulation and fibrinolysis in relation to exercise, 
found that strenous activity produced an apparent threefold rise in Factor XII 
along with marked increase in fibrinolytic activity. In Hageman Factor 
deficient subjects the fibrinolytic change was very small. It was therefore 
postulated that there was some dependence of the thrombolytic activity 
evolved on the amount of activated Hageman Factor available. 
The activation of the fibrinolytic system by exercise was studied 
closely by Cash (1967). Utilizing a standardised moderate exercise procedure 
on a treadmill, the degree of fibrinolytic activity evoked, as measured by 
the increase in euglobulin lysis activity, was found to be a reproducible 
phenomena in normal individuals, and there was a significant intra subject 
variation in response. A small group of these subjects had an apparently 
very poor fibrinolytic response to the exercise stress, and it was 
postulated that in situations of intravascular stress, these individuals 
might be at risk to conditions such as atherosclerosis, thrombosis and 
irreversible shock in which a defective fibrinolytic system has been shown 
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to play some part (Astrup, 1956; Hardaway, 1966). Closer analysis of the 
publications of other research groups also confirmed the presence in 
apparently normal populations, of poor fibrinolytic responders (Biggs et al., 
1947; Iatridis and Ferguson, 1963; Burt et al., 1964). Iatridis and 
Ferguson (1963), had attempted to assess the change of Factor XII and 
fibrinolysis in this group of subjects but without arriving at any firm 
conclusions. 
These previous investigations indicated that exercise studies 
of the stimulated coagulation and fibrinolytic systems in a group of normal 
subjects could conceivably lead to an elucidation of the relationship 
existing between Factor XII and fibrinolysis and as well as accumulating 
further information on the coagulation changes occurring in the poor 
fibrinolytic responder. The significant findings, in any individual 
might not necessarily be the resting level of either the coagulation or 
fibrinolytic system factors, but the way in which both mechanisms reacted 
following a standard exercise stimulus. Any detectable latent tendency 
towards a dis- equilibrium of the coagulation and fibrinolytic response 
might be of a pathophysiological relevance in those situations that could 
be associated with an episode of intravascular coagulation. Alternatively, 
the poor fibrinolytic responder might not be at a disadvantage if it could 
be shown that the coagulation system was also compensating by a lowered 
rate of fibrin formation. 
In summary, therefore, it was planned to investigate simultaneously, 
changes in both the coagulation and fibrinolytic systems in a group of 
apparently healthy subjects, following exercise stress. Reported alterations 
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in Factor XII activity were to be confirmed and correlations attempted 
between the coagulation and fibrinolytic test results, and equated with 
the dynamic equilibrium theory of haemostasis. At the same time, a 
detailed study of the coagulation system in the poor fibrinolytic responders 
could be made. 
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SUBJECTS and EXPERIMENTAL DESIGN. 
Prior to commencing; experiments on submaximal exercise procedures, 
studies were required to determine which coagulation tests would yield 
measurable alterations on exercise. A severe exercise procedure was therefore 
initially chosen, this stimulus being the most likely to produce marked 
changes in both the clotting and fibrinolytic systems. It was uroposed 
that coagulation tests demonstrating marked changes on severe exercise 
were to be used for submaximal exercise studies. 
A. Severe exercise study. 
Fourteen healthy volunteers (all male) were chosen for the 
severe exercise study. Eleven of these subjects were aged between 21 and 
31 years (mean age 25), the remaining three were known poor fibrinolytic 
responders, aged between 46 and 49 years (mean age 48). No young poor 
responders at this time were available. 
The group of young subjects were recruited from laboratory 
staff and other medical personnel; all had satisfactory medical histories. 
The three middle -aged volunteers were required to give a full medical 
history, and were submitted to a further medical examination, as outlined 
in B. 
The severe exercise.procedu.re consisted of walking on a treadmill 
at an elevation of 10o for three minutes at 3.4 m.p.h., followed by three 
minutes at 3.7 m.p.h. and then one minute at 4.0 m.p.h.; the speed was then 
increased to 4.2 m.p.h. until the subject removed himself from the trreadmill, 
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and the time required for this varied between one and eight minutes. Each 
exercise was preceeded by an obligatory supine rest period of 30 minutes. 
Blood samples were taken from an antecubital vein both prior to and 
immediately following the exercise; in some investigations additional 
samples were taken over the hour following the exercise. The mean pulse 
rate increase using this procedure was 192 
± 
13 /min., and was similar in 
both the young and middle -aged subjects. 
All experiments were conducted between 9.00 a.ni. and 12 noon, 
after a light breakfast, in a procedure room at 19 - 20 °C. Smoking and 
excessive exercise before the exercise procedure was discouraged. 
B. Moderate exercise study. 
From a panel of 50 middle -aged subjects recruited one year 
previously for fibrinolytic studies, 18 were again approached and asked if 
a further study exercise could be made. All subjects consented. The 
selection of subjects was made on the basis of their previously established 
fibrinolytic response; i.e. low, mid and high fibrinolytic responders were 
specifically chosen. The number in each category of fibrinolytic response 
is shown as follows :- 
Fibrinolytic response / No. of subjects 
0 - 20 2 
21 - 40 7 
41 - 60 6 
Over 60 3 
In this group there were 15 males and 3 females. The age range was 
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43 to 55 with a mean of 49 years. 
These middle -aged volunteers had been previously medically 
investigated, and the following parameters assessed. 
1. Medical history. 
2. Medical examination; including clinical examination of heart, 
peripheral pulses, chest and abdomen. 
3. Measurement of resting (supine 15 minutes) blood pressure (by 
auscultation). 
4. Urine analysis for sugar and albumin. 
5. Full Blood Count. 
6. Resting and post exercise (2 minutes step -up test) 
electrocardiography. 
With this new study, a year later, these parameters were again 
repeated on an initial visit to the laboratory. In addition, fasting blood 
samples were obtained for the following tests. 
1. Blood glucose. 
2. Serum cholesterol. 
3. Serum free fatty acids. 
4. Serum triglycerides. 
These latter tests were included to assess if any subject had 
latent biochemical evidence of changes commonly associated with cardiovascular 
disease. 
In some individuals changes were seen on the post exercise 
electrocardiographs in the absence of clinical symptomatology. These 
E.C.Gs. were referr6d to a cardiologist for assessment before exercise studies 
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were commenced, and full details are given in the appendix (page 365). 
The standard exercise used was an eight minute walk on a treadmill, 
móving at a speed of 3.4 m.p.h. at an angle of ° 5 elevation. Each exercise 
procedure was preceded by an obligatory rest period, lying down, of 30 minutes, 
and the same environmental conditions were observed as for the exhaustive 
exercise procedures. Blood samples were obtained from an ante- cubital 
vein, with minimal venous occlusion, prior to, and immediately following 
the exercise. All subjects were studied on more than one occasion with a 
time interval of at least a week, and often longer, between separate 
exercise procedures. 
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RESULTS. 
A. Exhaustive Exercise Study. 
The results of these experiments are summarised in Tables 
4:1, 2, 3 and 4. 
(a) Global tests of coagulation (Table 4:1). 
There was a significant change in the whole blood clotting time 
in silicone (t = 2.553, 0.05<p<0.025); the recalcified plasma clotting 
time both with platelet rich plasma (t = 7.000, p<0.001) and platelet poor 
plasma (t = 5.660, p<0.001); and the kaolin - cephalin clotting time (t = 4.585 
p<0.001). No significant change. was seen in the prothrombin time or 
thrombin 
The percentage change in the whole blood clotting time (mean 9%), 
and the kaolin -cephalin clotting time (mean 8%) could be explained by the 
alteration in haematocrit occurring post exercise (mean change 8%). There 
was a significant correlation between the K.C.C.T. and haematocrit (r = 0.79, 
0.02>p>0.01). No significant correlations were found between the percentage 
change between each type of clotting test. The changes in the coagulation 
tests of the three poor fibrinolytic responders (subjects 5, 6 and 7) were of 
a similar order to that of the other subjects examined. 
(b) Factor Assays (Table 4:2). 
Significant increase occurred in the levels of fibrinogen (t = 3.60, 
0.01 >p>0.005), Factor VIII (p<0.001), and H.P.F. (t = 4.463, 0.01 >p>0.02),. 
TABLE 4:1. 
THE EFFECT OF A SEVERE EXERCISE PROCEDURE ON THE GLOBAL TESTS OF COAGULATION, 
AND ON HEPARIN PRECIPITABLE FRACTION, IN FIFTEEN SUBJECTS. 
TEST 
ahole Blood Clotting 
Time (-Minutes) 










mgms100 ml. Glass Silicone Platelet Rich Platelet Poor 
(Seconds) 
Subject B A B A B A B A B A B A B A B A 
1 6.6 6.0 20.6.'16.0 120 104 149 112 36.2 34.1 15.1 15.1 
i 
12.0 12.0 - - 
2 7.5 6.0 17.1 15.6 117 84 174 107 37.3 35.4 14.9 15.1 13.1 12.0 35.2 44.9 
3 8.5 8.1 21.4 20.0 127 105 281 134 42.5 40.0 13.8 14.2 12.5 12.6 - - 
4 9.2 8.0 16.0 17.1 100 98 201 155 34.1 30.8 16.1 15.4 13.2 13.9 - - 
5* 9.0 10.0 22.4 20.1 92 56 190 120 38.2 35.3 - 
1 
- - - - - 
6* 6.2 5.9 16.1 14.2 125 111 171 156 35.1 33.2 13.8 13.8 14.2 14.1 - - 
7* 7 11.0 10.7 21.9 21.0 104 93 180 132 40.2 37.1 14.0 14.0 15.0 15.8 - - 
8 - - - - 118 99 196 173 37.6 35.0 15.0 15.1 12.0 12.8 38.7 67.9 
9 - - - - 110 98 231 181 39.2 36.3 14.9 15.0 13.2 13.3 29.0 45.0 
10 - - - - 140 119 292 192 40.6 36.1 14.0 12.8 - - 34.0 59.0 
54.0 11 
12 
- - - - - - - - 39.0 38.1 - - 12.3 12.4 34.0 
- - - - - - - - - - - - - - - - 
13 - - - - - - - - - - - - - - 44.3 97.4 
14 - - - - 125 108 184 132 35.5 34.5 14.0 14.0 - - - - 




































t = 1.5604 
N.S. 
t = 2.5525 
0.05)p,0.025 
t = 7.000 
pt0.001 
t = 5.6600 
pt0.001 
t = 4.5854 
p4-0.001 
t = 0.730 
N.S. 
t = 0.7385 
N.S. 
t = 4.4627 
0.01)p70.002 
* `Poor Fibrinolytic Responders' 
N.S. = Not Significant 
B = Before Exercise 
A = After Exercise 
TABLE 4:2. 









II V ____j_ VII 1 VIII IX X XII XIII "Contact Factor" 
Activity 
Figures are Expressed as a percentage of the pre exercise value (ó). 
mgm /100 ml. 
1 - - - - - 131 - - 105 - - 
2 - - 110 115 - - - 109 98 - - 
3 - - 105 121 - - - - 99 - - 
4 - - 113 107 - - - - 143 - - 
5* 263 284 - 105 - 142 - - 79 - - 
6* 221 226 - - - 196 - - 125 - - 
7* 373 437 - _ - 170 - --- 
89 - - -- ,---- --- - -- 
8 
_._____-____ 
204 221 89 - - 181 106 100 - - - 
9 162 174 - 98 - 135 115 96 - - - 
10 155 213 - - 106 214 92 103 - - - 
11 154 169 - - 97 252 103 110 - - - 
12 - 107 110 - - - - 98 - - 
13 169 187 - - 101 160 97 82 115 
110 
120 - 95 120 14 - - 100 - 89 181 90 




























t = 0.6267 
N.S. 
t = 0.6244 
N.S. 






t = 1.142 
N.S. 
t = 3.4778 
0.02> p > 0.01 
t = 0.1137 
N.S. 
t = 5.5535 
p 4. 0.001 
* Fibrinolytic Poor Responders. N.S. = Not Significant. 
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The percentage change in fibrinogen (8 %) was similar to the percentage 
increase of haematocrit (8 %). Factor VIII was increased post exercise 
to a mean of 180 but the percentage rise was not significantly correlated 
with the percentage increase in fibrinogen or other global clotting tests. 
Subjects 5, 6 and 7 (poor fibrinolytic responders) gave normal increases in 
the levels of Factor VIII. The percentage change in H.P.F. was 61f of the 
baseline value; this increase did not show a significant correlation with 
the percentage increase in fibrinogen. 
Small changes occurred in the levels of other clotting factors 
but none reached significant levels and were of no greater extent than would 
be expected from`_the alteration in haematocrit. Of particular note, was 
the absence of a significant change in Factor XII levels. 
(c) Fibrinolytic Tests. (Table 4:3). 
The changes in the fibrinolytic system are listed in Table 
There was,-significant decrease in the euglobulin lysis time (t = 3.0136, 
0.01> p> 0.005) and the mean percentage response (including the three poor 
fibrinolytic responders 5, 6 and 7) was 75 150. These changes were 
reflected in the fibrin plate assays (Table 4:3). 
Despite the marked increase in plasminogen activator levels, 
as evidenced by the greatly shortened euglobulin lysis time, there was no 
significant difference (t = 1.3707) post exercise, in the values of fibrin/ 
fibrinogen degradation products, in 7 subjects. 
The mean percentage change in fibrinolysis, as assessed by the 
estimations of the euglobulin lysis time was approximately three times the 
percentage change in coagulation as indicated by recalcification time of 
TABLE 4:3. 




Time (Minutes) Response 












B* A B A B A B A B A 
1 120 22 88 - - - - - - - - 
2 141 16 89 400 900 105 528 100 625 - - 
3 104 20 80 - - - - - - - - 
4 231 43 81 - - - - - - - - 
5** 765 413 46 100 240 loo 144 49 64 - - 
6** 525 300 
4 
52 225 380 100 100 0 0 - - 
7 ** 
e- _ 
73 0 5 9 324 64 81 0 0 - - 
8 135 40 70 455 700 121 225 138 360 3.6 14.3 
9 106 41 61 473 675 100 181 121 225 7.2 5.4 
10 99 23 77 361 702 132 398 100 400 9.0 12.8 
11 63 15 76 546 1422 121 599 100 729 9.3 12.3 
12 321 59 82 - - - - - - - - 
13 592 71 88 275 710 - - 56 182 5.4 3.6 
14 397 26 93 494 1177 - - 100 700 10.8 12.6 





























t = 5.3467 
p L 0.001 
t = 4.6488 
p 4 -0.001 
t = 2.8367 
0.05 > p >0.025 
t = 3.3714 
0.01 > p >0.005 
t = 1.3707 
Not significant 
* Abbreviations B = Before Exercise 
A = After Exercise 
** Fibrinolytic'Poor Responders' 
TABLE 4:4. 
THE EFFECT OF SEVERE EXERCISE ON SPECIFIC COAGULATION FACTORS 
I II V VII 
--1---- 






















































2 -3x increase 
(One stage assay) 
N° Change 
(One stage 
method) - No Change Slight Increase - - 






















- - - - 
158% 
Average increase 




































plasma. This observation is similar to that of Burt et al. (1964). 
The mean percentage decrease of the euglobulin lysis time in 
subjects 5, 6 and 7 was 50f, as compared with a mean of 81 %o in the other 
subjects. 
There were no significant positive correlations between the 
percentage decrease in euglobulin lysis times and the percentage change 
in any of the clotting tests. 
B. Moderate Exercise Study. 
The results of the severe exercise study indicate that 
submaximal studies of coagulation would be of limited value as only a 
few coagulation tests would yield significant changes. The moderate 
exercise experiments were therefore orientated towards a further assessment 
of fibrinolysis with a few selected coagulation tests included. 
(a) Fibrinolytic Tests. 
The results of the fibrinolytic study in the eighteen selected 
modle -aged subjects are shown in Table 4:5. The mean pre exercise 
baseline euglobulin lysis time was 251 ± 222 minutes, and there was no 
statistical difference between this value and that recorded in the study 
one year earlier (t = 0.5594, p = N.S.). A good correlation was also 
found between both the individual resting euglobulin lysis times, the 
percentage responses, and the previous studies of these parameters 
(r = 0.84, p<0.001; r = 0.86, p<0.001, respectively). The correlation 
between the f ibrinolytic responses in the two studies is illustrated in 
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II 0 I I I 
o 10 20 30 60 70 80 
° ° /oFIBRINOLYTIC RESPONSE (Ist. Study). 
40 50 
Fig. 4:1. Correlation between the percentage fibrinolytic responses in 
two separate studies performed one year apart. 
TABLE 4:5. 
THE RESULTS OF THE EUGLOBULIN LYSIS TIME ESTIMATION 














































































































































































t test 1 t = 4.0875,_ p '0.001 
Figures in parenthesis refer to subject number of previous study (Cash, 1967) 
TABL'I, 4:6 
COLPARISON OF TEE RESTING EUGLOBULIN LYSIS TIMES BEFORE 
AND AFTER IODERATE EXERCISE, AND THE PERCENTAGE RESPONSES, 
IN EIGHTEEN MIDDLE -AGED SUBJECTS, IN TWO SEPARATE STUDIES. 
Subject 
Mean resting euglobulin 
lysis time (minutes 
Mean percentage response 
1st. study 2nd study 1st study 2nd. study 
M 1 125 274 56 49 
M 2 79 246 45 51 
M 3* 865 581 10 13 
M 4 79 258 57 48 
M 5 140 137 34 43 
M 6 log 1g1 43 43 
M -7 596 402 36 35 
M 8 218 311 52 48 
M 9 202 378 59 54 
mio* 593 479 10 8 
Mal 429 307 48 44 
M12 173 120 58 47 
M13 114 268 3o 46 
M14 245 261 53 68 
M15 107 219 37 54 
F 1 104 240 32 28 
F 2 125 184 68 77 
F 3 206 346 65 58 
Mean + S.D. 251 + 222 289 + 116 44.1 ± 17 45.2 + 17 
"t "test 
t = 1.1743 
(Not significant) 




r = 0.84 
(pLa001) 
r = 0.86 
(p 4.001) 
* Poor fibrinolytic responder 
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The results of the F.B.P. assays are summarized in Table 4 :7. 
There is no significant increase post exercise (t = -1.1941, 0.3 >p >0.2). 
Some of the assays were repeated on several occasions, by separate technicianq, 
and the findings were confirmed. 
(b) Coagulation Tests . 
There were no significant changes in the pre and post exercise 
plasmas using the kaolih-cephalin clotting time, the recalcified plasma 
clotting time of platelet rich plasma, Factor V, VIII or XII levels. 
A test showing a significant change was the recalcified plasma clotting 
time on platelet poor plasma (Table 4:8). Experiments using a modified 
stypen time test suggested that the shortening of clotting time observed 
could be due to a phospholipid -like activity (similar to platelet Factor III 
activity) appearing in the plasma post exercise. There was no significant 
correlation in the percentage changes in this clotting time compared with 
the fibrinolytic response (t = 0.3267). 
There was again a significant increase in the level of heparin 
precipitable fraction (t = 2.2544, 0.05>T> 0.025) (Table 4:9) 
Reproducibility of baseline values and response by individuals was poor 
and there was no correlation with the fibrinolytic response. 
(c) Biochemical Changes. 
These are listed in Table 4:10. Most results are within the 
normal ranges for fasting serum samples. Two poor (M3 and 2a10), and two 
high responders (M12 and F3) had levels of serum triglycerides above the 





















































































































































































































































































































































































































































































































































































THE EFFECT OF A STANDAF.DISED MODERATE EXERCISE PROCEDURE ON TRIM RECALCIr2CATION 
TINE (SECONDS) OF PLATT+T,ET POOR PLASMA IN FIFTEEN SUBJECTS (30 OBSERVATIONS) 
Subject Before After % Response Subject Before After % Response 
M 1 199 182 9 M 9 218 172 21 
199 172 14 260 219 16 
M 2 216 185 14 M10* 170 152 11 
162 138 15 190 171 10 
M 3* 198 172 13 Ell 171 149 13 
186 171 8 182 149 18 
M 4 176 174 1 1112 237 219 8 
193 173 10 215 166 23 
M 5 201 172 14 1113 195 179 8 
180 150 17 152 129 15 
M 6 212 204 4 F 1 183 167 9 
190 159 16 197 163 17 
M 7 223 200 10 F 2 214 170 21 
174 151 13 198 139 30 
M 8 155 148 5 Mean 194 168 13 
166 142 14 S.D. +24 +22 +6 
"t"test t = 4.3168 
pG.001 
* Poor fibrinolytic responder 
TABLE 4:9. 
THE CHANGES IN HEPARIN PRECIPITABLE FRACTION (mgms. /100 mis.) AFTER A 
MODERATE EXERCISE PROCEDURE IN SEVENTEEN SUBJECTS (27 OBSERVATIONS) 
Subject Before After % Change Subject Before After % Change 


















N11 51.0 57.0 12 
41.0 52.0 27 






33 N13 26.5 32.2 21 



































47 M 8 28.0 48.4 72 
F 3 






"t "test t = 2.2544 
0.05<pC0.025 
* Poor fibrinolytic responder 
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serum F.F.A. Two subjects (M4 and M6) had levels of serum F.F.A. above 
the normal range but no other biochemical abnormality. One fibrinolytic 
good responder had an elevated cholesterol value (F2), with an elevated 
F.F.A. The significance of these isolated changes is not known. 
TABLE 4 :10. 













in nI /1 
(Normal range 





500 -700 mEgfl) 
Blood Glucose 
Upper limit of 
Normal 120 mgms. 2; 
M 1 7.9 251 110 754 60 
M 2 6.8 193 117 696 60 
M 3* 1.6 220 168 529 102 
M 4 11.9 185 83 1019 75 
M 5 8.6 231 103 745 78 
M 6 11.7 208 110 1009 90 
M 7 4.1 195 125 754 84 
M 8 3.1 226 129 619 94 
M 9 4.0 261 106 862 74 
M 10* 6.6 215 25o - 68 
M 11 4.5 274 118 552 92 
M 12 7.6 241 191 381 87 
M 13 11.7 251 72 75o 90 
M 14 4.0 23o 100 361 105 
M 15 14.3 221 117 532 87 
F 1 10.7 352 75 664 84 
F 2 4.7 200 93 931 100 
F 3 3.9 225 146 767 73 
* Fibrinolytic Poor Responders. 
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DISCUSSION. 
Severe, acute exercise procedures will produce changes in both 
global tests of coagulation, some specific factor assays, and in fibrinolysis. 
The results of this small study have confirmed that these changes take place 
but also indicate that inter. relationships of coagulation and fibrinolysis 
will be difficult to clarify using an exercise stimulus, particularly if it 
is to be controlled and submaximal. 
Global tests of coagulation would appear superficially attractive 
to assess the overall changes in blood coagulability. One of the first 
such tests to be described was that of the whole blood coagulation time 
(Lee and White, 1913; bills and Necheles, 1928), and with its varying 
modifications (Hartman, 1927; Biggs and Macfarlane, 1962), it has been used 
extensively. This test, although simple in principle, is profoundly affected 
by small variations in technique, and even with careful standardisation it 
can be insensitive to wide variations of blood coagulability. Small 
alterations in clotting times are therefore difficult to interpret. 
Nevertheless, using it as an estimation of post -severe exercise coagulability 
a significant shortening of the clotting time in silicone coated tubes was 
detected. This was, however, compensated for by an equivalent increase in 
haeralatocrit; the change therefore, is unlikely to be significant. This 
result is similar to that of Schneider and Zangara (1951); Rizza (1961) and 
Keeney and Laramie (1962), but is not in agreement with Iatridis and Ferguson 
(1963); and Finkel: and Cumming (1965). In the latter study, no allowance 
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was made for haemoconcentration and in the former, the sensitivity was 
higher, for reasons not clearly stated, than is usual with the Lee and 
White whole blood clotting time. Besides variations in technique it is 
possible that environmental changes can affect the whole blood clotting time 
test, as Finkel and Cumming% (1965) demonstrated that severe exercise at 
+25 °C produced a slight change in clotting time,but exercise at -20 °C did 
not. 
A significant differenc pre and post exercise, in the recalcification 
time of both platelet rich and platelet poor plasmas was demonstrated after 
severe exercise and this finding is similar to that of Burt (1964); Ikkala, 
(1963); and Iatridis and Ferguson (1963). The mean percentage decrease of 
clotting time as re-- oorted by Burt was 24a; in our study it was 28%. 
Ikkala (1963), tested platelet poor plasma and a statistically significant 
decrease in recalcification time persisted for up to 60 minutes post exercise. 
In both these global tests of coagulation, there was no correlation between 
the percentage change in the recalcification time and the percentage rise of 
Factor VIII, and the correlation between the two'methods of recalcification 
time technique was also poor (r = 0.4719, p = N.S.) It is considered that 
the inherent errors of these types of tests make them unsuitable for 
evaluating small changes within the normal range of values. 
Using the remaining global test of coagulation, the kaolin- 
cephalin clotting time, a small post severe exercise increase in coagulability 
could be demonstrated. The change was similar to that of the haematocrit 
(0) and there was a significant correlation between the two tests (r = 0.7928, 
0.02> p> 0.01). There was no correlation in the percentage change between 
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this test and the other clotting tests. These results are similar tó those 
of Iatridia and Ferguson (1963); Egeberg (1963); and Finkel and Cumming 
(1965), who all reported a shortening of the partial thromboplastin time, 
a test in which contact activation is only partly controlled. It might be 
considered that this test would be sensitive to increased levels of Factor 
VIII; but the correlation was low (r = 0.5927, 0.1 >p>0.05), and over- 
shadowed by the haematocrit change. 
Coagulation tests based upon measurements of changes in the 
extrinsic system of coagulation, e.g. the prot'hrombin time test, did not 
show a post exercise alteration ( Rizza, 1961; Iatridis and Ferguson, 1963; 
Ikkala et al., 1963). The results obtained are similar. 
The assay of specific coagulation factors was of interest. In 
most clotting factors, there was no significant alteration. Factor VIII, 
however, was unequivocally raised after severe exercise, as assayed by a 
one -stage assay system. This is in agreement with other recent work 
( Rizza, 1961; Ikkala, 1963; Veltkamp, 1968), and may be due to potentiation 
of Factor VIII activity in the blood stream (Ingram, 1965), or to splenic 
release (Webster et al., 1967) secondary to altered circulatory haemodynamics. 
Moderate exercise did not significantly raise the level of Factor VIII and 
from other studies it is apparent that a severe exercise procedure is 
required (Rizza, 1961; Veltkamp, 1968). There was no significant 
correlation between the percentage change in Factor VIII levels and the 
alteration in fibrinogen or other clotting tests. 
An interesting finding was the absence of a significant increase 
in Factor XII levels post exercise. This is not in accordance with Iatridis 
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and Ferguson (1963), who first detected a change. The explanation may lie 
in differences of methodology. The two stage assay system of Iatridis and 
Ferguson (1962a),is a modification of the Hicks and Pitney (1957) method for 
the assay of Factor VIII. Describing their method, Iatridis and Ferguson 
express reservations about the very wide range of normal values found and 
suggest that optimal kaolin activation at 4 °C might improve the reproducibility 
of the assay. No further reports describing their assay technique have 
appeared; and attempts to obtain reproducibility of the assay in this 
laboratory were not successful, in spite of considerable effort. Criticisms 
of the test include the use of non -siliconized ajparatus, and the consequent 
poor control of surface activation phenomena. The test is also sensitive 
to suboptimal levels of phospholipid in the incubation mixture as well as to 
relative decreases of Factor V and VIII, these latter being supplied by the 
Factor XII deficient substrate plasma. Another source of variation is the 
apparent sensitivity of the assay system to A.T.Pases, enzymes derived from 
platelets (Ferguson et al., 1967). The rise, post exercise, of Factor XII 
as first reported, must be questioned as the technique is unusual and 
dissimilar to methods more widely used for the assay of Factor XII. 
Egebere (1963), found small rises of Factor XII post exercise but only 
after repeated exercising; in the assay he describes, surfacé activation 
is poorly controlled and again the results must be interpreted with caution. 
Ikkala (1963), fouhld a post exercise increase in "Contact Product ", i.e. 
combined Factor XI and XII activity as prepared by the method of Waaler 
(1959). Using Nossel's method (1964), which is similar to that of 
Waaler, this increase of contact product could not be confirmed in several 
experiments in this laboratory (Table 4:2). It is also of relevance to note 
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that Factor XI, the other coagulation contact factor, does not alter in 
concentration post exercise (Egeberg, 1963). 
These other studies, therefore, though not strictly comparable, 
are all open to question as to specificity of the changes described; more 
recent work by Veltkamp (1968) has shown that Factor XII, as assessed by 
assays based upon the method of Hardisty and Macpherson (1962) is not 
increased post exercise. However, it is still possible that these other 
assay techniques may be measuring facets of coagulation that are as yet 
incompletely understood or may be measuring Factor XII in an activated 
state. Thus the study of Factor XII in this tÿpe of experimental situation 
did not yield positive information on the postulated relationships between 
coagulation and fibrinolysis. 
It is perhaps relevant to note, at this juncture, that the 
envisaged relationship existing between Factor XII and the activation of 
fibrinolysis, relies substantially on in vitro experiments. Niewiarowski 
and Prou- 'Nartelle (1959) and Iatridis and Ferguson (1960, 1962b): 
incubated normal plasma euglobulin with kaolin and observed an increase 
in lytic activity. This effect did not occur in plasma from patients with 
Factor XII deficiency. Aznar (1965) incubated a preparation of "contact 
factor" with streptokinase and found lytic activity was evolved but it is 
probable that plasminogen contamination could have easily occurred. As 
mentioned above, the in vivo post exercise rise of Factor XII must be 
reconsidered seriously and experiments such as those designed by Holemans 
et al., (1966) using venous occlusion as an in vivo activator of fibrinolysis, 
on both normal and a very small number of Factor XII deficient patients, were 
not conclusive as to the part played by Factor XII. Ratnoff (1966) confirmed 
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the observations of Niewiarowski and Iatridis, but also noted that Factor XI 
deficient plasma, when completely depleted of Factor XI with celite (but 
containing normal quantities of Factor XII and plasminogen), did not generate 
fibrinolytic activity on incubation with kaolin. Also, neither human nor 
bovine preparations are fibrinolytic in vitro (Ratnoff and Davie, 1962; 
Schoenmakers et al., 1963). Even more disturbing to the postulated 
relationship, is the observation that when ellagic acid, a potent in vitro 
and in vivo specific activator of Factor XII ( Botti and Ratnoff, 1964; 
Girolami et al., 1966) is injected into animals or humans, no enhancement 
of activator activity occurs, even though a marked hypercoagulable state is 
produced. It is apparent that evidence for Factor XII either in the "non 
activated" or "activated" form being able to initiate the activation of 
plasminogen is not yet strong, and much further work is required to reconcile 
the contradictory in vitro and in vivo experimental results. In particular 
the in vitro findings of Iatridis and Ferguson (1962), who are the main 
protagonists of the concept of Factor XII being involved in the activation of 
the fibrinolytic system, need to be equated with the negative in vivo results 
of Ratnoff et al. (1966), who are highly experienced in this field. It is 
still quite possible, however, that Factor XII may be indirectly linked in a 
manner yet to be elucidated, with fibrinolysis, but considerable clarification 
will be needed. 
Heparin precipitable fraction was significantly increased both 
after severe and moderate exercise procedures, and this has not previously 
been re-oorted. The increase of H.P.F. was not correlated with the increase 
in fibrinogen, or with any of the other clotting tests. It is possible that 
this test is revealing a physiological degree of increased coagulability, for, 
- 170 - 
if H.P.F., at least in part, represents a form of cryoprofibrin in which 
fibrinopeptide A has been removed by the action of thrombin (Shainoff and 
Page, 1962), increased levels post exercise could be interpreted as being 
the result of in vivo thrombin activity, possibly associated with the degree 
of hypercoagulability. 
The interpretation of these small changes occurring in both 
global and specific factor coagulation tests is problematical. It was not 
possible to achieve a consistently reproducible change in individuals tested 
at different times in spite of vigorous technical control of clotting tests, 
and the alterations were, in most cases, small. Investigation of the 
fibrinolytic "poor responders" gave essentially similar results to other 
subjects in this admittedly small study. This type of investigation may 
require techniques of finer discrimination, sensitivity and specificity 
before definitive cónclusions can be achieved. The assay of in vivo 
peptides released when fibrinogen is proteolytically digested by thrombin, 
would provide one possible avenue of relevant research. 
Subsequent to both moderate and severe exercise experiments the 
level of euglobulin lysis activity increases sharply. This increase is 
less marked in the poor fibrinolytic responders and the changes are also 
reflected in the fibrin plate assays. Despite these changes, there was 
no significant increase in the assayed level of fibrin /fibrinogen degradation 
products post exercise. However, in five of the severe exercise experiments, 
a small increase was noted; in the moderate exercise studies there was a mean 
small incregse post exercise which did not, however, reach significant levels. 
These results are at variance to preliminary studies reported by Das et al. 
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(1967). The explanation of this is not yet clear; minor alterations in 
technique have undoubtedly occurred since these earlier experiments, which 
perhaps have affected the discrimination of the assay in detecting small 
F.D.P. changes within the physiological range. However, using the present 
P.D.P. method, it is clear that following both exercise and adrenalin 
infusions (Section 4:2) it was not possible to demonstrate a significant 
alteration in the circulating levels of F.D.Ps.. 
If F.D.Ps. do not increase after exercise it could be considered 
that this was evidence mitigating against the theory of a dynamic balance 
between coagulation and fibrinolysis. However, it is conceivable that post 
exercise proteolysis of fibrin may have occurred, although not as far as the 
plasmin resistant moieties which are measured in the P.D.P. assay. The 
evidence for this is meagre, although Fisher et al. (1967) have demonstrated 
high molecular weight thrombin clottable proteolyl;ic fragments of fibrinogen 
in the sera of patients in whom pathological lysis was occurring, before there 
was other biochemical evidence of any change. It is not known if similar 
products occur in stimulated physiological situations. On the other hand, 
if a jfgm. increase of F.D.Ps. does occur post exercise this would represent 
in a 70 kilogramme subject a total body lysis of 30 mg. of fibrinogen; a 
not inconsiderable amount; such calculations, however, are based on the 
unlikely- assumption that the immuno -reactivities of F.D.P. and fibrinogen 
are equal, and may not be valid (Merskey et al., 1966; Israels et al., 
1968). 
These conflicting results will only be resolved when more sensitive 
techniques are available for measuring fibrin proteolysis products. The 
present assay is not suitable, without further refinement, for detecting 
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small physiological alterations in circulating levels of F.I.P., and techniques 
such as radioimmun -assay may prove valuable research tools. 
The significance of an increase in plasminogen activator to an 
exercise stimulus, as based on these F.D.P. results, must be questioned. 
The lysis of fibrin may not necessarily be increased post exercise, although 
the potential for lysis could be. It is suggested that the measurement of 
in vivo fibrinolysis is perhaps better assessed by the measurement of F.D.P. 
and it is possible that "fibrinolytic activity" is not synonymous with changes 
in plasminogen activator level, as has previously been assumed. 
It is apparent that the fibrinolytic response of an individual 
is a verifiable phenomena,and that over the time period of one year, no 
significant changes occurred in the individual responses. However, we are 
only a little further forward in our understanding of the significance of the 
fibrinolytic response to exercise. The coagulation investigations have -not 
substantially clarified the phenomena,and if coagulation and fibrinolysis 
are linked, the relationship may be complex, requiring techniques as yet 
not available, such as assays which are of greater specificity and 
sophistication. Also, although it is possible that the post exercise rise 
of plasminogen activator is a response to a low grade episode of intravascular 
coagulation,: these studies do not yield definite evidence in either direction. 
The biochemical investigations of the poor fibrinolytic responders also do 
not add significantly to the pathophysiological interpretation, although 
further follow -up studies will be of value. It was of interest to note 
thát although one poor responder (Itii3) developed definite ischaemic changes 
on the electrocardiograph, similar changes were also detected in a good 
responder (F2), and in both these subjects, the changes had not been present 
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one year previously. Also, one of the original good responders (68,ó) 
of the first study died after a posterior myocardial infarct. Ivecrospy 
revealed wide- spread coronary atheroma, and microscopy of the right coronary 
artery (Fig.4:2) showed a thrombus which had probably occurred secondary to 
haemorrhage into an atheriamatous plaque. 
It is thus perhaps premature to attach too much importance to 
the conception of a fibrinolytic response being of importance in pathophysiológica: 
events. The phenomena is probably a measure of both the release and removal 
of circulating plasminogen activator. In vivo thrombolysis is not necessarily 
dependent on levels of plasminogen activator, for the ability of the activator 
to dissociate from its anti -activator, the rapidity with which it can be 
adsorbed into a clot, the intra clot concentration and reactivity of plasmin- 
ogen, antiplasrains and anti- activators are almost certainly important factors 
contributing to in vivo clot dissolution. It is quite possible also that 
intravascular lysis can proceed normally with extremely low levels of 
plasminogen activator and this is suggested by the normally low levels of 
plasminogen activator in pregnancy and the lack of untoward clinical 
complications when E.A.C.A., a plasminogen activator inhibitor, is given 
to normal subjects. However, although the variations in fibrinolytic 
response may be only a reflection of the frequency distribution pattern 
expected in a normal population, with the "poor responders" at one end of 
the curve, modification of the respohse by factors such as diabetes (Cash 
and McGill, 1968), mental stress (Cash and Allan, 1967), and pregnancy 
(Woodfield et al., 1968) does suggest that the phenomena is of either 
physiological or pathological importance and warrants further intensive 
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Fig. 4:2. Photomicrograph of a section of the right coronary 
artery showing haemorrhage into an atheronatous 
plaque and thrombosis. 
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study of other influencing factors. If this can be achieved as a 
prospective study and aligned with additional investigations of other 
relevant parameters of vascular integrity, eventual clarification of these 
problems may be possible. 
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The coagulation and f ibrinolytic changes following both a 
severe and a standardised exercise procedure have been studied. The 
phenomena of the fibrinolytic response was verified, and poor fibrinolytic 
responders were again identified. There was no evidence that the 
coagulation system in these subjects differed from other individuals. 
There was no apparent correlation in the subjects studied between the 
coagulation and fibrinolytic tests, and the rise of plasminogen activator 
was not accompanied by an increase in the concentration of Factor XII. 
Lysis of fibrin,. as assessed by the - measurement of its degradation products, 
was not increased significantly after moderate or severe exercise. It is 
suggested that exercise studies of coagulation and fibrinolysis are hampered 
by the imprecise technical tests and further evaluation of the postulated 
dynamic equilibrium of coagulation and fibrinolysis using this approach may 
need to await improved methodology. 
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CHAPTER II 
THE EFFECT OF ADRENALIN AND BETA-ADRFN.ERGIC BLOCKAGE 
ON THE COAGULATION AND FIBRINOLYTIC SYSTEMS 
Introduction. 
Evidence accumulated since the beginning of this century has 
suggested that a link exists between the activity of the autonomic nervous 
system and the haemostatic mechanism. In 1903 Volburg and Richards injected 
adrenalin into the peritoneum of dogs and observed the appearance of a marked 
blood hypercoagulability. Cannon and Mendelhall (1914) confirmed and 
extended these observations in experiments in which the splanchnic nerve of 
dogs was excited by electrical stimulation, this being accompanied by a 
shortening of a modified whole blood clotting time. In further experiments 
it was proved that central nervous integrative functions could affect blood 
coagulability as shortened clotting times were obtained after cats were 
submitted to a severe stress. The common mediator for these neural induced 
coagulation changes was thought to be adrenalin. 
The effects of adrenalin on the whole blood coagulation time was 
further investigated by Waldron (1950) and Forwell and Ingram (1957) and 
much of the earlier work was confirmed and extended. Marciniakowna (1957) 
infused adrenalin into animals and detected a rise of Factor VIII, and in 
1961 Ingram demonstrated that the administration of adrenalin resulted in a 
rise of clotting Factor VIII, not only in the majority of human subjects, but 
also in some mild haemophiliacs. Similar findings were soon reported by 
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Egeberg (1963b); Goudemand et al. (1964); Naleczynska et al. (1966); and 
Libre et al. (1968). 
It had been recognized also that blood coagulability could be 
affected by mental stress (Schneider, 1951; Dreyfuss, 1956; Friedman et al., 
1958), and observations in patients with haemophilia have indicated that 
emotional disturbances contribute to the frequency of bleeding episodes 
(Browne et al., 1960). Variations in Factor VIII to mental stress have 
apparently not been reported in man but it is generally assumed, from 
adrenalin infusion studies, and the variations in Factor VIII that do occur 
in any one individual `Simone et al., 1967) that in vivo alterations of 
Factor VIII are possible in response to psychic stimuli. 
The effect of adrenalin on fibrinolysis was not investigated until 
the studies of Biggs et al. (1947). Subsequent work adequately verified and 
extended their observations (Truelove, 1951; Nwaan et al., 1956; Sherry et 
al., 1959; Genton et al., 1961; Doni et al., 1963; Neri Serneri, 1965; 
Cash and Allan, 1967). It was also recognized that acute mental stress 
could affect fibrinolysis tda,cfarlanc and Biggs, 1946; Schneider and Zangari, 
1951; Truelove, 1951; Ogston et al., 1962; Patsch, 1963; Ogston, 1964; 
Latner, 1967), and that this change was due to an alteration in the levels 
of circulating plasminogen activator. 
Anatomical evidence for a role of the central nervous system in 
haemostasis was provided by Gunn and Hampton (1967). By electrical stimulation 
of certain areas of the brain in dogs, either increases or decreases of 
circulating Factor VIII could be obtained. Similar results have been reported 
by Correll (1968) in cats. Benetato et al. (1964), using ultra short wave 
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irradiation of the hypothalmic region in man, produced an increase in blood 
fibrinolytic activity, as did electric shock treatment in isolated dog's 
head preparations (Kowarzyk et al., 1962). 
Thus, though the evidence was scanty there was enough experimental 
and circumstantial evidence to suggest that the autonomic and central nervous 
systems were in some way involved in the control of the coagulation and 
fibrinolytic systems. One important intermediary was adrenalin and thus 
much study has been directed towards it metabolic actions. 
Some of the many physiological effects of adrenalin are thought to 
be mediated through two separate types of receptors, named by Ahlquist (1948) 
alpha and beta receptors. Drugs which block these receptors are referred to 
as adrenergic blockers and are listed below. 
Stimulated by Blocked by 











In general, alpha -receptors mediate vasoconstrictor responses, and beta 
receptors both vasodilator responses, as well as stimulation of cardiac rate 
and force of heart beat. Alpha adrenergic stimulators, such as noradrenalin 
and methoxamine cause peripheral arteriolar vasoconstriction and contraction 
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of the uterus, ureter, dilator pupillae, splenic capsule and pilomotor 
apparatus along with relaxation of the intestine, while beta adrenergic 
stimulators such as isoprenalin cause peripheral vasodilation, relaxation 
of the myometrium and bronchi, and augmentation of the rate and force of 
contraction of the myocardium. 
Adrenergic'receptors are also intimately involved in other 
metabolic processes of the body. Alpha and beta. receptor stimulation by 
adrenalin results in a rise of free fatty acids (F.F.A.) derived from 
adipose tissue (Havel and Goldfien, 1959; Vaughan, 1961) and this increase 
is abolished by beta adrenergic blocking agents but not by alpha adrenergic 
blockers (Pilkington et al., 1962). The normal increase of blood sugar 
after adrenalin administration is blocked by the combined use of both alpha 
and beta blockers, but not by the individual blocking agents (Antonis et al., 
1967). 
Ingram and Vaughan -Jones (1966) investigated the effect of adrenergic 
blockers on the post adrenalin increase of Factor VIII. It was discovered 
that alpha blockade by phentolamine did not affect the increase of Factor VIII 
but beta blockade with pronethalol or propranolol completely blocked the rise. 
It was therefore assumed that the effect of adrenalin on Factor VIII was 
probably mediated by beta receptors. Another study in which the effect of 
an adrenergic blocker on the post adrenalin rise of Factor VIII was that of 
Ozag et al. (1966) who found that in animals there was a significantly 
lowered mean increase after the prior administration of the alpha blocker 
phenoxybenzamine. 
The effect of adrenergic blocking agents on fibrinolysis was 
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investigated by Ishioka et al (1967). Using equal doses they demonstrated 
that adrenalin did, and noradrenalin did not, shorten the euglobulin lysis 
time. They then assessed the effect of both alpha and beta blockade 
separately. It was found that the alpha blocker phenoxybenzamine did not 
modify the effect of the adrenalin induced fibrinolysis. On the other hand, 
the beta blocker pronethanol completely blocked the normal euglobulin lysis 
time response to adrenalin. The evidence thus suggested that the response 
of fibrinolysis to adrenalin was mediated in some way via beta receptors. 
On the other hand, Tanser and Smellie (1964) in four patients were not able 
to demonstrate any effect of pronethanol or BW 61-43 on fibrinolysis. 
Project Aims. 
This study was designed to answer various separate problems, some 
of which were related to the previous observations of Section 4:1 of this 
thesis, and others to the concept outlined in the introduction to this 
chapter. 
In the first instance, it is possible that the exercise stimulus 
to the coagulation system (Section 4:1) was not of a sufficient degree to 
evoke a significant alteration in the circulating levels of Factor XII. It 
is known that an adrenalin injection or infusion will increase the levels 
of Factor VIII and is an easily controllable and relatively simple procedure. 
An investigation was therefore made to ascertain if Factor XII would respond 
more readily to an infusion of adrenalin. Other changes in coagulation 
parameters were simultaneously measured and included the alterations occurring 
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in Factor VIII and cryofibrinogen (H.P.F.). 
-An investigation was also made of the effects of adrenalin on the 
fibrinolytic system. Not only could the well documented changes in plasmin- 
ogen activator be confirmed but the significance of this change could be 
assessed more readily by measurement of fibrin degradation products (F.D.P.). 
Finally, the effect of beta adrenergic blockade on both the 
coagulation and fibrinolytic systems was more fully investigated. This 
study was designed to throw additional light on the modifying influences 
affecting plasminogen activator levels and particularly the relationships 
existing between adrenergic receptor sites and changes in haemostatic 
parameters. The physiological properties of a new beta adrenergic blocker 
drug (ICI 50172) were also studied and compared with Propranolol. 
Subjects and Experimental Design. 
A. Subjects. 
Volunteers recruited for this study were medical colleagues, 
all of whom were accustomed to venepuncture and to intravenous infusion 
studies. All were in good health. Some of these subjects had taken 
part in previous investigations on the effect of adrenalin on fibrinolysis 
(Cash and Allan, 1967) and considerable experience had been gained on the 
technique and procedures associated with such infusions. The procedure 
was in general as outlined by Cash (1967). 
Before the initial infusion it was explained carefully to each 
subject the nature of the test and possible symptoms which might arise 
during the course of the experiment were outlined. In all cases continuous 
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electrocardiographic recordings were made before, during and for a variable 
time following the infusions. The majority of the investigations were 
performed in the Department of Medicine procedure rooms, and two qualified 
medical personnel (plus technical staff) were in attendance throughout the 
duration of the experiment. Infusions were terminated immediately if any 
untoward symptomatology arose. On two occasions the infusions were 
discontinued; once when a subject developed marked bradycardia following 
a propranolol infusion, and once during an adrenalin infusion in a subject 
known to be susceptible to the frequent development of supra ventricular 
extra systoles. Neither of these two subjects were studied further. All 
other infusions were uneventful. 
B. Procedures and Experimental Design. 
The basic procedure was as follows, but was modified according 
to the experimental requirements. 
After a supine rest period of 30 minutes a 20 gauge needle was 
inserted into a cubital vein and a resting blood sample obtained. After 
the removal of the syringe the needle was attached by means of an Anaesthesia 
Extension Set (Baxter - BR 335) to a 50 ml. syringe containing either saline 
or the adrenergic blocker drug already mounted in a Harvard Constant Infusion 
pump. The infusion was then commenced and continued for 10 -20 minutes 
depending on the experimental plan. At the end of this time, the syringe 
was disconnected and the next blood sample obtained. The needle was then 
connected in a-similar manner to a further 50 ml. syringe containing the 
adrenalin solution, and infusion continued for the planned time period. 
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Samples taken during the adrenalin infusion were obtained from the opposite 
arm, and -to avoid an excessive number of venepunctures the needle was often 
left in situ and kept patent by a slow running 0.9% saline infusion. Final 
blood samples were taken during, at the end of, or following the infusion. 
These procedures were established as a smooth running routine thus obviating 
undue subject anxiety. 
The adrenalin used was that of Parke -Davis (Batch number LFJ 308) 
each millilitre containing 1 mg. of adrenalin as the hydrochloride dissolved 
in normal saline with 0.5% chlorobutol as preservative. It was diluted with 
saline immediately before use to the required concentration. Ascorbic acid 
3 mg. /ml. was added as preservative for experiments which lasted for longer 
than five minutes. 
The adrenalin dose infused varied with the experiment and was 
usually related to total body weight, and details are included in the 
relevant experiments. 
The propranolol ( "Inderal ", ICI 45520) (L- isopropylamino -3- 
(L- nopthyloxy)- 2- propanol hydrochloride) used was diluted in 0.9% saline to 
the required concentration and was infused over a time period of ten minutes. 
A syringe containing atropine 1.2 mg. was also drawn up to be used if severe 
bradycardia or hypotension developed. This was used on one occasion (vide 
supra). 
Study I . 
In this study, the effect of adrenalin with and without beta - 
adrenergic blockade on both the coagulation and fibrinolytic systems was 
assessed. The design of the experiment was similar to that of Ingram (1966) 
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and was as follows :- 
1. Rest period 30 minutes. 
2. First blood sample taken. 
3. 0.9 saline or propranolol (1 mg. /mia infused for 
10 minutes. 
4. Second blood sample taken. 
5. Adrenalin (10- 15,,gm /min.) infused for 10 minutes. 
6. Third and fourth blood samples taken; removed from 
opposite arm at 5 and 10 minute mark respectively. 
Each subject was tested three times, at intervals greater than 
one week, twice with saline and adrenalin and once with propranolol and 
adrenalin. The following laboratory tests were performed on the blood 
samples so obtained. 
1. Factor XII assay. 
2. Factor VIII assay. 
3. H.P.F. assay. 
4. Euglobulin lysis time assay. 
5. F.D.P. assay. 
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Results. 
A. Factor XII. 
The results in six subjects (nine infusions) are tabulated in 
Table 4:11. There was no increase in Factor XII levels during or following 
the adrenalin infusion. The mean 95% confidence limits of the Factor XII 
assays was 78 - 12 of the observed results. 
TABLE 4:11 
M'YLCT OF A TER MINUTE INFUSION OF ADRENALIN 






% Factor XII 
J.D. 100 - 103 
100 - 92 
S.D. 100 105 125 
100 - 85 
L.F. 100 92 105 
R.F. 100 - 115 
P.D. 100 91 101 
100 - 119 
G.G. 100 - 100 
Mean 100 .96 105 
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B. Factor VIII. 
There was no detectable increase of Factor VIII levels after either 
the saline or propranolol infusions alone. The mean percentage increases of 
Factor VIII during and after the adrenalin infusion was 182% at 5 minutes, and 
225% at 10 minutes (Table 4:12). The increase of Factor VIII post adrenalin 
was completely blocked by the prior administration of propranolol (Table 4 :13). 
TABLE 4:12 
EFFECT OF A TEN MINUTE INFUSION OF ADRENALIN 







+5 I +10 
% Factor VIII 
J.D. - 100 - 150 
100 96 162 170 
C.M. 100 100 143 172 
100 98 162 148 
S.D. - 100 - 330 
100 115 181 236 
L.P. - 100 - 367 
100 106 225 237 
R.F. - 100 - 296 
100 89 246 215 
P.D. 100 103 173 208 
- 100 166 173 
Mean 100 101 182 225 
TABLE 4:13 
EFFECT OF A TEN MINUTE INFTJSION OF ADRENALIN (15,rAgm./min.) 
ON THE LVEL OF FACTOR VIII AFTER A PRIOR INFUSION 
OF 10 mgm. OF PROPRANOLOL. 
L inutes 
Subject -10 0 +5 +10 
Factor VIII 
J.D. 100 96 108 100 
C.M. 100 88 103 92 
S.D. 100 100 92 115 
C.F. 100 79 100 78 
R.F. 100 110 90 
P.D. 100 107 86 120 
Mean 100 97 100 99 
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C. CEyofibrinogen.LH.P.F.) 
In twelve assays on eight subjects (Table 4:14) there was no 
significant alteration in the post adrenalin levels of H.P.P. (t = 1.6599, 
p = N.S.). 
TABLE 4:14 
EFFECT OF AN ABFEMALIN INFUSION (15, -gm /min /l0mins) ON THE 





0 +5 +10 
mgn/100 ml. 
1 - 30.3 - 31.8 
- 36.1 - 35.4 
2 48.9 44.8 38.2 45.6 
- 56.3 - 60.4 
3 51.0 51.6 - 54.2 
4 39.8 38.7 - 43.7 
- 40.9 - 39.8 
5 - 46.4 48.0 47.9 
6 - 43e3 - 40.4 
- 53.o - 61.o 
7 - 45.0 - 44.8 
8 - 54.6 - 53.6 
Mean 46.6 45.1 43.1 46.6 
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D. F.D.P. 
There were no consistent alterations in the levels of F.D.P. during 
or post adrenalin infusion in the subjects studied (Table 4:15). Propranolol 
did not appear itself to affect F.D.P. levels. 
TABLE 4:15 
EFFECT OF A TEN MINUTE ADRENALIN INFUSION 





-10 J 0 
F.D.P.,gm. 
1 - 15.0 - 18.3 
- 6.1 10.3 10.3 
2 - 5.4 7.4 6.6 
7.8 8.4 6.5 6.5 
9.1 8.2 12.3 8.2 
3 12.3 11.1 11.1 - 
6.6 6.1 6.6 7.3 
4 - 13.2 - 12.2 
4.5 9.1 9.1 4.5 
5 7.6 8.6 7.6 - 
- 15.2 9.2 7.2 
Mean 8.0 9.7 8.9 9.0 
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E. Euglobulin Lysis Time. 
There was a marked decrease in euglobulin lysis time during, and at 
the conclusion, of the adrenalin infusion (Table 4:16). The changes occurring 
at both the 5 and 10 minute. period were highly significant when tested by a 
paired t test (t = 10.4287, p < 0.001; t = 7.8305, p < 0.001 respectively). 
After prior propranolol infusion, the fibrinolytic response to adrenalin was 
impaired (Table 4:17 and Fig. 4:3) but not completely blocked. 
TABLE 4:16 
EFFECT OF A TEN MINUTE INFUSION OF ADRENALIN 
(15,4, gm. /min.) ON THE EUGLOBULTN LYSIS TIPS. 
Subject 
Minutes 
-10 0 +5 +10 
E.L.T. in Minutes 
J.D. - 508 - 100 
211 250 56 58 
C.M. 378 307 75 75 
527 459 164 140 
S.D. - 179 - 34 
335 350 63 60 
L.F. - 61 - 21 
- 203 31 37 
R.F. - 258 - 45 
- 281 44 48 
P.D. - 142 - 40 
- 381 84 82 
483 460 61 75 
Mean 387 295 72 63 
TABLE 4:17 
EFFECT OF A TEN MINUTE ADRENALIN INFUSION ON THE EUGLOBULIN 
LYSIS TIME SUBSEQUENT TO AN INFUSION OF 10 mgm. PROPRANOLOL. 
Subject 
Minutes 
-10 0 +5 +10 
E.L.T. in Minutes 
J.D. 413 412 210 168 
C.M. 445 360 320 241 N 
S.D. 745 666 488 341 
L.F. 135 148 68 56 
R.F. 250 232 - 130 
P.D. 259 330 208 176 
Mean 375 358 259 185 









Fig. 4:3. Effect of a ten minute infusion of adrenalin 
òn the euglobulin lysis activity. 
(A - Adrenalin; P - Propranolol) 
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Comparison of the euglobulin lysis times at the 5 and 10 minute 
mark, with and without beta blocker, revealed that there was a statistically 
significant blockade of the plasminogen activator response to the adrenalin 
infusion (t = 2.6743, 0.05 <p<0.025; t = 3.3010, 0.025 <p<0.02, respectively). 
The decrease of euglobulin lysis times after prior propranolol 
blockade was, however, still significant at both the 5 and 10 minute mark 
(t = 4.1472, 0.005 >p >0.01; t 4.5570, 0.001 <p<0.005, respectively). 
Propranolol has therefore not completely blocked the post adrenalin increase 
in plasminogen activator levels. 
Study II. 
ICI 50172 (4- (2- hydroxy -3 isoproprylaminopropoxy) acetanilide) 
is a new experimental beta adrenergic blocking drug. Animal work has 
indicated that it has a selective action, blocking catecholamine effects on 
the heart but not on the peripheral vascular tree. It appears to have no 
local anaesthetic action as has propranolol. In animals ICI 50172 will 
prevent the isoprenalin induced mobilization of free fatty acids although 
less strongly than propranolol. It is now under investigation at several 
centres to assess its clinical use in the treatment of cardiac arrythmias. 
In this study, the effect of adrenalin after prior blockade with 
this beta adrenergic drug, ICI 50172, on selected parameters of the coagulation 
and fibrinolytic system was evaluated and compared with that of propranolol. 
The degree of blockade achieved with this new drug was assessed separately 
by measurements of the changes occurring in response to adrenalin of free 
fatty acid levels. (The assay method used was that of Mosinger (1965), 
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Each experiment was preceded by a 30 minute rest period. 0.9A 
saline was infused at a rate of 5 ml. /minute. A total dose of 10 mgm. of 
propranolol or 60 mgm. of ICI 50172 was administered in the 10 minute period 
of beta adrenergic.blockade. Adrenaline was infused at a rate of 
0.1,- gm /kgm /minute. 
Each of the five subjects was tested on three occasions -at weekly 
intervals. The first infusion was of saline and adrenalin, the subsequent 
tuo infusions were of either propranolol of ICI 50172 and adrenalin. 
The following laboratory tests were performed on the blood samples 
so obtained. 
1. Euglobulin lysis time. 
2. F.D.P. assay. 
3. Factor VIII assay. 
4. Free fatty acid assay. 
Results. 
A. Effect on Euglobulin Lysis Time (E.L.T.) Assay. 
The results, after conversion to plasminogen activator units, are 
tabulated in Table 4:18 and Fig. 4 :4. Tnfusions of saline or adrenergic 
blockers did not significantly alter the levels of circulating plasminogen 
activator. There was, as expected, a marked increase in the level of 
plasminogen activator in response to the adrenalin infusion. However, at 
the 30 minute mark the response was less than that at the 15 minute mark. 
When preceded by an infusion of propranolol the plasminogen activator 
response was decreased, this being significant at the 5;4 level (t = 2.0936, 
0.05 >p>0.10). 
Fig. 4:4. 












I I I I I I I I I 
0 10 20 30 40 50 60 70 80 
TIME IN MINUTES 
Effect of a thirty minute infusion of 
adrenalin on the euglobulin lysis activity 
with and without prior infusion of 
Propranolol or ICI 50172. 
TABLE 4:18. 
THE EFFECT OF A THIRTY MINUTE ADRENALINE INFUSION, WITH AND WITHOUT PRIOR ADRENERGIC BLOCKADE, 
ON PLASMINOGEN ACTIVATOR LEVELS. 
ADRENALINE ICI 50172 + ADRL3L;iLINL PROPRANOLOL + ADR2 liALIN 
PLASHINOGEN ACTIVATOR UNI2S 
+30 +60 -20 Subject -20 -10 0 +15 +30 +60 -20 -10 0 +15 -10 0 +15 +30 +60 
S.M. 3.1 3.5 3.1 9.8 10.1 4.5 2.2 2.2 2.2 9.6 8.7 3.6 9.1 9.6 9.6 16.5 16.6 10.5 
D.F. 14.5 14.6 14.4 31.7 27.1 
- 
18.5 16.2 17.5 16.4 36.1 32.5 20.6 - 8.3 10.1 13.6 20.9 12.0 
D.3. 7.1 7.1 8.1 26.5 23.6 11.1 9.4 10.0 10.3 31.0 31.0 12.5 4.3 4.2 4.2 16.8 13.0 4.5 
P.D. 8.1 7.8 6.3 26.5 14.9 4.1 8.5 7.6 8.1 21.0 19.1 6.5 9.3 9.3 10.4 17.1 17.3 10.3 
J.C. 7.8 7.9 8.4. 26.0 24.5 13.5 5.7 6.9 7.1 20.0 16.9 10.2 6.6 6.6 7.1 12.7 13.o 10.8 
Mean 8.1 8.1 8.0 23.9 20.0 10.3 8.4 8.8 8.8 23.5 21.6 10.7 7.3 7.6 8.3 16.3 16.2 9.6 
S.D.f 4.1 4.0 4.1 8.2 7.2 6.1 5.1 5.6 5.2 10.3 10.0 6.5 2.3 2.2 2.6 2.2 3.3 2.9 
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ICI 50172 however did not appear to modify the plasminogen activator 
response to adrenalin (Fig. 4:4). 
B. F.D.P. Assam. 
The results are summarised in Table 4:19. There were no detectable 
changes in the circulating levels of F.D.P. post adrenalin in the four 
subjects studied, this being in accord with the results observed in Study I. 
ICI 50172 had no effect on F.D.P. levels either with or without adrenalin 
administration. 
C. Factor VIII Assay. 
There was a significant increase of Factor VIII in response to 
the adrenalin infusions which was not significantly modified by the prior 
administration of ICI 50172. However, the increase of Factor VIII was 
completely blocked by the propranolol infusion, as in Study I (Table 4:20 
and Fig. 4:5). 
D. Free Fatty Acids (F.'.A.) Assá. 
There was a highly significant increase of F.F.A. (Table 4 :21) 
in response to the adrenalin infusion when the results were statistically 
evaluated by a paired t test (t = 9.2436, p < 0.001). 
This response was blocked completely by propranolol but only partly 
by ICI 50172 (Fig. 4:6). 
DISCUSSION. 
The absence of a significant change in Factor XII levels after a 
ten minute infusion of adrenalin is similar to recent reports by Ratnoff 
(1966) and Naleczynska et al. (1966). As a relatively high dose of adrenalin 
TABLE 4:19 
F.D.P. LEVELS -WORE, DURING MID AFTER A THIRTY MINUTE 
ADRENALIN INFUSION, WITH AND i"lITHOUT A PRIOR INFUSION 









+30 i +60 
(,*;m. /m1.). 
ADBT:"SALIN INFUSION 
S.M. 7.2 9.0 5.4 5.4 7.2 5.4 
D.B. 6.3 7.2 7.2 7.2 9.0 10.8 
D.P. - 7.2 6.3 7.2 7.2 
P.D. - 5.4 5.4 5.4 5.4 5.4 
J.C. - - - - - - 
Mean 6.8 7.2 6.3 6.1 7.2 7.2 
ICI 50172 PLUS ADRENALIN INFUSION 
P.D. - 5.4 7.2 - 10.8 5.4 
D.F. 10.8 9.0 7.2 10.8 7.2 7.2 
D.B. 3.6 5.4 10.8 7.2 7.2 7.2 
S.M. 10.8 8.0 10.8 10.8 10.8 7.2 
J.C. 8.4 7.0 9.0 9.6 9.o 6.8 
Mean 8.4 7.0 9.0 9.6 9.0 6.8 
Fig. 4:5. 



















ADRENALIN --° + ICI 50172 
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TIME IN MINUTES 
Effect of a thirty minute infusion of 
adrenalin on Factor VIII levels with 
and without prior infusion of 







































































































































































































































































































































































































































































































































































































































--------- ------------------- x ADRENALIN 
+ PROPRANOLOL 
ADRENALIN 
I I I I I 1 I I I 
0 10 20 30 40 50 60 70 80 
TIME IN MINUTES 
Fig. 4:6. Effect of a thirty minute infusion of adrenalin on 
the serum free fatty acid level with and without 
a prior infusion of Propranolol or ICI 50172. 
TABLE 4:21 
THE EFFECT OF SALINE, ICI 50172 OR PROPRANOLOL, AND ADRENALINE 
ON TNF LEVEL OF FREE FATTY ACIDS (mEgJL) 
Subject 
ADRENALINE ICI 50172 + ADRENALINE PROPRANOLOL + ADRENALINE 
SALILI -NG TIME (mins.) 
-20 -10 0 +15 +30 +60 -20 -10 0 +15 +30 +60 -20 -10 0 +15 +30 +60 
S.M. 416 526 387 825 1131 569 376 576 520 680 1000 296 660 583 472 431 521 347 




624 1060 1503 785 635 599 416 380 474 489 
D.B. 492 500 400 1203 1658 775 526 883 1409 613 531 648 430 703 750 477 
P.D. 752 664 704 1312 1704 992 625 617 586 869 1195 773 390 494 636 429 312 357 





Mean 532 572 542 1130 1561 768 472 591 522 840 1242 599 527 591 554 473 
S.D.± 141 78 146 198 289 234 99 37 103 153 209 201 122 60 88 140 180 140 
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(10 -15,« gm /min.) was used in the present study, it is unlikely that the lack 
of an increase was due to inadequate dosage. The absence of an increase of 
Factor XII after both exercise and adrenalin stimuli, using a widely accepted 
assay technique, casts further doubt on the previously accepted changes of 
Factor XII post exercise reported by Iatridis and Ferguson (1963). 
There was no significant change of cryofibrinogen (H.P.F.) after 
the adrenalin infusion. This might indicate that mechanisms for generating 
cryofibrinogen in the exercise and adrenalin stress situations are quite 
different. The increase of cryofibrinogen post exercise is less likely 
to be dependent on the endogenous production of adrenalin and other unrecognized 
factors may be more relevant, such as the release of local tissue thrombo- 
plastins. Further elucidation is required of this interesting finding, 
particularly if more refined methods of measuring cryofibrinogen can be used.. 
The effect of adrenalin on circulating Factor VIII levels.is 
similar to that of other investigators (see introduction). The individual 
response of Factor VIII to repeated adrenalin infusions varied, and this is 
probably a reflection of the inaccuracy of assay techniques when measuring 
high levels of a clotting factor. In general, subjects could be divided 
into either high, mid or low Factor VIII responders to the adrenalin infusion. 
Ingram and Vaughan -Jones (1966) in their experiments selected only those 
volunteers who consistentlygave high responses. In the present study 
subjects were not selected on this basis. 
In both studies it was confirmed that complete blockade of Factor 
VIII could be achieved by propranolol (Ingram and Vaughan- Jones, 1966). 
It has been suggested that altered circulatory dynamics may be the basis 
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for changes in Factor VIII elevations following adrenalin (Libre et al., 
1968). - The splanch:n.ic circulation is probably influenced by adrenalin 
through both alpha and beta receptors (Price et al., 1967). Changes in 
blood flow through the sphlanchnic circulation and particularly through the 
spleen thus could occur under beta adrenergic blockade, decreasing the 
release of Factor VIII from this area. However, such an explanation is 
perhaps too simplified as it would not appear to explain the complete absence 
of a post adrenalin rise of Factor VIII after propranolol. 
A post adrenalin increase in the level of circulatory F.D.P. could 
not be detected following either a ten or thitty minute adrenalin infusion 
in these studies. These results are at variance to preliminary observations 
previously reported from the laboratory (Das et al., 1967). However, the 
previous experiments were performed on sera removed after two minute, infusions 
of lower doses of adrenalin, and these present studies are not directly 
comparable. Differences in assay techniques may also have occurred, perhaps 
with a decrease in discrimination of the assay, although this is less likely 
in view of the excellent sensitivity of the assay system in other concurrent 
studies. The differing results are not easily explainable but from the 
present experiments it is probable that if an elevation of F.D.P. does occur 
after an adrenalin infusion the rise is transient and certainly not great. 
Further studies using more sensitive techniques are required. Both 
propranolol and ICI 50172 alone had no consistent effect on levels of F.D.P. 
The changes in response to an intravenous infusion of adrenalin 
of plasminogen activator levels have been noted previously (introduction). 
In the present experiments adrenalin produced a marked shortening of the 
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euglobulin lysis time. After thirty minutes of adrenalin infusion (Study II) 
there was a tendency for the lysis times to lengthen again (Fig. 4:4) and 
this may represent some exhaustion of the mechanis:mfor producing plasminogen 
activator, or perhaps an increase of plasminogen activator inhibitors in 
response to adrenalin. These alternatives were not investigated but it would 
be of interest to measure the effect of a prolonged infusion (hours) of 
adrenalin on the euglobulin lysis time, coupled with an assessment of 
inhibitor levels. The exact mechanism for the appearance of plasminogen 
activator in the circulation after adrenalin administration is not known. 
Naleczynska et al. (1966) state that it is probably due to the release of a 
tissue activator of plasminogen into the blood stream. The observation of 
a significant correlation between the blood flow and plasminogen activator 
responses to adrenalin infusions could be relevant in this context (Cash 
et al., 1968). It is also possible that release of plasminogen activator 
from vessel walls is controlled, at least in part, by the sympathetic 
nervous system. 
Both studies demonstrated that the administration of propranolol 
modified the response of plasminogen activator to the adrenalin stimulus 
(Figs. 4:3 and 4:4). These results are not in accord with Ishioka (1967) 
who was able to achieve complete blockade of the fibrinolytic response 
using the beta adrenergic blocker pronethalol. It is unlikely that the 
difference is explainable on incomplete adrenergic blockade as in the 
second study, using propranolol, the free fatty acid response to adrenalin 
was completely blocked as was the Factor VIII increase. The possibility 
exists, however, that not all receptor sites affected by beta adrenergic 
-202- 
drugs, show equal dose sensitivity. ICI 50172 had no detectable effect on 
the plasminogen activator response to adrenalin and in view of this it might 
be deduced that different beta adrenergic drugs, of varying chemical 
composition, may have differing actions on receptor sites. This could 
conceivably explain the variation in results between pronethalol and 
propranolol infusions, and it would be of interest to repeat the work of 
Ishioka (1967). 
Although both the present results and those of Ishioka suggest 
that adrenalin stimulated changes in plasminogen activator may be mediated 
in part through the so- called beta receptors, the varying metabolic effects 
of separate beta drugs are not consistent with a simple classification of 
the adrenergic receptors into alpha and beta types. Much further doubt 
has been case on this concept by the work of Himms -Hagen (1967), who 
regards the Ahlquist theory as untenable in view of the conflicting evidence 
obtained from both animal and human studies. Similar views have been 
noted by Epstein and Braunwald (1966). 
In the present studies, the newly developed beta adrenergic drug 
ICI 50172 differed markedly in action from propranolol. Not only was it 
unable to block completely the post adrenalin increase in Factor VIII, but 
it modified only slightly the free fatty acid response. Although this may 
have been a dose effect, i.e. the amount of ICI 50172 infused may have been 
too low to affect these particular parameters, further increases in dosage 
were not regarded as justifiable, as in animals comparable doses had been 
able to produce adequate blockade (Fitzgerald, 1968). The effect of this 
drug therefore may be to divide beta adrenergic sites into at least two 
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groups - those affected and those not affected by ICI 50172 - thus even 
further complicating the simple concept of alpha and beta receptor sites. 
It is clear from these preliminary observations that until much 
more is known of the exact nature of the so- called adrenergic receptor and 
its chemical reactions with blocking drugs, as well as the chemistry of 
reactions occurring at the cellular level, progress will not be rapid. 
However, this does not invalidate the basic premise of a regulatory 
relationship existing between the sympathetic nervous system and haemostasis 
and further studies, although difficult, will be of considerable interest. 
SUKKAKY. 
The effect of adrenalin and beta adrenergic blockade in normal 
subjects was assessed by measurement of selected coagulation and fibrinolytic 
parameters. 
There was a marked post adrenalin increase in the circulating 
levels of Factor VIII, plasminogen activator and free fatty acids. There 
was no change in Factor XII, cryofibrinogen or F.D.P. levels. 
Prior beta adrenergic blockade with propranolol completely blocked 
the post adrenalin increase of Factor VIII and F.F.A., but only partially 
blocked the rise of plasminogen activator. With prior adrenergic blockade 
with ICI 50172 no effect on the post adrenalin increase of Factor VIII or 
plasminogen activator was noted, although there was a slight decrease in the 
maximum level of F.F.A. achieved. 
The results are discussed briefly in the light of current concepts 
of adrenergic blockade and haemostasis. 
SECTION 5 
COAGULATION, FIBRINOLYSIS AND PREGNANCY. 
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COAGULATION FIBRINOLYSIS and PREGNANCY. 
Introduction. 
During the temporary, reversible physiological process of pregnancy, 
numerous alterations take place in the haemostatic mechanism. Not only is 
there a marked elevation of some coagulation factors, but fibrinolytic 
activity is significantly decreased, to such an extent that similar changes 
occurring in other circumstances might be considered abnormal. 
This unusual biological situation could be of the utmost importance 
in our understanding of the control and mechanisms of coagulation and 
fibrinolysis. A clearer elucidation of these systems might provide relevant 
information in terms of the hypothesis of a dynamic equilibrium between 
coagulation and fibrinolysis, and clarify aspects of pathological haemorrhagic 
or thrombotic emergencies now known to occasionally complicate pregnancy. 
Accordingly, a study was undertaken of selected facets of the 
haemostatic mechanism in pregnancy. A basic investigation of some of the 
reported changes in coagulation and fibrinolysis was first made, followed 
by additional studies of the reactivity of these systems to both exercise 
and surgical stresses. Finally, clinical instances of abnormal alterations 
in coagulation and fibrinolysis were diagnosed, investigated and treated 
and interpreted in the light of recent research developments. 
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CHAPTER I. 
NORMAL LEVELS OF HAEMOSTATIC FACTORS IN PREGNANCY. 
A. Introductory review of coagulation and fibrinolytic chames occu-rrina 
in normal rp errancy. 
The numerous alterations taking place in the various parameters 
of the coagulation and fibrinolytic systems in pregnancy, have been well 
documented. The changes described in coagulation include an increase in 
fibrinogen levels (D-iec_kmann and Wegner, 1934; Ratnoff and Holland, 1959; 
Pritchard and Brekken, 1967), and the concentrations of Factors VII and X 
(Loeliger and Koller, 1952; Alexander et al., 1956; Rutherford et al., 
1964). There is no significant change in Factors II or V levels (Ratnoff 
et al., 1954; Pechet and Alexander, 1961; Kasper et al., 1964; Todd, 
1965; Nossel et al., 1966). Some controversy remains regarding the 
levels of Factor VIII, but the most recent studies suggest that there is a 
significant rise (Strauss and Diamond, 1963; Kasper et al., 1964; 
Preston, 1964). With Factor I.X levels, some investigators have found an 
increase, while others regard any changes as variable or not present 
(Koch, 1956; Ross, 1963; Todd, 1965; Nilsson and Kullander, 1967). 
Factors XI and XII have been less well studied, but are apparently unchanged 
or lowered in late pregnancy (Hilgartner and Smith, 1965; Nossel et al., 
1966). Reports of Factor XIII levels are not available although Nossel 
et al. (1966) states that Factor XIII was present in all pregnant subjects 
investigated. 
It has been known for some time that fibrinolysis, as assessed by 
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the various methods that measure plasminogen activator, is decreased in 
the latter part of pregnancy ( Biezenski and Moore, 1958; Gillman et al., 
1959; Biezenski, 1960; Shaper.et al., 1965; Nilsson and Kullander, 1967). 
The apparent alteration in the fibrinolytic activity has been related to 
variations in levels of fibrinolytic inhibitors. Brakman and Astrup (1963) 
noted a selective increase in urokinase inhibitors in pregnancy and this 
finding was confirmed by Shaper et al (1968) and Kawano et al. (1968), 
although not by Nilsson and Kullander (1967). The latter authors did 
however detect an increase of antiplasmins and antiactivators in pregnancy. 
Guest (1954), Phillips and Skrodelis (1958) and Naidoo et al. (1960) were 
also able to find increased antifibrinolytic activity in pregnancy, but the 
specificity of the changes noted have not been clarified. 
Few reports on the levels of plasminogen in pregnancy are 
available, but the consensus of opinion is that levels are slightly 
elevated (Mitchell and Cope, 1965; Brakman, 1966; Nilsson and Kullander, 
1967). There is a fall in the platelet count throughout pregnancy 
(Shaper et al., 1963) and recent work has demonstrated that platelet 
adhesiveness does not alter (Nilsson and Kallander, 1967; Shaper et al., 
1968). 
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B. Experimental stud of the normal levels of selected coagulation 
and fibrinolytic parameters in pregnancy. 
1. Subjects and Methods. 
(a) Subdects. 
The blood samples for these studies were collected at routine 
ante -natal clinics of the Simpson Memorial Maternity Pavilion. 
Two studies were required for the investigation of F.D.P. in 
pregnancy. In the first study, specimens collected were divided approximately 
equally between trimesters. Blood samples were collected from 147 apparently 
healthy pregnant women. A further 21 samples were collected from non- 
pregnant pre -menopausal women. 
the second study, samples were similarly from 169 
pregnant, and 43 non -pregnant women of a similar age group. The second 
study was necessary for technical reasons connected with the F.D.P. assay. 
Subjects were selected at random, all were in good health at the 
time of examination, and without evidence of pre -eclamptic toxaemia. Most 
had had a short rest either seated or lying down immediately prior to 
venepuncture. 
(b) Collection of blood sam les and assa methods. 
Venous blood was collected from an antecubital vein by the usual 
method. Excessive venous occlusion or traumatic venepunctures were avoided. 
Blood was collected into either a'bitratd'tube, kept at 4 °C (for plasminogen 
and euglobulin lysis time assays) and /or a'_Trasylol- citratd+'tube (for F.D.P. 
and /or fibrinogen assays) and /or a'Trasylol serui' tube (for F.D.P. assays). 
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The euglobulin lysis time assay was performed immediately; other plasma or 
serum samples were stored at -4000 until assayed. Each tube was given a 
code number and all technical staff were unaware of the clinical details 
of each subject. 
(i) The euglobulin lysis time and plasminogen.assays were performed as 
previously described. 
(ii) The fibrinogen assays were performed either by the method of 
Ellis and Stransky (1961), or by the Thorpe heat precipitation 
assay (1968). Both gave similar results. 
(iii) The F.D.P. assay was as earlier described,apart from the following 
special arrangements. 
In the first study which was run on serum prepared from blood 
collected into Trasylol- citrate, each trimester group was run 
separately. Samples were run at a single antisera concentration. 
Values above 20/44 gm /ml. were repeated, but subsequent experiments 
demonstrated poor reproducibility related to the preparation of the 
Trasylol citrate specimens. The study was thus repeated. 
In the second study on Trasylol serum samples, F.D.P. runs were 
carefully planned. The total number of specimens in each F.D.P. 
runs were divided approximately equally between the trimesters and 
the normal control sera specimens. Two concentrations of antisera 
were used in most instances. F.D.P. values above 20/4- gm /ml. were 
repeated with good reproducibility. Additional fibrinogen standards 
were included as well as a standard control serum. 
Both F.D.P. studies are reported; in the final analysis both gave 
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similar results. However, it was considered that the findings were 
of such import that the results of the first study required fuller 
confirmation. Absolute values vary between the two separate studies; 
this is because different fibrinogen standards were used for each 
study, which in turn affects both the calculated sensitivity of the 
assay system and hence absolute F.D.P. values. The values obtained 
in the second study are representative of those now obtained 
routinely. 
2. Results. 
(a) Eu lobulin L sis Time Assay. 
A total of 111 assays of the euglobulin lysis activity were 
performed. These were divided approximately equally between the trimesters 
(1st trimester -40; 2nd trimester 33; 3rd trimester 38). The results 
after conversion to plasminogen activator units are depicted in Fig. 5:1 
and Table 5;1. There is a gradual decrease in the circulating level of 
plasminogen activator throughout pregnancy, commencing at the 12th -16th 
week. Very low activator levels occur near the commencement of the 
third trimester, which are maintained until the termination of pregnancy. 
This "cross sectional" study of plasminogen activator levels throughout 
pregnancy is very similar to results obtained in a "longitudinal study" 
of nine pregnant subjects described in the following chapter of this 
thesis. The decrease in circulating plasminogen activator concentration 
is highly significant between the first and second (t = 12.6866, p .0.001); 
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Plasminogen Activator levels throughout pregnancy 
( Ill Observations. ) 
Fig. 5:1. 
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(t = 7,5953, p<0.001) trimesters of pregnancy. 
TABLE 5 :1 
iUGLOBULIN LYSIS TIES ASSAYS THROUGHOUT PREGNANCY 
(111 OBSERVATIONS) 
1st Trimester 2nd Trimester 3rd Trimester 
Euglobulin lysis time 
(Minutes) 
(i<<TMean and S.D.) 
+ 
100 - 26 
(33 *) 
+ 
336 - 200 
(42) 
+ 









2.8 1.5 - 0.3 
t = 12.6866, p< 0.001 
t = 22.8767, p <0.001 
* Number of specimens. 
(b) Fibrinogen Assay. 
The results of 56 separate assays are depicted in Fig. 5 :2 
and Table 5:2. There was a highly significant increase of fibrinogen 
levels between the first and third trimester (t = 4.0511, p <0.001). 
The increase was also significant between the first and second 
(t = 2.7715, 0.01> p > 0.005), and the second and third trimesters 
(t = 2.5961, 0.02 >p >0.01). 
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Fig. 5:2. Fibrinogen levels throughout pregnancy. 
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TABLE 5;:2 
FIBRINOGEPT LEVELS THROUGHOUT PREGNANCY (56 ASSAYS) 
1st Trimester 2nd Trimester 3rd Trimester 
m.o /100 ml. 
250 ± 32 
(11*) 
296 ± 49 
(22) 
344 ± 74 
(23) 
t = 2.7715, 0.01).p). 0.005 
t=4.0511, p<0.001 
* Number of specimens. 
(c) Plasminoc'en Assay. 
In 45 assays there was a significant increase of plasminogen 
levels throughout pregnancy (Table 5485 The increase over the mean value 
of the first trimester was 20¡. The increase in the third trimester as 
compared with the first trimester was highly significant (t = 3.6631, p<0.001). 
TABLE 5 :3. 







5.00 ± 0.81 
(15 *) 
5.59 ± 0.87 
(11) 
5.98 - 0.75 
(19) 
t = 1.7692, 0.1> p> 0.05 
t = 3.6331, p < 0.001 
* Number of specimens. 
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(d) F.D.P. Assay. 
The results of the first study are set out in _Table 5:4, and of the 
second study in Table 5;4 and Fig.5 :3. In both studies there was a highly 
significant rise in the level of F.D.Ps between the first and third 
trimester (t = 4.1895, p40.001, and t = 7.4213, t<0.001). 
The same pattern was seen in each study between the control normal groups and 
the third trimester (t = 2.9329, 0.005).p>0.001, and t = 6.9313, p<0.001 
respectively). In addition, in the second study, the rise between the first 
and second trimesters was significant (t = 2.5672, 0.02>p>0.01). There 
was a wide scatter of F.D.P. values in both the second and third trimesters. 
TABLE 5:4. 
FIBRIN /FIBRINOGEN DEGRADATION PRODUCTS LEVELS 
THROUGHOUT PREGNANCY. 




(mean and 4.4 2.7 3.9 - 2.4 6.9 - 3.0 4.4 ± 3.6 
S.D.) (48 *) (50) (49) (21) 
2nd Study 
(Mean and 6.6 ± 2.6 8.2 ± 4.1 14.0 6.9 6.5 ± 2.1 
S.D.) (53) (57) (59) (43) 
* Number of specimens. 
Euglobulin lysis time assays were performed on 36 of these 
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Fibrin/ Fibrinogen Degradation Products throughout pregnancy. 
Fig. 5:3. 
- 216 - 
trimesters. There was no correlation between the observed euglobulin 
lysis times and the F.D.P. values (r = 0.1085, p = N.S.). 
Fibrinogen assays were performed on 48 Trasylol citrated plasma 
samples, again evenly distributed throughout the trimesters. There was no 
correlation between the individual fibrinogen and F.D.P. values (r = 0.0515, 
p = N.S.) either within the complete group, or within trimesters. 
In addition the available hospital and ante -natal clinic reports 
of the majority of subjects tested were reviewed. There was no significant 
difference in the mean ages of the groups of subjects tested. There was 
also no apparent correlation between parity, subsequent obstetrical 
complications encountered and the F.D.P. levels. In particular, higher 
levels of F.D.P. did not appear to be associated with haemostatic or 
thrombotic complications. 
3. Discussion. 
A decrease in the lytic activity of the euglobulin fraction of 
plasma was first detected by Gillman et al (1959). They noted that 
fibrinolytic activity decreased sharply between the 13th and 28th week 
of pregnancy. One year previously Biezenski and Moore, in a study of 
260 subjects and using a clot lysis technique, demonstrated that an 
appreciable decrease of fibrinolysis was evident by the 16th - 20th week 
of pregnancy. In this present study of 111 subjects, using a sensitive 
euglobulin:lysis time (ELT) technique for the measurement of plasminogen 
activator, it was demonstrated that changes in lysis time were detectable 
by the 12th - 16th week of pregnancy. The mean E.L.T. of the 40 subjects 
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in the first trimester of pregnancy was 101 minutes, with a range of 
71 - 143 minutes. In a previously studied control group of 25 resting 
non -pregnant subjects (Cash, 1966), between the ages of 18 and 30 years, 
the mean E.L.T. was 154 minutes with a range of 68 - 595 minutes. The 
difference in mean values might be explained by the fact that the pregnant 
population samples were not taken while the subjects were necessarily in a 
resting state, but at a busy ante -natal clinic, where factors such as stress 
and exercise may have influenced the circulating levels of plasminogen 
activator. Notwithstanding, Biezenski and Moore observed that fibrinolysis 
was present in 93% of the control population but in every subject between 
1 - 10 weeks gestation, and it is possible that marginal elevation of 
plasminogen activator levels may occur prior to the fall in the second 
trimester. Further controlled studies would be of interest, as little 
interest had been taken hitherto in changes occurring in early pregnancy. 
There have been various explanations advanced for the decrease 
in lysis activity throughout pregnancy. The decrease could be due to 
increased levels of inhibitors as suggested by Biezenski and Moore (1958); and 
Gillman et al. (1959), but published reports on the behaviour of fibrinolytic 
inhibitors during pregnancy are still contradictory (Guest 1954; Phillips 
et al., 1958; Naidoo et al., 1960; Bienzenski, 1960; Correll and 
Sjoerdsma, 1962; Brakman and Astrup, 1963; Nilsson and Kullander, 1967; 
Kawano, 1968; Shaper et al., 1968). The relating of changes in plasma 
urokinase inhibitor levels to plasma activator concentrations is debatable 
as urokinase cannot normally be detected in peripheral blood (Kucinski et al., 
1968), and this enzyme may be more sensitive to inhibition than plasma 
- 218 - 
activator (Brakman and Astrup, 1963). In the E.L.T. assay:, fibrinolytic 
inhibitors are normally not precipitated with the euglobulin, but it is 
possible that very small amounts of inhibitors may be present. If this 
were a constant phenomena, and inhibitors did progressively increase in 
potency throughout pregnancy, the lengthening of the euglobulin lysis time 
could be explainable on this basis. However, we have no experimental 
evidence to support this theory, for in previous experiments no urokinase 
inhibitors could be detected in eulobulin precipitates from normal 
subjects. Also, inhibitors of fibrinolysis are normally present in 
plasma in excess of normal requirements and small increases in their 
absolute levels may not necessarily mean that there is greater inhibition 
of lysis activity. It is clear that until the fibrinolytic inhibitors 
are more precisely distinguished and their exact physiological role 
elucidated in relation to detected changes of circulating plasminogen 
activator,. progress will be delayed. 
It is unlikely that the decrease in euglobulin lysis activity 
can be attributed to substrate alterations in fibrinogen concentrations, as 
normal levels of plasminogen activator can be demonstrated post partum in 
the presence of even higher fibrinogen levels. There is also no correlation, 
at least in normal subjects, between variations in the euglobulin lysis times 
and plasminogen levels (Cash, 1966). Brakman (1966), regards absolute 
levels of plasminogen activator as being reduced in pregnancy and this 
concept is supported by Nilsson and Kullander (1967). If it could be 
proved that euglobulin was completely free of all fibrinolytic inhibitors 
the present results would also be consistent with this view. 
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The physiological mechanism by which lysis activity is reduced 
in pregnancy is not known. Theories advanced include changes in both 
adrenal and sex hormones (Gillman et al., 1959), and placental hormones 
(Shaper et al., 1966), although the part played by these substances in the 
control of normal fibrinolysis is not understood, as exogenous administration 
of derivatives of these hormones cannot duplicate the changes seen in 
pregnancy. However, it would be reasonable to suggest that the placenta 
could be intimately involved in the changes occurring in plasminogen activator. 
Not only do plasminogen activator levels increase soon after removal of the 
placenta (Shaper et al., 1966), but the placenta is rich in urokinase and 
trypsin in'nibito±s (Kawano et al., 1968), and does not contain, unlike most 
other organs, tissue activators. The study of fibrinolysic inhibitors 
produced by the placenta might therefore be of great interest as it is 
possible that one explanation of the low levels of plasminogen activator in 
pregnancy may be one of placental inactivation or neutralization of this 
enzyme. Plasminogen activator levels may be reduced because of excessive 
consumption in pregnancy, perhaps as part of a physiological mechanism to 
retain vascular patency in the heterografted placental bed. Also, little is 
known of other routes of excretion of plasminogen activator in pregnancy, 
such as by the liver or kidney, and whether excretion by such pathways is 
enhanced. 
It is apparent that considerably more experimental work using 
monospecific tests are required if the significance and control mechanisms 
of this change in lysis activity is to be elucidated, although the 
measurement of F.D.Ps (vide infra) may be an important contribution to our 
understanding. 
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Reports of plasminogen levels during pregnancy are conflicting. 
Philips and Skrodelis, (1958); Rockstuhl et al., (1962; Mitchell and Cope, 
(1965); Hedner and Nilsson, (196); and Nilsson and Kullander, (1967), all found 
a moderate increase throughout pregnancy, while Shaper et al., (1965), and 
Bra1nan (1966) found no change. Some of the differences can be explained 
on methodology, as varying techniques have been used. However, in this 
laboratory, using a caseinolytic assay similar to that of Shaper et al. 
(1965), in a larger number of subjects, a small but significant increase 
in plasminogen could be demonstrated. It is possible this change is 
related to alterations in hormone levels occurring in pregnancy as 
administration of exogenous progestational agents can result in an increase 
of plasminogen levels.(Beller and Porges, 1967). 
The increase in fibrinogen levels throughout pregnancy are well 
documented and the results presented here are similar. Pritchard and Brekken 
(1967), in a very large study of fibrinogen levels throughout pregnancy, found 
that the mean concentration increased about 50%; this is in agreement with 
the present study where the mean change as compared with a mean non- pregnant 
level of 225 mgm /100 ml. was 47%. Most studies have noted considerable 
individual variations and this is particularly evident in the wide spread 
of results in the third trimester. The plasma fibrinogen is elevated in 
many situations associated with physiological and pathological stresses 
(McKenzie et al., 1963) and the significance of its alteration in 
pregnancy is not known, although some writers have considered the change 
of teleological advantage in the control of haemorrhage at parturition. 
Although fibrinogen levels have been intensively investigated by 
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other workers, it is of some importance that separate coagulation laboratories 
establish a normal range of fibrinogen values of pregnancy; not only do 
methods for measurement of fibrinogen vary with consequent differences in 
absolute values, but in some situations in pregnancy, a normal fibrinogen 
result may not exclude a pathological consumption of this protein. 
It can be considered that the measurement of fibrinogen, 
plasminogen, plasminogen activators and inhibitors in pregnancy, provides 
only partial information on their dynamic interactions in vivo. Fibrinolysis 
has commonly been equated with plasminogen activator activity, but it is now 
increasingly apparent that such measurements may not necessarily be 
synonymous with in vivo lysis of fibrin. With the introduction of the F.D.P. 
assay, an entirely new approach can be made to the problems of in vivo lysis 
of fibrin, as it is assumed that the measurement of these degradation products 
represents the end product of dynamic in vivo reactions of coagulation 
and fibrinolytic factors. In the light of presently available evidence 
of a decrease in plasminogen activators and an increase of fibrinolytic 
inhibitors, it could be considered that actual lysis of fibrin would be 
decreased in pregnancy. To investigate this hypothesis a study of F.D.P. 
in pregnancy was made. Such a study has not previously been reported 
and the results noted in this thesis may be of considerable relevance to our 
understanding of the complex haemostatic changes occurring in pregnancy. 
As can be observed from both sets of results (Table 5:4), F.D.P. 
levels increase throughout pregnancy. The finding of no correlation between 
the levels of serum F.D.P. and plasma fibrinogen in the pregnant group as a whole 
and in any one trimester indicates that the rise is not an artefact due to 
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unclotted fibrinogen remaining in the serum, but is a true reflection of the 
level of circulating, immunologically reactive F.D.P. Furthermore, it is not 
a simple reflection of plasminogen activator levels, as these decrease 
throughout pregnancy and no correlation could be found between activator 
concentration and the corresponding P.D.P. value. 
One interpretation of these findings is that fibrinolysis is not 
decreased in pregnancy, but is in fact increased in the latter portion of the 
gestational period. Such a conclusion would require considerable 
qualification as the haémostatic changes occurring in normal pregnancy are 
complex, and, in the present state of knowledge, it would be hazardous to 
oversimplify such a system. 
Most studies of fibrinolysis in pregnancy have centred on the 
measurement of blood plasminogen activator. The enzyme probably originates 
from venous and capillary endothelium (Todd, 1959) and is intimately linked 
with the intravascular lysis of fibrin (Sherry et al., 1959). The 
contribution tissue activators make to the circulating level of plasminogen 
activators has not been clearly defined. 
On the other hand, F.D.Ps are an "end stage" in the proteolysis 
of fibrin and fibrinogen, and though circulating F.D.P. may represent only 
intravascular lysis, it is possible that they also partly represent active 
fibrinolysis in extravascular tissues. It is known that extravascular 
lytic activity can be considerable, for not only do most organs contain 
activators of plasminogen fulfilling important physiological roles in lysis 
associated with repair and inflammatory processes (Astrup, 1966), but 
fibrinogen is also present in an extravascular location (Gitlen et al., 1953) 
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and may represent 20 - 25% of the total body fibrinogen (Hammond and Verel, 
1959; Lewis et al., 1961). Benz (1968) has been able to demonstrate 
extravascular lytic activity in tissues by the measurement of F.D.Ps. in 
both transudates and exudates, in the absence of degradation products in the 
simultaneously tested sera. Extravascular and intravascular lysis may 
therefore contribute to the circulating intravascular level of F.D.Ps. 
although definite evidence of this is lacking. This could also be one 
explanation of the poor correlation between the low observed levels of 
circulating plasminogen activator in pregnancy and the normal or 
elevated levels of F.D.P. 
The uterus is particularly rich in tissue and vascular activators 
of plasminogen (Albrechtson, 1958). Mackay et al. (1967) have shown a 
marked arterio- venous gradient of plasminogen activator and F.D.Ps. across 
the non -pregnant uterus and suggest that fibrinolytic activity within the 
uterus is contributing to the systemic circulation. In pregnancy, with 
the greatly increased uterine vascularity, blood flow and tissue mass, the 
contribution of the uterus may be proportionately greater. Blood flow in 
the uterus increases from less than 100 ml. /minute in the first trimester 
to 700 - 800 ml. /minute at term (Metcalf et al., 1955; Assali et al., 
1960; Huckabee, 1962). This could suggest that the uterus itself may 
be a source of circulating F.D.P. in late pregnancy. 
It has not yet been defined clearly how F.D.Ps. are eliminated 
from the body but available evidence implicates hepatic and reticulo- 
endothelial (Gans and Lowman, 1967), and renal (Herschlein and Steichele, 
(1968) pathways. There is no evidence that renal function (Chesley and 
Chesley, 1939; El-Mahallarvi et al., 1968) or reticulo -endothelial 
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activity (McKay et al., 1964) is altered in normal pregnancy but there is 
sore evidence that hepatic excretory function may be affected. Both 
Tindall (1965), using a modified bromsulphthalein excretion test, and 
Kessler and Aredos (1964), utilizing a battery of liver function tests were 
able to demonstrate small changes in liver metabolism in pregnancy. Simcock 
and Forster (1967) also found progressive cholestasis and impairment in mean 
hepatic excretory function. Delayed or slow excretion could possibly 
explain the increase in F.D.P., but this conclusion is unlikely for it has 
been shown that some patients with severe hepatic cirrhosis and a marked 
deterioration of all liver function tests, may have normal serum F.D.P. 
values (Das and Cash, 1968). 
Earlier work in normal subjects has shown that exercise will 
increase the level of circulating F.D.P. in some individuals (Das et al., 
1967). It could be assumed that the increased energy expenditure in 
attending the ante -natal clinic in the latter months of pregnancy could 
have led to a rise in F.D.P. However, there is no evidence that a fixed 
exercise procedure demands a higher energy expenditure in later pregnancy 
(Seitchi4 1967), and experiments to be described in the following chapter 
demonstrate that a significant rise in serum F.D.P. does not occur 
following moderate exercise in pregnancy. 
Venous occlusion of the lower limbs occurs in normal pregnancy 
so that the femoral vein pressure gradually increases after the 20th week 
(Maclennan et al., 1943; Wright et al., 1950). Venous occlusion has been 
shown to increase the F.D.P. concentration in the occluded vessels (Nilehn 
et al., 1964), and it is conceivably possible that this could explain the 
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observed increase in circulating F.D.P. in late pregnancy. The other source 
of venous occlusion, i.e. that at the time of blood sampling, was reduced by 
removing all blood with minimal occlusion of the arm. 
In some clinical and experimental hypercoaguable states there 
appears to be an increased turnover of fibrinogen (Izak, 1965). Studies of 
fibrinogen turnover in pregnancy do not appear in the literature and the only 
available information relevant to this topic is from Regoeczi (1968), who 
found the catobolic rate of fibrinogen was increased in one monkey in the 
third trimester. If fibrinogen turnover is increased in late pregnancy and 
assuming that the fibrinolytic system is, at least in part, involved in the 
metabolism of fibrinogen, it could be considered that this factor could 
explain the finding of increased F.D.P. levels. Further studies would be 
of considerable interest. 
In a series of experiments on pregnant golden hamsters, Brown 
and Stalker (1960) have shown that following both spontaneous premature 
placental separation and the artificial application of trauma to the placenta, 
white emboli resembling fibrin emboli are released from the placental bed 
into the maternal and foetal circulations. If the damage is sufficiently 
severe, the animals develop a characteristic defibrination syndrome. In a 
recent report by Devi et al. (1968) attention has been focussed on the high 
incidence (64) at term in normal pregnancies of macroscopic placental lesions 
in the form of Kline's haemorrhages, intervillous thrombosis, placental 
infarctions and retro placental haematoma. The presence of these lesions 
appeared to be associated with evidence of transplacental haemorrhage 
(foetal cells into the maternal circulation). Woodrow and 
Finn (1966) have 
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demonstrated a linear increase in the incidence of foetal cells in the 
material circulation during the third trimester. These observations, 
coupled with those of Brown and Stalker (1968) suggest that the incidence 
in circulating F.D.P. could be causally related to an increasing incidence 
of placental damage. 
It is possible, although by no means proved, that the low levels 
of plasminogen activator in pregnancy are reflecting an increased consumption 
of this enzyme, subsequent to increased intravascular coagulation. 
Additional evidence for this could be the finding of a progressive fall in 
circulating platelet levels throughout pregnancy (Shaper, 1968). The 
present findings of increased F.D.P. levels would be consistent also, although 
the interactions between these various compounds is still far from clear 
and requires further elucidation. 
It is unlikely that the significance of the elevation of F.D.P. 
in late pregnancy will be clarified until considerably more is understood 
of the metabolism and excretion of these products. However, despite these 
qualifications it is now possible to suggest that fibrinolysis is not 
necessarily decreased in pregnancy, as has been previously assumed. 
This reviewed concept of the place of fibrinolysis in pregnancy might go 
some way in explaining the relative infrequency of thrombotic episodes in 
the gestational period (Aaro, 1966) assuming, as would seem reasonable, that 
fibrinolysis has an important physiological function in removing intravascular 
fibrin associated with thrombi formation. The concept might also be 
incompatible with the theory that the increase of coagulation factors in 
pregnancy is a secondary effect of decreased fibrinolysis (Pechet et al., 
1961). 
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4. Summary. 
The changes in the intravascular concentrations of fibrinogen, 
plasminogen, plasminogen activator, and F.D.P. have been studied throughout 
normal pregnancy. The elevation of fibrinogen and plasminogen levels has 
been confirmed as well as the decrease in plasminogen activator concentration. 
In addition a new finding, that of increased F.D.P. with advancing pregnancy, 
has been presented and is further discussed in the light of the present 
knowledge of the coagulation and fibrinolytic systems. 
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CHAPTER 2. 
THE ErrLCT OF MODERATE EXERCISE ON THE 
FIBRINOLYTIC SYSTEM THROUGHOUT PREGNANCY 
Introduction. 
Earlier investigations from this laboratory, had established 
that the ability of a normal healthy individual to generate circulating 
plasminogen activator to a physiological stress such as moderate exercise 
was a reproducible phenomenon, that there was a significant difference 
between individuals and that it was possible to isolate a small sub -group 
whose fibrinolytic response appeared to be consistently impaired (Cash, 1966; 
Cash and Woodfield, 1960. This impairment was also evident following 
intravenous adrenalin and an exhaustive exercise procedure (Cash and Allan, 
1967; Cash and Woodfield, 1967). Moreover, it was shown that in a 
population of 100 normal subjects, there was no correlation between the 
resting level of circulating plasminogen activator of an individual and his 
or her ability to respond. Thus on many occasions, subjects with low resting 
levels of plasminogen activator were observed, who subsequently responded well 
to the exercise and adrenalin stimuli. It was concluded that while these 
two aspects of in vivo fibrinolysis c uld have a complementary patho- 
physiological significance, their physiological control might be independent. 
In view of these findings and conclusions it was postulated that the ability 
of an individual to increase the level of circulating plasminogen activator 
might be of importance in clinical situations associated with acute focal 
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or disseminated intravascular coagulation and if so the so called "poor 
fibrinolytic responders" could be at risk (Cash, 1968). 
These considerations suggested that an examihation of the re- 
activity of fibrinolytic system in pregnancy, a condition known to be 
associated with unexpected episodes of intravascular coagulation would be 
of value, particularly in view of the already well documented work on 
Shwartzman type reactions. 
The generalised Shwartzman reaction is one in which, following 
two suitably spaced injections of bacterial endotoxin or thrombin, animals 
develop a characteristic lesion of bilateral renal cortical necrosis. 
(Thomas and Good, 1952). There is evidence to show that the renal lesion 
arises following the obstruction of the glomerular capillaries by fibrin 
thrombi subsequent to widespread intravascular coagulation (McKay and 
Shapiro, 1958; McKay et al., 1ß59; Bohle et al, 1959). There is also 
indirect evidence to show that one important protective mechanism acting 
against this pattern of events is the endogenous fibrinolytic response 
to the episode of intravascular coagulation (Margaretten et al., 1964, 1967; 
Phillips et al., 1968). 
Pregnancy has been shown to "prepare" animals for the Shwartzman 
reaction, so that pregnant animals will succumb to a single injection of 
endotoxin or thrombin. There is suggestive evidence that a similar 
phenomenon can develop in the human species, for approximately two thirds 
of human cases of renal cortical necrosis occur in pregnant women (Duff and 
Murray, 1941). The complications of pregnancy in which they may arise are 
septic abortion, premature rupture of the membranes, abruptio placentae and 
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eclampsia, conditions all known to be associated with intravascular 
coagulation (McKay, 1964). It has been suggested that an important 
factor determining the state of "preparedness ", and therefore a heightened 
susceptibility to Shwartzman type reactions in pregnancy, is the depression 
of fibrinolysis that occurs in the second and third trimesters (Biezenski 
and Moore, 1958; Gillman et al., 1959; Shaper et al., 1965; Nilsson and 
Kullander, 1967). This conclusion is based upon evidence obtained from 
pregnant women in the resting state and in view of the earlier observations, 
at least in non -pregnant human subjects, it cannot be assumed that their 
ability to effect a sudden increase in fibrinolytic activity following an 
appropriate stimulus is necessarily impaired. The present study was 
therefore designed to investigate this problem, using as a stress procedure 
a short treadmill exercise. In addition, the opportunity was taken to 
assess the response of other parameters to an exercise stress procedure. 
In vivo lysis of fibrin was assessed by the fibrinogen degradation products 
(F.D.P.) assay and the changes occurring in cryofibrinogen by measurement 
of heparin precipitable fraction (H.P.F.). 
Subjects and Methods. 
Volunteers for this study were recruited from a routine antenatal 
clinic of the Simpson Memorial Maternity Pavilion. liine pregnant subjects 
were selected, aged between 22 and 32 years, Mean 25.8 years. All were in 
good health and physical examination was normal in all cases. Both medical 
and obstetrical histories were found to-be uncomplicated, and four 
subjects were multiparous. One subject (A.S.) developed mild 
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hypertension at the 33rd week and another (D.ß.) a prolonged upper 
respiratory tract at 28 weeks, and studies at these stages were discontinued. 
Five of the subjects were followed throughout pregnancy, while the other 
four were investigated either in the second or third trimester. All were 
eventually delivered of live infants, and there were no major complications 
of note either at delivery or in the post partum period. 
A degree of exercise was chosen which in preliminary experiments 
on 6 non -pregnant subjects (14 observations), produced a mean fibrinolytic 
response of 34%. The exercise was within the capabilities of all subjects 
even in late pregnancy, and the mean pulse rate increase was 62 
± 
11 /minute. 
The procedure was repeated several times at weekly intervals, and then less 
frequently, until term. Venous blood was collected in the usual manner, 
both pre and post -exercise, from separate cubital veins. 
The fibrinolytic assay methods used were :- 
(a) The euglobulin lysis time. 
(b) Euglobulin and plasma drops incubated on human fibrin 
plates. 
(c) Fibrin degradation products assay. 
(d) Heparin Precipitable Fraction (H.P.F) assay. 
The fibrinolytic response was calculated as previously described. 
RESULTS. 
The results of the resting euglobulin lysis time estimations in 
all subjects are summarised in Table 5:5 arid Fig.5:4. There was a gradual 
decrease of plasminogen activator levels throughout pregnancy with greatly 
lowered lytic activity in the latter half of the third trimester. Both 
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TABLA 5:5. 
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E.D. - - - - - - - - - - - - - - - 876 443 49 953 613 36 
884 686 22 
I.S. - - - - - - - - - - - - - - - - - - 655 602 8 870 
650 25 
* Abbreviations B = Before Exercise 
A = After Exercise 
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euglobulin and plasma drops assayed on human fibrin plates showed a similar 
pattern. The decrease in activator levels between the 2nd and 3rd trimester 
was highly significant (t = 7.498, p,(0.001). 
The percentage plasminogen activator response in all pregnant 
subjects to the exercise stress is also recorded in Table 5;9. In some 
subjects there was a progressive decrease in the fibrinolytic response with 
advancing pregnancy, while in others, the changes were less marked or absent. 
Fig.5 :5 illustrates the decrease of fibrinolytic response that occurring in 
the 5 fully studied subjects (A.D., P.L., L.H., A.S. and M.F.). The 
fibrinolytic response to the exercise stress, in these subjects, showed a 
highly significant decrease in the third as compared with the second 
trimester (t = 5.102, p< 0.001). In the 4 less completely studied 
individuals 2 showed no change in the fibrinolytic response and in 2 the 
response was diminished. There was no correlation, in the complete group 
of 9 subjects, between the resting level of plasminogen activator and the 
fibrinolytic response (Fig. 5i,6,). The changes in fibrinolytic response were 
also reflected in both the euglobulin and plasma drops on fibrin plates, 
although the difficulties in accurate assessment of small areas of lysis 
made this method of study less reliable than the euglobulin lysis time 
estimation. 
The results of the assays of fibrin degradation products are 
recorded in Table 5:6. In 36 observations in the 9 subjects at various 
gestation stages there was no statistically significant difference between 
the pre and post exercise means (t = 0.7854, p = H.S.). Furthermore, no 
subject showed a consistent change in the F.D.P. level on repeated testing. 
Only a small number of H.P.F. assays were performed. There 
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TABLE 5:6 
FIBRIN DEGRADATION PRODUCTS Ougms. /ml.} ASSAYED BEFORE AND AFTER A 
MODERATE EXERCISE PROCEDURE IN NINE PREGNANT SUBJECTS (36 OBSERVATIONS) 

















































THE RESULTS OF H.P.F. ASSAYS, PRE AND POST MODERATE EXERCISE, 
IN SEVEN PREGNANT SUBJECTS AT VARIOUS STAGES OF PREGNANCY. 
(mgm /100 ml.) 
Subject Before After Gestation (wks.) 
M. L. 42.4 69.3 14 
48.0 56.0 29 
M. F. 28.7 33.9 16 
30.1 29.9 28 
L. H. 43.3 47.4 16 
34.0 42.0 24 
A. D. 19.0 45.1 21 
A. B. 52.3 56.6 38 
A. S. 36.7 45.6 24 
D. R. 39.8 65.1 23 
Mean 37.4 49.1 
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was a post exercise increase in H.P.F. which when statistically tested by 
a paired t test was significant (t = 2.9958, 0.02< p< 0.01).(Table 5:7). 
DISCUSSION. 
A. Plasminogen Activator Baseline and Response Study. 
The results of this study have confirmed the findings of other 
workers that the resting level of circulating plasminogen activator, as 
measured by the euglobulin lysis time and fibrin plates, is depressed in 
the latter months of normal pregnancy. However, an entirely new phenomenon - 
the development of a marked depression in the ability of some pregnant women 
to shorten the euglobulin lysis time following a standard exercise stimulus 
in the third trimester, has been observed. The good agreement between the 
euglobulin lysis time and fibrin plate assays during the periods of depressed 
response would suggest that the phenomenon is not related to changes in 
reactivity of plasminogen nor the increase in urokinase inhibitor levels 
described by Brakman and Astrup (1963); but that a defect had arisen in the 
production of plasminogen activator following the exercise stimulus. Unlike 
the marked depression of resting levels of plasminogen activator in the third 
trimester,a..depression:in response was not observed in all the subjects. This 
finding, as well as the absence of a significant correlation between baseline 
plasminogen activator levels and fibrinolytic response, appears to add 
further indirect evidence of a dissociation in the control mechanisms of 
these two fibrinolytic parameters (Cash and Allan, 1967) 
The mechanisms of this change in fibrinolytic reactivity to 
exercise during pregnancy are unknown. The fibrinolytic response in any 
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one individual is related, in part, to the energy expenditure of the exercise 
procedure (Cash, 1967; Menon et al., 1967), so that the greater the energy 
expenditure the greater the fibrinolytic response. Few studies have been 
performed on the energy expenditure in pregnancy following a standard 
exercise procedure. Seitchik (1967) observed no difference between tWo 
populations of non -pregnant and pregnant women but noted that pregnant 
women, between 24 and 35 weeks, were the most efficient. Although it is 
tempting to use these findings to explain the results and although Seitchik's 
exercise procedure was sub -maximal, it was, however, a non -weight bearing 
procedure (bicycle ergometer) and, as he emphasised, the situation on a 
treadmill may be quite different. 
It is believed that the release of plasminogen activator following 
such stimuli as exercise and epinephrine is a secondary passive phenomenon 
subsequent to vasoconstriction or vasodilation (Holemans, 1963). The 
peripheral blood flow in normal pregnancy, in terms of hand and foot blood 
flow, is increased. This vasodilation is believed to be due to a release 
of sympathetic vasoconstrictor tone, rather than from the direct effect of 
a circulating vasodilator humoral agent (Ginsburg and Duncan, 1967). 
Although Gibbon and Landis (1932) observed a further small increase in blood 
flow during indirect heating experiments it is conceivable that larger 
increases are impossible because vasodilation is near its maximum in the 
resting condition in pregnancy. Such a state of affairs could explain the 
depression in the fibrinolytic response to exercise in these experiments 
but does not explain why some subjects exhibited a normal response to the 
stress. It is interesting to note that the other occasion on which a 
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marked deterioration in fibrinolytic response to exercise has been observed, 
was in individuals during a period of severe mental stress (Cash and Allan, 
1967) and Kelly has shown that severe mental anxiety may result in a 600 per 
cent increase in forearm blood flow due to intense vasodilation in the 
muscles (Kelly, 1966 and 1967). 
Little work has been done on the measurement of the vascular 
response to physiological stimuli in pregnancy, but the work of Dolezal 
and Figar (1965), raises a further possible explanation of the findings. 
Using such stimuli as pain, cold and mental stress, they demonstrated that 
the vascular response of skin vessels in the hands during the first and 
second trimester was dominantly vasodilator and that in the third trimester 
most women displayed a vasoconstrictor response to these same stimuli. 
Mann et al (1967) have shown that in monkeys (Macaca nemestrina) the 
fibrinolytic response to drugs which produced a vasodilator response was 
ten times greater than that seen following vasoconstrictor drugs. It is 
conceivable, therefore, that the changes in fibrinolytic response during 
pregnancy may be a secondary effect of an altered vasoactive response, 
from dilation to constriction. 
During pregnancy the concentration of circulating oestrogens and 
progesterone increases markedly (Short and Eton, 1959; Roy et al., 1963) 
and following delivery these fall precipitously, particularly oestradiol 
(Roy and Mackay, 1962). Although there is a certain degree of parallelism 
between the changes in concentrations of these hormones and the alterations 
in resting fibrinolysis there is no evidence that they are causally related 
(Shaper et al., 1966). Indeed, Bennet et al. (1966), found no significant 
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change in 8 male volunteers of the euglobulih lysis time following the 
administration of 3 mg. oestriol daily for 14 days. These results were 
confirmed by Brakman et al. (1967), who studied coagulation and fibrinolysis 
in both males and females, using oral contraceptive hormones. They also 
noted that a combination of progesterone and oestrogen increased resting 
spontaneous fibrinolysis and therefore did not reproduce the changes seen 
in normal pregnancy. Although the evidence at present is against a direct 
relationship between progesterone and oestrogens and the resting level of 
circulating plasminogen activator in pregnancy it is possible that they may 
influence the fibrinolytic response. Villadolid et al. (1965) have 
demonstrated that the conjugated oestrogens and oestriol succinate can 
impair the fibrinolytic response to intravenous adrenaline in adult male 
volunteers. 
Evidence is now accumulating that certain organs, particularly 
the kidneys and uterus, may contribute to the maintenance of the circulating 
level of plasminogen activator (Buluk and Furman, 1962; Niewiarowski et al., 
1964; Januszko et al., 1966; MacKay et al., 1967). Whether these organs 
play any part in the fibrinolytic response to a treadmill exercise procedure 
is unknown. Certainly, a variety of vasoactive agents, including adrenaline, 
produce a release of plasminogen activator from the kidneys of dogs 
(Holemans et al., 1965) and it is possible that this finding is also 
applicable to humans (Menon et al., 1968). Moderate exercise stimulates an 
increase in the concentration of plasma adrenaline (Von Euler and Hellner, 
1952; Vendsalu, 1960), and it is possible that the kidneys are responsible, 
in part, for the elevation in the circulating level of plasminogen activator. 
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If this is so, then the observation of Epstein (1966) of diminished plasminogen 
activator in the endothelium of renal glomeruli in pregnant rats may be 
relevant and would partly explain our findings. 
It is clear that until the fundamental mechanisms concerned in the 
release of plasminogen activator following stimuli such as exercise are 
understood, further progress in elucidating the cause of the deterioration 
in response in pregnancy will be delayed. 
The clinical significance of a depressed fibrinolytic response 
to exercise in pregnancy must remain hypothetical. Certainly, there is no 
evidence that it is secondary to frank pathological changes in pregnancy - 
all the women, apart from one subject, studied in this investigation had an 
entirely hormal pregnancy; all produced normal live babies, at term. It is 
possible that the condition of "preparedness" in pregnancy is more directly 
related to the ability to generate, rapidly, plasminogen activator to 
fibrinolytic stimuli. However, it is not known whether this depressed 
response is absolute, for Cash and Woodfield (1967) have already reported 
that some non -pregnant poor responders to a short sub -maximal exercise 
procedure will behave quite normally if the exercise is more prolonged. 
Furthermore, it cannot be assumed that the physiological type of response 
observed in the context of an exercise stress necessarily mirrors what might 
arise in pathological states of disseminated intravascular coagulation. 
It is also possible that, even in a state of impaired physiological 
fibrinolytic reactivity, copious quantities of tissue plasminogen, activators 
may be released into the circulation, as in abruptio placentae. In such 
clinical circumstances - which may be quite unlike those seen in experimental 
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Shwartzman reactions - it is less likely that renal cortical necrosis and 
the associated sequelae would arise. 
Despite these reservations, in the human species it is in pregnancy 
that the Shwartzman type of reaction is most commonly seen. The complications 
which give rise to this phenomenon are known to be associated with an 
uncompensated episode of intravascular coagulation. If the fibrinolytic 
enzyme system plays an important protective role in such circumstances, then 
the findings of a depressed responsitivity of the fibrinolytic system in the 
third trimester of pregnancy may be a crucial factor in determining whether 
the complications of intravascular coagulation are sustained, and in 
particular, renal cortical necrosis. 
B. Fibrin Degradation Products Stilly. 
The finding of no significant change in the circulating level of 
fibrin degradation products after exercise is similar to the earlier results 
following both moderate and exhaustive exercise procedures. 
The coagulation changes occuring in pregnancy have been described 
as constituting a physiological hypercoaguability (Pechet et al., 1961); in 
such a susceptible milieu it might be expected that if a minor or perceptible 
degree of intravascular coagulation normally did occur in response to an 
exercise stimulus, fibrin formation and a compensatory lytic episode with 
the formation of F.D.P. could conceivably more easily take place. The 
negative findings in these experiments, do not however exclude this 
possibility. Firstly, any transient small change occuring may not be 
detectable by this type of assay. Secondly, the assay is sensitive to 
serum products of fibrinolysis which are plasmin resistant (Alkjaersig 
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et al., 1962), and not to the large molecular fragments released in the 
early stages of fibrin proteolysis by plasmin, which could conceivably be 
present in post exercise plasma (although this is unlikely, Sherry, 1967). 
On the other hand, as earlier stated (Section 4:1), the 
plasminogen activator rise post exercise may be only a physiological 
mechanism to increase the potential for lysis if required. Actual lysis 
of fibrin in vivo may be quite unaltered despite the marked changes in 
activator levels. It is possible that a more severe exercise procedure 
may have provoked a change in the fibrin lysis rate, but this is unlikely in 
view of the previous studies on severe exercise (Section 4:1). From these 
results,however, it would appear that changes in levels of plasminogen 
activator within the physiological range, do not result in alterations in 
the degree of fibrin lysis in vivo. 
C. Heparin Preitable Fraction.). 
These limited studies complement the studies performed on H.P.F. 
in both the moderate and exhaustive exercise procedures. There is again 
evidence of a significant rise in the post exercise level of H.P.F. and 
similar considerations apply to this finding as have been previously stated 
in earlier chapters. The number of observations is too small to comment on 
the degree of H.P.F. change; but it is of similar order to that of the 
moderate exercise experiments. No particular trend can be detected with 
increasing pregnancy. 
These latter two studies do not progide definite evidence for or 
against the concept of a continuous fibrin formation- fibrin lysis mechanism 
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operative in vivo. It is quite possible that these two systems may be 
separately stimulated by physiological procedures such as exercise and 
only become linked when disseminated fibrin or plasmin formation exceeds 
a predetermined haemostatic mean. Further experiments using techniques 
such as assays of coagulation peptides and the estimation of cryprofibrin 
(Shainoff, 1960), may be able to demonstrate whether fibrin formation has 
commenced and these, coupled with a more sensitive assay for early and late 
degradation products of fibrin may aid in the clarification of these 
complex haemostatic changes. 
Summary. 
The fibrinolytic response to an exercise stress throughout 
pregnancy was studied in nine volunteers. There was a highly significant 
decrease in fibrinolytic reactivity in most subjects as well as a significant 
decrease in plasminogen activator levels. There was also no correlation 
between baseline plasminogen activator levels and the percentage fibrinolytic 
response. Fibrin /fibrinogen degradation products were not increased after 
exercise, but there was an increase in cryofibrinogen (H.P.F.). 
The possible relevance of decreased reactivity of the fibrinolytic 
system is discussed in the light of Shwartzman -type reactions and it is 
suggested that a decreased fibrinolytic response to stress in the third 
trimester of pregnancy could be a factor in determining whether the 
complications of intravascular coagulation, and in particular, renal 
cortical necrosis, are sustained. 
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CHAPTER III 
SURGERY, COAGULATION AIN FIBRINOLYSIS IN BOTH PREGNANT 
AND NON -PREGNANT SUBJECTS 
INTRODUCTION. 
Increased fibrinolytic activity following surgery was first 
observed by Macfarlane (1937). Using a simple clot lysis technique he 
detected fibrinolysis in 75% of patients subsequent to surgery. Imperati, 
(1937) made similar observations and Macfarlane and Biggs (1946) attributed 
the changes to both the effects of mental stress and surgical trauma. 
Further studies, using more sensitive techniques revealed that an increase 
of fibrinolysis was particularly common during thoracic surgery (Mathey et al., 
1950; Coon and Hodgson, 1952; Penn and 'Walker, 1954; Cliffton et al., 
1956; Ingram and Mann, 1959), and prostatic surgery (Scott et al., 1954; 
Lombardo, 1957; Ladehoff and Rasmussen, 1961). With the advent of cardiac 
bypass operations using extracorporeal circulations, interest in the 
fibrinolytic changes accompanying such surgery increased (Osborn et al., 
1955; Von Kaulla and Swan, 1957; Nillson and Swedberg, 1959; Gans et al., 
1961; Douglas et al., 1966) in an effort to identify and treat significant 
haemostatic problems. These investigations established that one main 
fibrinolytic change occurring in many different types of surgical procedures 
was a variable increase of circulating plasminogen activator (Anderson et al., 
1962). Excess lytic activity could result in depletion of plasminogen 
and /or fibrinogen levels with or without bleeding complications. Lesser 
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degrees of fibrinolytic activation appeared to be of little pathological 
significance (Anderson and Mendelow, 1964) . 
Varied changes have also been reported in the coagulation system 
in response to a surgical system. Kultiple or single defects of clotting 
factors had been detected (Cliffton et al., 1956; "(Orison and Lerner, 1961) 
sometimes resulting in a bleeding diathesis. Minor alterations in the levels 
of circulating clotting factors are common and the changes can be attributed 
to their consumption in the clotting processes associated with surgery or 
to their proteolysis by fibrinolytic enzymes (Bergentz and Nilsson, 1961). 
Alterations in these factors however may be difficult to detect by conventional 
coagulation assay techniques although careful, systematic pre and post 
operation sampling will often reveal frequent diminutions of specific 
clotting factors, the extent of which will depend partly on the severity and 
site of the surgery (Gollub, 1964). 
It is possible that some of the observed changes in fibrinolysis 
are a response to relatively minor degrees of intravascular coagulation 
occurring during the surgical process. Such a hypothesis would be 
difficult to prove or disprove conclusively, but one method of investigation 
would be to assess the end products of the clotting and lytic systems. 
If coagulation is activated with consequent fibrin formation, the lytic 
activity of the fibrin dissolving system might also be secondarily 
stimulated with fibrin lysis and the appearance of fibrin split products. 
The measurement of these products might not only reveal the significance of 
apparent changes in lytic activity occurring, but be an indirect measurement 
of the activity of the coagulation system. 
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Of no less interest are the alterations occurring in coagulation 
and fibrinolysis following surgery as the frequent occurrence of thrombotic 
phenomena still remains a major source of long term disability and appreciable 
mortality. Post -operation studies of coagulation have revealed a tendency 
to hypercoagulability (Gardikas et al., 1959; Egeberg, 1962; Davidson and 
Tomlin, 1963) associated with an apparent depression of fibrinolysis (Olow, 
1963; Bennett.e.t al., 1967). The significance of these changes in relationship 
to thrombosis is not known. 
The project was thus designed to measure the changes occurring in 
selected parameters of coagulation and fibrinolysis in subjects submitted to 
an intra- abdominal operation, both in the operative and post -operative phase. 
To assess if pregnancy modified the fibrinolytic response of a subject to the 
stress of surgery, a group of subjects undergoing a Caesarian Section 
operation were also studied in a similar manner. 
METHODS. 
A. Selection and Management of Subjects. 
Two groups of subjects were studied. The first group of patients 
were those admitted for a Caesarian Section operation with or without tubal 
ligation. The other group consisted of patients admitted for an intra- 
abdominal operation, usually a total or subtotal hysterectomy. 
(a) Caesarian Section Operation Studies. 
With the co- operation of the Obstetrical staff, Simpson 
Maternity Memorial Pavilion, selected patients were seen soon after their 
admission to the ward. In some cases, the admissions had been arranged in 
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advance; others were emergency admissions and details are given in the 
appendix. Each patient was interviewed, an explanation of the proposed 
study outlined and their permission and co- operation gained before blood 
sampling was commenced. It was possible to do this with some patients on 
the day prior to operation, but in others interviewing was done on the day 
of delivery. Most patients were very helpful and good liaison was achieved 
despite the repeated venepuncturing. 
The mean age of the group studied was 30.8 years with a 
range of 20 to 40 years. The average stay in hospital (including pre- 
operative period) was 13.7 days. Complications occurring in the operative 
or post -operative period are detailed in the appendix or referred to in the 
relevant text. These Caesarian Section operations, which were often 
accompanied by a tubal ligation procedure, were usually completed within 
45 minutes (range 30 -65 minutes). 
(b) Intra- abdominal Gynaecological Opperation Subjects. 
These patients were selected from the routine waiting list 
admissions of the gynaecological wards. Similar considerations apply to 
these patients as above. Most had been admitted for hysterectomy. All 
were premenopausal. Again, full details are given in the appendix. 
The mean age of this group of women was 35.2 years, with 
a range of 21 -43 years. The average stay in hospital, including pre- 
operative period, was 13.8 days. Case histories are referred to in the 
relevant text and appendix. The gynaecological operations were performed 
in an average of 53 minutes, with a range of 35 -84 minutes. 
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B. Blood Sampling Methods. 
In the Caesarian Section subjects it was planned to collect 
blood on (i) the day of admission; (ii) immediately prior to operation; 
(iii) as the umbilical cord was clamped; (iv) as the placenta was removed; 
(v, vi, vii and viii) 20, 40, 60 and 120 minutes after removal of placenta; 
(ix, x and xi) on days 1 and 2 post operation; and thereafter on alternate 
days. 
In the gynaecological subjects, samples were to be obtained on 
(i) the day of admission; (ii) immediately prior to operation; (iii, iv, 
v and vi) 20, 40, 60 and 120 minutes after commencement of the operation; 
_(vii, viii and ix) on days 1, 2 and 3 post operation; and thereafter on 
alternative days. 
It was not possible to sample at all these points. The reasons 
for this were varied. In a few patients in the post -operative period, 
venepunctures were discontinued because of undue patient stress. Other 
investigatory procedures commonly precluded venepuncture on the planned 
day. On occasions, despite good liaison with the clinical staff, the 
patient had already been venepunctured. Some patients felt too unwell to 
co- operate, while others developed complications such as chest infections 
and anaemia; in these situations, venepuncture was not always performed. 
Some were discharged or transferred from hospital relatively soon after 
operation. Technical laboratory considerations also precluded sampling 
on a few occasions. 
In the operative period, multiple blood samples were usually 
obtained from a cubital vein catheter inserted prior to operation. In 
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a few patients, separate venepunctures on varying veins were performed and 
minimal venous occlusion was used on all occasions. 
In the post -operative period, samples were obtained by venepuncture 
from the least damaged vein after ensuring, wherever possible, that the 
patient had been resting for at least 30 minutes prior to sampling. 
The volumes of blood collected were kept to a minimum compatible 
with laboratory test requirements. In addition, the volume of blood 
collected at each sampling point was varied according to the requirements of 
the assay. 
C. Assay Techniques. 
(a) Euglobulin Lysis Time. 
This assay was performed immediately and specimens were not 
kept at 4 °C for longer than 10 minutes before centrifugation. 
(b) Fibrinogen Assay. 
Blood, collected into a tube containing both trasylol and 
sodium citrate, was centrifuged, the plasma separated and stored at -40 °C 
until assayed by the Ellis- Stransky method. 
(c) Fibrin/Fibrinogen Degradation Products Assai. 
Blood was collected into a glass tube containing trasy;ol. 
Serum was stored in duplicate plastic tubes at -40 °C until assayed by the 
previously described method. All specimens from an individual patient were 
assayed in one large single assay, and high values (above 50,4,gm /m1.) were 
repeated. Controls were as previously described. 
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RESULTS. 
A. Gynaecological Operations. 
(a) Euglobulin L sis Time Assay. 
The complete results are summarized in Table 5 :8 and Fig.5 :8. 
It can be seen that there was a marked increase in euglobulin lysis activity 
occurring during the operative period, with a fall below the pre -operative 
level in the days following surgery. 
There was a slight increase of euglobulin lysis activity in 
the blood specimen removed on the day of operation as compared to that 
removed on the day prior to surgery, but the change was not significant when 
assessed by a paired t test (t = 1.0271, 0.4 >p>0.3). 
The alteration in euglobulin lysis activity reached significant 
levels within 20 minutes of commencement of the operation (t . 2.8933, 
0.01 <p<0.005). At the 40 and 60 minute stage the increase was highly 
significant (t=3.8311, p<0.001; t = 5.2877, p<0.001 respectively) but by 
120 minutes, the difference was no longer significant (t . 1.6688, 0.2 <p<0.1). 
The change of lysis activity was therefore a transient one. In the post- 
operative period, the decrease of euglobulin lysis activity, as compared 
with the pre -operative level was significantly lowered until the 7th to 8th 
days. The significance levels are summarised in Table 5:9. 
(b) Fibrinogen Assay. 
The fibrinogen assay results are tabulated in Table 5:10 
and charted in Fig. 5:9. 
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Fig. 5:8. The affect of an intra- abdoiìinal gynaecological operation 
on the euglobulin lysis activity prior to, during and 
following surgery. 
TABLE 5:8. 
FIBRINOLYSIS (EXPRESSED IN EUGLOBULII; LYSIS ACTIVITY UNITS) PRIOR TO, 
DURING, AND FOLLO,iING AN INTRA -J DOLiINAL GYNAECOLOGICAL OPERATION IN TEN SUBJECTS 
Subject 
* 




B2 10 20 40 60 120 1 2 3 4 5 6 7 8 9 10 11 12 
II 1 18.6 26.0 27.0 24.0 25.0 68.4. 22.4 2.2 2.2 2.1 - - 1.8 - 3.1 - 7.4 - - 
2 - 10.0 - 26.5 - 54.1 - 8.8 5.8 6.1 - 8.7 - 5.3 - - - - - 
3 16.0 9.2 - 22.4 - 27.0 26.5 9.0 14.1 - 6.6 - 7.6 - 9.0 - - - - 
4 11.5 13.2 12.4 17.1 24.0 28.2 25.4 7.5 - 7.8 - 14.6 - 7.9 - - 15.8 - - 
5 - 29.5 - 29.5 41.9 76.4 - 14.4 1.8 15.6 7.8 12.0 - 13.8 - 18.0 - -- - 
6 - 8.7 - - - 43.3 6.9 4.3 4.5 4.4 1.4 - - 6.4 - - 10.2 - - 
7 15.4 21.6 17.8 20.9 24.1 15.2 - 7.7 12.3 - 15.2 - 13.5 - 12.6 - 8.3 - - 
8 7.3 15.2 13.8 14.2 21.3 18..9 19.7 1.8 9.3 - 6.6 - 5.0 - - - - 1.8 - 
9 11.8 7.9 - - - 43.3 7.8 2.2 2.2 10.8 9.6 - - 8.7 - - - 10.0 - 





























Times after commencement of operation 
*M- B1 = Day prior to operation 
B2 = Immediately prior to operation 
TABLE 5:9. 
SUMMARY OF SIGNIFICAiTCE TESTS (PAIRED t TESTS) OF CHANGES 
IN EGGL0BULIN LYSIS ACTIVITY FOLLO,JING SURGERY. 
Euglobulin Lysis Activity 
Pre -operation : Post -operation Paired t Test 
Pre -operation : Day 1 3.0631 0.005 >p>0.001 
Pre -operation Day 2 2.7594 0.01 >p>0.005 
Pre- operation Day 3 2.0141 0.1 >p>0.05 
Pre -operation : Day 4 2.2226 0.5 > p>0.025 
Pre- operation : Days 5 + 6 2.1788 0.05>p>0.025 
P 
Pre- operation : Days 7 + 8 1.7762 0.1 > p>0.05 
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-Fig. 5 :9. Fibrinogen levels prior to, during and following an 
intra- abdominal gynaecological operation. 
TABLE 5:10. 
FIBRINOGEN LEVELS (mgm /100 ml.) PRIOR TO, DURING, AND FOLLOWING 
AN INTRA-ABDOMINAL GYNAECOLOGICAL OPi,PATION IN TEN SUBJECTS. 
Subject 




20* 40 60 120 1 2 3 4 5 6 7 8 9 10 11 
R 1 283 264 274 283 250 244 441 515 607 - - 562 - 548 - 548 - 
2 - - 214 - 225 - 350 444 451 - 451 - 437 - - - - 
3 194 196 191 - 186 194 343 398 - 482 - 457 - 491 - - - 
4 219 - - - - - 386 - 510 - 541 - 480 - - 369 - 
5 - 183 201 - 181 - 281 - - 349 349 - 346 - - - - 
6 173 - 184 - - - - 474 436 474 - - 387 - - 35o - 
7 162 - - - - - 309 - 429 - 349 - 322 - 303 - - 
8 - - - - - - 373 474 - 447 - 357 - - - - 252 
9 - - - - 184 177 393 419 514 476 - - 364 - - - - 



























Times after commencement of operation 
** B1 = Day prior to operation 
B2 = Tmmediately prior to operation 
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post -operative levels.(t = 0.0505, p = N.S.). A slight fall of mean 
fibrinogen levels was detectable at the 120 minute stage, but this latter 
change did not reach significance levels (t _ 0.5428, p = N.S.). All 
levels of fibrinogen elevation were significant in the days following 
operation (t values ranged between 5.1816 and 9.9711, p<0.001), with 
maximum values being obtained on the third day post operation. The peak 
value was then followed by a slow decrease in concentration, with fibrinogen 
levels being still elevated on discharge from hospital. 
(c) Fibrin Deradatioñ Product Assáy, 
All results obtained are recorded in Table 5:11 and Fig. 5:10. 
It can be seen that there was a small increase in the circulating levels of 
F.D.P. in the operative period, although the change did not reach significance 
levels on the small number of results (t = 1.9291, p = N.S.). There was 
no significant difference between the two "before operation" samples 
(r = 1.2742, p = N.S.) 
In the post -operative period, the changes were more marked. 
It can be seen that subjects H.1, H.2 and H.10, exhibited marked elevation 
of F.D.P. levels on either day 2 or 3 (Table 5:11 and Fig. 5:15). As these 
results were considerably at variance to the remainder of the assayed values 
(differing by over two standard deviations from the mean), they were 
excluded from Calculation of the mean of the results. After calculating 
the means of the remaining results, there was now a significant increase, 
as compared with the pre - operative levels, of F.D.P., which persisted until 
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Fig. 5:10. Fibrin /fibrinogen Degradation products prior to, during 
and following an intra- abdominal gynaecological operation. 
TABLE 5:11. 
FIBRIN DEGRADATION (//gm /ml.) PRIOR TO, DURING, AND FOLLOgING 
AN INTRA- ABDOMINAL GYNAECOLOGICAL OPERATION IN ELEVEN SUBJECTS. 
Subject 






10 20 40 60 120 1 2 3 4 5 6 7 8 9 10 11 
H 1 - 8.2 8.2 8.2 11.9 6.9 11.9 16.5 115.0* 132.1* - - 33.0 - 33.0 - 16.5 - 
2 - 10.0 - 7.1 - 16.5 - 10.0 19.1 93.8* - 28.3 - - - - - _ 
3 5.0 5.9 - 5.9 - 5.9 8.1 23.0 23.1 - 23.1 - 9.6 - 14.4 - - - 
4 3.6 7.2 5.4 5.4 10.8 9.0 5.4 7.2 - 21.6 - 14.4 - 14.4 - - 21.4 - 
5 - 6.5 - 4.1 - 5.0 - 13.4 11.0 8.1 13.5 18.5 - 22.5 - 20.1 - - 
6 - 3.0 - - - 8.3 5.9 6.9 6.9 6.9 38.1 - - 47.4 - - 33.0 - 
7 5.9 5.9 - 7.4 5.9 - - 14.4 11.8 - 11.8 - 5.2 - 5.9 - 5.2 - 
8 5.4 5.4 5.4 7.2 5.4 7.2 5.4 - 3.6 - 14.4 - 14.4 - - - - 7.2 
9 3.8 3.8 - - - - - 14.4 14.4 28.8 - - - 28.8 - - - - 
10 5.9 5.9 - 8.3 8.3 8.3 11.8 19.9 19.9 366* - 47.4 - 47.4 - 19.9 - 28.1 
































* Not included in Mean. ** B1 = Day prior to operation 
B2 . Immediately prior to operation 
* 10 0 Times after commencement of operation 
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TABLE 5 :12. 
SUMHARY OF SIGNIFICANCE TESTS (PAIRED t TESTS) OF CHANGES 




F.D.P. Paired t Test 
Pre- operation : Day 1 3.2783 0.01 >p>0.005 
Pre -operation : Day 2 4.2871 0.005 >p>0.001 
Pre -operation : Day 3 2.8723 0.05 >p>0.025 
Pre- operation : Days 4 + 5 3.8532 0.005 >p>0.001 
Pre- operation : Days 6+ 7 3.8993 
I 
0.005 >p>0.025 
Pre -operation : Days 8 + 9 3.5004 0.02 >p>0.01 
Pre -operation : Days 10 + 11 2.5970 0.05 >p>0.025 
Patients H.1 and H.2 had uneventful post -operative courses; 
patient H.10 developed a clinically diagnosed deep venous thrombosis of the 
right leg and was subsequently treated with anti -coagulants. 
B. Caesarian Section Operations. 
(a) Euglobulin Lysis Activity. 
The complete results are summarized in Table 5 :13 and 
Fig. 5:11. The resulting levels of euglobulin lysis adtivity was very low 






-1 I 0 I 20 40 60 80 100 120 
PRE-OP MINUTES 
DAY 
1 1 1 1 1 1 1 1 1 1 1 
1 2 3 4 5 6 7 8 9 10 11 
DAYS POST- OPERATION 
Fig. 5:11. Englobulin lysis activity prior to, during and following 
a Caesarian Section operation. 
TABLE 5:13. 
PIBRINOLYSIS (EXPRESSED IN EUGLOBULIN LYSIS ACTIVITY UNITS) PRIOR TO, 









CC PR 20 40 60 120 1 2 3 4 5 6 7 8 9 10 11 
CS 1 1.7 1.9 - 8.1 12.7 13.0 12.8 - 7.3 7.5 11.1 - 10.5 - 9.5 - 9.9 - _ 
2 - 1.4 I 1.8 2.1 23.2* 48.0* 24.5 14.9 8.0 
., 
1.7 - - 10.6 9.2 7.9 - 7.3 - _ 
3 1.3 1.8 1.9 - 2.7 4.3 - 13.0 1.9 6.2 6.8 6.1 6.1 - - - - - - 
4 1.3 2.6 1 - 3.6 3.9 3.9 6.3 14.8 4.8 8.0 - 12.9 - 7.7 - - 9.2 - 11.8 
5 2.2 En 
1.1 
7.1 - 8.6 20.3 20.0 22.0 1.2 14.0 10.6 - 11.8 - - - 11.6 - - 
6 - - 1.7 1.7 - 2.2 5.4 5.9 7.5 - 10.6 9.o - 10.9 - - 7.7 - 
7 2.0 1.8 - 2.2 2.3 10.5 17.1 17.6 4.0 7.3 - 8.6 - 8.1 - - - - - 















1.8 3.3 - 6.2 4.9 7.9 - - 10.1 8.3 - 15.3 - - - 
2.6 - - 18.1 10.9 - 11.2 - - - - - - 9.2 - 
12 - 1.5 - 
11111 




2.7 3.2 7.6 6.5 6.8 8.6 - - 
- - - - - _ - - --- - --- 


































* Not included in Mean ** Abbreviations B1 = One day prior to operation 
B2 = Immediately prior to operation 
CC = Cord cut 
PR = Placenta removed 
20 = Minutes after PR, etc. 
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increase of lytic activity, reaching a maximum 60 minutes after the commencement 
of the operation and sustained until the 120 minute period. In the post- 
operative phase there was a depression of lysis activity in the first and 
second post -operative days, with a subsequent slow return to non -pregnant 
levels. 
The increase in euglobulin lysis activity between the pre- 
operative day and that immediately prior to operation was not significant 
(t = 1.6603, 0.2 >p>0.1). There was also no significant difference between 
the pre -operative samples and the blood sample taken at the time of clamping 
of the umbilical cord and removal of the placenta (t = 1.7068, 0.2 >p>0.1). 
However, within 20 minutes subsequent to removal of the 
placenta there was a significant increase in the euglobulin lysis activity 
(t = 2.8882, 0.01 >p>0.005) and this difference was sustained up until at 
least the 120 minute mark. 
On the post -operative day, there was a significant increase 
of lytic activity over the pre -operative level (t = 4.4146, p<0,001), and this 
was maintained until discharge. However, the lytic activity on the first two 
post -operative days was significantly less than that of the subsequent days. 
(b) Fibrinogen Assays. 
The results are summarised in Table 5 :14 and Fig. 5:12. 
The mean resting levels of fibrinogen was elevated as compared with the non- 
pregnant concentration. There was no difference between the two "before 
operation" samples (t = 0.8722, p = 1v1.8.). There was again a slight fall 
in fibrinogen levels during the operative period, but the decrease was not 
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Fig. 5:12. Fibrinogen levels during and following a Caesarian 
Section operation. 
TABLE 5:14. 
FIBRINOGEN LEVELS (ma /100 ml.) PRIOR T0, DURING, AND FOLLOWING 
CAESARIAN SECTION Iii ELEVEN SUBJECTS. 
Subject 
Pre- Operation Operation. Period - Minutes Post Operation Period - Days 
B1 # B2 * *CC PR 20 40 60 120 1 2 3 4 5 6 7 8 9 10 11 
CS 1 274 - - - - - - - 286 361 463 - 311 - 273 - 266 - - 
2 - 385 350 368 369 279 301 350 - 392 - - 346 346 312 - 334 - - 
3 - 445 400 - 425 420 - 410 395 446 680 570 - - - - - - - 
4 236 194 - 202 260 - - 251 261 376 - 360 - 360 - - 305 - 317 
5 - 293 357 - 326 372 384 344 312 365 257 - 359 - - - 300 - - 
6 - 230 - 242 203 - 251 225 284 486 - 421 494 - 468 - - 411 - 
7 329 308 - 349 352 403 324 358 414 599 - 570 - 463 - - - - - 
8 - 434 442 458 412 439 - 349 376 - - 589 367 - - - - - - 
9 - 220 - 175 - 266 226 254 269 362 - 300 - 238 - - - - - 
10 302 369 241 262 304 - - 277 314 - - - - - - - - - - 

























* * Abbreviations - B1 = One day prior to operation 
B2 = Immediately prior to operation 
CC = Cord cut 
PR = Placenta removed 
20 = Minutes after PR, etc. 
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The increase of fibrinogen levels on the first-post- operation 
day was not significant (t = 0.2600, p = N.S. ) but changes in Days 2, 3 and 4 
were highly significant when compared with pre -operative levels (t = 3.2384, 
0.005)p50.001; t = 3.3391, 0.005 >p )0.001, respectively). The peak level of 
fibrinogen occurred on the fourth day post -operation although only a few blood 
samples were obtained on the third day post -operation. There was a subsequent 
continued fall of fibrinogen levels until discharge from hospital. 
(c) F.D.P. AssaZ. 
The complete results are summarized in Table 5 :15 and Fig.5 :13. 
The mean resting level of F.D.P. is at the upper level of the normal limits, 
this being consistent with the gestational period. An elevated Value of 
F.D.P. on subject CS.4 was not included in the mean results. 
The increase of F.D.P. throughout the operation was significant 
at the 5/. level (t = 2.3020, 0.1 >p>0.05). Post- operatively, although a 
definite trend is apparent, similar to that of the other surgical groups, 
the levels of significance were not as great when compared with the pre- 
operative level. However, when compared with the normal non -pregnant level 
of P.D.P., the changes were then highly significant. 
Patients CS.2 and CS.5 exhibited marked changes in F.D.P. 
levels in either the operative or post -operative phases. These changes 
followed a different pattern from the remaining twelve patients and the 
values were -thus not included in the means. The results obtained in CS.2 
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Fig. 5 :13. Fibrin /Fibrinogen Degradation products prior 
to, during and following a Caesarian Section 
operation., 
TABLE 5:15. 
FIBRIN /FIBRINOGEN DEGRADATION PRODUCTS (14 gm /ml.) PRIOR TO, DURING, AND FOLLOWING CAESARIAN SECTION IN TPIELVE SUBJECTS 
Subject 
Cs 1 
Pre -Operation Operation Period - 
... __ ___ ._..------ -- -- -- 














3 4 5 6 7 8 9 10 11 













- 13.6 - 18.6 - 18.6 - - 
2* 8.1 - - 33.4 23.7 - 22.5 16.5 11.9 - 23.6 - - 
3 7.1 10.0 10.0 - 10.0 7.1 - 10.0 16.5 14.2 28.3 - - - - - - - 
4* 5.9 8.3 - 11.9 16.5 11.9 11.9 23.7 
f 
23.7 149.0* - 37.1 - 18.6 - - 18.6 - 11.9 
5* 14.0 14.9 
38.9 
62.1* 173.3* 110.7* 295.0* 1 90.1* 22.9 12.7 - 14.0 - - - 26.1 - - 
6 - 17.8 1 - 31.0 21.4 - 17.8 12.4 16.5 - 14.2 - - 37.1 - - 27.8 - 
7 8.2 16.5 - 11.9 33.0 - 23.7 - 47.4 - 47.4 - 33.0 - - - - - 
8 - 11.0 22.0 16.8 22.0 22.0 - 11.0 16.8 - - 33.6 22.0 - - 16.8 - - - 
9 - 21.6 - 14.4 7.2 21.6 14.6 28.8 28.8 14.4 - 21.6 - 21.6 - - - - - 
10 20.0 28.3 - 24.2 17.1 24.2 21.9 28.3 24.7 28.6 20.2 - 20.0 17.1 - 20.0 - 21.9 - 
11 10.5 3.9 6.6 5.2 6.6 - - 10.5 21.0 21.0 - - - - - - - - - 
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* Not included in Mean. ** B1 = Day prior to operation 
B2 = Immediately prior to operation 
CC = Cord cut 
PR = Placenta removed 
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Fig. 5:14. Fibrin /Fibrinogen Degradation product levels in patients C.S.2 
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Fig. 5:15. Results of Fibrin /Fibrinogen Degradation Products Studies 
on subjects H.1 (B), H.2 (C), H.10 (A). 
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TABLE 5 :16 
SUMARY OF SIGNIFICAÀTCE TESTS (PAIRED t TESTS) OF CHANGES 
IN F.D.P. POLLWING SURGERY (CAESARIAN SECTION) 
F.D.P. (Caesarian Section) 
Pre- operation : Post -operation Paired t Test 
Pre -operation : Day 1 2.2063 0,1 >p>0.05 
Pre -operation Day 2 2.2779 0.1 >p>0.05 
Pre -operation : Days 3 + 4 2.9303 0.O2 >p>0.01 
Pre -operation : Days 5 + 6 2.1434 0.1 >p>0.05 
Pre -operation : Days 7 + 8 1.3208 N.S. 
Pre -operation : Days 9 - 11 2.2701 0.05 >p>0.025 
C. Comparisons of Operative Results of Normal and Prenant Sub'ects. 
The response of the pregnant group to the operative stimulus, as 
measured in euglobulin lysis activity units, was less than in the non- 
pregnant subjects. The pattern of response was however similar, although 
the results suggest that lysis activity persisted longer in the pregnant 
group following operation. It could also be seen that the post -operative 
changes in the two groups, apart from the first day post- operation, are 
similar. (Fig.5:16.) 
In Fig. 5 :17 the results for the fibrinogen assayshave been combined. 
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Fig. 5:16. Comparison of euglobulin lysis activities in gynaecological 
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Fig. 5:17. Comparison of fibrinogen levels in gynaecological and 
Caesarian Section operation subjects. 
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fibrinogen was delayed to the second day in the pregnant group. Both groups 
reached similar mean values of fibrinogen, but the rate of fall in the pregnant 
group was, in these studies, more rapid than the non -pregnant group. 
The change in F.D.P. in the operative period in both groups was 
small. In the post - operative period, the mean values in the Caesarian group 
are generally slightly higher than in the hysterectomy group but similar 
patterns are evident, with significantly elevated levels of F.D.P. persisting 
until discharge from hospital. 
Apart from the euglobulin lysis activity, other parameters measured 
had not returned to non -pregnant levels by the time the patients were discharged 
from hospital. 
.DISCUSSION._ 
A. Intra -operation Changes. 
(a) Euglobulin Lysis Activity. 
Most investigators who have studied fibrinolysis during 
surgical procedures have used methods designed to measure circulating plasminogen 
activators (Franz et al., 1961; Andersson et al., 1962; Anderson and 
Mendelow, 1964; Olow, 1963). From these studies it has become clear that 
during the operative period, there is a variable increase in the level of 
lytic activity, which can be inhibited by the use of exogenous fibrinolytic 
inhibitors such as E.A.C.A. The exact mechanism by which plasminogen 
activator levels are increased is not Down but factors such as pre- operative 
stress (McFarlane and Biggs, 1946), release of tissue activators into the 
circulation (Hardawey, 1966), and ischaemia (Kwaan and McFadzean, 1956) 
have all been regarded as providing evoking stimuli. Because of the numerous 
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factors known to increase activator levels, and also the lability, short half 
life and rapid changes that are known to affect the levels of this enzyme, 
it has not been possible to define adequately the exact effect of specific 
surgical procedures on fibrinolysis, as the changes occurring are undoubtedly 
complex. For these reasons Douglas et al (1966) believe that measurement 
of activator levels may yield misleading information and prefer to rely for 
evidence of activation of fibrinolysis on sequential plasminogen assays. 
Such an approach would appear entirely logical and using this technique they 
have been able to demonstrate that activation of fibrinolysis, as evidenced 
by lowered plasminogen levels does occur frequently during cardiac by -pass 
operations. 
It is possible, however, that the increase of plasminogen activator 
levels during surgical procedures may be a response to the inevitable 
activation of blood coagulation that is assumed must occur during surgery to 
maintain haemostasis. If plasminogen activator plays an important part in 
the control of physiological fibrinolysis (Sherry et al., 1959) it might be 
expected that the intra- operative increase of plasminogen activator is a 
normal response of the body to maintain intravascular patency in the face 
of an increased local or systemic tendency towards fibrin formation. 
Intravascular coagulation could possibly provoke intravascular fibrinolysis 
and the rise of plasminogen activator levels would be a natural concomitant 
of the process. 
If this hypothesis was correct, it should also be possible to 
demonstrate increased levels of the end products of fibrin or fibrinogen in 
the circulation during surgical operations representing in vivo activation of 
the fibrinolytic system. 
-268- 
In the present study, both changes in euglobuliü lysis 
activity (representing both plasminogen activator and plasmin concentrations) 
and fibrin degradation products have been assessed in considerable detail, in 
an attempt to provide some answer-: to the relative importance of the alterations 
in euglobulin lytic activity occurring in association with intra- abdominal 
surgical operations in both normal and pregnant patients. 
The studies have confirmed that euglobulin lytic activity 
increases steadily throughout the duration of surgery in both groups of 
patients. In terms of euglobulin lysis activity, the response was much less 
in the pregnant group but followed a similar pattern of increase, with maximum 
levels being attained approximately one hour from commencement of the operation. 
Levels in the non -pregnant subjects fell rapidly in the immediate post - 
operation period but appeared to be sustained in the pregnant group. It is 
difficult to compare the rate of increase of activator in the two groups, 
although from Fig. 5 :16, it is possible that there was slower evolvement of 
activator in the pregnant group. Also, the peak of the activator increase 
may not have been attained in the Caesarian Section subjects as sampling was 
not performed between one and two hours post operation. 
These marked changes in euglobulin lysis activity was complex 
in origin. Although it is.conceivable that anaesthesia alone may activate 
fibrinolysis, Bergentz and Nillson (1961) were unable to show an increase 
in euglobulin lysis activity after prolonged anaesthesia in dogs not submitted 
to any surgical trauma, and Cuocolo et al. (1965) could not demonstrate any 
systemic changes in fibrinolysis using a wide range of anaesthetic procedures. 
In the surgery groups described in this thesis, the length of. time each patient 
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was anaesthetised before the surgical procedure commenced, was not noted 
in all cases; however, in six Caesarian Sections the time interval before 
the initial skin incision was 4.3 minutes, and in seven gynaecological 
operations, the interval was 12.6 minutes. In both instances, during this 
interval, no significant change in euglobulin lysis activity was noted; on 
the contrary, in some subjects the euglobulin lysis times, when studied at 
five minute intervals, tended to lengthen. Although the evidence-is in no 
way conclusive it would appear unlikely that the administered general 
anaesthesia was significantly contributing to the observed intense activation 
of the fibrinolytic system. 
Pre - operative stress of the patient, which was marked in some 
subjects was the most reasonable explanation of the slightly shortened 
euglobulin lysis times observed immediately prior to operation. However, 
comparison of the lysis times of the two "before operation" samples was not 
significantly different in either group and it is thus less likely that the 
shortening of lysis time during operation could be explained completely by 
endogenous stress, as suggested by Macfarlane and Biggs (1947). 
The surgical procedure itself could have provoked the 
fibrinolytic reaction. With the incision and manipulation of various tissues, 
such as muscle and myometrial tissue, fibrinolytic tissue activators may have 
been released into the systemic circulation. Alternatively, as these tissues 
also contain thromboplastin, release of these agents may have promoted in vivo 
activation of coagulation, with a secondary response of the fibrinolytic 
system. In a small series of six closely studied patients, both pregnant 
and gynaecological, it was found that the first significant shortening of the 
euglobulin lysis time occurred 11.6 minutes (range 3 -15) after the initial 
- 270 - 
skin incision, although the anaesthetic period prior to this time varied 
considerably - 8.8 minutes (range 1 - 15.5). This might suggest that the 
changes in fibrinolysis was related to tissue trauma although further_study would 
be required to separate surgical effects from other possible factors. Such 
a study would not be easy as the many variables of surgery would be difficult 
to control. 
With the Caesarian Section subjects, another factor may be 
relevant` Shaper et al. (1966) found that fibrinolysis in normal labours, as 
assessed by the euglobulin lysis time, increased immediately after delivery 
of the baby and before the cord was clamped. They attributed this increase 
of lytic activity to the stress of labour and also partly to a reduction of 
inhibitory mechanisms associated with removal of the placenta. During the 
Caesarian Sections, any effect of physical effort and subsequent adrenalin 
secretion of the mother is absent and it thus might be thought possible to 
assess the rapidity with which fibrinolysis returns to normal after placental 
removal. This initial hypothesis was, however, negated by the findings in 
the hysterectomy subjects, for it is apparent that the changes in lysis occurring 
with intra- abdominal operation alone will obscure the real pattern of change of 
fibrinolysis occurring following placenta removal. Notwithstanding, it will 
be seen from the results that at the time of clamping of the cord and removal 
of the placenta the euglobulin lysis activity was not statistically significant 
from the pre -operative level and it was not until 20 minutes after placental 
removal that fibrinolysis was significantly increased in a proportion of the 
subjects. By the 40 or 60 minute mark, however, all subjects were demonstrating 
increased lytic activity. Although it is difficult to separate the effects 
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of surgery from the effects of placental separation, it would Appear that 
removal of the placenta did not result under these circumstances in a rapid 
marked increase of lytic activity. Again, it would be difficult to design 
an experiment to assess the effect of placental removal alone, in which 
the effect of extraneous maternal factors are excluded. 
The increase of lytic activity appeared to be progressive 
throughout the operative period in the hysterectomy patients, and in some 
cases, lytic activity reached its maximum level in the blood specimen taken 
at the conclusion or subsequent to the operation. Although other 
investigators have investigated fibrinolysis within the operative period 
(Andersson et al., 1962; 01ow, 1963) the timing of specimens has not always 
been mentioned. Anderson and Mendelow (1964) in a careful study of by -pass 
operation patients found that maximum lytic activity occurred between 30 and 75 
minutes after the commencement of operation, and these findings are similar 
to those of Gans and Lowman (1967) who also studied by -pass patients. It is 
therefore possible to suggest that the changes occurring in lytic activity in 
the intra- abdominal operative situation are basically similar in timing, if not 
in degree, to those occurring in by -pass operations, and may represent some 
form of normal physiological response to a surgical stress. This would also 
be consistent with the findings in the Caesarian Section patients, although 
other factors may be influencing the degree of response. Also, it is possible 
to conclude that the peak lytic activity may occur subsequent to completion 
of the surgical procedure, as occurred in several of the gynaecological and 
Caesarian Section operations. Such a phenomena has been noted in cardiac 
by -pass operations (Douglas et al., 1966). 
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The mean fibrinolytic response to the operative stress in 
the -Caesarian. Section patients was much less than in the hysterectomy 
subjects. The pattern of response of the euglobulin lysis activity varied 
both in degree and time of onset between subjects. Although this may 
reflect to some extent variations in operative procedure and technique, 
it is now known that differences do exist in fibrinolytic (plasminogen 
activator) reactivity to a wide variety of stimuli (Cash and Allan, 1967), 
and that the fibrinolytic response is reduced, at least to an exercise 
stimulus, in late pregnancy (Woodfield et al., 1968). 
Amongst the Caesarian Section patients, there were two 
subjects (CS.2 and CS.5) during the surgical procedure who exhibited 
relatively marked increases of euglobulin lysis activity. Both these 
patients had intra- operative complications and will be discussed further 
in the section dealing with F.D.P. 
(b) F.D.Ps. 
The presence of F.D.Ps. in serum is, in the present state of 
knowledge, incontrovertible evidence for either active primary or secondary 
fibrinolysis. As indicated in the introduction to this chapter, it might be 
expected that the lysis of fibrin, either as a response to increased fibrin 
formation or as a reaction to the release of tissue plasminogen activators, 
would be increased during surgical procedures. Evidence for this could be 
sited from the considerable increase of euglobulin lysis activity that occurs 
regularly during surgery. However, in these present investigations it can be 
seen clearly that the lysis of fibrin, as assessed by the assay of F.D.P., is 
increased only marginally during the operative period in both the obstetrical 
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and gynaecological patients, despite greatly increased levels of plasminogen 
activator. 
The operative findings would support the supposition that 
immediate appreciable lysis of fibrin or fibrinogen does not usually occur as 
a direct response to surgical interference. It is quite possible, however, 
that other factors may activate fibrinolysis to an excessive degree with the 
production of elevated levels of F.D.P. The results in two of the Caesarian 
Section patients (CS.2 and CS.5) are illustrated in Fig. 5:14, and in these 
subjects it is apparent that F.D.P. has increased considerably during the 
operative period. Although the exact explanations of these findings are 
uncertain it is of interest to note that in one patient (CS.5) a large 
incision was inadvertently made in the placenta before access was obtained 
to the baby. The placenta was subsequently removed in several parts. No 
other exceptional circumstances were otherwise evident during the operation, 
but the sudden increase of F.D.P. at the time of clamping of the cord and 
placental removal might be regarded as circumstantial evidence of a relationship 
with the physical damage of the placenta. Euglobulin lysis activity in this 
patient was also well above the mean value of the other subjects although no 
significant changes in fibrinogen levels were recorded. As the placenta 
does not contain plasminogen activators (Albrechsten, 1957), but is rich in 
tissue thromboplastins, it is possible that either placental tissue or 
amniotic fluid was able to gain access to the maternal circulation with 
activation of coagulation and subsequent secondary fibrinolysis. Leary and 
Hertig (1950) have demonstrated that amniotic fluid may enter the maternal 
circulation via blood vessels opened by the uterine incision or'perhaps via 
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the intervillous spaces if the placenta is incised. Amniotic fluid 
embolism has been reported during Caesarian Section operations (Leary and 
Hertig, 1950; Ellis and Hunan, 1956; Barno and Freeman, 1959; Scott, 1963; 
Willocks et al., 1966) and it would thus seem possible that in this patient 
a similar mechanism might have been operative, although not of sufficient 
degree to produce overt clinical symptoms. 
The operation on the other patient (CS.2) was complicated by 
the presence of many intra- abdominal adhesions, and one pint of blood was 
transfused during surgery, followed by a further two pints post operatively. 
Although full details of operative difficulties are not now available, it 
appears probable that blood loss was excessive. Euglobulin lysis activity 
was greatly increased (Table 5:13). 
In both these patients extraneous factors had complicated the 
normal pattern of fibrinolytic response to the surgery, resulting in the 
appearance in the circulation of excess lytic products, apparently, at least 
in one patient, without untoward clinical effects. These unexpected observations 
could be of some importance in the interpretation of the bleeding complications 
accompanying major surgery, for it is possible that the formation of excess 
levels of fibrin degradation product in other similar circumstances may herald 
the onset of a bleeding diathesis. 
Generalised oozing from small blood vessels may occur during 
surgery and although this is usually of short lived or minor duration, on 
occasions it may be excessive, prolonged and intractable (Zucker et al., 1957). 
Both the bleeding time and platelet adhesiveness functions may be altered in 
fibrinolytic conditions associated with elevated levels of F.D.Ps. (Coopland 
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et al. 1968). The incidence of surgical oozing, particularly after major 
surgery, is significantly correlated with the occurrence of multiple changes 
in haemostatic parameters (Zucker et al., 1967) perhaps as a result of 
intravascular coagulation from the release of tissue thromboplastin into the 
blood (Hardaway, 1966) and consequent formation of F.D.P. It is therefore 
conceivable that "surgical ooze" may be in some way related to the changes 
occurring in F.D.P. and the effect of these polypeptides on blood vessels 
and platelets. Much more prospective investigation is required to evaluate 
this hypothesis. 
B. Post Operation Changes. 
(a) Euglobulin Lysis Activity. 
The post -operative changes in euglobulin lysis activity are of 
considerable interest. Not only was there a marked variation in the pattern 
of response but differences exist be reen the two surgical groups. 
In the hysterectomy group, there was a statistically significant 
decrease of euglobulin lysis activity after surgery. The explanation of this 
finding is not known, although Olow (1963); Bennet et al. (1967); and 
Littlewood (1967) were able to detect an increase of serum or plasma urokinase 
inhibitors post operatively in patients submitted to cholecystectomy, 
gastrectomy or hysterectomy operations respectively. The increases generally 
reflected the apparent decrease of lytic activity. No changes in antiplasmin 
activity was found. Although it is tempting to suggest that the change in 
urokinase inhibitors is the explanation of the decreased lytic activity, it 
has not yet been proved that the measurement of urokinase inhibitors is relevant 
to circulating plasminogen activator as urokinase cannot normally be demonstrated 
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in the peripheral blood (Kucinski et al., 1968). Measurements of specific 
plasma plasminogen activator inhibitors are required, but accurate assay 
techniques are not yet readily available. On the other hand, the decrease 
in activator levels may be due to increased consumption of this enzyme for fibrin 
lysis without rapid and adequate replacement. The finding of increased F.D.P. 
levels postoperatively might support this supposition but definite proof is 
lacking. 
In the Caesarian Section group, the pattern of post surgical 
euglobulin lysis activity followed closely that of the gynaecological group, 
apart from the first two days post operatively when lytic activity was even 
further decreased. Shaper et al.(1968) have demonstrated that plasma 
urokinase inhibitors fall slowly following normal delivery, and Nilsson and 
Kullander (1967) state that anti -activator activity also decreases gradually 
after delivery. This early post- operative decrease of euglobulin lysis 
activity might therefore be explainable on the effect of remaining, but 
gradually disappearing, exogenous inhibitors of pregnancy coupled with the 
normal increase of post surgical fibrinolytic inhibitors. Alternatively, 
the post -operative decrease may represent the movements of a compensatory 
biological system which "overswings" following prolonged supression throughout 
pregnancy. 
The relationship of these changes in lytic activity to the 
incidence of thrombo embolism is not known. Certainly, the only known patient 
in this series to develop a clinically diagnosed deep venous thrombosis (H.10) 
exhibited minimal post -operative changes in lytic activity. It is still 
possible, however, that decreased lytic potential in the post -operative phase 
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could predispose towards venous thrombosis. Experiments in'rrats and 
rabbits have shown that after E.A.C.A. administration and femoral vein ligation, 
the incidence of thrombi is increased over that of control animals (Borgstrom 
et al., 1969; Bergentz and Nilsson, 1961). Much further work is required 
as the predisposition towards post -operative venous thrombostatis phenomena 
is almost certainly multifactorial. 
(b) F.D.Ps. 
Of no less interest are the alterations in levels of circulating 
F.D.P. occurring on the post- operative days. The significant elevation of 
F.D.P. in both groups might be explainable on the repair processes that follow 
the surgically induced damage to tissue. Extravascular tissue repair processes 
with deposition and resolutioli by lysis of locally deposited fibrin, could 
result in increase of intravascular levels of F.D.P. although there is no 
available evidence as yet to support this concept. Plasminogen activator, 
generated at the time of surgery, may actively be adsorbed onto fibrin as it 
is being laid down in tissues and subsequent slow local lysis might result 
in a continuous and steady release of lytic products in the post -operative 
period. 
An alternative explanation of the increase is that the release 
of products of coagulation,such as tissue thromboplastin and serum, from damaged 
tissue into the circulation promotes a low grade intravascular coagulation 
syndrome with secondary fibrinolysis. Such a hypothesis might be investigated 
by observing the effects of heparin in a group of surgically treated patients 
on the post operation increase of F.D.P. as it might be expected that if the 
coagulation rate is decreased F.D.P. formation would also be raduced. On the 
other hand, tissue activators of plasminogen may be released from traumatised 
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tissue although this is a less likely explanation as the euglobulin lysis activity, 
would; if this were the situation, be increased rather than decreased in the 
post -operative period. It is also possible that small episodes of intravascular 
fibrin formation may commonly occur after surgery and the F.D.P. increase is a 
reflection of a compensatory fibrinolytic activity. 
The post- operative changes of the gynaecological and obstetrical 
patients were similar, although the initial levels of pre -operative F.D.P. in 
the pregnant groups were higher as would be expected from patients studied late 
in the third trimester. In the first two post -operative days, the F.D.P. 
concentration is slightly higher in the Caesarian Section patients than in the 
gynaecological patients, but subsequently the levels are similar. As the 
Caesarian Section operation, in most instances, is associated with greater 
tissue trauma than the hysterectomy operation, it might be expected that post- 
operative F.D.P. values would also be higher if F.D.P. values are related in 
some way to the degree of tissue damage. That this was not clearly so could 
be considered as evidence against a simple release of F.D.P. from regenerating 
tissue; on the other hand, it may be that the physiological control mechanisms 
for the control and excretion of F.D.P. levels are similar in both groups 
of patients. 
It is quite clear that until more is known of the basic 
physiological control of coagulation and fibrinolysis as well as the anatomical 
pathways and biochemical routes of excretion of F.D.Ps, further progress in 
our understanding of these dynamic changes may be delayed. 
Four patients exhibited a marked increase of F.D.P. either 
on the second or third day post operation (CS.4, H.1, H.2 and H.10). The 
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first three subjects made an uneventful recovery from their surgery; the 
fourth subject developed a clinically diagnosed deep venous thrombosis of the 
right leg, and was commenced on anticoagulants. 
The evidence for the deep vein thrombosis was not entirely 
conclusive. This patient (see appendix) had, on a previous post surgical 
occasion,developed a deep vein thrombosis, and had had intermittent leg pain 
subsequently usually associated with her periods. On this admission, and 
three days after surgery, sudden severe pain developed in the same leg, and 
this was accompanied by an increase in calf diameter of in to 4 ". There was 
local tenderness but Homan's sign was negative. In view of the past history 
she was immediately commenced on anticoagulants and, apart from other minor 
surgical complications, made an uneventful recovery. No further swelling 
of the leg occurred. Radiological investigations were not undertaken. 
The diagnosis cannot therefore be established conclusively 
although the circumstantial evidence was strong. The finding of a high 
level of F.D.P. within three hours of the first clinical symptom is of 
considerable interest. F.D.P. have been noted previously in patients with 
embolic phenomena such as disseminated carcinoma with multiple thrombi and 
venous thrombosis (Merskey et al., 1966). These authors comment that the 
amount of lytic products found appeared to be correlated with the amount of 
intravascular fibrin formed. It is difficult to conceive alternative reasons 
for the elevation of F.D.P. in patient CS.10. The F.D.P. concentration on the 
previous day was normal and it must be assumed that the fibrinolytic response 
was secondary to the formation of either a localised or disseminated episode 
of intravascular coagulation. 
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The increase of F.D.P. may not necessarily Have been a direct 
result of the formation of a deep vein thrombosis although this is one 
possibility. When clotting takes place, thrombin is adsorbed into fibrin 
(Quick, 1957). With contraction of the clot, serum rich in thrombin may 
become separated and, if this is released into the general circulation, may 
evoke an episode of disseminated intravascular coagulation with formation of 
lytic products of fibrin. Such a mechanism has been suggested for syndromes 
of intravascular clotting occurring in relation to pulmonary embolism (McKay 
et al., 1967). 
Only a small fraction of patients with thrombo embolic 
phenomena exhibit clinical symptoms (Sevitt, 1965; Tessler, 1965), and 
perhaps only 501 of cases of pulmonary embolism are diagnosed before death 
(Smith et al., 1965). Surgery is well known to be associated with an 
appreciable incidence of post- operative thrombotic complications (Sharnoff 
et al., 1963; Storm, 1967), and in a series of post mortem studies on 
post -operative patients, the peak incidence of pulmonary embolism was found 
in the first post -operative week (Morrell and Duni, 1968), these results 
being similar to those of Dehlinger and Riemenschneider (1949) and Evans 
and Boller (1947). It was also noted that 62.8% of the patients who had had 
an operation had definite evidence of pulmonary embóli, although these were 
not always the cause of death. In view of these known facts, the finding of 
exceptionally elevated levels of F.D.P. in the early post - operative period 
in patients with no overt clinical symptoms may be of some importance. 
Although it is not possible at this stage to provide definite evidence, it 
might be reasonable to suggest that the increases in F.D.P. could reflect 
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isolated episodes of intravascular fibrin formation with subsequent lytic 
activity. Further intensive studies are required, partccularly if other 
methods of diagnosing the formation of venous thrombi (Reich et al., 1966) 
at an early stage can be utilized. Such investigations may support the more 
extensive use of anticoagulants following surgery in selected groups of 
patients, known to be at exceptional risk, as in prostatic surgery (Held, 
1965), or even after general surgery (Sevitt and Gallagher, 1959). 
(c) Fibrinogen. 
Shaper et al. (1968a) comment on the lack in the literature 
of detailed information of fibrinogen levels following surgery. In their 
study of a total of 21 African women undergoing Caesarian Section, the plasma 
fibrinogen concentration increased progressively until the fourth post -operative 
day and thereafter remained significantly elevated until the seventh day. 
These results are very similar to those reported in this study. 
The plasma fibrinogen level in this present investigation 
was not significantly different from the pre- operative level on the first 
post -operative day; this being in marked contrast to the rise on the first 
post -operative day in the hysterectomy patients. Godai and Skaga (1966) 
who treated five patients undergoing surgery for peptic ulcer with trasylol, 
a fibrinolytic inhibitor, found that the post -operative rise of fibrinogen 
was less steep than in control patients. In view of the significant 
depression of euglobulin lytic activity on the first and second post- operative 
day in the Caesarian Section patients, it is conceivable that the lack of 
increase in fibrinogen could be a reflection of endogenously available 
inhibitors still circulating post delivery, perhaps coupled with a post- 
- 282 - 
surgical increase of inhibitors as described by Olow (1963) and Bennet et al. 
(1967). Some support for this hypothesis is derived from the work of Shaper 
et al. (1968a) who demonstrated that the increased urokinase inhibitor levels 
of pregnancy fell gradually and progressively rather than precipitously 
following delivery. 
The fibrinogen levels in the hysterectomy patients rose 
sharply post operatively, even though there was a significant post -operative 
decrease of euglobulinlÿsis activity. This inhibition of the post -operative 
days was not as marked as in the Caesarian Section group, and was less 
constant. Although Bennett et al. (1967) have been able to demonstrate 
a rise in urokinase inhibitor following surgical operations that mirrors the 
depression of euglobulin lysis activity, it is still possible that the 
fibrinolytic inhibitors present in the post Caesarian and post hysterectomy 
situations may be dissimilar in both type and /or action and /or concentration 
and have different effects on the response of fibrinogen to surgical stress. 
Further experiments to assess the effect of different exogenous inhibitors on 
the post -operative rise of fibrinogen would be of interest, to clarify the 
influence of fibrinolytic inhibitors on the metabolism of fibrinogen. A 
clarification of the importance of the fibrinolytic inhibitor system to 
in vivo thrombolysis would also be a major contribution to our understanding. 
In other respects the fibrinogen changes post -hysterectomy 
follow the pattern as described by other workers, although direct comparisons 
are difficult. Peak levels of fibrinogen were found on the third day post 
operation by Warren et al. (1950); Godal and Fichera (1961); Olow (1963); 
and Bennett et al. (1966), and most investigators agree that at'least three 
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weeks are required for the plasma fibrinogen to return to pre -operative levels. 
Apart from the present study and that of Shaper et al. (1968a) there are no 
other reported studies of post Caesarian Section fibrinogen levels available. 
It was of interest that despite widely different baseline 
values of fibrinogen concentrations in the two studies, the peak elevations 
were similar. As these two groups of patients were similar in age and all 
were pre -menopausal, the similarity of responses suggests that there is a 
homeostatic mechanism involved in the control of fibrinogen levels. However, 
neither the mechanism nor the stimulus for the production of hyperfibrinogenaemia 
is known (Eisenberg, 1966), and increased levels occur in a variety of 
clinical conditions. These rises have usually been attributed to a 
nonspecific response to stress and fibrinogen has been included in the "acute 
phase reactive" group of proteins by Crockson et al. (1966). Clearly, there 
is considerable room for investigation. The speed of rise and fall of plasma 
fibrinogen could be related to its in vivo turnover but evidence is lacking. 
The role of the liver in fibrinogen metabolism as suggested by Foster and 
Whipple (1922), and Ram and Curtis (1938), has not been defined and the 
relationship of changes in fibrinogen to alterations in other proteins could 
also prove interesting. 
The recent work of Kropatkin and Izak (1968) is also relevant 
as these workers appear to have demonstrated that some thrombin or urokinase 
proteolytic products of fibrinogen or fibrin may provide the stimulus for 
increased production of fibrinogen by the liver. This new concept might 
be regarded as consistent with the present findings of increased F.D.P. after 
surgery. The measurement of the thrombin proteolytic products of fibrinogen 
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( "coagulation peptides "), following surgical procedures might also provide 
further evidence for the concept of intravascular coagulation in these 
situations. 
The role of raised plasma fibrinogen levels in the pathogenesis 
of thrombotic disease is not known (Ogston and Ogston, 1966). Although 
fibrinogen levels have been reported to be elevated in patients with 
ischaemic heart disease (Merskey et al., 1960; Katz et al., 1963) not all 
reports are in agreement (Naimi et al., 1963). In a comparative study of 
African and European subjects (Franz et al., 1961) post -operative changes of 
fibrinogen concentrations in both groups were similar although the incidence 
of venous thrombosis was very much higher in the European group. These 
reports would appear to indicate that although hyperfibrinogenaemia may 
possibly be implicated in the pathogenesis of venous thrombosis, other factors 
are also operative. High levels of fibrinogen (above 1,000 mgm. %) can also 
be obtained in certain clinical conditions (e.g. replacement therapy in 
haemophiliacs) without apparent untoward effects. In the present study, 
the subject (H.10) who developed a deep vein thrombosis, did have the 
highest fibrinogen level of the hysterectomy group studied. It was also 
noticed that H.1, who had elevated levels of F.D.P. on Days 2 and 3 without 
clinical symptoms, also had high sustained levels of fibrinogen. Although 
these observations may be coincidental there is considerable room for 
further meticulous investigation, particularly if other parameters, apart 
from fibrinogen can be assessed simultaneously... 
SUMMARY. 
Euglobulin lysis activity, fibrinogen levels and F.D.P. concentrations 
- 285 - 
have been measured, in a linear study, prior to, during and following both 
Caesarian Section and intra- abdominal gynaecological operations. The main 
findings were :- 
1. The fibrinolytic response to surgery, as assessed by the euglobulin lysis 
time assay, was decreased in the pregnant group. The post- operative 
changes in both groups were similar with slight but significant 
decrease of euglobulin lysis activity. 
2. Fibrinogen levels in both groups followed a similar pattern, with marked 
post -operative increase. 
3. F.D.P. levels were not increased significantly in the operative period 
despite high levels of euglobulin lytic activity. In both groups 
of subjects, F.D.P. values were elevated above the normal non -pregnant 
levels in the post -operative period. 
4. One patient with a deep venous thrombosis exhibited very high levels of 
F.D.P. on the third day post operation; three other subjects had 
elevated levels on the second or third day post -operatively without 
clinical symptoms. 
It is concluded that these new and interesting findings could provide 
a basis for further intensive investigation of the inter relationships of 
coagulation and fibrinolysis in the surgical patient. 
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CHAPTER IV. 
HAEMOSTATIC PROBLEME OF PREGNANCY. 
Introduction. 
In the previous studies outlined in this thesis, the variations of 
haemostatic parameters in response to exercise, adrenalin and surgical stress 
procedures have been considered. For these studies, coagulation and 
fibrinolytic assay technioues had been developed and standardised and 
the natural extension of this work was their application to clinical problems. 
In this section, therefore, potentially dangerous haemostatic problems 
occurring in pregnancy have been identified and extensively investigated, 
using as many specialised laboratory procedures as practical. 
The studies are presented as a basis for the further discussion of 
the aetiology, diagnosis and treatment of the disordered haemostatic mechanism 
in pregnancy, and provide further confirmation of the concept of disseminated 
intravascular coagulation as an intermediary of certain generalised haemorrhagic 
syndromes. Although a proportion of these laboratory studies were performed 
retrospectively, it was impossible, owing to the close association between 
laboratory and obstetric staff to provide much of the information in the 
acute clinical phase. With the further development of such liaison it should 
be possible to provide an even more rapid and accurate diagnostic service 
thus directly effecting both maternal and foetal morbidity and mortality. 
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Methods. 
The patients investigated in these studies were referred to the 
Coagulation Laboratory staff by Obstetricians of the Simpson Memorial 
Maternity Pavilion. Most patients were seen very soon after a coagulation 
abnormality was suspected. In some patients, it was possible to obtain 
serial blood specimens, and although it was not always practical to collect 
blood samples under ideal circumstances, the general principles for vene- 
puncture, as outlined in the appendix, were observed. 
After the initial urgent coagulation tests had been performed, 
residual plasma or serum samples were stored in small aliquots at -40 °C. 
Relevant coagulation and fibrinolytic assays were then performed in a group 
at a later date. It was not always possible to obtain enough plasma or 
serum for complete research haemostatic investigations, and on occasions, 
technical considerations precluded complete studies. All patients, however, 
were tested for the presence of serum F.D.P. 
The pilot investigations on patients with antepartum haemorrhage, 
retroplacental haemorrhage and intrauterine death were also performed in 
conjunction with the Obstetrical staff. As soon as possible after admission, 
blood was withdrawn for assay; the subsequent clinical histories were then 
assessed by personal observations coupled with reviews of the case notes. 
The coagulation and fibrinolytic assays employed are documented 
in the tables included with each study. 
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1. ABRUPTIO PLACENTAE. 
A relatively common problem presenting in most obstetric hospitals 
is th+t of the accidental concealed and /or revealed retroplacental haemorrhage 
associated with premature separation of the placenta (abruptio placentae). 
This syndrome can be characterised by multiple changes in the coagulation and 
fibrinolytic mechanisms, as well as by hypofibrinogenaemia. Two case studies 
are reported, representative of moderate and severe cases respectively. 
Case Reports. 
Patient A. 
Mrs. í3.N., aged 26, a paragravida 1 + 1, had been first pregnant 
in 1963. The pregnancy had been normal throughout the gestational period 
but at term she had developed a sudden rise in blood pressure to 170100 
with foetal distress. A forceps delivery resulted in the birth of a live 
baby. A second pregnancy in 1967 was complicated by hypertension and 
ended in a complete abortion at 20 weeks. During the present pregnancy 
she had had mild hypertension and was followed closely at the ante -natal 
clinic, her blood pressure averaging 14595. 
At the 23 week gestational stage, she developed very severe lower 
abdominal pain which became progressively worse, and was soon associated with 
vaginal bleeding. Foetal movements had not been felt since the previous 
day. On admission she was shocked, with a blood pressure of 
100/60 
and a 
pulse rate of 60 per minute; the uterus was hard, tender and of a 26 week 
gestational size; vaginal bleeding was moderate. A syntocinon infusion was 
commenced and blood was matched. Coagulation investigations revealed a plasma 
- 289 - 
fibrinogen level of 85 mgm. per cent. Two bottles of blood were administered 
and six hours after admission, i.e. thirteen hours after the initial symptoms, 
she delivered, spontaneously, a stillborn baby, along with a small placenta 
adherent to which was a large amount of retroplacental clot (approximately 
350 ml.). Bleeding was not excessive and the uterus was well contracted. 
The puerperium was uneventful, but on the second day post partum 
she discharged herself from hospital, against medical advice. Serial 
laboratory results are tabulated in Table 5:17 and Fig. 5:18. 
Patient B. 
The obstetric flying squad was called to the home of Mrs. L.L., 
aged 33, after she had developed a severe revealed /concealed accidental 
haemorrhage. She was then at 21 weeks gestation and had been well during 
the pregnancy. There had been one previous child and during that pregnancy 
she had had mild toxaemia. There was no other medical history of note. 
On initial examination her blood pressure was 140 /90, pulse rate 
110 per minute, and the uterus was hard and tender, and equivalent in size 
to a 28 -30 week pregnancy. Because of marked bleeding, she was immediately 
transfused with three bottles of 0, Rhesus Negative blood as well as with 
Ringer's solution. 
On arrival at the hospital her general state was very poor, as 
additional haemorrhage had occurred during transport. Vaginal examination 
revealed an undilated cervix, a presenting part could not be felt and it was 
impossible to perform a surgical induction. She was thus started on an 
intravenous syntocinninfusion. Her blood pressure at this stage was 90/60 
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Fig. 5:18. Results of laboratory investigations 
on Mrs. H.M. (Abruptio placentae). 
TABLE 5:17 
RESULTS OF IiNESTIGATI0NS ON MRS. H.N. (MODEi3A'l'L CONC"iAI.SD%PEr'ALED REl'ROPLACELi1>L AIlTEPAßTUM HAIriORRHAGE) 
Hours after 
Initial 
S ni toms y p 
L zglobulin Lysis 
Activity (Units) 















9 7.0 784 144 4.3 85 117 230.0 115,000 10.4 
13 - - - - 95 89 461.0 115,000 11.0 
26 - - - 3.85 170 141 37.6 - - 
45 15.9 400 100 - 212 194 14.4 100,000 11.0 
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and she was pale and shocked. An additional bottle of blood was administered 
and blood specimens were taken for future blood matching procedures. Bruising 
at venepuncture sites was excessive (Fig. 5:19). 
Haemorrhage however continued and clotting investigations two hours 
after admission revealed incoagulable blood. The blood pressure was now 
120/90. 
Further blood was administered and she was sedated. Four hours 
after admission the blood pressure was 
110/60 
and 8 gm. of Cohn Fraction I 
(clottable protein approximately 5 gm.) was infused along with two additional 
bottles of blood. 
Six hours after admission her clinical condition was greatly 
improved. The blood pressure was now 
120/60, 
with a pulse rate of 120 
per minute. A surgical induction was performed as haemorrhage was now much 
less. Eight- and -a -half hours after admission a stillborn foetus was 
delivered along with a large amount of retroplacental clot. She had been 
transfused a total of nine bottles of blood and 8 gm. of Cohn Fraction I, 
but her haemoglobin was still only 66¡0. 
The puerperium was complicated by a B. Coli urinary tract infection 
which responded to Ampicillin. The low haemoglobin responded to iron 
therapy and a low platelet count also improved by the fifth day. She was 
discharged in good health and a post natal examination did not reveal any 
other abnormalities. 
Serial laboratory results are tabulated in Table 5:18. 
Comment. 
The exact mechanisms by which the haemostatic changes Occur in 
patients with abruptio placentae are not yet completely clear. Some 
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Pig. 5119. Excessive bruising from venepuncture sites. 
(Mrs. E.L., severe abruptio placentae) 
TABLE 5:18 
COAGULATION AND FI73RIPJOLYTIC RESULTS ON MRS. E.L. (SEV ».tE CONCEALED/REVEALED RLTROPLACri:IlTsá.I, .ANTI2ARTULI HA}rJI:ORRIiAGE) 
Fibrinogen 
(mgms /100 ml.) F.D.P. 
(A.gms /ml. ) 
Platelets 
per cmm. 
K.C.C.T. (secs.) Prothrombin Time (secs.) 
Hours 
E.S.* R.i;i.* Test Control I,ixture Test Control 





- 563.0 - - - - - - 
- 563.0 40,000 64 33 40 - - 
52 121 121 563.0 58,000 55 35 41 18 13 
15 155 169 140.0 34,000 38 33.5 33.5 13. 11 
33 227 222 26.0 16,000 - - - - - 
57 253 244 35.o 56,000 - - - - - 
81 222 198 8.8 - - - - - - 
132 322 348 17.6 325,000 - - - - - 
180 272 - 6.6 - - - - - 
1 
- 
* Abbreviations : E.S. = Ellis -Stransky Assay 
R.M. = Ratnoff Menzies Assay. 
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authorities believe that the passage of tissue thromboplastin from placenta 
and decidua into the maternal circulation leads to a "consumption coagulopathy" 
in the plasma resulting in deficiencies of fibrinogen and several clotting 
factors (Schneider, 1959; McKay, 1965). Compensatory excessive fibrinolysis 
may further enhance this process with the production of either a- or hypo - 
fibrinogenaemia. In 10A of patients a severe bleeding syndrome results. 
Alternatively, decrease of fibrinogen and clotting factors might 
be explained on local deposition of fibrin at the placental site (Pritchard 
and Wright, 1959; Willoughby, 1966) . It has been calculated that loss of 
one litre of blood from the circulation will reduce the circulating fibrinogen 
pool by approximately 1.8 gm. and with spontaneous restoration of blood volume 
the plasma fibrinogen level will be reduced 50 mgm. /100 ml. (Sherry, 1966). 
Pritchard and Wright (1959) claim that the hypofibrinogenaemia in abruptio 
placentae can be accounted for by the fibrinogen sequestrated in the fibrin 
clot. Nilsen (1963) found that 2.5 -20.0 gm. of fibrin could be recovered 
from the placental clot and this alone was regarded as enough to explain the 
hypofibrinogenaemia in 21 of their 24 patients. Although local deposition 
may be a factor in some cases of abruptio placentae it is difficult to 
explain severe hypofibrinogenaemia states solely on this mechanism. 
In the patient under discussion it was more probable that a 
"consumption coagulopathy" or disseminated intravascular coagulation process 
was responsible for the hypofibrinogenaemia. The elevated levels of F.D.P. 
and lowered platelet levels indicated that intravascular coagulation had 
occurred with the formation of fibrin and secondary lytic activity. Specific 
coagulation factor assays were not performed but the finding of prolonged 
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clotting times in both the kaolin -cephalin and prothrombin time tests for 
Patiènt B is indicative of multiple decreases of clotting factors. This is 
confirmed by the satisfactory partial correction of these tests by the 
addition of normal plasma. . 
It is possible that D.I.C. occurs more frequently than previously 
suspected in patients with abruptio placentae. Basu (1967) found that in 
20 cases of clinically suspected premature placental separation of which only 
six exhibited bleeding manifestations, high levels of F.D.P. were commonly 
found, often in association with normal levels of fibrinogen. In Table 5 :19 
can be seen the results of F.D.P. and fibrinogen assays in seven incompletely 
studied subjects with proven retroplacd.ntal haemorrhages. F.D.P. levels were 
elevated in most patients but not always to a degree commensurate with the 
volume of ret-roplacental clot. A possible explanation for the discrepancy 
could reside in the time at which blood specimens were removed. F.D.P. 
have been stated to have a half life of 9.6 hours (Fletcher et al., 1962), and 
if specimens are not taken in the acute clinical phase or soon after, the 
initial main F.D.P. rise may appear small or even not detectable. However, 
most of these specimens were removed soon after admission to hospital and 
usually within 4 -6 hours of the first clinical symptoms. Alternatively, it 
could be concluded that only in a percentage of patients does thromboplastic 
material or serum gain entry to the maternal circulation, with subsequent 
activation of coagulation. However, Skj/ dt (1967a) in 20 patients with 
premature separation of the placenta was able to demonstrate the presence 
of "serum thrombotic accelerator" (Wessler, 1955) in each subject and this 
could be regarded as good evidence for the frequent occurrence of coagulation 
TABLE 5:19. 
CLINICAL STATE AND LABORATORY INVESTIGATIONS IN SEVEN PATIENTS 
















1 32 2 Yes - 230 400 
2 32 10 Yes 2 4 57.6 "Large - j/3 of placenta" 
3 37 2 - 12 No 335 39.4 400 
4 30 2 Yes - 278 480 
5 33 6i No 160 63.0 600 
6 36 ?6 No - 49.9 200 
7 35 4 No - 16.8 480 
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activation in patients with abruptio placentae. Further studies using 
serial F.D.P. assays might clarify this problem. 
Although the clinical picture in most patients with abruptio placentae 
is reasonably clear cut, there are many cases of ante -partum accidental 
haemorrhage in which the aetiology of the haemorrhage is not known. A pilot 
study was therefore conducted to assess if the measurement of F.D.P. might 
aid in the detection of those patients with some degree of retroplacental 
haemorrhage as opposed to those with other ante -partum bleeding conditions. 
The results of 25 consecutive patients with ante- partuni haemorrhages are 
recorded in Tables 5 :19 and 5:20. It is apparent that in nearly all the 
patients with ante- partum haemorrhage, whether idiopathic or due to placenta 
praevia, there was no marked increase of F.D.P. This is in comparison with 
the seven patients with proved retroplacental haemorrhages in whom six a rise 
of F.D.P. was demonstrated. In one patient (16) (Table 5 :20), in whom severe 
abdominal pain indicated the possible diagnosis of a concealed haemorrhage, 
the low level of F.D.P. was regarded as not being indicative of this 
diagnosis and subsequently a diagnosis of severe reflex oesophagitus was made. 
This small study indicates that,providing blood samples are obtained soon 
after the onset of symptoms, the measurement of F.D.P. may be of use in the 
diagnosis of abruptio placentae. Further intensive study of a wider range 
of subjects in greater detail is required to substantiate this hypothesis. 
Numerous workers have attempted to find evidence of fibrinolytic 
activity in patients with abruptio placentae (Willoughby, 1966; Pritchard 
and Brekken, 1967) but the results have usually been equivocal. The 
explanation of this now appears clear. The techniques which have been 
TABLE 5:20. 












1 33 A.P.H.** Cervical poly;. Slight 7.9 
2 34 Placenta praevia Placenta praevia 2 pint transfusion 23.9 
3 31 A.P.H. ? Cause* Slight 16.0 
4 32 A.P.H. ? Cause* Slight 15.8 






6 39 A.P.H. ? Cause* Slight 4.0 
7 38 A.P.H. ? Cause* Slight 4.1 
8 28+ A.P.H. ? Cause* Slight 7.9 
9 29+ A.P.J. ? Cause* Slight 7.1 
10 36 A.P.H. ? Cause* Slight 12.7 





2.9 12 37 A.P.H. ? Cause* 1 pint transfusion 
13 35 A.P.H. Anencephaly Slight 6.4 
14 33 Placenta praevia Placenta praeVia Moderate 6.4 
15 32 A.P.H. ? Cause* Slight 4.1 
16 36 Abdominal pain Reflux 
Oesophagitus 
Nil 3.0 
17 37 A.P.H. Placenta praevia Slight 3.0 
18 38 A.P.H. Placenta praevia Slight 6.4 
* No retroplacental clot. ** A.P.H. = Accidental antepartum haemorrhage. 
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used have been dependent on clot lysis in in vitro systems and,unless special 
precautions are taken and the blood specimen is removed close to the time of 
release of plasminogen activator (or plasmin), the results may lie within the 
normal range. Plasmin is neutralized rapidly in vivo by antiplasmins and the 
half life pf plasminogen activator is known to be 13 ±5 minutes (Fletcher et 
al., 1964); thus the possibility of obtaining evidence of increased lytic 
activity is greatly decreased. The thrombin time, although sensitive to the 
presence of anti- thrombic agents, such as F.D.P., lacks both sensitivity and 
specificity, and cannot be regarded as an accurate test. The assay of 
F.D.P. as specific indicator of active in vivo fibrinolytic activity would 
therefore seem a more reasonable and valuable measurement. In both the 
present patients high levels of F.D.Ps. were noted and provided unequivocal 
evidence of excess lytic activity. The elevated levels of F.D.P. fell 
rapidly after institution of treatment and subsequent to uterine clearance. 
Thrombocytopenia is common in severe D.I.C. and in Patient B, the 
changes were particularly marked. Platelet levels are often slow to 
increase after episodes of defibrination and McKay (1967) stated, that in his 
experience,this haemostatic parameter is the slowest to reach normal levels 
after a defibrination. It is of interest to note that Coopland et al (1968) 
were able to demonstrate decreased platelet adhesiveness and prolonged 
bleeding times in two cases of abruptio placentae carefully studied. It was 
suggested that such an abnormality of platelet and vascular function may be 
related to the known effect of F.D.P. on platelets (Kowalski et al., 1964). 
Further strudies may well assist in assessing the importance of this 
observation. 
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There was no evidence of renal failure in these patients. Premature 
separation of the placenta is a common cause of renal cortical necrosis and 
has been stated to occur once in every 100 -20G patients with this disorder 
(Williams, 1963). In the last five years in the Simpson Memorial Maternity 
Pavilion, of 362 patients with confirmed accidental revealed /concealed 
haemorrhages four patients developed renal failure. 
McKay et al. (1953) have suggested that renal cortical necrosis 
following abruptio placentae is a direct consequence of a generalised 
Shwartzman -like reaction occurring in man. It has been established that 
bilateral cortical necrosis of the kidneys can occur in pregnant animals 
after only one injection of endotoxin (Apitz, 1935; Wong, 1962) and 
Margaretten et al. (1964) were able to produce renal cortical necrosis in 
pregnant rats after an intravenous infusion of thrombin. It is possible 
that the production of endogenous thrombin in man, as may occur in intra- 
vascular coagulation, may result in similar pathology, of varying degrees, 
developing. As decreased.fibrinolysis in pregnancy has been implicated as 
a sensitising factor for the generalised Shwartzman reaction, the reactivity 
of the individual fibrinolytic system to a pathological stress, such as 
thrombin release, may be of some importance, perhaps determining whether 
complications such as renal cortical necrosis develop. In a previous 
section (5:2) it was shown that the ability of some pregnant women in the 
third trimester to respond to an exercise stress by generating plasminogen 
activator was reduced greatly and this finding could be in some way related 
to pathogenesis and incidence of renal cortical necrosis in pregnancy. 
However, some authorities (Sheehan and Moore, 1953; Sheehan, 1966) believe 
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that vascular spasm is responsible for the ischaemic necrosis and that thrombi 
fórm later as a consequence of ischaemic vascular damage. These approaches 
to the problem have stimulated a great deal of research endeavour, summarised 
adequately by Hjort and Rapaport (1965). 
Both patients responded rapidly to the infusion of blood and /or 
a concentrate of fibrinogen. In Patient B the response to blood alone was 
less satisfactory. This is not altogether surprising in view of the fact 
that each bottle of blood contains only 0.75 -1.0 gm. of fibrinogen, and will 
usually be deficient,to at least a moderate degree, of Factors V and VIII 
which are usually decreased in syndromes of D.I.C. These latter factors 
will only be available in fresh blood and their absence may contribute to 
the bleeding diathesis. However, the infusion of blood will supply a 
source of antiplasmins and this may aid in the reduction of excess plasman 
activity. Verstraete et al. (1963) prefer to use heparin in association with 
fibrinogen infusion in an effort to reduce the risk of promoting additional 
intravascular clotting resulting from residual thromboplastic substances in 
the maternal plasma. Although this would appear a logical and reasonable 
therapy, Pritchard and Brekken (1967) point out that in their extensive study 
of 141 cases of severe abruptio placentae the only death occurred as a result 
of inadequate blood replacement and no evidence was found of vascular 
thrombotic obstructions. The importance of adequate uterine retraction in 
post partum haemostasis must also not be underestimated.(Hibbert and Jefcoate, 
1966). 
The use of proteolytic inhibitors in abruptio placentae is probably 
limited to the very uncommon case with severe generalised bleeding associated 
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with hypofibrinogenaemia, marked clot lysis and very rapid disappearance from 
the circulation of doses of fibrinogen usually regarded as adequate to raise 
the blood fibrinogen level. Even in such cases, the use of heparin to 
decrease the rate of coagulation may be more logical although the concomitant 
use of small doses of proteolytic inhibitor to reduce any residual lytic 
activity might not seem »nreasonable. Amris and Kjeldsen (1966) reported 
the use of trasylol in abruptio placentae but the advantages (if any) of=this 
therapy cannot be determined from the studies as both blood and fibrinogen 
were also used. 
2. INTRA- UTERINE DEATH. 
Another complication of pregnancy is intra- uterine death. The 
following one report describes haemostatic complications associated with the 
syndrome, but occurring subsequent to delivery. 
Case Report. 
Mfrs. A.K., aged 29, was first seen at an out -patient clinic of 
the Simpson Memorial Maternity Pavilion in January, 1968. She had Previously 
had two normal deliveries as well as a miscarriage at 10 weeks, but her 
medical history Was otherwise uneventful. 
She had again become pregnant and at the visit to the Clinic it 
was noted that the uterine size was small (16 weeks) for the calculated 
dates (20 weeks). Earlier the following month she was admitted to hospital 
for investigation of a brownish vaginal discharge. While in hospital slight 
vaginal bleeding became evident and the foetal heart could not be heard on 
the ultradrop. Evacuation of the uterus was therefore carried out and at 
operation the uterus was found to be of 8 -10 weeks size and contained a 
macerated foetus. There was minimal bleeding at this time. 
Two hours later vaginal bleeding became profuse and coagulation 
investigations revealed low fibrinogen levels couples with other abnormal 
fibrinolytic tests..(Table 5:22). The blood pressure was 80/? and the 
pulse rate 100 per minute, and she was obviously shocked. An infusion of 
blood was commenced as well as 12.0 gm. Cohn Fraction I and 5 gm. of 
Epsilon Amino Caproic Acid (E.A.C.A.) Four hours after the initial 
bleeding her clinical condition was greatly improved and the vaginal 
bleeding settling. She was continued on a small dose of E.A.C..A. and her 
subsequent progress was uneventful. 
The full details of all the coagulation_ and fibrinolytic studies 
are tabulated in Tables 5:21 and 22, and Figs. 5 :20 and 21. 
Comments. 
Intra- uterine foetal death is not uncommonly associated with 
disorders of coagulation and fibrinolysis. Hodgkinson et al. (1964) 
state that hypofibrinogenaemia occurs in 25% of subjects when the duration 
of foetal death is five weeks or more. Lerner et al. (1967) thus suggest 
that fibrinogen levels should be measured at the time foetal death is 
diagnosed and thereafter weekly. If the level falls below 150 mgm. /100 ml. 
the pregnancy should be terminated and similar policies are commonly followed 
in many obstetric hospitals in this country. 
With this patient the diagnosis of intra- uterine death was not 
made prior to hospital admission. The history of recent but slight vaginal 
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Fig. 5:21. Further laboratory results on Mrs. A.K. (intra -uterine death) 
TABLE 5:21. 
RESULTS OF COAGULATION AND FIBRINOLYTIC STUDIES ON KIRS. A.I. (I TRA- UTERINE DEATH) 
Hours after 
Initial Episode 







Fibrin P atelets 
(mm H.P.F. 
(mgm /100 ml.) 
Platelets 





R -M Euglobulin Plasma 
0 73 59 1,546.0 1.10 46.40 549 724 - 100,000 
1 76 143 51 1,843.0 - - - - 94.6 - 
2 166 253 - 387.0 1.85 
r 
2.43 132 - 88.7 95,000 
3 266 235 166 387.0 2.92 2.39 167 - 113.0 110,000 
5 236 249 - 774.0 - - - - - 100,000 
16 234 249 - 193.0 1.82 1.09 203 95 - 110,000 
40 288 264 - 48.0 2.08 11.50 716 144 - 99,000 
64 356 225 215 24.0 4.48 12.30 - - 72.6 130,000 
89 261 210 - 5.1 4.51 9.70 813 156 77.8 110,000 
113 202 157 - 2.7 4.95 10.80 676 144 36.2 310,000 
1 month later 222 197 - 3.0 3.70 15.66 - 307 51.8 185,000 
* Abbreviations E-S = Ellis Stransky Assay 
T -N = Thorpe Nephelometer Assay 
R -M = Ratnoff-Menzies Assay 
TABLE 5:22. 
RESULTS OF COAGULATION AND FIBRINOLYTIC STUDIES ON MECS. A.K. (INTRA- UTbRINE DEATH) 
Time 
Hours 
Coagulation Factor Thrombin Time (seconds) Arvin Time (seconds) -- 

























2 98 40 58 - 87 16.3 11.7 15.5 I 21.0 19.2 21.4 
3 - 41 61 108 81 15.5 11.7 14.3 
1 
20.9 19.2 - 
5 90 53 74 - 88 16.1 13.9 15.2 23.9 21.2 22.7 
16 - 91 82 - 100 13.3 13.9 13.9 
I 
15.2 15.3 15.2 
40 - 147 204 - 
1111111111111 
13.1 - 1 13.6 13.2 - 
6 4 - 174 198 - - 12.6 12.6 - 
l 
13.4 14.6 
89 - 82 107 - - 
I 
13.4 12.6 - 14.6 14.6 - 
113 - 100 108 - - 13.0 12.6 - 13.7 14.6 - 
1 month 
later 
109 103 - - - - - - - - 
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haemorrhage coupled with the absence of foetal heart sounds was taken as 
evidence of a spontaneous miscarriage and the uterus was thus evacuated. 
No coagulation studies were performed prior to operation. In retrospect, 
it was apparent that the diagnosis was that of a missed abortion, and gauged 
by maternal dates and the size of the macerated foetus, death in utero had 
probably occurred 8 -10 weeks earlier. It was thus quite possible that the 
initial vaginal haemorrhage may have been early evidence of a pre -existing 
coagulation defect which was aggravated by the operative procedure, as 
profuse bleeding did not commence until two hours after surgery. 
The patient exhibited many of the clinical and laboratory hall- 
marks of disseminated intravascular coagulation. Clinically, the onset 
of haemorrhage associated with severe shock inconsistent with the degree 
of blood loss is common in the fully developed syndrome. The laboratory 
findings of lowered levels of coagulation factors V and VIII, a prolonged 
thrombin time, hypofibrinogenaemia, diminished levels of platelets, 
hypoplasminogenaemia, cryofibrinogenaemia and increased F.D.P. concentrations 
were all consistent with this diagnosis. 
The euglobulin lysis time estimation was also greatly shortened 
and although this may have been a reflection of diminished fibrinogen and 
plasminogen levels in the euglobulin substrate, fibrin plate assays of 
plasma fibrinolytic activity also demonstrated increased lysis, this being 
attributed to either plasmin or plasminogen activator activity. 
The linear study of both coagulation and fibrinolytic parameters 
subsequent to delivery are of considerable interest. It is apparent from 
Table 5:22.+ Fig. 5 :21that F.D.P. are exerting an antithrombic effect on the 
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thrombin- fibrinogen reaction for at least 10 -16 hours after the initial 
episode, by which time the F.D.P. levels had fallen to 193,4..gm /m1. Both 
thrombin and Arvin times were initially affected by lowered fibrinogen levels 
but the combination of prolonged thrombin time in conjunction with a normal 
Arvin time on the patient /control mixture in the early tests,is itself 
highly suggestive of either a heparin or heparin -like activity being present. 
Although it is possible that intravascular heparin may occur in certain 
clinical conditions in man, it is now being recognised increasingly that 
F.D.P. have anti -thrombic properties similar to heparin and can be partially 
or completely neutralised by protamine in vitro (Vreeken et al., 1966). 
Previous reports (Willoughby, 1963; Bloom and Campbell, 1965) of heparin - 
like anticoagulants in situations now Down to be associated with D.I.C. 
would now seem more explainable on the presence of circulating F.D.P. 
Cryofibrinogen is an intermediate product of fibrinogen- fibrin 
conversion. The presence of elevated levels of heparin precipitable fraction 
in the early stages of this haemorrhagic episode, is strong evidence for the 
presence of cryofibrinogen; and, if so, is pathogonomic of D.I.C. (Hardaway, 
1966). Although there are many reports of cryofibrinogen occurring in 
animals with D.I.C., studies of its occurrence in man in similar situations 
are meagre. It can be seen that H.P.F. levels were markedly elevated above 
the normal values for the laboratory (44.5 f 10.9mgm. /100 ml.) and remained 
so for up to 90 hours after delivery. However, without further study the 
results must be interpreted with caution and need not necessarily represent 
a response to D.I.C. For instance, the changes (if any) occurring of 
H.P.P. in patients with intra- uterine foetal death prior to delivery and 
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following uterine evacuation operations, is not known and additional 
investigations are required. 
In view of the marked activation of the fibrinolytic system as 
evidenced by the very low plasminogen levels and high F.D.P. levels it was 
notable that platelet counts were never greatly reduced. In seven patients 
with hypofibrinogenaemia secondary to interuterine death in whom there was 
severe bleeding (Pritchard and Ratnoff, 1955), the comment is made that 
marked thrombocytopenia did not occur, although in some patients, values 
were depressed below the lower limits of normal. There is little other 
reliable data in the literature and further studies of platelet levels 
would be of interest. Moderate thrombocytopenia is common in D.I.C. and 
its absence might indicate that the platelet levels were supranormal prior 
to the pathological process commencing. Platelet levels in the third 
trimester are, according to Ward and McArthur (1948) and Shaper et al. 
(1968), lowered, thus this former conclusion is less likely to be valid. 
The diagnosis of D.I.C., however, cannot be excluded by the mere absence 
of thrombocytopenia as demonstrated by Merskey et al (1967). 
After therapy the decreased levels of clotting factors returned 
rapidly to normal but by 40 -64 hours post delivery there was clear evidence 
of increased levels of these factors. The increases were not sustained and 
by 89 hours values were well within the normal ranges. Rachmilewitz et al. 
(1967) describe a patient who exhibited the defibrination syndrome followed 
by a hypercoagulable state and the development of multiple pulmonary emboli. 
Kropatkin and Izak (1968) report a similar case and although elevated levels 
of clotting factors are not always associated with thrombo embolic phenomena, 
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such incidents are more common when clotting factors are elevated than when 
they are in the normal range. It is also possible that the products of 
clotting released during the transformation of fibrinogen to fibrin 
stimulate not only an increase in fibrinogen but also of other clotting 
factors. Kropatkin and Izak (1968) infused thrombin into rabbits and 
were able to produce a hypercoagulable state in the post defibrination 
period and further experiments suggested that the effect could also be 
produced by the injection of the supernatent of clotted purified 
fibrinogen. 
Hypofibrinogenaemia is by no means universal in patients with an 
intra- uterine death, and lowered levels of fibrinogen do not usually occur 
earlier than the fifth week after foetal death (Pritchard and Ratnoff, 1955). 
The mechanism b;;which the hypofibrinogenaemia arises is still not clear. 
Reid and Diamond (1953) and Schneider (1954) suggest that tissue thrombo- 
plastins from the degenerate foetus and placenta may enter the maternal 
circulation causing intravascular coagulation and consumption of fibrinogen. 
It is also possible that fibrinolytic activators from the macerated foetus 
pass into the maternal circulation and promote intravascular lysis of fibrin 
(Jïirgens and Beller, 1959). However, Brakman and King (1965) made a 
detailed study of the fibrinolytic system in two patients but could not 
account for the decrease in fibrinogen by action of this system. Blood 
fibrinogen may also be precipitated progressively in the inter villous 
spaces of the placenta (Ashworth and Stouffer, 1956; Little and Phillips, 
1962) thus reducing fibrinogen levels. It might be expected that if 
reduction of fibrinogen levels was dependent on the action of the fibrinolytic 
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systeni4 levels of F.D.Ps. which reflect intravascular lytic activity, would 
be increased. In six patients studied in this laboratory with an average 
estimated time of intra- uterine death of five weeks, the F.D.P. levels were 
similar to those expected in the third trimester (Table 5:23). However, 
none of these patients were hypofibrinogenaemic. A prospective study of 
F.D.P. levels in a selected group of "high risk intra- uterine death" 
subjects would be of value. It might then be possible to assess the 
relevance of fibrinolytic activity to the decrease of fibrinogen levels. 
In the present patient intra- uterine death had probably occurred 
almost ten weeks previously. It is thus possible that fibrinogen levels 
were low prior to operation and the surgical manipulation of the uterus 
had resulted in the release of tissue thromboplastins or lysins into the 
circulation with the resultant defibrination. Skj /dt (1967) was able to 
demonstrate, using a variant of the thromboplastin activation test as 
described by Astrup and 011endorff (1961), that thromboplastic activity 
similar to the "serum thrombotic accelerator" of Wessler (1958), was present 
in the plasma of a patient who had sustained an intra- uterine death. 
From Table 5:21 it can be observed that the heat precipitation 
method for assay of fibrinogen is not accurately reflecting the level of 
thrombin clottable fibrinogen. These results are similar to those obtained 
in the patient to be described next and provides further evidence for the 
unreliability of the assay method in certain clinical situations associated 
with high levels of F.D.P. 
This patient was treated with a blood transfusion, a concentrate 
of fibrinogen and F.A.C.A. (Fig. 5:20). Fibrinogen and whole blood have 
TABLE 5:23. 
FIBRINOGEN' AND F.D.P. VALUES IN SIX PATIENTS 
WITH INTRA- UTERINE DEATH. 
Subject 
Fibrinogen 
mgm /100 ml. 
F.D.P. 
r- gm /ml. 
Intra -Uterine Death 
(weeks) 
1 200 14.0 6 
2 354 13.6 7 
3 228 5.9 5 
4 285 10.0 3 
5 190 14.0 4 
6 400 14.0 4 r 
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been used frequently in this syndrome and the mortality is relatively low 
- (McKay and Muller- Berghaus, 1967). Although E.A.C.A. was administered in 
this patient on the basis of greatly increased lytic activity demonstrable 
in the in vitro fibrinolytic tests, some authorities consider that the use of 
E.A.C.A. should be avoided if intravascular clotting is still proceeding. 
Spraitz et al. (1963) report one case in detail, treated with 6.0 gm. of 
fibrinogen and 4.0 gm. of E.A.C.A. The patient recovered but developed 
renal failure presumably secondary to non lysable fibrin thrombi in the 
kidney, and required dialysis on three occasions. In another patient with 
an intra- uterine death described by Rachmi.lewitz et al. (1967), multiple 
pulmonary emboli developed subsequent to E.A.C.A. therapy following an 
episode of D.I.C., although other factors were also operative in this 
patient. Pfeffer (1966), however, treated patients successfully with 
E.A.C.A. without untoward effects. Another approach to therapy is to 
administer heparin to decrease the rate of intravascular coagulation. 
Both Skj /dt (1967) and Lerner et al. (1967) report the successful use of 
heparin in patients with retention of a dead foetus and marked D.I.C. 
There was an increase of clotting factors, including fibrinogen, following 
heparin infusion and delivery was effected without the aid of either 
blood or fibrinogen. Phillips and Sciarra (1965) and Sherman and 
Middleton (1958) describe similar cases. In all these subjects, haemorrhage 
was not initially a presenting symptom although skin petechiae and ecchymosis 
were present Lerner et al. (1967) state that if hypofibrinogenaemia and 
bleeding co- exist, heparin will not immediately reverse the D.I.C. and blood 
or fibrinogen should be used in the first instance. This situation was 
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applicable to the present patient.. 
In summary, this patient developed the typical features of 
disseminated intravascular coagulation following evacuation of the uterus 
for an intra- uterine death of 8 -10 weeks. Treatment with whole blood, a 
concentrate of fibrinogen, and E.A.C.A. resulted in rapid complete recovery' 
with an uneventful convalescence. 
3. AtiIOTIC FLUID INBOLISM. 
Amniotic fluid embolism, a rare but serious complication of 
pregnancy, was first clinically described by Meyer (1926). Much more 
interest was taken in the disorder after the work of Steiner and Lusbaugh 
(1941), who demonstrated both experimentally and in pathological studies, 
the exact nature of the syndrome. Up until 1967, over 100 cases of this 
disorder had been -reported -in the English literature.(Anderson, 1967), and 
its incidence has been stated variably from 1:8,000 to 1:37,000 of live 
births (Steiner and Lusbaugh, 1941; Hemmings, 1947; Barno and Freeman, 
1959). Although the incidence is thus relatively low, amniotic fluid embolism 
remains an important cause of maternal and foetal death.(Phillips, 1964; 
Russell and Jones, 1965). There are only seventeen cases of non -fatal 
presumed amniotic fluid embolism reported in the English literature, and 
amongst these patients some have been left with residual neurological 
defects. 
The following case report is an account of a non -fatal but 
severe episode of disseminated intravascular coagulation occurring in mid - 
pregnancy and clinically presenting as an amniotic fluid embolism. 
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Case Report. 
Mrs. F.B., a paragravida 4 + 1, aged 28, was seen at a 
gynaecological clinic with a request from her General Practitioner that 
termination of pregnancy should be considered. She was then four months 
pregnant, but had intermittently noticed slight vaginal bleeding with an 
associated brown discharge. There was also a history of some suprapubic 
pain but she had been well otherwise. 
After admission to hospital subsequent investigations revealed 
that the vaginal discharge was minimal, pregnancy tests were positive, 
and the foetal heart could be heard. It was considered there were no 
grounds for termination of pregnancy but she remained in hospital for 
observation. 
Progress over the following week was satisfactory; the pain 
settled and the vaginal discharge was much less. Foetal movements were 
felt. There were no other clinical symptoms and she was apyrexie. 
Suddenly at 11.0 p.m., while sitting in bed knitting, the patient 
collapsed. She was seen by the staff almost immediately and found to be 
unconscious and breathing stertorously. There was cyanosis and the blood 
pressure was unrecordable. Further examination revealed a tachycardia with 
a gallop rhythm and multiple extra systoles. Numerous scattered rhonci 
were heard over both lung fields and the jugular venous pressure was 
raised. Oxygen administration was commenced and the blood pressure rose 
to 100/40 and the patient recovered consciousness. She complained of 
severe lower abdominal pain and on examination the uterus was hard and 
tender. Slight fresh vaginal bleeding was now noticed. There was no 
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evidence of calf tenderness or pain. 
An electrocardiograph confirmed the presence of a tachycardia 
with multiple extra systoles and evidence of right heart strain. A portable 
chest X -ray showed patchy changes in both lung fields and particularly in 
the right mid zone, with some dilatation of the right side of the heart, 
the appearance being consistent with multiple pulmonary emboli. A sample 
of venous blood obtained was incoagulable, and further coagulation invest- 
igations revealed a complete afibrinogenaemia with evidence of increased 
fibrinolysis. Evidence of a slight metabolic acidosis was present with a 
p CO2 of 12 IEgJL. 
The foetal heart could not now be heard and as it was considered 
that abortion might occur, preliminary correction of the coagulation defect 
was advised. Vaginal bleeding was still only minimal, but some bruising 
had occurred at venepuncture sites. The patient's general condition was 
otherwise improving. 
Two- and -a -half hours after the initial episode an infusion of 
2.5 gm. of E.A.C.A. was commenced followed by 4.0 gm. of Cohn Fraction I 
(60% clottable protein). Diamorphine was also administered for abdominal 
pain. Bleeding was still minimal. A similar E.A.C.A. /fibrinogen infusion 
was repeated over the next (,wo hours and the fibrinogen level seven hours 
post collapse rose to 102 mgm./100 ml. Her general condition continued to 
improve with an increase of both blood pressure and pulse rate. A further 
1 gm. of E.A.C.A. and 4.0 gm. of Cohn Fraction I was continued by intra- 
venous infusion. 
By ten hours post collapse her condition was good. The slight 
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vaginal bleeding had ceased and the abdominal pain had disappeared. Full 
coagulation studies, summarised in Table 5:24 demonstrate that as well as 
an afibrinogenaemia there had been a decrease of platelet levels, coagulation 
Factors V (proaccelerin) and VIII (antihaemophilic factor), and a marked 
increase in the level of fibrin /fibrinogen degradation products. A diagnosis 
of disseminated intravascular coagulation, presumably secondary to an amniotic 
fluid embolus, was made. Subsequent coagulation tests after therapy 
demonstrated improvements in all parameters measured. Urine had been 
passed and it was noticed that it was heavily laden with albumin and was 
discoloured red. There was no sign of labour commencing an on vaginal 
examination the cervical os was not dilated. Small doses of E.A.C.A. and 
fibrinogen were continued for another five hours and therapy was then 
discontinued. 
It was decided that the uterus should be emptied without delay, 
but that an oxytocin drip would be inadvisable. An abdominal hysterotomy, 
under cover of fibrinogen, was therefore performed 82 hours after the 
initial acute collapse. 
At operation the uterus Was of size appropriate to that of the 
calculated gestation period and was of normal appearance. On opening the 
uterus no liquor was present and the dead foetus was removed. The placenta 
was firmly adherent to the uterine wall and no significant retroplacental 
clot was present. There was no difficulty with haemostasis and immediate 
post operative progress was satisfactory. 
Two days after the operation she complained of right side lower 
chest pain, made worse on inspiration. Chest X -ray was clear and E.C.G. 
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Fig. 5:22. Results of laboratory investigations on Mrs. E.B. 
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5:23. Further results of investigations on Mrs. E.B. 
(amniotic fluid embolus) 
TABLE 5:24. 
RESULTS OF COAGULATION AND FIBRINOLYTIC STUDIES ON MIRS. E.B. (AMNIOTIC FLUID EMBOLUS) 
hours 
Fibrinogen 
























Assays Test Control Test Control 
0 o 1572 No clot - 425 2.25 35.0 60 5 15 100 85 - 41 - 14 
1 0 1311 - - - 2.25 - 67 - - - - - - - - 
3 61 1290 5.00 100 72 - - 48 5 24 103 92 74 40 27 14 
5 80 1894 4.83 483 105 1.99 - 38 15 - - - 54 40 21 14 
7 102 1125 2.77 - - 1.50 - - - - - - - - - - 
10 140 643 3.19 279 45 - 105.0 41 49 5o - 93 38 45 17 13 
17 147 308 - - - 2.06 110.0 51 - - - 96 - - 15 14 
40 179 6o - - - 3.16 - 75 - - - - 38 35 - - 
58 188 30 5.99 420 - 4.34 200.0 81 102 147 - 123 - - - - 
82 194 15 - - - - 200.0 95 - - - - 33 40 - - 
84 225 - 6.57 506 223 4.51 150.0 - - - - - - - - - 
106 296 10 - - - 4.15 150.0 - - - - _ 29 33 15 13 
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showed no specific changes. The symptoms settled spontaneously and the 
remainder of her convalescence was uneventful. She was discharged two 
weeks later in good health. 
Laboratory results are tabulated in Tables 5 :24 -27 and Figs. 5:22 -25. 
Comments. 
To establish the definitive diagnosis of an amniotic fluid embolus 
access to autopsy material is required to demonstrate the presence of squames 
from amniotic fluid or meconium mucus in the lungs or in the blood from the 
right side of the heart. However, the syndrome should be suspected 
clinically when sudden collapse and shock occur before, during and after 
labour, especially if accompanied by pulmonary and haemorrhagic manifestations 
(Scott, 1963). In this patient, the diagnosis could not fortunately be 
established with certainty and although the clinical picutre was consistent 
with the diagnosis of an amniotic fluid embolus several unusual features 
were present. 
In a survey of 32 cases of proved amniotic fluid embolism 
(Anderson, 1967) the duration of gestation varied from 38 to 44 weeks. 
Despite a careful search of the literature,cases of amniotic fluid embolism 
occurring in mid -pregnancy have not been found. The present patient was 
between 16 and 18 weeks pregnant and labour had not commenced. Although 
this might be indicative of an alternative diagnosis other clinical conditions 
producing such alarming clinical and haematological findings are even less 
likely. Multiple pulmonary emboli from thrombi in the legs or pelvis 
might explain the pulmonary findings but are unlikely to produce such a 
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severe complete defibrination. There was also no clinical history or 
physical evidence of deep vein thrombi. In view of the slight vaginal 
discharge prior to the episode, infection may have been a factor. However, 
the history is quite unlike that usually seen in septic abortions or 
chorioamnionitis. In this patient the foetus was alive, there was no 
pyrexia, and the patient was quite well. Culture of the vaginal discharge 
was, however, not performed. It is also unlikely, as the patient had been 
in hospital under observation for a week prior to this acute episode, that 
there had been any physical interference with the pregnancy. The symptoms 
could also not be explained onheart disease as no abnormalities were detected 
when the patient was subsequently examined by a cardiologist. There was no 
history of Mendelson's syndrome due to inhaled vomit. It was therefore 
still clinically possible that an amniotic fluid embolus had occurred, even 
at the relatively early stage of pregnancy. 
Amniotic fluid emboli do not usually occur without some evidence 
of labour. Anderson (1967) notes four cases without labour occurring late 
in pregnancy but the remaining 28 subjects described were all in labour. 
The typical case history described in the literature is that of an elderly 
woman of high parity, late in gestation, who during labour develops the 
signs and symptoms of sudden embolism. The use of oxytocic stimulation of 
the uterus has also been implicated in the pathogenesis of the disorder 
(Anderson, 1967) although the statistical evidence to support this 
supposition is lacking. Neither labour nor the use of oxytocins were 
relevant features in this patient. 
The route by which amniotic fluid enters the maternal circulation 
-317- 
has not clearly been defined. Leary and Hertig (1950) found foetal squames 
in abnormal locations within the normal placenta and membranes after 
uncomplicated deliveries. They deduced that transient tears in the 
choriomniotic membrane permitted fluid to enter the maternal circulation 
through subplacental sinusoids. Josey (1961, 1966) suggested that amniotic 
fluid enters the circulation by way of lacerated venous sinuses in the lower 
segment of the uterus. He describes several patients with hypofibrinogenaemia 
in whom there was detected significant rupture of the lower segment of the 
uterus. Further evidence comes from Landing (1950) who demonstrated that 
amniotic fluid could be introduced into the circulation by way of abnormally 
Opened myometrial or placental vessels in such conditions as ruptured 
uterus or placenta accrete. Schneider and Moya (1961) indicated that it 
was probable that the increased intra- uterine pressure during labour would 
tend to drive amniotic fluid towards the lower segment and cervix, thus 
perhaps facilitating infusion of fluid into the maternal circulation. 
Such an explanation is unlikely in this patient as labour was not in 
progress. 
The syndrome of amniotic fluid embolism is generally believed to 
be due to the embolization of amniotic fluid particulate material (Steiner 
and Lusbaugh, 1941; Cron et al., 1952) or maternal fibrin which has resulted 
from the thromboplastic activity of the infused amniotic fluid (Weiner, 1950) 
or possibly platelet thrombi (Brozman, 1961). Although Thompson et al. 
(1966) found that two separated infusions of filtered amniotic fluid produced 
an augmented decrease of fibrinogen in dogs, most authorities now accept 
that an allergic or anaphylactic mechanism probably does not play a 
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significant part in the pathogenesis of the syndrome. Tio (1956) infused 
clarified amniotic fluid in volumes of 5 -500 ml. into 73 human subjects with 
no untoward results, and similar findings in animals have been reported by 
MacMillan (1968) and Stolte et al. (1967). 
This concept of amniotic squames and meconium being responsible 
for the clinical manifestations of amniotic fluid embolisation would be at 
variance to the picture seen in Mrs. E.B. There is a paucity of squames 
in amniotic fluid prior to the 32nd week of pregnancy (Josey, 1966) so it 
is less likely that the pulmonary symptoms were due to embolisation of 
particular material. MacMillan (1968) also noted that the severity of 
embolic effects appeared to be related to the number of cells infused (in 
rabbits) but did not regard the embolic effects of amniotic fluid sufficient 
alone to account for sudden death during labour. The volume of amniotic 
fluid between 16 and 20 weeks ranges between 250 -290 ml. (Hytten and Leitch, 
1964) or even slightly lower (Rhodes, 1966) and this volume of fluid, even 
if infused rapidly would appear unlikely to produce severe respiratory 
embarrassment and collapse. The diagnosis of amniotic fluid embolus must 
therefore be a tentative one held in the absence of an adequate alternative 
explanation of the dramatic findings. 
The clinical onset of an amniotic fluid embolism is characterised 
by the sudden development of acute shock accompanied by severe dyspnoea, 
cyanosis and often unconsciousness. Cron et al. (1952) reported that when 
liquor, rich in squames was injected into rabbit ear veins, pronounced 
dyspnoea and sudden death occurred. When the same liquor was injected 
into the femoral artery shock was not produced and the animals survived. 
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They therefore deduced that it was the particulate matter of amniotic fluid 
that caused the pulmonary clinical symptoms and radiological changes. These 
views have been supported by most other workers and it is thought that the 
mechanical obstruction in the distal pulmonary tree results in vagus 
mediated vaso constriction of both pulmonary and coronary arteries, with a 
consequent fall in blood flow, and cardiac output resulting in hypotension. 
There is also often enlargement of the right side of the heart, due to 
pulmonary hypertension and radiological opacities in the lung field are 
common (Scott, 1963). Electrocardiographic changes also occur (Arnold 
et al., 1961) and usually non specific changes compatible with right heart 
strain are present. The present patient demonstrated most of these 
clinical, radiological and electrocardiographic changes, and the findings 
were quite consistent with a diagnosis of amniotic :£ldid lung emboli. 
The slight metabolic acidosis would also be in keeping with this diagnosis. 
Although the aetiology of the initial collapse was debatable 
there could be no doubt that in this patient a massive episode of disseminated 
intravascular coagulation had occurred. There was afibrinogenaemia, a 
marked decrease in the assayed level of several clotting factors, 
prolongation of the clotting times in several clotting tests, thrombocyto- 
penia, increased levels of F.P.P. and decreased plasminogen levels (Table 
5 :24). Despite these marked changes haemorrhage was minimal. Improvements 
in most of these parameters occurred after therapy was commenced. 
Blood incoagulability occurs in as many as 40 of patients who 
survive the first hour after the initial episode (Aguillon et al., 1962). 
It is thought to be due to the thromboplastic activity of cellular components 
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from the amniotic fluid resulting in the formation of fibrin and consumption 
of fibrinogen. This process is enhanced by the activation of the fibrino- 
lytic system either by a direct effect of tissue activator released from 
the amniotic cells or by a secondary compensatory reaction as a result of 
the excess fibrin formation. Plasminogen, converted to plasmin, acts 
proteolytically on fibrin and fibrinogen as well as on several clotting 
factors, thus depleting these haemostatic factors even further. It is 
also possible that platelet aggregation around particulate material in 
the pulmonary arterioles and capillaries with consequent release of 
platelet- factor -3 may enhance the activity of the coagulation system. 
However, despite marked alterations in haemostatic mechanism parameters, 
bleeding externally or into the skin was not present in this patient and 
our knowledge of the factors maintaining vascular integrity is thus still 
very probably far from complete. 
The value of the assay of F.D.P. can clearly be seen. Concentrat- 
ions of degradation products reached high levels and then decreased 
subsequent to therapy. The recent introduction of the rapid assay of 
F.D.P. as described earlier in this thesis will undoubtably facilitate the 
identification of lytic states, ani thus provide more adequate knowledge 
on which to base therapy. In conjunction with the F.D.P. assay, immuno- 
electrophoretic investigations of the series of pathological plasmas and 
sera from Mrs. E.B. was performed (Figs. 5 :24 and 25). The initial 
immunoelectrophoretic patterns closely resemble that produced by the 
in vitro digestion of fibrinogen by either plasmin (Fig. 5;24) or urokinase 


































Fig. 5:24. The in vitro digestion of fibrinogen by plasmin 
or 
urokinase courtésy of Dr. P.C. Das and Dr. I.M. Riding). 
The lytic products of fibrinogen can be identified in 
























































studies on Mrs. E.B. (amniotic 
fluid embolus). 
Plasma and serum samples 
were each run against a 
fibrinogen antisera. There 
is a good agreement between 
the TRCHII and IE techniques 
for the identification of 
F.D.P. The similarity of 
the F.D.P. in the first four 
IE slides to the end products 
of the in vitro digestion of 
fibrinogen by plasmin or 
urokinase can be seen (as 
illustrated in Fig. 5:24). 
Abbreviations: 
S = Serum 
P = Plasma 
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F.D.P. from both plasma and sera can be seen clearly, and can be correlated 
with both the level of fibrinogen and F.D.P. (as assayed by the T.R.C.H.I.I.) 
Fibrinogen assay results, as deteimined by three separate methods, 
are tabulated in Table 5:26. It is at once apparent that the heat 
precipitation method (Thorpe Nephelometer) is an inaccurate techrique in the 
presence of high levels of F.D.P. There is, however, a good correlation 
between the other two methods of fibrinogen assay, Fibrinogen assays that 
rely on the physko- chemical properties of fibrinogen may yield misleading 
results in patients with the defibrination syndrome as evidenced by the 
work of Sharp et al. (1958) using an ammonium sulphate-turbidity measurement. 
It is also known that methods of fibrinogen determination that rely on 
heat precipitation can be unreliable in the presence of fibrinogen 
derivatives as these share the property of precipitation with fibrinogen 
(Fletcher et al., 1966). The present results would be in accord with these 
findings but the good correlation of fibrinogen values between the other two 
methods is in agreement with the studies of Merskey et al. (1967). 
Serial studies clearly demonstrate the marked improvement in the 
laboratory tests following therapy. Fibrinogen concentrate and E.A.C.A. 
in small doses was administered as a precaution against premature labour 
commencing. In the initial blood specimen there was evidence of increased 
lytic activity on the fibrin plate assay system, indicative of either 
residual plasmin or plasminogen activator, and it was thought that this 
activity should be reduced before fibrinogen was infused. Plasminogen 
levels did not immediately increase after therapy and prothrombin levels 
apparently fell. This might indicate that intravascular coagulation was 
TABLE 5:26 
RESULTS OF FIBRINOGEN ASSAYS BY THREE DIFFERENT METHODS 
ON MRS. E.B. (AMNIOTIC FLUID EMBOLUS) 
Hours 
Ellis & Stransky 
(mgm./100 ml.) 







0 0 10.0 180 1,570 
1 0 7.5 173 1,311 
3 61 70.0 194 1,290 
5 61 100.0 215 1,894 
7 102 110.0 205 1,125 
10 140 128.0 179 643 
17 147 146.0 144 308 
40 179 184.0 100 60 
58 188 192.0 134 30 
82 194 - - 15 
84 225 - - - 
106 296 - - 10 
130 436 - - - 
- 324 - 
continuing and this conjecture might be supported by the even further 
increased level of F.D.P. after fibrinogen and E.A.C.A. therapy. Although 
it was not considered the most reasonable therapy at-the time, it would 
have been of considerable theoretical interest to see the effect of E.A.C.A. 
and heparin alone in this type of obstetrical situation. 
The thrombin times are of some interest. From Table 5:25 it can 
be seen that the low levels of fibrinogen are prolonging both the Ca- thrombin 
and Ca -Arvin times up to lour five. However, the 1 :1 mixture of test plasma 
and control plasmas show that although the Ca- thrombin time was still 
prolonged even when fibrinogen levels are normal, the Ca -Arvin time on the 
mixture was normal. This is strong evidence for heparin -like activity 
being present. In this situation F.D.P. was probably exerting antithrombin 
effect, as Arvin is unaffected by the presence of F.D.P. or heparin. It 
can also be seen that the addition of protamine (10 mgm. /ml.) is correcting 
the thrombin time at the seven hour mark. Before this stage only a small 
effect is present. Protamine has been shown to correct long thrombin times 
associated with the presence of F.D.P., but much larger amounts are required 
to neutralise heparin (Vreeken et al., 1966). Willoughby (1963) used 
protamine in vivo.in a haemorrhagic state in the puerperium associated with 
defibrination with temporary cessation of bleeding. It is possible that 
varying molecular weight sizes of F.D.P. may act in different manners with 
protamine and further studies would be of great interest. 
One of the most interesting facets of this case study was the 
appearance of haemolysis in specimens removed before fibrinogen or E.A.C.A. 
was administered. Plasma haemoglobins and haptoglobin levels are tabulated 
TABLE 5:27 
RESULTS OF PLASMA HAEMOGLOBINS AND HAPTOGLOBINS 









0 35 0 82 
1 28 0 - 
3 12 - - 
5 12 - - 
7 8 - 69 
17 4 - 68 
40 3 - 78 
82 - 30 - 
106 6 50 76 
Normal 
Range 
0 - 4 30 - 200 100 
in Table 5:27 and Fig. 5:23. 
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Loeliger (1966) mentions severe acute haemolytic 
anaemia occurring in conjunction with amniotic fluid embolism and Hart (1966) 
comments on the appearance of intravascular haemolysis in such varied 
clinical conditions as gastric carcinoma, haemolytic- uraemic syndrome and 
eclampsia, all of which were associated with D.I.C. Studies by Brain and 
Beck (1965) suggest that the haemolysis occurring in the syndrome of 
disseminated intravascular coagulation may be due to trapping of red cells 
in microthrombi which accumulate temporarily in small blood vessels. 
Using an elegant cine microphotography technique these workers have been 
able to demonstrate that in in vitro models, fibrin networks, in a moving 
stream of blood can distort and damage red cells with the consequent 
release of haemoglobin (Rubenberg et al., 1967; Bull et al., 1968). This 
attractive theory is supported by sporadic case reports in which haemolysis 
and intravascular coagulation have been associated (Hart, 1966; Loeliger, 
1966; Baker and Brain, 1967; Schneider, 1968). The present patient 
exhibited similar features with macroscopic haemolysis being visible in the 
specimens taken immediately after the initial collapse. The changes in 
plasma haemoglobin were fortunately not complicated by the infusion of 
blood. 
It can also be seen from Table 5:27 that red cell haemoglobin 
levels fell appreciably during the acute episode, despite no marked vaginal 
haemorrhage. Renal failure did not develop in this patient but it was 
observed that the urine on the first occasion after the embolus was red 
in colour and contained considerable protein. This may have represented 
renal excretion of haemoglobin but unfortunately the specimen was not 
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specifically investigated. Disturbances of the renal function are not 
uncommonly associated with amniotic fluid emboli (Scott, 1963) but no reports 
of renal cortical necrosis appear in the literature, this perhaps being a 
reflection of the high immediate mortality of the disorder, Fibrin thrombi 
in the kidneys have, however, been reported in the kidneys at autopsy 
(Tuller, 1957). 
This case history thus demonstrates the main changes occurring 
in the haemostatic mechanism in a situation associated with severe 
disseminated intravascular coagulation. Successful therapy of such an 
emergency depended on the prompt recognition and subsequent therapy of the 
underlying condition, coupled with adequate coagulation and fibrinolytic 
investigations as a guide to both diagnosis and subsequent progress. 
4. TERCaIINATION OF PREGNANCY. 
Therapeutic abortion using intra- amniotic hypertonic solutions 
has become a commonly accepted procedure in many hospitals and the history 
of the method has been reviewed by Kerr et al. (1966). The simplicity of 
the technique coupled with the low incidence of complications and high 
success rate has further encouraged its use (Menzies and Hawkins, 1968). 
However, termination of pregnancy is still not without risk. In series 
studied in Denmark and Sweden, the incidence of maternal death is 2:1,000 
(Oram, 1952), and there is a morbidity rate of 5 - 15% (Berthelsen and 
Ostergaard, 1959). 
Complications of this relatively new method of therapeutic 
abortion are now becoming available. Wagatsuma (1965) reported 25 deaths 
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after intra- amniotic injection and two deaths have been reported in Britain 
(Cameron and Dayan, 1966). Goldstein (1968) recently reported the occurrence 
of a probable amniotic fluid embolus after an injection of intra- amniotic 
saline. 
The following case report outlines further similar complications of 
this method of inducing abortion. 
Case. 
Mrs. R.S., aged 31, was admitted to a peripheral hospital for 
termination of pregnancy on the grounds of severe d.ndogenous depression. 
She had had two previous uncomplicated pregnancies and there was no 
significant medical history of note. The pregnancy had advanced to the 
21 week gestation stage and she had been quite well. Soon after admission 
200 ml. of 20% hypertonic saline was injected into the amniotic sac, after 
prior removal of a similar volume of amniotic fluid. Labour did not 
commence immediately and 18 hours later she was noted to be pyrexic (102 °F) 
and was started on Crystunycin. Uterine contractions became evident. 
During the labour the patient became unduly distressed and brisk 
haemorrhage commenced. Hypotension was marked and the initial blood loss 
was estimated at 500 ml. Delivery was effected and it was noted that blood 
taken for matching did not clot. 
With supportive measures there was some improvement in blood pressure 
but bleeding continued and a tachycardia (120 /min.) remained. In view of the 
blood loss three bottles of blood was infused as well as 4 gm. of fibrinogen. 
Blood pressure improved rapidly on this regime with cessation of haemorrhage. 
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Fig. 5:26. Results of investigations on Yrs. R.S. (termination of pregnancy) 
TABLE 5:28: 
RESULTS OF COAGULATION AND FIBRINOLYTIC INVESTIGATIONS 











4 - - 1167.0 95,000 
7 101 1.51 292.0 - 
9 165 1.14 292.0 - 
25 310 3.05 60.8 - 
49 280 3.02 36.5 - 
73 261 4.61 9.8 170,000 
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health, apart from a haemoglobin of 68% 
The laboratory findings are summarised in Table 5s28 and Fig. 5:26 
Comment. 
The laboratory findings in this patient are consistent with an 
episode of disseminated intravascular clotting. There was a lowered level 
of platelets, a hypofibrinogenaemia, very low plasminogen levels, and a 
marked elevation of F.D.P. Specific coagulation assays were not performed 
although whole blood clotting times done at the bedside were within normal 
limits. 
The aetiology of the event is less clear. In view of the pyrexia 
it is possible that sepsis associated with the retained products of conception 
was a factor, although premature separation of the membranes or a small amniotic 
fluid embolus cannot be excluded. It also cannot be proved that the method 
of induction of abortion was related to the pathological findings. The 
association is, however, suggestive and again points clearly to the potential 
risk in such procedures. This patient may not have survived in situations 
where blood transfusion facilities were not available quickly. 
It can be seen that plasminogen levels did not increase rapidly 
after the episode and by nine hours the level was still greatly decreased, 
despite the infusion of plasminogen contaminated fibrinogen. This phenomena 
was also noticed in other of the subjects (2 and 3) studied and might suggest 
that either the production of plasminogen is delayed or utilization for 
lytic activity is still proceeding. In situations where intravascular 
coagulation is still continuing, the administration of fibrinogen may further 
promote the continuation of the disorder. Sk jdt (1967) advises the use 
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of fibrinogeninfusions only after delivery when the risk of the passage of 
tissue thromboplastin to the maternal circulation is eliminated. McKay 
and Muller- Berghaus (1967) also warn of the theoretical risk of fibrinogen 
therapy when procoagulant agents are still acting in vivo as there is an 
increased risk of further fibrin deposition in susceptible organs. However, 
it is difficult to identify by presently available laboratory techniques, 
procoagulant substances in plasma and clinical judgement is required i .the 
use of fibrinogen on the basis of a general knogledge of the disease process. 
One possible compromise method of therapy would be to administer fibrinogen 
and heparin together; one to correct any deficiency and the other to decrease 
the rate of activity of remaining residual thromboplastic substances. 
This patient did not require the administration of E.A.C.A. as an 
adequate response was obtained by the use of whole blood and fibrinogen. 
Although E.A.C.A. is a useful antifibrinoly tic drug its use in situations 
associated with continuing intravascular clotting can be hazardous. After 
E.A.C.A. treatment fibrin clots are preserved beyond the time they would be 
lysed spontaneously and the protective effect of the fibrinolytic system in 
clearing the vascular bed is thus greatly decreased. Several reports of 
bilateral renal cortical necrosis and thrombi in other organs have appeared 
following its use (Naeye, 1962; Andersson, 1963; Stamm et al., 1963; 
Nilsson et al., 1966). 
In the acute phase of this illness, three bottles of blood and 
4 gm. of fibrinogen were required for clinical resuscitation. It is possible 
that the blood loss which occurred before treatment was commenced was under- 
estimated as the haemoglobin level on discharge was only 68/0;,. This perhaps 
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underlines the severity of the defibrination process as the haemoglobin before 
delivery was known to be 96 %. 
This case study underlies the protean nature of the syndrome of 
disseminated intravascular coagulation. It can occur in a variety of 
obstetrical situations and unless the clinician is alert to its detection 
unnecessary mortality and morbidity may occur. Once evidence of its 
presence is detected therapy must be rapid and judged carefully, and the 
value of adequate coagulation and f ibrinolytic investigations are self 
evident. 
5. SECONDARY POST- PARTUM HA ORRHAGE. 
This case report is presented as an unusual example of post- partum 
haemorrhage in which a fibrinolytic process was apparently maintained for a 
prolonged period without recognition. 
Case Report 
Ivirs. M.S., a 29 year oldparagravida I was admitted to the Simpson 
Memorial Maternity Pavilion with a diagnosis of a secondary post -partum 
haemorrhage. Ten days prior to admission she had delivered at home a full 
term normal male babe. Blood loss was said to be marked at this delivery. 
Lactation had been supressed with Stilboestrol but on the fourth day of the 
peurperium she was started on phenylbutazone, 100 mgm. t.d.s. for a super- 
ficial thrombophlebitus behind the right knee. This treatment had been 
continued up to the day of admission, as had been the Stilboestrol. Prior 
to admission she had started passing blood clots and continued to bleed in 
spite of the administration of ergometrine by her General Practitioner. The 
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uterus was also noted to be enlarged up to the umbilicus. 
r 
On initial examination her blood pressure was 00/60; pulse 90; 
and she was apyrexie. Blood was matched and she was started on a syntocinon 
drip. The uterus was evacuated under general anaesthesia but no definite 
placental tissue was found. She continued to bleed briskly. Blood 
pressure fell and pulse rate increased despite additional ergometrine, 
antibiotics and transfusion of four bottles of blood. Clotting investigations 
demonstrated increased fibrinolytic activity associated With hypofibrinogen- 
aemia and 4 gm. of Cohn Fraction I was therefore administered as well as 
2.5 gm. of E.A.C.A. She improved slowly on this therapy and in all was 
given 8 gm. of Cohn Fraction I and 5.0 gm. of E.A.C.A. 
She remained well, if rather apprehensive, for the next few days 
but on the sixth day post operation she had another small vaginal bleed 
which was not of sufficient note to warrant therapy. She was finally 
discharged ten days post operatively, with a haemoglobin of 86¡ and 
apparently well. 
On a subsequent visit six weeks later she had remained in good 
health with no recurrence of the bleeding. 
The coagulation and fibrinolytic results are recorded in 
Table 5:29 and Fig. 5:27. 
Comments. 
This is an unusual case history and the aetiology of the initiating 
disorder can only be conjectured. The puerperium was complicated by both 
a primary post -partum haemorrhage and the development of a thrombophebitis, 
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Fig. 5:28. Results of Fibrinogen /Fibrin Degradation Products and 
Fibrinogen Assays on ,Mrs. 'M.S. (post partum haemorrhage). 
TABLE 5:29. 









(mgm /100 ml.) 
F.D.Ps. 




1 0 44.80 841 333 3.74 103 115.0 86,000 




- - 4 - - - 3.70 195 
2 8.55 778 361 3.90 - 43.2 125,000 
3 8.02 613 255 - 210 115.0 
4 8.22 638 138 - 162 115.0 110,000 
5 8.97 - - - 153 57.6 - 
7 10.80 587 187 - 100 30.0 145,000 
8 10.40 695 170 - 121 21.6 290,000 
16 14.77 489 - - 129 7.2 285,000 
30 - - - - 187 14.4 210,000 
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treated with phenylbutazone. 
The commonest causes of secondary post- partum haemorrhage are 
retention of a portion of the products of conceptionlor infection. In this 
patient there was very little tissue found on careful curretage of the uterus, 
although some enlargement of the uterus was noted. Infection wac suspected 
although no definite evidence of this was available, i.e. the patient was 
apyrexic, there had been no excessive lochial discharge, uterine tenderness 
was not marked, and a high vaginal swab was negative. A pregnancy test was 
also negative. A common side effect of phenylbutazone therapy is 
thrombocytopenia, but in this patient, although platelet levels were decreased, 
they were not reduced to a level at which bleeding usually occurs. An exact 
diagnosis thus remains elusive. 
However, there is little doubt from the laboratory findings that 
this patient had good evidence of excessive fibrinolytic activity. Levels 
of F.D.P. were elevated and there was a marked decrease in the concentration 
of fibrinogen which is usually normally elevated in the post partum period 
(Rathoff et al., 1954; Shafer et al., 1968). There was also evidence of 
increased plasma proteolytic activity, either from increased levels of 
plasminogen activator or plasmin. The decrease of platelets is consistent 
with active intravascular coagulation although the reservation must be made 
that the drug therapy may also have affected this haemostatic parameter. 
It is conceivable that this patient may have developed the rare 
syndrome described by Merskey et al. (1967) as idiopathic primary pathological 
fibrinolysis. These patients do not appear to have any specific provoking 
agent demonstrable for the activation of coagulation and exhibit hypo- 
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fibrinogenaemia coupled with marked evidence of clot or fibrin lysis in 
in vitro assays. There is usually a lesser disturbance of the coagulation 
system and the presentation of this patient could be consistent with this 
picture. However, separation of fibrinolysis into primary and secondary 
forms may not necessarily be valid and may only hide our ignorance of the 
basic etiology and mechanisms of coagulation occurring in this type of 
clinical situation. 
The concentration of F.D.P. initially fell after the E.A.C.A./ 
fibrinogen /blood therapy and by the following day levels were approaching 
the normal range. However, by the following day F.D.P. again increased 
to the pre -treatment level and remained high for the next three days. As 
these specimens were assayed in retrospect this was an unexpected finding, 
but repeat assays confirmed these changes. At the same time changes in 
fibrinogen levels occurred with a marked fall in concentration. This 
fall was only reversed when F.D.P. levels had fallen close to the normal 
range (Fig. 5:28). At about the time the fibrinogen was at its lowest 
level a small vaginal bleed occurred but this was not regarded as clinically 
important. It is thus probable that the provoking stimulus for the D.I.C. 
was of a continuous low grade nature, resulting in a slow incomplete 
defibrination of the patient, but not proceeding to a level which was 
clinically overt. 
In retrospect, the use of heparin to decrease the rate of intravascular 
coagulation may have been a more reasonable treatment in this patient, 
particularly in view of the history of thrombophlebitis. Although the 
aetiological nature of the fibrinolytic stimulus remains obscure, this study 
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points to the importance of careful follow -up of patients who exhibit features 
of D.I.C., for not only may they occasionally develop thromboemboli phenomena 
in the convalescent phase but the fibrinolytic process may apparently continue 
in some patients in an undetected form. 
DISCUSSION. 
The recognition that hypofibrinogenaemia may be an important factor 
in haemorrhagic states associated with pregnancy has stimulated a great deal 
of fundamental research into clotting and lytic mechanisms. Although based 
largely upon animal experimental work the concept of disseminated intra- 
vascular coagulation being relevant in human disease has considerably extended 
both the laboratory and clinical approach to disorders of haemorrhage and 
thrombin, and now, perhaps for the first time, clinicians engaged in treating 
these problems are gaining an integrated picture of these two complex 
haemostatic systems. 
It is apparent that disseminated intravascular coagulation, 
particularly in the obstetrical situation, is but an intermediary mechanism 
of the disease and we are still largely unaware of the basic processes whereby 
the coagulation system is initially stimulated. Treatment thus must be aimed 
at the management of laboratory -detected coagulation and fibrinolytic 
abnormalities in conjunction with conventional therapy directed towards 
correction of the underlying disease process. Treatment of individual 
patients must therefore be tailored to their particular needs and no 
standard therapy is as yet available. Indeed, it may be difficult to 
decide immediately on the most appropriate therapy and clinical experience 
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of comparable situations can be invaluable. 
In the case reports presented in this chapter it can be seen that 
syndromes of D.I.C. can be identified specifically in a variety of obstetrical 
complications. It might be conjected that the subjects who develop D.I.C. 
are included in the small group of individuals whose fibrinolytic response 
to stress is normally very low, and is decreased even further in pregnancy. 
There is no evidence to date to substantiate this latter theory but a follow - 
up and assessment of the fibrinolytic reactivity in patients who have 
exhibited the features of D.I.C. might be informative. 
Previously, the substantiation of the diagnosis of D.I.C. has 
depended on comparatively non -specific coagulation tests, but using the 
recently developed rapid assay for F.D.Ps. it is now possible for the 
coagulation. laboratory to state clearly if lysis of fibrin is excessive. 
Such information is clearly of the utmost value to the clinician and further 
close investigation of the use of this assay in obstetrical situations is 
indicated. A significant laboratory advance would be a simple and quick 
method for the identification of excessive thromboplastic -like activity in 
plasma, for this information might be indicative of a need to use anti- 
coagulant drugs rather than replacement of coagulation factors. 
One of the many questions which remains to be answered is "Why 
do only a small proportion of at risk' subjects in pregnancy develop 
haemostatic problems ?" The answer is clearly not a simple one. Hjort and 
Rapaport (1965) point out in their review on the Shwartzman reaction that 
normal animals can cope with extensive disseminated intravascular coagulation 
with few ill effects. However, alterations in reticulo- endothelial activity, 
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granulocytic activity, blood flow, immunity status and fibrinolysis, may 
modify the body's response to the stress with the appearance of Shwartzman- 
type reactions. In pregnancy fibrinolytic activity, as measured by plasminogen 
activity, is decreased, as is also the ability of some pregnant women to respond 
to a stress such as exercise. If superimposed on this, other factors such 
as those noted above and others as yet unknown are added, the combination of 
circumstances may be enough to allow the complications of disseminated intra- 
vascular coagulation to develop. This may only occur in a few patients, 
possibly explaining why only a small minority of subjects exhibiting features 
of D.I.C. develop severe haemorrhagic or thrombotic phenomena. 
These reports are of particular interest as well documented cases 
of disseminated intravascular coagulation using a battery of assay systems 
are uncommon in the literature. The adequate laboratory investigations and 
satisfactory clinical outcome are a reflection of close liaison between 
clinical and laboratory staff. 
SUMMARY. 
The case histories of six patients, each exhibiting the features 
of D.I.C. and of different primary aetiologies, are presented. 
The diagnosis and treatment of these patients are discussed in 






Although in recent years the evolution of our knowledge of 
haemostatic mechanisms has been progressive, there still remain large gaps 
in our basic concepts of these systems. One important reason for this is 
the problem of methodology. In many instances the laboratory procedures 
developed for the measurement of parameters of coagulation and fibrinolysis 
have lacked specificity, accuracy or reproducibility, or have been designed 
solely for clinical recognition of major haemostatic pathology. The 
application of such methods to physiological studies has not been completely 
satisfactory, as parameter changes are often small and outside the sensitivity 
of the laboratory techniques. Coagulation assay techniques are a typical 
example of this problem as further standardisation of present methodology, 
relying as it does on the detection of fibrin end points, would appear 
unlikely to increase assay precision substantially. 
Experience with conventional coagulation assay techniques reported 
in the present studies soon established that their application to physiological 
measurements of small, but perhaps important, homeostatic changes in coaulation 
was strictly limited. Numerous variables were inevitably present and despite 
careful standardisation, consistent and accurate reproducibility of results 
was not easy to maintain, this being particularly noticeable in measurements 
in the normal and supra -normal ranges of each clotting factor. However, it 
was possible to confirm some of the coagulation studies from other centres, 
thus implying that measurements were being made of similar biochemical entities. 
The changes occurring in Factor VIII for instance, both with exercise and 
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adrenalin, were clear cut, but on the other hand the results of the Factor XII 
assays were dissimilar to one other group of workers. With new more specific 
assay techniques it might be possible to resolve such differences and measure 
accurately small differences in concentration. 
Because of the need to increase our understanding of the various 
inter -actions of these important enzyme systems coagulation and fibrinolysis 
are now being investigated by techniques previously allied to other 
disciplines. Sensitive biochemical and immunological methods have, for 
instance, contributed considerably to our insight of sequential molecular 
events occurring in the proteolysis of fibrinogen by thrombin and plasmin. 
With the development of immunological techniques for the'identification and 
quantitative assay of fibrin /fibrinogen degradation products, a new approach 
is now possible to certain aspects of the haemostatic mechanism. 
It would appear that the use of immunological assays in coagulation 
and fibrinolytic studies is probably only commencing. As specific components 
of the haemostatic system become biochemically purified and concentrated, it 
will become increasingly possible to produce monospecific antisera and, 
coupled with haemagglutination, radio -immunoassay and other techniques, 
further elucidation will be possible in both physiological and pathological 
studies. Measurement of coagulation Factor XII has already been adapted to 
a haemagglutination assay (Smink et al., 1967) and Factor II can be assayed 
by an immunochemical method (Nilehn and Ganrot, 1968). With development of 
the serological work reported by Denson (1967) basically similar measurements 
of other clotting factors may also be feasible. These techniques are also 
applicable to fibrinolysis, as demonstrated by the studies of Kucinski et al. 
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(1968) who have developed an antisera to purified urokinase. Future 
investigatory procedures thus appear most promising and major advances in 
our fundamental knowledge can reasonably be expected. 
Partly because of the limitations of techniques it was not possible 
to extend appreciably the concept of a dynamic balance existing between fibrin 
formation and lysis. Alterations in absolute levels of coagulation factors 
could not be related to changes in fibrinolytic parameters, and although the 
measurement of cryofibrinogen was of interest, the specificity of changes in 
its concentration is still not clear. The demonstration of F.D.P. in nearly 
all sera examined might be regarded as definitive proof of a continuous 
intravascular balance but, as we have indicated earlier, these polypeptides 
may be derived from extravascular sources (Das et al., 1968) and much more 
information is required before such a concept could be accepted. Perhaps 
a dynamic equilibrium could be assessed more adequately if measurements of 
either the in vivo changes of fibrin monomer or the peptides released on 
thrombin proteolysis of fibrinogen and fibrin could be made. In this thesis, 
various changes in cryofibrinogen in the form of heparin precipitable protein 
have been demonstrated but the detection of cryoprofibrin (Shainoff, 1962) in 
normal plasma might be a more relevant measure of fibrin monomer. The 
development of a reliable immunological measurement of fibrinopeptides 
A and B might also be an advance in our interpretation of the theory and some 
work is already in progress (Berglund and Blombäck, 1965). Nevertheless, 
the demonstration of these products in normal plasma would still not be 
final proof of such an equilibrium as there would be a need to establish the 
contribution made by extravascular sources to the intravascular pool. It 
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might, however, be theoretically possible to equate fibrin formation and lysis 
by measuring simultaneously the response of the coagulation and fibrinolytic 
peptides to stimuli regarded as activating both these systems. Sensitive 
methods for measuring fibrinogen turnover could also reveal much relevant 
to physiological haemostasis. Thus much depends on improved methodology, 
and research in the next few years should uncover much of value. 
A concept frequently noted in this thesis is that of the 
"fibrinolytic reactivity" of the plasminogen activator system. The relevance 
of this concept to pathophysiological events is not yet known, and will 
probably not be, until more is known of the exact in vivo role of plasminogen 
activator coupled with an understanding of its origin, metabolism, inhibition 
and excretion. The measurements of this labile enzyme depends upon in vitro 
systems that greatly magnify its lytic potential, after prior removal or 
diminution of naturally occurring inhibitor activity. Although circulating 
plasminogen activator may be the component responsible for routine fibrin 
lysis, a real need will be fulfilled when a rapid overall assessment of blood 
fibrinolytic activity is available and it might then be possible to assess 
more completely the physiopathological importance of changes in the components 
of this enzyme system. We do not understand, for instance, the significance 
of prolonged euglobulin lysis times occurring in apparently healthy subjects, 
or the relevance of the varying levels of plasminogen activator between 
individuals, not only within and between days but also in response to diverse 
stimuli. It is probable that these questions will remain unanswered until 
further epidemiological, physiological and pathological studies are carried 
out using improved methodology. A strong possibility exists that measurement 
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of activator levels represents only one factor in continually and dynamically 
changing mechanism, and that a realistic picture can be obtained only when 
other parameters,such as the various fibrinolytic inhibitors, are 
simultaneously measured. 
Pathological fibrinolytic activity in pregnancy is a not uncommon 
clinical entity and as its effects on maternal and foetal mortality are 
marked, investigations of its pathophysiological variations are of some 
importance. However, although it is now possible to measure the quantitative 
changes in some coagulation and fibrinolytic parameters, such information 
raises only fresh problems of interpretation. Insight into the significance 
of these changes and particularly their inter- action, control, and metabolism 
still completely evade us. Are these alterations of teleological significance 
in haemostasis or are they representative of non -specific responses to stress? 
To what extent do these systems integrate to maintain vessel patency in the 
vascular bed of the placenta and do placental metabolic products modify this 
process? The many questions which arise serve only to emphasize our 
incomplete concepts of these systems and provide considerable room for further 
research. Nevertheless, further investigation in pregnancy of the concept 
of fibrinolytic reactivity might provide an alternative approach to the study 
of clinically evident Shwartzman -type reactions and their associated 
haemostatic changes. There is a. need to establish if this phenomena plays 
a major or minor part in the bleeding or clotting problems of pregnancy and 
to develop simpler methods of assessing fibrinolytic reactivity. 
Fibrinolysis cannot simply be equated with changes in plasminogen 
activator levels since lysis of fibrin, as measured by the F.D.P. assay, may 
-345- 
be quite unaltered. The study of F.D.P. in pregnancy perhaps emphasizes 
this point. Low plasminogen activator levels cannot simply be linked with 
low fibrinolytic activity and theories based on the sole measurement of this 
parameter in vascular disease will require to be reviewed. Doubts as to the 
value of the observation of the speed of lysis of euglobulin clots has been 
expressed by Jacobsen (1968) who, in a study of the proteolytic capacity of 
plasma within family groups, was not able to show that greatly decreased 
fibrinolysis predisposed towards thrombosis. 
Measurement of the coagulation and fibrinolytic changes occurring 
in the operative and post operative phases will gradually reveal more of 
the mechanisms of bleeding and thrombotic phenomena. Certain lines of 
investigation have already been suggested in this thesis but such studies 
will be of less value unless other relevant parameters, such as fibrinogen 
turnover and platelet function studies, are assessed simultaneously. It is 
almost certain that the background to many haemostatic emergencies is 
multifactorial in origin and adequate investigation will demand integration 
of specialist investigations, in combined, projects, to achieve the maximum 
advance in knowledge. Perhaps the paramount problem is the early diagnosis 
of pre -thrombotic states. Conventional coagulation and fibrinolytic 
techniques have not contributed greatly to the understanding of this phenomena 
and there is a need to orientate new assay techniques towards the investigation 
of thromboembolism. Confirmation and extension of the post operation findings 
reported in this thesis might have a direct effect on the management of 
selected patients in the post operative phase, although much more exacting 
study is required. 
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Specific identification of many abnormal states of fibrin lysis 
can now be made using the F.D.P. assay. It can be shown that excessive 
lytic activity is possible in the absence of significant haemorrhage and the 
development of rapid F.D.P. assays now allows early confirmation of suspected 
fibrinolytic problems. A rapid method for the identification of the 
earlier products of fibrinogen proteolysis by plasmin would be a useful 
advance, as would be a more specific method for measuring the varying sized 
degradation products. However, the F.D.P. assay, especially in obstetrical 
pathology,should, even at the present time, prove a valuable ancillary routine 
diagnostic tool in the coagulation laboratory. It will now be possible 
to define more clearly the significance and frequency of syndromes of 
disseminated intravascular coagulation. 
The challenges still existing in the biochemical unravelling of 
these complex and integrated systems and the elucidation of their relationships 
to haemorrhage and thrombosis still remain, but it can confidently be expected 
that the new and developing laboratory techniques will answer many of the 
.fundamental problems outlined in these studies. Such elucidation might be 
of considerable significance in many distinct areas of clinical medicine. 
APPENDIX 
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APPLIdDIX 
A. Collection and Storage of Blood Specimens. 
Blood specimens were normally collected from an antecubital vein 
by careful venepuncture using the minimum of venous occlusion of the arm. 
All venepunctures were performed by experienced medical staff and where 
there was difficulty entering a vein the specimen was discarded. Plastic 
syringes and disposable needles (gauge size 20 or 21) were used throughout 
the studies. After collection the blood was carefully mixed, without 
frothing, with the anticoagulant or protease inhibitor. For some tests, 
e.g. the euglobulin lysis time assay and some clotting tests, the blood 
was stored for short periods on melting ice. 
After centrifugation of the blood samples, plasma was separated 
using pasteur pipettes and either assayed immediately or stored in small 
aliquots at -40 °C. 
B. Statistics. 
Routine statistical computations were made on the Olivetti 100 
Desk Computer with programmes which included the following mathematical 
formulae. 
(a) Standard Deviation 
S.D. . 
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JN.x2 x)2 
N(N-1) 
Where x = variate value 
N = number of values. 
(b) Coefficient of Linear Correlation and Rate of Regression. 
The calculation was based on the Bravais -Pearson coefficient 
of linear correlation. 
r = 
Nixy - X)( 1Y) 
JNx2 - (1x)2] [Nfy2 - (iy)2J 
Where x and y = variate values 
N = number of observations. 
The probability (p) of x and y being cotrelated was obtained from 
correlation coefficient tables where the degrees of freedom were equal to N - 1. 
The programme also computed the parameters a and b of the regression lines 
between the two variables x and y. 
y = a + bx 
b 
Nixy - (1,x)( 1Y) 
Nlx2 (x)2 
a = iy 
- bzx 
N 
Where x and y = variate values 
N = number of observations. 
The results were plotted by inserting the values for a + b into 
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for formula y = a + bx, and drawing the regression line for arbitrary 
values of x. 
(c) Students t test for significance. 
(i) The value of t was computed to ascertain whether the mean 
of two samples, taken from the same populations, differ significantly. MM - x 








_ N2y2 ()2 
2 
(N1 - 1)S12 + (N2 - 1)S22 
Standard Deviation 








+ N2 - 2 
Where IV,I1 = arithmetic mean of first sample 
M2 = arithmetic mean of second sample 
S12 . variance of first sample 
S22 _ variance of second sample 
id1 = number of values in first sample 
il2 = number of values in second sample 
x and y = variate values. 
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The p (probability) was obtained from a Students t - distibrution 
table, with the degrees of freedom being equivalent to N1 + N2 - 2. Values 
of p equal to or less than 0.05 were regarded as being significant. 
(ii) This additional t test was used for testing for significance 
between paired samples from the same subject. One mean calculated from the 




i d2 T( 2 
l.(YT - 1) 
Where N = number of samples 
d = difference between pairs 
R = mean of sample of measurements x. 
The significance of the value t was obtained from t test tables, 
waere the .degrees of freedom was equal to the number (N) of paired samples. 
Values equal or less than 0.05 were regarded as significant. 
Statistical tables used were obtained from either Documenta Geigy, 
"Scientific Tables ", 6th Edition 1962, or from "Statistical Methods in 
Biology" by N.T.J. Bailey (1959). 
(d) Mathematical formulae for computer programme 
These mathematics were used for calculation of potency ratio and 
confidence limits between test and control plasma clotting times and are 
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as prepared for the K.D.F. - 9 Computer . These mathematical procedures 
can be equated with the text of Section 3:5, "Coagulation and the Computer':. 
(i) Calculation of re session equations for both test and 
control plasma clottingr times. 
(x1 - ) (Y) - 771 ) 
b1 
(x) 21>G 
i (x2 - x2) (Y2 - 3'2) 
b2 
(x2 - x2) 
Where . b1 = slope of control plasma 
b2 = slope of test plasma 
x1 + x2 = log dilutions at which plasmas tested 
y1 + y2 = 
clotting times patient's plasma 
v1 + v2 = mean clotting times control plasma 
_ summation over all readings. 
Each regression is then tested for linearity. Only dilutions 
(x) with 2 or more clotting times (y) readings can be used in the computation 
of k (the number of dilution readings) must be not less than 3. A standard 











2 i = 1 
k - 2 
N - k 
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Where k = number of x readings 
m = number of y readings 
Y. is calculated from regression equation 
N = number of values included in computation. 
(ii) Test for homogeneity of variance. 
(a) The variances about the regression lines having 
been computed the F test is again applied as an indication of any differences 
between variances of the test and control plasmas. 
Variance = 
bSXY 
n - 2 
Where SXY = 1.17_7 








n = number of readings in experiment. 
The pooled residual variance (Vr) is then calculated. 
Vr = 
1 
(y )2 - 
( íx, - x1)(y - y), 
+ _r 
n + n2 - 4 1 (x1 - x1) 2 
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The standard error of the difference between the'two slopes is 
computed from the formula :- 
S.2.(b b) - Vr ( 1 + 1 
1 2 i (x1 x1)2 £(x 2 - x2)2 
t 
(b) Application of t test. 
b1 - b2 
- 
o .! . (b1 - b2 ) 
Degrees of freedom (df) = n1 + 
n2 
- 4 
The probability of obtaining by chance as great or greater a ratio 
is obtained from a t test table. 
(iii) If the dose response curves are not significantly non -parallel 
the log potency ratio (LT) is obtained :- 
= - ( B 12 Y1) 
1 
'1 
+ = mean tested concentrations of the two plasmas in 
real log. units. 
= mean responses for the two plasmas in real (or 
transformed units) of response. 
B = common slope obtained from the formula :- 
B 
-(x1 - 71)(Y1 - 5-1) + f (x2 - 22)(3'2 
i(x1 x1)2 + f(x2 - x2)2 
The potency of the patientas plasma in terms of the control plasma 
is given by antilog M. 
calculated :- 
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The Standard error of the lom potency ratio is 
Vr 1 
+ L. ,22.2._21)2 
B2 n1 n2 B 
5.E. _ 
(x1 
(Pooled residual variance (vr) is calculated from n1 + n2 - 3 
decrees of freedom at this stage.) 
The 95 confidence limits of the log potency ratio 
= M ± SE(m) x t0.05 
(v = 
n1 f n2 - 3) 
By taking antilogs., the limits are then obtained as percentages 
of the antilog. of M. 
* These computations are adapted from those of Ingram (1962). Acknowledge- 
ments are gratefully made to Dr. G.I.C. Ingram (St. Thomas' Hospital, 
London) and Dr. Y. Hills (London School of Hygiene and Tropical Medicine) 
for advice on preparation of this programme; to Mr. W. Lutz for his 
interest and supervision in the development of the final programme, 
and to Mss. Chalmers for her helpful consideration and technical aid. 
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C. Clinical Details of Surgical Patients. 
(a) Caesarian Section Group. 
C.S. 1. Mrs. M.K. age 20; Para. 1. 
History of an unstable lie at 39 weeks and contracted pelvis. 
An abnormal glucose tolerance test curve was noted. 
Lower Segment Caesarian Section ( L.S.C.S.) was performed with 
delivery of a live babe (wt. 10 lbs.. No post operative complications. 
C.S. 2. Mrs. L.O.; age 36; Para. 2 + 1. 
History of small antepartum haemorrhage at 38 weeks. Two previous 
pregnancies had been uneventful; medical history normal. 
L.S.C.S. for Type 1 placenta praevia at 38 weeks with delivery 
of live babe. At operation there was numerous adhesions involving uterina 
appendages and bowel. One part of blood was transfused during the operation. 
Given two bottles of packed cells post operatively for anaemia and Cycloserine 
for a urinary tract infection. No other complications. 
C.S. 3. Mrs. L.P.; age 25; Para. 2 + O. 
Admitted bedause of Rhesus immunisation. Intra- uterine transfusions 
had been performed at 24, 28 and 31 weeks. Medical history otherwise normal. 
L.S.C.S. performed at 34 weeks. Live but severely affected male 
babe delivered. Post operative course was uneventful. 
C.S. . IJirs. G.McM.; age 22; Para. 3 + O. 
History of three previous Caesarian Sections for contracted 
pelvis. Medical history otherwise uneventful. 
L.S.C.S. at 38 weeks with delivery of a live babe. Post operative 
course was normal. 
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C.S. 5. Mrs. I.R.; age 42; Para. 5 + 1. 
Admitted to hospital at 36 weeks because of unstable lie. No 
significant medical or obstetrical history. 
L.S.C.S. at 38 weeks with delivery of a live babe. Bilateral 
tubal ligation was also performed. At operation the placenta was inadvertently 
incised as uterus was being opened. Operation otherwise uneventful. 
Post operative period uncomplicated. 
C.S. 6. Yrs. R.P.; age 24; Para. 3 + O. 
Admitted for suspected Rh disease, with high Anti (C +D) titres. 
Previous pregnancies had been uneventful and there was no other significant 
medical history. 
L.S.C.S. was performed at 34 weeks with delivery of a live babe 
severely affected with Rhesus immunisation. Post operative course 
uneventful. 
C.S. 7. Mrs. A.L.; age 26; Para. 1 + 2. 
Previous history of Caesarian Section for contracted pelvis. 
Two previous miscarriages. Medical history uneventful. 
L.S.C.S. performed at 39 weeks, with bilateral tubal ligation. 
A live babe was delivered. The placenta was removed manually. Post 
operative course uneventful. 
C.S. 8. Mrs. E.A.; age 34; Para. O. 
Previous history of infertility for 6 years. Admitted for 
hypertension occurring near term, associated with a slight antepartum 
haemorrhage which settled on conservative treatment. 
L.S.C.S. was performed at ?42 weeks as an emergency, for foetal 
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distress, with delivery of a dead babe (cord round neck). Slight pyrexia 
post operatively, attributed to chest infection, otherwise no other 
complications. 
C.S. 9. Mrs. E.1,ß.; ade 36; Para. 3 + 0 
Admitted for elective Caesarian Section at 39 weeks after previous 
pelvic floor repair. Medical history satisfactory. 
L.S.C.S. and tubal ligation was performed. A live babe was 
delivered. Post operative course uneventful. 
C.S. 10. Mrs. C.C.; age 34; Para. 2 + 1. 
History of an unstable lie at 39 weeks. Also had had a previous 
Caesarian Section. 
L.S.C.S. performed with delivery of a live babe. Uneventful post 
operative course. 
C.S. 11. Mrs. J.S.; age39; Para. 0 + 1. 
Previous history of infertility and a recent miscarriage. 
Admitted for ? post maturity, excessive weight gain and maternal age. 
Elective L.S.C.S. performed at 38 weeks by dates, with delivery 
of live babe. Post operative course uneventful. 
C.S. 12. Mrs. M.S.; age 28; Para. 2. 
This patient had had two previous Caesarian Sections for a 
contracted pelvis. 
Elected L.S.C.S. performed with tubal ligation, and delivery of 
a live babe. Post operative course was complicated by a chest infection 
and a urinary tract infection. Both responded to Ampicillin. 
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C.S. 13. Mrs. R.M.; age 24; Para. 4 + 3. 
Admitted at 39 weeks gestation for elective Caesarian Section 
following previous section. 
L.S.C.S. performed with tubal ligation. Live babe born. Post 
operative course complicated by a mild chest infection responding to Ampicillin. 
C.S. 14. Mrs. A.C.; age 40; Para. 0. 
History of failed external cephalic version of breech positioñ at 
33 weeks. Admitted for elective Caesarian Section in view of age and 
breech presentation. 
L.S.C.S. performed with delivery of live babe. No complications. 
Post operative course uneventful. 
(b) Intra- abdominal Gynaecological Operation Group. 
H. 1. Mrs. M.A.; age 42. 
Admitted with a history of a mass in the lower abdomén for six 
months associated with heavy periods. 
A total hysterectomy, but leaving one ovary, was performed. A 
large uterine fibroid was found. Post operative course uneventful. 
H. 2. Yrs. H.McL.; age 39. 
Admitted following laboratory report of a suspicious cervical 
smear. 
At operation a partial hysterectomy was performed. Pathology 
of the cervix showed a small carcinoma - in situ. Post operative course 
uneventful. 
H. 3. Mrs. B.S.; age 34. 
Admitted after a history of six months menorrhagia. 
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At operation a total hysterectomy was performed. Pathology of 
the uterus was normal. Post operatively she developed a pyrexia and a vaginal 
vault haematoma. Treated with Ampicillin and made a slow recovery. 
H. 4. Mrs. H.E.; age 28. 
Admitted for a ventro suspension operation for retroversion of the 
uterus for dyspareunia. This was performed along with salpingectomy and 
appendicectomy. 
Post operatively a chest infection developed which settled with 
Penicillin. Two weeks after the operation she was again admitted with a 
chest infection which settled without further treatment. 
H. 5. Miss A.B.; age 35. 
Admitted for investigation of irregular period and dysmenorrhoea. 
No other medical history, apart from congenital eye and skeletal defects 
since birth. 
A total hysterectomy was performed. Nil abnormal found. Post 
operative course satisfactory. 
H. 6. Mrs. D.S.; age 32. 
Admitted for investigation of menorrhagia. Nil abnormal found 
clinically. 
At operation a partial hysterectomy was performed. The uterus 
was bulky but otherwise normal. Post operative course uneventful. 
H. Mrs. J.B.; age 30. 
History of two previous Caesarian Sections for contracted pelvis; 
also recent development of a depressive illness. Recommended for 
sterilization by G.P. No other significant medical history. 
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Bilateral salpingectomy was performed. Post operative course 
was uneventful. 
H. 8. Mrs. L.W.; age 43. 
History of lower abdominal mass for six months. 
At operation large fibroids were found. A total hysterectomy 
was performed. Developed an infected haematoma post operatively which 
settled without specific treatment. 
H. 9. Mrs. A.C.; age 41. 
Admitted for investigation after suspicious cervical smear 
laboratory report. 
Total hysterectomy and left salpingoophorectomy performed. No 
evidence of carcinoma on histological examination of the cervix. Post 
operative course was satisfactory. 
H. 10. Mrs. J.M.; age 33. 
History of a deep vein thrombosis five years previously. Since 
then had had left leg pain associated with periods. More recently developed 
menorrhagia. 
At operation a subtotal hysterectomy was performed. Three days 
post operatively she developed left leg pain and tenderness. Treated as a 
deep venous thrombosis with heparin and anticoagulants and these were 
continued for four weeks. For a urinary infection she was given Ampicillin. 
Also sustained a vaginal haematoma with consequent anaemia. Made a slow 
recovery and discharged from hospital on anticoagulants. 
H. 11. Miss E.T.; age 21. 
History of a lower abdominal mass for six months with polymenorrhoea. 
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No other medical history of note. 
At operation a large cystic left ovary found. Right 
salpingoophorectomy performed. Post operative course satisfactory. 
D. General Reagents. 
1. Buffers. 
(a) Tris buffer pH 7.8. 
73 gm. of tris hydroxymethyl arninomethane (Koch Light 
Laboratories) was dissolved in 2 litres of distilled water and the pH 
adjusted to 7.8 with N Hydrochloric acid. Solution then made up to 
4 litres with distilled water and the pH checked. 
(b) Veronal acetate buffer pH 7.4. 
9.714 gm. of sodium acetate trihydrate and 14.714 gm. of 
sodium diethylbarbiturate were dissolved in 500 ml. of distilled water. 
This stock solution was stored at 4 °C. 
A working solution was made by fixing 25 ml. of stock veronal 
acetate buffer and 25 ml. of 0.1 N HCl and the volume made up to 500 ml. 
with 0. ï0 saline. The pH was adjusted to 7.4 with either 0.1 N hydrochloric 
acid or 0.1 N sodium hydroxide. The solution was stored at 4 °C. 
(c) Clyoxaline (Imidazole) buffer (Mertz and Owen, 1940). 
680 mg. of glyoxaline (I{och Light Laboratories) was 
dissolved in 50 ml. of distilled water. The buffer at pH 7.3 was prepared 
by mixing 2.5 parts of this base with 1.86 parts of 0.1 N hydrochloric acid, 
and 5.64 parts of distilled water. To each 100 ml. of buffer was added 
0.585 gm. of sodium chloride. The buffer was stored at 4 °C. 
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(d) 0.05 ml. Tris buffer pH 7.2. 
24.30 gm. of tris buffer (Koch Light Laboratories) was 
dissolved in 1 litre of distilled water. From this stock solution 250 ml. 
was added to 42 ml. of N hydrochloric acid and the volume made up to 940 ml. 
with distilled water. The pH was adjusted to 7.4 at room temperature (20°C). 
(e) 0.1 I'dI Barbitone- saline buffer pH 7.22. 
5.71 gm. of sodium barbitone and 2.93 gm. of sodium chloride 
were added to 960 ml. of distilled water and the pH adjusted to 7.22. The 
volume was then made up to 1 litre with distilled water. 
(f) 0.1 Li Phosphate buffer pH 7.6. 
13.6 gm. of potassium dihydrogen phosphate was dissolved in 
1 litre of distilled water. 14.2 gm. of disodium hydrogen phosphate was 
similarly made up to 1 litre with distilled water. 870 ml. of the former 
and 130 ml. of the latter was then mixed and the pH checked. 
2. Other Reagents. 
( 
) Sodium hydroxide 0.5 N. 
10 gm. of sodium hydroxide was dissolved in 500 ml. of 
distilled water. 
(b) Sodium hydroxide 10 %. 
50 gm. of sodium hydroxide was dissolved in 500 ml. of 
distilled water. 
(c) 5ó Trichloroacetic Acid. 
25 gm. of trichloroacetic acid were dissolved in 500 ml. 
of distilled water. 
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(d) Tannic Acid. 
A stock solution is prepared by adding 100 mgm. of tannic 
acid to 10 ml. of distilled water. 
(e) Acetic acid for Euglobulin Lysis Time Estimations. 
5 ml. of glacial acetic acid was added to 500 ml. of 
distilled water. 19.5 ml. of this 1% solution of acetic acid was added 
to 2 litres of distilled water for use in the E.L.T. estimation. 
(f) 3% Formal Saline. 
30 ml. of Formaldehyde solutions (Evans) was added to 
1 litre of 0. saline and the pH adjusted to 7.25 with N. NaOH. 
(g) Calcium Chloride Solutions. 
0.05 Pit and 0.025 11 calcium chloride solutions were made from 
a stock solution of 11 Calcium chloride (British Drug Houses Ltd.) 
(h) Solution of Epsilon Amino Caproic Acid (E.A.C.A.) for 
Fibrinogen Assay. 
710 mgm. of E.A.C.A. was dissolved in 1 litre of distilled 
water. 
(i) Dye for Fibrin Plates. 
0.5 gm. of Bromothymol Blue powder was added to a mixture of 
250 nil. of Ethyl alcohol and 250 ml. of 0.5 N sodium hydroxide. 
E. Cleaning and Siliconization of Glassware. 
1. Cleaning of Glassware. 
(i) Test tubes and other glassware. 
(a) Glassware immersed for at least 24 hours in strong 
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detergent solution of Pyroneg (Diversey U.K.) 
(b) Boiled in a solution of strong pyroneg for 30 minutes. 
(c) Washed thoroughly to remove all traces of detergent. 
(d) Immersed in chromic acid for a minimum of 24 hours. 
(e) Rinsed free from chromic acid in running water. 
(f) Washed with a minimum of three changes of hot water and three 
changes of cold water. 
(g) Final wash for three changes of distilled water. 
(h) Dried in hot air oven overnight. 
(ii) Pipettes 
After use, soaked for at least 24 hours in a dilute 
solution of Pyroneg; then rinsed for 2 hours with running hot water in an 
automatic pipette washer, followed by 2 hours using cold water. The final 
three washes were with distilled wáter. Pipettes were dried in a hot air 
oven overnight. 
2. Siliconization of Glassware. 
In initial experiments, glassware was siliconized by immersion 
in a 3/ solution of I.C.I. M550 silicone in trichlorethylene for 2 hours; 
then dried in a hot air oven, rinsed at least six times in distilled water 
and re -dried overnight in a similar manner. 
In later experiments all glassware was siliconized with "Siliclad" 
(Clay Adams, N.Y.) in a 1j solution. After siliconization, glassware was 
similarly washed and dried in a hot air oven. 
P. 
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MIDDLE -AGED VOLUNTEERS - ELECTROCARDIOGRAPH REPORTS 
1966 1967 
M1 Normal Normal 
T12 11 11 
M3 " Post exercise depression of ST segment 
indicative of ischaemia. 
174 
It Normal 





MS 11 11 
119 It 11 
T110* 11 11 
N11 il if 
M12 11 11 
M13 It t1 
1:714 Right Bundle 
Branch Block 
Normal Otherwise. 
Right Bundle, Branch Block. 
Normal Otherwise. No Change. 
N15 Normal Normal 
F1 It 
tt 
F2 It Post exercise ischaemia changes present 
F3 It Normal 
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